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Background: Preterm birth may result in short- and long-term health problems for the child. Accurate
diagnoses of preterm births could prevent unnecessary (or ensure appropriate) admissions into hospitals
or transfers to specialist units.
Objectives: The purpose of this report is to assess the test accuracy, clinical effectiveness and
cost-effectiveness of the diagnostic tests PartoSure™ (Parsagen Diagnostics Inc., Boston, MA, USA),
Actim® Partus (Medix Biochemica, Espoo, Finland) and the Rapid Fetal Fibronectin (fFN)® 10Q Cassette
Kit (Hologic, Inc., Marlborough, MA, USA) at thresholds ≠50 ng/ml [quantitative fFN (qfFN)] for women
presenting with signs and symptoms of preterm labour relative to fFN at 50 ng/ml.
Methods: Systematic reviews of the published literature were conducted for diagnostic test accuracy (DTA)
studies of PartoSure, Actim Partus and qfFN for predicting preterm birth, the clinical effectiveness following
treatment decisions informed by test results and economic evaluations of the tests. A model-based economic
evaluation was also conducted to extrapolate long-term outcomes from the results of the diagnostic tests.
The model followed the structure of the model that informed the 2015 National Institute for Health and
Care Excellence guidelines on preterm labour diagnosis and treatment, but with antenatal steroids use,
as opposed to tocolysis, driving health outcomes.
Results: Twenty studies were identified evaluating DTA against the reference standard of delivery within
7 days and seven studies were identified evaluating DTA against the reference standard of delivery within
48 hours. Two studies assessed two of the index tests within the same population. One study demonstrated
that depending on the threshold used, qfFN was more or less accurate than Actim Partus, whereas the other
indicated little difference between PartoSure and Actim Partus. No study assessing qfFN and PartoSure in the
same population was identified. The test accuracy results from the other included studies revealed a high
level of uncertainty, primarily attributable to substantial methodological, clinical and statistical heterogeneity
between studies. No study compared all three tests simultaneously. No clinical effectiveness studies
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evaluating any of the three biomarker tests were identified. One partial economic evaluation was identified
for predicting preterm birth. It assessed the number needed to treat to prevent a respiratory distress
syndrome case with a ‘treat-all’ strategy, relative to testing with qualitative fFN. Because of the lack of data,
our de novo model involved the assumption that management of pregnant women fully adhered to the
results of the tests. In the base-case analysis for a woman at 30 weeks’ gestation, Actim Partus had lower
health-care costs and fewer quality-adjusted life-years (QALYs) than qfFN at 50 ng/ml, reducing costs at a
rate of £56,030 per QALY lost compared with qfFN at 50 ng/ml. PartoSure is less costly than Actim Partus
while being equally effective, but this is based on diagnostic accuracy data from a small study. Treatment
with qfFN at 200 ng/ml and 500 ng/ml resulted in lower cost savings per QALY lost relative to fFN at 50 ng/ml
than treatment with Actim Partus. In contrast, qfFN at 10 ng/ml increased QALYs, by 0.002, and had a cost
per QALY gained of £140,267 relative to fFN at 50 ng/ml. Similar qualitative results were obtained for women
presenting at different gestational ages.
Conclusion: There is a high degree of uncertainty surrounding the test accuracy and cost-effectiveness
results. We are aware of four ongoing UK trials, two of which plan to enrol > 1000 participants.
The results of these trials may significantly alter the findings presented here.
Study registration: The study is registered as PROSPERO CRD42017072696.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Antenatal corticosteroid therapy Therapy administered to women when preterm delivery is anticipated,
to enhance fetal lung maturation. The aim of treatment is to prevent respiratory distress syndrome and
reduce mortality and morbidity among preterm infants.
Bronchopulmonary dysplasia A chronic lung disease that affects premature infants requiring oxygen
therapy. It commonly occurs secondary to respiratory distress syndrome.
Cervical length Cervical length measurement via transvaginal ultrasound scan is a technique used to
assess the risk of preterm delivery in high-risk women or women presenting with signs or symptoms of
preterm labour. Shortening of the cervical length is correlated with a higher risk of preterm delivery.
Cervical os Opening of the uterine cervix (anatomy). It dilates during childbirth to allow the passage
of the baby.
Comparative study A study design that assesses (but does not necessarily directly compare) the
performance of two different diagnostic tests within the same population.
Concordance The proportion of cases in which the result of the test agrees with the clinical outcome.
Diagnostic yield The number of positive results divided by the number of samples.
Fetal fibronectin Adhesion protein that binds the fetal sac to the uterine lining. After 35 weeks’
gestation, the protein begins to degrade to prepare for delivery. Detection of fetal fibronectin in
cervicovaginal secretions earlier than 35 weeks can be used to predict onset of preterm delivery
(fetal fibronectin test).
Gestational age The number of completed weeks of pregnancy. This is usually calculated from the first
day of the woman’s last menstrual period or from clinical examination or ultrasonography. Reported
as weeks+days.
Gravidity The number of times a woman has been pregnant.
Iatrogenic delivery A delivery that is medically initiated or accelerated, such as through the
administration of labour-inducing drugs or delivery via caesarean section.
Incremental cost-effectiveness ratio A term used in health economics to compare the difference in the
cost and the effectiveness of two interventions/tests:
where C1 = cost of intervention, C0 = cost of control, E1 = effectiveness of intervention and
E0 = effectiveness of control.
Intraventricular haemorrhage A condition associated with preterm delivery, characterised by bleeding
into the ventricles of the brain. Severity is categorised by four grades: grades 1 and 2 denote a smaller
amount of bleeding and grades 3 and 4 denote more severe bleeding.
Incremental cost-effectiveness ratio = (C1− C0)/(E1− E0), (a)
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xix
Likelihood ratio In this study, the likelihood of a given test result in a patient who has a preterm delivery
compared with the likelihood of the same result in a patient who does not deliver preterm.
Positive likelihood ratio: how much more often a positive test result occurs in people who deliver preterm
than in those who do not:
Negative likelihood ratio: how much less likely a negative result is in people with preterm delivery than in
those without preterm delivery:
Meta-analysis A statistical technique that combines data from various studies evaluating the same index
test to calculate pooled diagnostic accuracy estimates.
Multiple gestation pregnancy A pregnancy in which the number of fetuses exceeds one.
Negative predictive value In this study, the proportion of people with a negative result who will not
deliver preterm (within 48 hours or 7 days):
Parity The number of times a woman has carried a pregnancy to a viable gestation.
Phosphorylated insulin-like growth factor-binding protein-1 A protein produced by decidual cells
that leaks into cervical secretions when delivery is imminent and can be used to predict the onset of
preterm labour [Actim® Partus (Medix Biochemica, Espoo, Finland)].
Placental alpha microglobulin-1 This protein is secreted by the decidual cells into the amniotic fluid
throughout pregnancy. This protein can be detected in cervicovaginal secretions when delivery is imminent
[PartoSure™ (Parsagen Diagnostics Inc., Boston, MA, USA) test].
Positive predictive value In this study, the proportion of people with a positive result who will deliver
preterm (within 48 hours or 7 days):
Preterm birth/delivery The delivery of a live baby before 37+ 0 weeks’ gestational age: < 28 weeks’
gestational age = extremely preterm, ≥ 28 weeks’ and < 32 weeks’ gestational age = very preterm and
≥ 32 weeks’ and < 37 weeks’ gestational age = moderate to late preterm.
Preterm premature rupture of membranes Premature (< 37 weeks’ gestation) rupture of the amniotic
sac surrounding the fetus before the onset of established labour. Women experiencing preterm premature
rupture of membranes are at increased risk of amniotic infection and preterm delivery.
Positive likelihood ratio =
P(Test + ve j preterm)
P(Test + ve j not preterm) =
Sensitivity
1 − Specificity
. (b)
Negative likelihood ratio =
P(Test − ve j preterm)
P(Test − ve j not preterm) =
1−Sensitivity
Specificity
. (c)
Negative predictive value = true negative / (true negative + false negative). (d)
Positive predictive value = true positive / (true positive + false positive). (e)
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Prevalence In this study, the proportion of women actually delivering preterm (within 48 hours or 7 days).
Quality-adjusted life-year A measure of disease burden that combines length and quality of life.
Receiver operating characteristic plot A graphical depiction of diagnostic test accuracy data for all
included studies.
Reference standard The best diagnostic test currently available, against which an index test is assessed.
Owing to the predictive nature of the index tests in this study, the reference standard for all included
studies was preterm delivery within 48 hours or 7 days.
Respiratory distress syndrome A breathing disorder that commonly affects premature babies and is
attributable to insufficient surfactant production in immature lungs.
Sensitivity The ability of a diagnostic test to correctly identify women in whom delivery is imminent
(within 48 hours or 7 days):
Single-gate study A study design in which participants’ disease statuses are unknown and the index test
result is evaluated against the reference standard to confirm the diagnosis.
Specificity In this study, the ability of a diagnostic test to correctly identify women for whom delivery is
not imminent (within 48 hours or 7 days).
Test failure The rate of non-informative test results.
Time to test The time required to obtain test results.
Tocolytic therapy Drugs administered to delay the onset of established preterm delivery to allow time
for in utero transfers. Tocolytic therapy was previously used to allow time to complete corticosteroid
administration; however, this is no longer recommended practice.
Sensitivity = true positive / (true positive + false negative). (f)
Specificity = true negative / (true negative + false positive). (g)
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RCT randomised controlled trial
RDS respiratory distress syndrome
ROC receiver operating characteristic
SD standard deviation
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WHO World Health Organization
Note
This monograph is based on the Technology Assessment Report produced for NICE. The full
report contained a considerable number of data that were deemed confidential. The full
report was used by the Appraisal Committee at NICE in their deliberations. The full report
with each piece of confidential data removed and replaced by the statement ‘confidential
information (or data) removed’ is available on the NICE website: www.nice.org.uk.
The present monograph presents as full a version of the report as is possible while retaining
readability, but some sections, sentences, tables and figures have been removed. Readers
should bear in mind that the discussion, conclusions and implications for practice and research
are based on all the data considered in the original full NICE report.
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Plain English summary
Infants may suffer from health problems if they are born early. If a mother has symptoms of labourbefore her baby is due, a test could be used to predict if the symptoms are real or a false alarm. A test
could help the doctor to decide whether the mother needs treatment or to move to a specialist hospital or
if she could be sent home (if it is a false alarm).
Our report compares three tests [PartoSure™ (Parsagen Diagnostics Inc., Boston, MA, USA), Actim® Partus
(Medix Biochemica, Espoo, Finland) and the Fetal Fibronectin (fFN) Test (Hologic, Inc., Marlborough, MA,
USA)] on how well they predict an early birth and how the costs and the long-term health outcomes
of the child compare between and among tests.
All the published literature reporting the accuracy of the three tests and their costs was reviewed.
We developed a new cost-effectiveness model, which estimated the long-term health outcomes of the
child based on the test results.
Twenty of the studies reviewed looked at how good the tests were at predicting an early birth within the
next 7 days, and six looked at predicting birth within 48 hours. The designs of the studies and the women
taking part in the studies varied greatly. This meant that comparing the accuracy of the tests was very
difficult and it would be unfair to decide which test was the best.
Our model suggested no firm conclusions for the cost-effectiveness of fFN compared with Actim Partus.
PartoSure appears to be less costly than Actim Partus and equally good at predicting preterm birth, but
this is based on a study of very few patients. There were no data that allowed us to compare all three
tests together.
The accuracy of the results is uncertain, mainly because all the studies are very different. We are aware of
four related UK trials that are currently ongoing that plan to include large numbers of women.
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Scientific summary
Background
Preterm (premature) birth, as defined by the World Health Organization, refers to birth of alive baby before
37 weeks of gestation. Approximately 8% of births in England and Wales are premature. Preterm birth can
result in serious short-term health issues for the infant, including difficulties with breathing [respiratory
distress syndrome (RDS)] and feeding and increased risk of infections and bleeding within the brain
[intraventricular haemorrhage (IVH)]. Moreover, long-term problems include an increased risk of cerebral
palsy, cognitive and visual impairment and respiratory illnesses.
Current National Institute for Health and Care Excellence (NICE) guidelines (published in 2015) recommend
that women presenting with symptoms of preterm labour who have intact membranes should undergo a
clinical assessment. If the clinical assessment suggests that the woman is in suspected preterm labour and
she is ≤ 29+ 6 weeks pregnant, treatment for preterm labour is recommended. If the clinical assessment
suggests that the woman is in suspected preterm labour and she is ≥ 30+0 weeks pregnant, then the
following tests should be conducted:
1. a transvaginal ultrasound scan measurement of cervical length (positive if < 15 mm)
2. if transvaginal ultrasound scan measurement of cervical length is unavailable or unacceptable, a fetal
fibronectin (fFN) test (positive if concentration is ≥ 50 ng/ml).
Accurate diagnoses of preterm births could prevent unnecessary (or ensure appropriate) admissions into
hospitals or transfers to specialist units.
Objectives
The purpose of this report is to assess the following three biomarker diagnostic tests for their test accuracy,
clinical effectiveness and cost-effectiveness:
1. PartoSure™ (Parsagen Diagnostics Inc., Boston, MA, USA) – a point-of-care dipstick test that detects
placental alpha microglobulin-1 (PAMG-1) in vaginal secretions
2. Actim® Partus (Medix Biochemica, Espoo, Finland; distributed by Alere Inc.) – a point-of-care dipstick
test that detects phosphorylated insulin-like growth factor-binding protein-1 [ph(IGFBP-1)] in
cervical secretions
3. Rapid fFN® 10Q Cassette Kit (Hologic, Inc., Marlborough, MA, USA) [referred to in this report as
quantitative fFN (qfFN)] used with a threshold ≠50 ng/ml – a point-of-care quantitative test that
detects the concentration of fFN in cervicovaginal fluid.
This assessment comprises three systematic reviews of published literature corresponding to:
l diagnostic test accuracy (DTA) studies of the biomarker tests in symptomatic women with
intact membranes
l clinical effectiveness (end-to-end) studies of the biomarker tests for symptomatic women with
intact membranes
l economic evaluations of the biomarker tests for predicting preterm birth for symptomatic women with
intact membranes.
In addition to these reviews, an independent economic evaluation was conducted.
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Review of test accuracy
Methods
A systematic review was undertaken to assess the DTA of PartoSure, Actim Partus and qfFN. Studies
were identified by searching seven bibliographic databases, searching trial registries, web searching and
additional supplementary search methods. Studies were selected if they met the following criteria:
l population – symptomatic women with intact amniotic membranes
l index tests – PartoSure, Actim Partus and qfFN at thresholds ≠50 ng/ml
l reference standards – preterm delivery within 48 hours or within 7 days
l comparators – clinical assessment of symptoms alone, qualitative fFN, or qfFN at a threshold of 50 ng/ml
l outcomes – primarily sensitivity, specificity, positive predictive value and negative predictive value.
Titles and abstracts were independently double-screened for inclusion and disagreements were resolved
by discussion. Studies meeting the inclusion criteria at the title and abstract stage were double-screened as
full texts.
The methodological quality of each included study was assessed using QUADAS-2, data were extracted,
tabulated and narratively synthesised. When the data allowed, summary receiver operating characteristic
plots were generated and meta-analyses were conducted.
Results
Twenty studies met the inclusion criteria: 16 studies assessed Actim Partus, four assessed PartoSure and
two assessed qfFN.
Sufficient evidence for pooling the test accuracy data was available only for Actim Partus and PartoSure
against the 7-day reference standard and for Actim Partus against the 48-hour reference standard.
However, there was substantial methodological, clinical and statistical heterogeneity between studies,
raising considerable uncertainty about the most valid estimate of accuracy for each index test.
Studies offering the greatest certainty when comparing tests were those that assessed two or more
different tests within the same population. We identified two such studies. In the first study, depending on
the threshold used, qfFN was more or less sensitive and specific than Actim Partus. In the second study,
there was little difference between the sensitivity and specificity of PartoSure and Actim Partus. No studies
assessed qfFN and PartoSure within the same population.
When looking at all the studies identified for each of the tests and the ranges of results, the magnitude
of the substantial heterogeneity between the studies is clearly apparent. Against the 7-day reference
standard for Actim Partus (n = 16 studies), the study with the best overall sensitivity and specificity results
had sensitivity of 94.7% [95% confidence interval (CI) 89.9% to 97.7%] and specificity of 92.4% (95% CI
88.9% to 95.1%), whereas the study reporting the worst results had sensitivity of 33.3% (95% CI 4.3%
to 77.7%) and specificity of 74.1% (95% CI 69.1% to 78.6%). For PartoSure (n = 4 studies), the study
with the best overall sensitivity and specificity results had sensitivity of 100.0% (95% CI 73.5% to
100.0%) and specificity of 95.4% (95% CI 88.6% to 98.7%). The study reporting the worst results had
sensitivity of 0.0% (95% CI 0.0% to 97.5%) and specificity of 97.5% (95% CI 96.8% to 99.9%); the
low sensitivity reported in that study is attributable to only one woman delivering preterm (within 7 days)
and her testing (falsely) negative within the study sample of size 41. fFN at a threshold of 10 ng/ml (n = 2
studies) had a sensitivity range of 93.8% (95% CI 82.8% to 98.7%) to 95.7% (95% CI 87.8% to 99.1%)
and a specificity range of 32.2% (95% CI 27.7% to 37.0%) to 42.3% (95% CI 36.5% to 48.4%), at a
threshold of 200 ng/ml, sensitivity ranged from 70.8% (95% CI 55.9% to 83.0%) to 71.0% (95% CI
58.8% to 81.3%) and specificity ranged from 78.6% (95% CI 74.3% to 82.5%) to 83.6% (95% CI
78.8% to 87.8%), and at a threshold of 500 ng/ml, sensitivity ranged from 29.2% (95% CI 17.0% to
44.1%) to 42.0% (95% CI 30.2% to 54.5%) and specificity ranged from 94.3% (95% CI 91.6% to
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96.4%) to 95.7% (95% CI 92.7% to 97.8%). Given the large ranges between studies assessing the same
test and the significant overlapping of CIs, it would be premature to attempt to deduce which test was
superior against the 7-day reference standard.
We were only able to assess Actim Partus (n = 6 studies) and PartoSure (n = 1 study) against the 48-hour
reference standard, because no studies were identified that assessed qfFN. Similar to the 7-day results,
accuracy results for Actim Partus varied substantially across studies. Given also that there was only one
PartoSure study, it would be premature to attempt to deduce which test was superior against the 48-hour
reference standard.
Review of clinical effectiveness (end-to-end) studies
Methods
The same literature search and screening methods were used as for the review of DTA to identify
randomised controlled or controlled studies of the tests (PartoSure, Actim Partus or fFN at thresholds
≠50 ng/ml). Studies could compare the tests with each other or with fFN at a threshold of 50 ng/ml,
or with clinical assessment of symptoms alone. Clinical outcomes were sought.
Results
No eligible studies were identified.
Review of economic evaluations
A systematic review was undertaken to identify previous economic evaluations of PartoSure, Actim Partus
and qfFN. The methodology was identical to that used for the systematic review of test accuracy (described
above). From 2252 records, 63 full texts were assessed for eligibility. Only one suitable (but unpublished)
study was identified; that study modelled the cost-effectiveness of a ‘treat-all’ strategy, relative to testing
with qualitative fFN to determine treatment. Based on the findings of that study, we calculated that the
incremental cost-effectiveness ratio (ICER) of treating all suspected cases of preterm labour with antenatal
corticosteroids (ACSs) is £20,942 per quality-adjusted life-year (QALY) gained.
This identified study also compared the use of four different qfFN thresholds (10, 50, 200 and 500 ng/ml).
Based on the results, we also calculated that testing at 200 ng/ml dominates testing at lower thresholds,
owing to treatment and health-care costs saved. However, the ICER of testing at 200 ng/ml, relative to a
higher threshold of 500 ng/ml, was found to be £10,415 per QALY gained. Therefore, our calculations
may support the study authors’ conclusions that using a 200-ng/ml threshold for qfFN was the optimal
testing threshold. However, owing to the low number of false-negative cases in the study, there is a high
level of uncertainty in their results.
To provide a more thorough examination of the evidence on modelling approaches, studies that modelled
diagnostic interventions for suspected preterm labour were also reviewed. Six different model structures
were identified, and all utilised a decision tree. The only cost–utility model identified was developed for
the 2015 NICE guidelines for preterm labour. In addition to the decision tree structure, this model also
extrapolated diagnostic results to obtain long-term health outcomes for the child. The remaining studies
were either cost-minimisation or cost-effectiveness analyses.
Other major design aspects in which the six models differed were:
l length of time horizon
l assumptions surrounding adherence to treatment following a particular test result
l type of treatment administered.
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Two studies conducted cost minimisation analyses (i.e. did not consider effectiveness in terms of quantity
or quality of life). The first was a Canadian study that found that testing with fFN added total costs of
approximately US$4M, relative to no testing. The second was a UK study that compared clinical examination
alone with clinical examination with a fFN test. This study found that using fFN saved the NHS £23.88 per
patient, with the additional test costs offset by the savings in hospital resource costs being resulting with
from treating fewer women.
Three studies provided cost-effectiveness analyses. The first (in the UK) compared testing with fFN with
a ‘treat-all’ strategy. This model was unique in allowing for < 100% admission following a positive test
result. However, it did not consider outcomes for false positives, or compute results based on gestational
age. The second study (in the USA) found that treating all patients had incremental costs of US$433,000
per case of RDS avoided and US$1,300,000 per neonatal life saved relative to fFN (1999 prices). It differed
from other models by explicitly modelling preterm birth within 48 hours of testing. The third study (in the
Netherlands) measured a variety of adverse outcomes as a composite measure, but only up until time of
discharge (or death).
The 2015 NICE guidelines model presented a ‘what if?’ analysis of various testing strategies against a
‘treat-all’ approach. This involved varying the sensitivity and specificity of a hypothetical test to find the
optimal values at which a test would be cost-effective, given a £20,000 per QALY threshold. The model
was unique in measuring long-term outcomes by gestational age. We comment in detail on NICE’s
model in this report and conclude that it provides the most suitable structure for the decision problem on
which to base our own model.
Independent economic assessment
We developed a new model that adopted the best published methodological practice including that of
the 2015 NICE guidelines model. It models diagnostic outcomes as a decision tree structure and projects
long-term health outcomes many years into the future based on the occurrence of major neonatal adverse
events. Unlike the NICE model, which assumed that all treatment involved tocolysis, our model considers
treatment with ACSs only. Use of tocolysis is only assumed in case of hospital transfer. This is based on
both recent evidence and current practice.
Key features of the model include:
l accounting for costs and lifetime QALY loss for an infant as a result of mortality, IVH or RDS, as well as
the QALY loss to the mother in a scenario analysis
l differentiating costs and benefits by gestational age
l distinguishing between hospital levels, and therefore accounting for the costs of a transfer from a
hospital with a lower neonatal unit to a higher-level unit hospital in mothers of the youngest
gestational ages
l accounting for the costs and benefits of ACSs for treatment of preterm labour, and the cost of
tocolysis for transfers
l using gestational age of birth-specific inpatient costs estimated from national registry data on level of
care received by newborn premature infants until hospital discharge.
The structure of the model is described briefly as follows: a woman with intact membranes, between
24 and 36 weeks’ gestation, presenting with signs and symptoms of preterm labour, and for whom
transvaginal ultrasound scan is not available or acceptable, is tested using one of fFN, Actim Partus or
PartoSure. Regardless of the result, this woman can:
1. give birth (preterm) within 7 days of the test
2. give birth (with a gestational age of < 37 weeks) > 7 days after testing
3. give birth (with a gestational age of ≥ 37 weeks) > 7 days after testing.
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If a woman tests positive, she is treated with steroids. If the gestational age is < 28 weeks, and she
presents at a hospital with a level 1 or 2 neonatal unit, she will also be given tocolysis and transferred to a
level 3 (tertiary) hospital. In addition to the three tests, the model also considers a ‘treat-all’ strategy for
comparison.
A review of health-related quality-of-life studies for preterm labour informed the selection of utilities for
preterm survivors, IVH, RDS and mothers. Owing to a lack of suitable data in the literature, we used proxy
utility values for IVH and RDS. Because only one study provided data for the quality of life of mothers who
had had previous adverse pregnancy outcomes, we do not include their utility as part of the base case.
Overall, we improve on the utility data used in the model that informed the existing NICE guidelines.
A review of cost studies informed the selection of relevant costs for inclusion in the model. Unlike the
economic analysis that informed the NICE guidelines, our model accounts for the additional costs of saving
a preterm neonatal life.
As there was no study that compared all the diagnostic options, we produced an economic assessment
for the individual comparative studies separately. The results from our base-case analysis (for a woman
presenting at 30 weeks’ gestation) are as follows. Using test accuracy data from one study, we find that
Actim Partus is £346 cheaper and 0.006 QALYs less effective than fFN at 50 ng/ml. This results in an ICER
for Actim Partus of a £56,030 cost saving per QALY lost versus 50 ng/ml of fFN. Using test accuracy data
from another study, we find that PartoSure is less costly than Actim Partus while being equally effective.
Indirectly comparing PartoSure with 50 ng/ml fFN (using data from two studies) yields a saving of £81,922
per QALY loss with the former relative to the latter test. This estimate is highly uncertain given the indirect
comparison source and the small size of one of the studies used. Furthermore, qfFN at the 200 ng/ml and
500 ng/ml thresholds saves £25,209 and £17,025 per QALY loss, respectively, relative to 50 ng/ml of fFN.
qfFN at 10 ng/ml was the only test option that increased QALYs, by 0.002, relative to 50 ng/ml fFN, and
had an incremental cost per QALY gained of £140,267. The discounted QALY differences between new
test options against 50 ng/ml fFN were all smaller than 0.03.
Conclusion
There is a high degree of uncertainty surrounding the test accuracy results, primarily as a result of the
substantial methodological, clinical and statistical heterogeneity between included accuracy studies and the
lack of any study of the tests on decision-making and clinical outcomes. Nevertheless, our results suggest that
the NICE guideline recommendation that symptomatic women presenting at 30 weeks’ gestation be
admitted to hospital (i.e. the no-test, treat-all policy) may not be cost-effective. We are also aware of four
ongoing UK trials, two of which are planning to enrol > 1000 participants, the results of which are likely to
affect these conclusions.
Study registration
The study is registered as PROSPERO CRD42017072696.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background and definition of the
decision problem(s)
Conditions and aetiologies
Preterm (premature) birth, as defined by the World Health Organization (WHO), refers to babies born alive
before 37 weeks and 0 days of gestation (37+0 weeks).1
Preterm birth can be serious for an infant in terms of both short- and long-term health problems and an
increased risk of mortality. For example, short-term problems include difficulties with breathing [respiratory
distress syndrome (RDS)] and feeding and an increased risk of infections and bleeding within the brain
[intraventricular haemorrhages (IVHs)]. Meanwhile, long-term problems include an increased risk of cerebral
palsy, cognitive and visual impairment and respiratory illnesses.2,3
Aetiology, pathology and prognosis
The WHO1 subcategorises preterm birth based on gestational age as:
l extremely preterm – < 28 weeks’ gestational age
l very preterm – ≥ 28 weeks’ and < 32 weeks’ gestational age
l moderate to late preterm – ≥ 32 weeks’ and < 37 weeks’ gestational age.
Iatrogenic preterm births are medically instigated deliveries, such as early labour induction or caesarean
section.4 These elective deliveries aim to reduce health risks to the mother or fetus owing to complications
such as hypertension, intrauterine growth restriction or pre-eclampsia.4
Spontaneous preterm labour is a multifactorial condition with various underlying pathologies including
infection, breakdown of fetal–maternal tolerance, stress, decidual senescence and uterine distension
(commonly associated with multifetal pregnancies).5 Spontaneous preterm deliveries can be broadly
categorised as either spontaneous labour with intact membranes or those following preterm premature
rupture of membranes (PPROMs).4 Factors associated with an increased risk of preterm delivery include
stress, tobacco use, drug abuse, trauma, multifetal gestations, in vitro fertilisation, low body mass index
(BMI) before pregnancy, extremes of maternal age, diabetes mellitus, high blood pressure and infection.6,7
However, previous preterm delivery is the greatest risk factor for preterm birth.8
Symptoms of suspected preterm labour include painful contractions or cramps, abdominal and low-back
pain and an increase or change in vaginal discharge.9 Symptoms do not always result in progression to
established labour and birth; they may occur but then settle, allowing the pregnancy to continue towards
term. It is understood that > 90% of women presenting with symptoms of preterm labour do not go
on to deliver in the next 2 weeks and, of these, 50% will continue with pregnancy until full term.10,11 It is
important to determine whether or not preterm labour is the cause of the symptoms and to assess the risk
of preterm delivery to allow appropriate management to begin as soon as possible.12
The focus population for this report is women presenting with signs and symptoms of spontaneous
preterm labour with intact membranes.
Epidemiology
Data from the England and Wales 2016 birth cohort13 report 54,143 live, preterm deliveries in accordance
with the WHO definition of preterm birth (< 37 weeks’ gestational age), corresponding to 7.8% of all live
births. Of these deliveries, 5.9% were categorised as extremely preterm (< 28 weeks’ gestation), 10.4%
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1
were very preterm (gestational age of ≥ 28 to < 32 weeks) and 83.7% were moderate to late preterm
(≥ 32 to < 37 weeks’ gestation).13
The 2016 UK birth cohort data collected by the Office for National Statistics (ONS)13 show that the rate of
preterm births varies between ethnic populations, with the highest proportion of preterm births occurring in
black Caribbean and Indian populations (10.4% and 8.03% of pregnancies in these populations, respectively)
and the lowest rate of preterm births occurring in women of ‘white other’ ethnicity (6.6%). The rate of preterm
delivery in the population in which ethnicity was ‘not stated’ was 8.3%.13 In the UK, preterm labour, particularly
extreme preterm labour, disproportionately affects women from low socioeconomic backgrounds.14,15
Incidence and/or prevalence
Improvements in perinatal health-care services have resulted in vastly improved outcomes for babies born
preterm, yet the prevalence of preterm birth continues to rise.1,16
Preterm birth rates vary between countries, with higher prevalence and poorer outcomes in lower-income
countries.16 However, preterm birth is a global issue that also affects developed countries.
Impact of the health problem
Globally, preterm birth complications are directly responsible for 35% of all neonatal deaths and are the
second leading cause of death in children aged < 5 years.16,17
Morbidities associated with preterm birth are both acute and chronic and can affect all organ systems.
Respiratory distress can progress to bronchopulmonary dysplasia18 and cerebral pathology (e.g. IVHs and
ischaemia can lead to neurodevelopmental disorders including learning and behavioural difficulties).19,20
In addition, gastrointestinal disorders and immunodeficiencies are also associated with preterm birth.21,22
Although mortality and morbidity rates are higher for infants delivered at lower gestational ages and lower
birthweights, near-term premature infants remain at a considerably higher risk of complications than their
full-term counterparts.20
Preterm deliveries place a significant cost burden on the NHS. In addition to initial hospitalisation,
rehospitalisation and rehabilitation, other direct medical costs include medication, aids and devices such
as wheelchairs, visits to physicians and home care.23 Direct non-medical costs such as special education,
adaptations to homes or cars, special meal requirements, higher insurance premiums and other disease-
associated costs are an expensive burden on both families and the state.23
Current guidelines
The National Institute for Health and Care Excellence (NICE) guideline24 on preterm labour (Figure 1) and
birth states that women reporting symptoms of preterm labour who have intact membranes should have
a clinical assessment that includes:
l clinical history-taking
l observations of the woman, including the length, strength and frequency of her contractions; any pain
she is experiencing; pulse, blood pressure and temperature; and urinalysis
l observations of the unborn baby, including asking about the baby’s movements in the last 24 hours;
palpation of the woman’s abdomen to determine the fundal height, the baby’s lie, presentation,
position, engagement of the presenting part, and frequency and duration of contractions; and
auscultation of the fetal heart rate for a minimum of 1 minute immediately after a contraction
l a speculum examination (followed by a digital vaginal examination if the extent of cervical dilatation
cannot be assessed).
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If the clinical assessment suggests that the woman is in suspected preterm labour and she is 29+6 weeks
pregnant or less, treatment for preterm labour is recommended.24
If the clinical assessment suggests that the woman is in suspected preterm labour and she is ≥ 30+0 weeks
pregnant then the following tests should be conducted:24
l Transvaginal ultrasound scan measurement of cervical length (as a diagnostic test to determine
likelihood of birth within 48 hours).
¢ If cervical length is > 15 mm, the woman is unlikely to be in preterm labour and could be discharged
home with routine follow-up in the community and advised to return if symptoms reappear.
¢ If cervical length is ≤ 15 mm, the woman is diagnosed as being in preterm labour and should be
offered treatment.
l If transvaginal ultrasound scan measurement of cervical length is indicated but is not available or not
acceptable, then fetal fibronectin (fFN) testing as a diagnostic test may be used for women who are
≥ 30+0 weeks pregnant.
¢ If the fFN test result is negative (concentration of < 50 ng/ml), the woman is unlikely to be in preterm
labour and could be discharged home with routine follow-up in the community and advised to return
if symptoms reappear.
¢ If the fFN test result is positive (concentration of ≥ 50 ng/ml), the woman is diagnosed as being in
preterm labour and should be offered treatment.
It is not recommended to use transvaginal ultrasound scan measurement of cervical length and fFN testing
in combination to diagnose preterm labour.
Diagnosis of preterm labour (section 9)
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FIGURE 1 Diagnosis of preterm labour from section 9 of the 2015 NICE guidance on preterm labour and birth.24
FN, fetal fibronectin; PTL, preterm labour. Reproduced from: Royal College of Obstetricians NICE Guideline 25
Preterm Labour and Birth, London, ROCG, November 2015, with the permission of the Royal College of
Obstetricians and Gynaecologists.24
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Description of the technologies under assessment
Accurate diagnoses of preterm birth using a biomarker test could prevent unnecessary, or ensure
appropriate, admissions into hospitals, transfers to specialist units and/or treatment.
Summary of the technologies
Following the NICE guidance, the technologies under assessment in this review would appear in the
treatment pathway where the fFN test (at the threshold of 50 ng/ml) is currently being used. A summary of
information relating to the tests is given in Table 1.
PartoSure
PartoSure™ (Parsagen Diagnostics Inc., Boston, MA, USA) is a CE-marked qualitative lateral flow,
immunochromatographic point-of-care test that detects placental alpha microglobulin-1 (PAMG-1) in
vaginal secretions. PAMG-1 is a protein produced by decidual cells lining the uterus and is secreted into
amniotic fluid, its concentration in vaginal discharge is usually low and studies have shown that the
presence of PAMG-1 in vaginal discharge is predictive of imminent delivery.25
Actim Partus
Actim® Partus (Medix Biochemica, Espoo, Finland; distributed by Alere Inc.) is a CE-marked qualitative
immunochromatographic point-of-care test that detects phosphorylated insulin-like growth factor binding
protein-1 [ph(IGFBP-1)] in cervical secretions. ph(IGFBP-1) is made by cells lining the uterus and leaks into
the cervix when delivery is imminent.12
Rapid Fetal Fibronectin 10Q Cassette Kit
The Rapid fFN® 10Q Cassette Kit (Hologic, Inc., Marlborough, MA, USA) is a CE-marked point-of-care test
for use in the PeriLynx system or the Rapid fFN 10Q system. This test quantifies the concentration of fFN
present in cervicovaginal fluid. fFN is a glycoprotein that connects membranes of the uterus and fetal
membranes, which begins to degrade after 35 weeks of pregnancy or soon before preterm birth.
Population
For the purpose of this report, the population of interest is women with signs and symptoms of preterm
labour with intact amniotic membranes, who are not in established labour and for whom a transvaginal
ultrasound scan is not available or acceptable.
Identification of important subgroups
The following women are at different risks of preterm delivery and consequently adverse neonatal
outcomes. The clinical utility of the test may vary across these groups and the relative value of accurate
identification of true-positive and true-negative cases is different from that in the overall population:24
l women with history of preterm delivery
l women presenting with symptoms at < 28 weeks’ gestation
l women presenting with symptoms at ≥ 28 and < 32 weeks’ gestation
l women presenting with symptoms at ≥ 32 weeks’ gestation
l women with multiple fetuses
l women from lower socioeconomic groups (i.e. in most disadvantaged decile).
Current usage in the NHS
Current NICE guidelines are described in Current guidelines.
Advising clinicians report that the guidelines are not always followed in typical clinical practice.
Symptomatic women presenting irrespective of gestational age will usually have the fFN test administered.
In addition, clinicians advise that transvaginal ultrasound scan is rarely used in routine practice owing to a
lack of trained staff available, experience or equipment availability.
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TABLE 1 Summary of index tests
Category
Actim® Partus (Medix Biochemica, Espoo,
Finland)26
PartoSure™ (Parsagen Diagnostics Inc., Boston,
MA, USA)27
Rapid fFN® 10Q Cassette Kit (Hologic, Inc.,
Marlborough, MA, USA)28
Gestational age From 22 weeks From 20+0 weeks to 36+6 weeks From 22+0 weeks to 35+6 weeks
Contraindications Ruptured membranes, vaginal bleeding (moderate
or heavy), amniotic fluid
Significant blood on the swab, within 6 hours of
vaginal disinfectant solutions or medicines.
Inaccurate results may be likely with previous
placenta previa or digital examination or in presence
of meconium, antifungal creams, suppositories,
lubricants, moisturisers, talcum powder or baby oil
Advanced cervical dilatation (≥ 3 cm), ruptured
membranes, cervical cerclage, placental abruption,
placenta previa (moderate) or vaginal bleeding
(heavy). Inaccurate results may be likely with sexual
intercourse, digital cervical examination or
transvaginal ultrasound scan and bacteria, bilirubin
and semen. A negative test result is still valid if in
the presence of semen
Instructions 1. Take a 10- to 15-second swab from the cervical
os during sterile speculum examination before
any other investigations
2. Swirl the swab vigorously in the specimen
extraction solution for 10–15 seconds
3. Place the dipstick in the specimen extraction
solution until the liquid reaches the result area
4. Remove dipstick from sample solution and lay
horizontally for 5 minutes
Negative results (one blue line) should be confirmed
at 5 minutes: highly unlikely that patient will deliver
within the next 2 weeks
Positive results (two blue lines) can be read as soon
as it becomes visible (if before 5 minutes). Risk of a
preterm delivery is elevated
1. Open the solvent vial and place in a vertical
position by holding by the cap with all the liquid
at the bottom
2. Remove sterile flocked swab from packaging and
with the patient lying on her back and by
holding the middle of the swab shaft, insert into
the vagina until the fingers contact the skin
(5–7 cm deep) for 30 seconds
3. Place the swab in the solvent vial and rinse by
rotating for 30 seconds
4. Insert test strip into the solvent for 5 minutes
Negative results (one line) should be confirmed at
5 minutes
Positive results (two lines) can be read as soon as it
becomes visible (if before 5 minutes)
1. Perform daily analyser quality control
2. During speculum examination, collect swab
sample from the posterior fornix of the vagina
and transfer to the transfer tube
3. Mix sample in transport tube prior to removing
swab expressing as much liquid as possible from
the swab to tube
4. Mix the patient sample by removing the fFN 10Q
Cassette from the foil pouch, enter necessary
information into analyser and insert the cassette
into analyser
5. When prompted pipette 200 µl of patient sample
into sample application
6. Wait 10 minutes (7 minutes of incubation and
2–3 minutes of analysis)
7. fFN concentration will be displayed
continued
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TABLE 1 Summary of index tests (continued )
Category
Actim® Partus (Medix Biochemica, Espoo,
Finland)26
PartoSure™ (Parsagen Diagnostics Inc., Boston,
MA, USA)27
Rapid fFN® 10Q Cassette Kit (Hologic, Inc.,
Marlborough, MA, USA)28
Kit components l One sterile polyester swab for specimen
collection
l One tube of specimen extraction solution
(0.5 ml). This phosphate-buffered solution
contains bovine serum albumin, protease
inhibitors and preservatives
l One dipstick in a sealed aluminium foil pouch
with desiccant
l One sterile flocked vaginal swab for specimen
collection
l One plastic vial with solvent solution. Solution
contains 0.9% NaCl, 0.05% NaN3 and 0.01%
Triton X-100
l One PartoSure test strip in foil pouch with
desiccant
l Rapid fFN 10Q Cassette Kit
l PeriLynx™ (Hologic, Inc., Marlborough, MA, USA)
analyser, printer, user manual and PeriLynx
QCette® (Hologic, Inc., Marlborough, MA, USA)
or Rapid fFN 10Q analyser, printer, user manual,
and Rapid fFN 10Q QCette
l Rapid fFN Control Kit (Hologic, Inc., Marlborough,
MA, USA)
l 200-µl pipette
Cost £15 per test excluding VAT £32 per test excluding VAT £35 per test excluding VAT
Storage The kit should be stored between 2 °C and 25 °C The kit should be stored in a dry place between
4 °C and 25 °C
The kit should be stored at room temperature
between 15 °C and 30 °C
Transport specimens at 2 °C to 25 °C, or frozen.
Specimens are stable for up to 8 hours at room
temperature
Specimens not tested within 8 hours of collection
must be stored refrigerated at 2 °C to 8 °C and
assayed within 3 days of collection, or frozen and
assayed within 3 months to avoid degradation of
the analyte. Specimens arriving frozen should be
subject to a single freeze–thaw cycle only
Test range The test has a limit of detection of 10 µg/l and a
measuring range of 10 to 8000 µg/l
The test has a limit of detection of 1 ng/ml and a
measuring range of 1–40,000 ng/ml
The test has a detection range of 0–500 ng/ml,
concentrations of > 500 ng/ml will be displayed as
> 500 ng/ml
User personnel The test is intended for professional use and results
must be interpreted in the light of other clinical
findings
The test is designed to be used in conjunction with
clinical assessment and by health-care professionals
The test is intended to be used in conjunction with
other clinical information
VAT, value-added tax.
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Anticipated costs associated with the intervention
The cost of the Rapid fFN 10Q System is usually £35 per test, not including value-added tax (VAT). The
cost per control is £40 and this is usually incurred twice per year for each site. Additional costs associated
with equipment maintenance and test consumables are negligible (request for information from NICE to
Hologic, Inc., 2017, personal communication from NICE).
The cost per Actim Partus test is £15, not including VAT. No other costs are associated with this test
(request for information from NICE to Alere Inc., 2017, personal communication from Alere Inc.).
The cost per PartoSure test (PAMG-1) is £32, not including VAT. No other costs are associated with this
test (request for information from NICE to Parsagen Diagnostics Inc., 2017, personal communication from
Parsagen Diagnostics Inc.).
Comparators
The two comparators from the NICE scope (for the clinical and cost-effectiveness reviews) are fFN, used at
a threshold of 50 ng/ml, and clinical assessment.
Fetal fibronectin used with a threshold of 50 ng/ml
Point-of-care, qualitative fFN tests currently in use in the UK include QuikCheck fFN™ (Hologic, Inc.,
Marlborough, MA, USA) and Rapid fFN for the TLiIQ® System (Hologic, Inc., Marlborough, MA, USA).29
QuikCheck fFN
QuikCheck fFN is a CE-marked, lateral flow immunoassay. The test kit includes a sterile applicator, test strip
and a tube containing an extraction buffer. Additional materials required are a test tube rack and timer.29
The specimen is obtained from the posterior fornix using the applicator provided. The tip of the applicator
is inserted into the extraction buffer and vigorously mixed for 10–15 seconds, the applicator tip is pressed
against the side of the tube to remove as much liquid as possible and discarded. The ‘dip area’ of the test
strip is suspended in the extraction mixture for 10 minutes and then removed. Two lines indicate a positive
result and a high risk of preterm delivery within 7–14 days; one line indicates a negative result and a low
risk of delivery within 7–14 days; if no lines appear, the test result is invalid. The detection limit of the test
is 50 ng/ml.29
The QuikCheck fFN test must be run within 15 minutes of the sample collection. The sample should be
obtained before digital examination is conducted as cervix disruption may affect the test results. The
presence of semen and gross vaginal bleeding may also affect the test results. The test is indicated for
women presenting with threatened preterm labour and intact amniotic membranes.29
Rapid Fetal Fibronectin for the TLiIQ System
Rapid fFN for the TLiIQ System (Hologic, Inc., Marlborough, MA, USA) is a CE-marked immunochromatographic
assay. The Rapid fFN test kit includes cassettes and a directional insert. Other materials required include a
200-µL pipette, a Rapid fFN Control Kit (includes positive control, negative control and directional insert)
and the TLiIQ System, which contains an analyser, printer and TLiIQ QCette.29
A cervicovaginal sample is obtained from the posterior fornix or the ectocervical region of the external
cervical os using a swab. The swab is rolled against the inside of the specimen transport tube to express
the liquid into the extraction buffer and the swab is then discarded. The TLiIQ analyser is set to internal
incubation mode and the cassette containing the sample is inserted. Thereafter, 200 µl of the patient
sample is dispensed into the sample application well of the Rapid fFN Cassette. After 20 minutes, the TLiIQ
analyser will display a result: positive, negative or invalid. The detection limit of the test is 50 ng/ml.29
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This test is indicated for use in routine prenatal visits between 22+0 weeks’ and 30+ 6 weeks’ gestation,
to assess the risk of delivery at ≤ 7 or ≤ 14 days from testing. Disruption to the cervix (i.e. through sexual
intercourse, digital vaginal examination or transvaginal ultrasound scan) may result in a false-positive result.
Douches, semen, white blood cells, red blood cells, bacteria and bilirubin may interfere with test results.
However, if the patient reports sexual intercourse within the previous 24 hours, a negative fFN test result is
still valid.29
Clinical assessment of symptoms alone
Clinical assessment consists of taking a clinical history, observations of the woman and unborn baby and a
speculum examination. See Current guidelines for more details.
Care pathways
Clinical assessment and use of the biomarker tests aid clinicians in their decisions regarding whether
women presenting with signs and symptoms of preterm labour can be safely sent home or need to be
admitted to hospital for treatment to delay birth and improve neonatal outcomes.24 Typically, the results
would be used in combination with clinical judgement. For example:
l If the test result is negative and the symptoms of preterm labour have settled, the woman would be
discharged home with routine follow-up in the community and advised to return if symptoms reappear.
l If the test result is negative but symptoms of preterm labour continue, the woman would be admitted
and monitored and symptoms treated as appropriate and monitored. If symptoms were managed
successfully, the woman would be discharged home.
l If the test result is positive, the woman would be admitted and symptoms managed as appropriate
and monitored.
Once a woman has been diagnosed with threatened preterm labour, she will typically be offered tocolytic
therapy, corticosteroids and magnesium sulphate.24
Tocolytic therapy
Tocolytic therapies increase the latency period for up to 48 hours. The aim of this therapy is to allow time
for neonatal transfers and to complete the course of antenatal corticosteroids (ACSs).30 There are many
classes of tocolytic drugs with different mechanisms of action.30
The NICE guidelines24 recommend nifedipine for women between 24+ 0 and 33+6 weeks’ gestation in
suspected or diagnosed labour with intact membranes. If nifedipine is contraindicated, NICE recommends
oxytocin receptor antagonists [e.g. Atosiban (Sun Pharmaceuticals UK Ltd)] for tocolytic therapy.
Our clinical advisors suggest that tocolytic therapy is not commonly used in routine clinical practice.
This may be attributable to recent evidence on the potential harms to the fetus and infant.30,31
Antenatal corticosteroids
Antenatal corticosteroids {e.g. dexamethasone [Alliance Healthcare (Distribution) Ltd] or betamethasone (AAH
Pharmaceuticals Ltd)} are prescribed in cases of threatened preterm labour to stimulate fetal lung development
to reduce infant mortality and morbidity.32 Following administration of steroids, there is a window within which
the steroids appear to be most beneficial for the infant (Figure 1C, Norman et al.).33 The primary documented
negative effect of giving steroids is a negative reduction in birthweight of approximately 100 g.34
The National Institute for Health and Care Excellence currently recommends ACSs for women between 26+0
and 33+6 weeks’ gestation in suspected, diagnosed or established preterm birth, PPROM or undergoing
planned preterm delivery. ACSs should be considered for extremely preterm (between 24+ 0 and 25+6
weeks’ gestation) and near-term (34+0 and 35+ 6 weeks’ gestation) women in suspected, diagnosed and
established preterm labour, PPROM or undergoing iatrogenic deliveries.24 However, evidence regarding the
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effectiveness of corticosteroid treatment at very low gestational ages remains uncertain.24 NICE recommends
that clinicians should discuss the benefits and risks associated with ACSs with the patient and their family.
Repeat doses are contentious owing to possible risks, although this needs to be weighed against potential
benefits of reduced RDS and serious adverse infant outcomes.32,35 For this reason, some cases of repeat
dosing may be acceptable depending on the interval since last dose, gestational age and likelihood of
delivery within 48 hours.24
Magnesium sulphate
Magnesium sulphate is a neuroprotective agent that significantly reduces neurological morbidities such as
cerebral palsy in preterm infants.36
The National Institute for Health and Care Excellence recommends magnesium sulphate for women
at 24+0 to 29+6 weeks’ gestation in established labour or with iatrogenic delivery planned within 24 hours.
Magnesium sulphate should also be considered for women between 30+0 and 33+6 weeks’ gestation. A 4-g
intravenous bolus dose of magnesium sulphate should be administered over 15 to 20 minutes, followed by
an intravenous infusion of 1 g per hour for 24 hours or until delivery. Patients should be routinely monitored
for signs of magnesium toxicity.
Outcomes
The accuracy of biomarker testing for predicting preterm labour has been evaluated against the reference
standard of preterm delivery within 48 hours or 7 days. Clinically important outcomes relevant to test
accuracy include:
l Sensitivity – the probability of correctly identifying someone who will deliver preterm:
Sensitivity =
True positive
True positive + False negative
(1)
l Specificity – the probability of correctly identifying someone who will not deliver preterm:
Specificity =
True negative
False positive + True negative
(2)
l Likelihood ratio (LR) – the likelihood of a given test result in a patient who has a preterm delivery
compared with the likelihood of that same result in a patient who does not deliver preterm.
¢ Likelihood ratio for a positive test result (LR+) – how much more often a positive test result occurs
in people who do deliver preterm compared with those who do not:
Postive LR =
P(Test + ve j preterm)
P(Test + ve j not preterm) =
Sensitivity
1−Specificity
(3)
l Likelihood ratio for a negative test result (LR–) – how much less likely a negative test result is in people
with preterm delivery compared with those without preterm delivery:
Negative LR =
P(Test−ve j preterm)
P(Test−ve j not preterm) =
1−Sensitivity
Specificity
(4)
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l Positive predictive value (PPV) – the probability of someone with a positive result actually having a
preterm delivery:
PPV =
True positive
True positive + False positive
(5)
l Negative predictive value (NPV) – the probability of someone with a negative test result actually not
having a preterm delivery:
NPV =
True negative
True negative + False negative
(6)
l Diagnostic yield (also known as test positivity rate or apparent prevalence) – the number of positive test
results divided by the number of samples.
l Concordance – the proportion of cases in which the result of the test agrees with the clinical outcome.
l Prevalence – the proportion of women actually having a preterm delivery.
l Test failure (non-informative test result) rate.
l Time (required) to (obtain a) test result.
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Chapter 2 Assessment of test accuracy
This report contains reference to confidential information provided as part of the NICE appraisal process.This information has been removed from the report and the results, discussions and conclusions of the
report do not include the confidential information. These sections are clearly marked in the report.
Methods for reviewing test accuracy
The diagnostic accuracies of PartoSure, Actim Partus and Rapid fFN 10Q Cassette Kit [at thresholds other
than 50 ng/ml, referred to in the remainder of this report as quantitative fFN (qfFN)] were assessed by
conducting a systematic review of the research evidence for these three index tests. This review was
undertaken following the general principles published by the University of York Centre for Reviews and
Dissemination.37 The protocol was registered on PROSPERO (reference number CRD42017072696).
Methods of the systematic review
The aim of this systematic review was to identify and summarise the diagnostic test accuracy (DTA) data
for PartoSure, Actim Partus and qfFN (at thresholds other than 50 ng/ml) from test accuracy studies that
provide data for one or more of these index tests.
Identification of studies
Study sources and searches
To identify studies, the following bibliographic databases were searched from inception until July 2017
(the search was conducted in July 2017): MEDLINE (R), MEDLINE(R) Epub Ahead of Print, MEDLINE In-Process
& Other Non-Indexed Citations, MEDLINE (R) Daily and EMBASE (all via Ovid), Cumulative Index to Nursing
and Allied Health Literature (CINAHL) (via EBSCOhost); BioSciences Information Service and Web of Science
(via Clarivate Analytics) and The Cochrane Library [Cochrane Database of Systematic Reviews, Cochrane
Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE), Health
Technology Assessment (HTA) database and NHS Economic Evaluation Database (NHS EED) (all via Wiley
Interface)]. The search strategies were developed by a senior information specialist (CC), and comprised
terms designed to identify the index tests. Methodological filters for test accuracy studies were not used to
limit the study designs retrieved as these have been shown to reduce sensitivity38 and also because the search
results were used to screen studies for the other two reviews described in this report (see Chapters 3 and 4).
Search results were limited to English-language studies. The full search strategies for each database are
reproduced in Appendix 1. The search results were exported to EndNote X8 [Clarivate Analytics (formerly
Thomson Reuters), Philadelphia, PA, USA] and deduplicated using automatic and manual checking.
Additional sources were searched:
l Systematic reviews identified by the bibliographic database searches were screened for includable
studies. For the purpose of this review, a systematic review was defined as one that had a focused
research question; explicit search criteria that are available to view; explicit inclusion/exclusion criteria;
sufficient data on included and excluded studies to populate a PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) flow diagram; a critical appraisal of included studies, including
consideration of internal and external validity of the research; and a synthesis of the included evidence
(narrative or quantitative).
l Trial registries were searched via the ClinicalTrials.gov website [https://clinicaltrials.gov/ct2/home
(accessed July 2017)] and ISRCTN (International Standard Randomised Controlled Trial Number)
[www.isrctn.com/editAdvancedSearch (accessed July 2017)] using terms designed to identify the index
tests (see Appendix 1).
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l Google Advanced Search (Google Inc., Mountain View, CA, USA) was used to conduct web searching
(September 2017), using terms designed to identify the index tests (see Appendix 1). For each term
searched using Google Advanced Search, the first 50 hits were screened.
l Items included after full-text screening were forward citation chased and screened using Scopus (Elsevier).
l The reference lists of included studies were screened.
l The industry submissions to NICE were cross-checked for additional studies.
Study selection
Relevant studies were screened in two stages. First, titles and abstracts returned by the search strategy were
examined independently by two reviewers (two of JVC, SD, MB and HC) and screened for possible inclusion,
using prespecified inclusion and exclusion criteria (see Inclusion and exclusion criteria). Disagreements
were resolved by discussion within the review team. Full texts of studies included at the title and abstract
screening stage were obtained, as were full texts of studies identified from systematic reviews, from trial
registry searches, from forward and backward citation chasing, from references provided by the companies
and from web searching. Two researchers (two of JVC, SD, MB and HC) independently examined full texts
for inclusion or exclusion. Disagreements were again resolved by discussion within the review team.
Inclusion and exclusion criteria
Population
In line with the NICE scope,12 studies were included if they recruited pregnant women with signs and
symptoms of preterm labour who were not in established labour and who had intact amniotic membranes.
Studies were eligible regardless of whether they were based on samples that were at high or low risk for
preterm labour. Studies were also eligible regardless of whether or not it was stipulated that the recruited
population had access to transvaginal ultrasound scans. There were no specific inclusion criteria relating to
the number of weeks of gestation of the women recruited; however, the study was required to define its
population as preterm. The unit of assessment was individual women with a single result for each test.
Initially, studies were included only if all participants were expecting a singleton pregnancy. However,
owing to the lack of evidence, a protocol amendment was made to include studies in which twin or
multiple pregnancies were included but made up ≤ 20% of the total population recruited. We are not
aware of any published evidence to suggest that multifetal pregnancies would alter the DTA of any of
the tests.
Index tests
In accordance with the NICE scope,12 the index tests to be considered were:
l PartoSure (with or without a clinical assessment)
l Actim Partus (with or without a clinical assessment)
l Rapid fFN 10Q Cassette Kit (qfFN), used with a threshold other than 50 ng/ml (with or without a
clinical assessment).
Studies were eligible for inclusion if one or more index test was assessed against a reference standard.
Reference standard
Studies using one or more of the following reference standards were eligible for inclusion:
l preterm delivery within 48 hours or within 7 days
l clinical assessment of symptoms alone
l fetal fibronectin at a threshold of 50 ng/ml (qualitative or quantitative test).
ASSESSMENT OF TEST ACCURACY
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In addition, studies that provided test accuracy data by comparing the results of one index test with
another (i.e. by using one of the index tests as a reference standard) were also eligible for inclusion. It was,
however, expected that most studies would use preterm delivery within 48 hours, or within 7 days, as the
reference standard.
Outcomes
In accordance with the NICE scope,12 the outcomes assessed for index tests were:
l sensitivity – true positive/(true positive + false negative)
l specificity – true negative/(false positive + true negative)
l likelihood ratio for positive test result
l likelihood ratio for negative test result
l positive predictive value – true positive/(true positive + false positive)
l negative predictive value – true negative/(true negative + false negative)
l diagnostic yield (also known as test positivity rate or apparent prevalence)
l concordance
l prevalence (or incidence) of preterm delivery within 7 days and/or within 48 hours
l test failure (non-informative test result) rate
l time to test result.
Study design
Single-gate prospective or retrospective diagnostic studies with random or consecutively recruited participants
were considered the optimal design for evaluating test accuracy of the index tests and were, therefore,
eligible for inclusion. Ideally, studies assessing two or more index tests in the same population were sought,
but studies assessing the accuracy of only one index test were also included. Studies assessing an index test
and a test out of scope would be eligible for inclusion providing that data were reported specifically for all
women receiving the index test. Two-gate diagnostic studies were also eligible for inclusion.
Studies in which the index test was conducted within 7 days of the reference standard were included.
In addition, a protocol amendment was made to include studies using frozen samples (i.e. use not in line
with clinical practice), even when the test was analysed outside the window stipulated in the manufacturers’
guidelines owing to a lack of evidence.
Studies were eligible for inclusion in the DTA review whether or not the index test results were used in the
clinical management of patients.
We did not consider unpublished data without sufficient study methodology for quality appraisal.
Data extraction strategy
Data were extracted by one reviewer (SD) using a standardised data extraction form and checked by a
second reviewer (JVC). Disagreements were resolved by discussion, with involvement of a third reviewer
(HC) as necessary. Data were then transferred to standardised tables.
Critical appraisal strategy
The methodological quality of the studies was assessed by one reviewer (SD) and judgements were
checked by a second reviewer (HC), in accordance with criteria specified by phase 3 of the QUADAS-2 tool
(see Appendix 2).39 Any disagreements were resolved by discussion, with involvement of a third reviewer
(JVC) as necessary.
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Methods of data synthesis
For all included studies, sensitivity, specificity, positive and negative predictive value, positive and negative
LR, prevalence, concordance and diagnostic yield for delivery within 48 hours and 7 days were calculated
from true-positive, true-negative, false-positive and false-negative values. Where the raw values were not
provided, they were derived using back-calculation from other suitable available data. Summary receiver
operating characteristic (ROC) plots were generated to provide graphical depiction of the sensitivity and
specificity data. These were produced for each test separately against the 48-hour and 7-day reference
standards, and for qfFN they were also produced separately for each testing threshold.
Summary ROC plots were generated subject to a minimum of three studies per plot. In accordance with
Stata® requirements, the minimum number of studies for a diagnostic meta-analysis was four. Whenever
this requirement was met, consideration was given to conducting meta-analysis. According to the
Cochrane DTA handbook,40 heterogeneity cannot be assessed for diagnostic meta-analysis in the same
way as for meta-analysis of interventions, and no quantitative summary statistic for heterogeneity can
be derived.
Meta-analysis against the 7-day delivery reference standard for Actim Partus was conducted using the
metandi command for sensitivity and specificity. Meta-analysis against the 48-hour delivery reference standard
for Actim Partus and against the 7-day reference standard for PartoSure was conducted using a mixed-effects
multilevel logistic regression to refine the parameters used in metandi to improve model convergence in
the presence of a low proportion of preterm births in the study by Werlen et al.41 No meta-analysis was
undertaken for qfFN at any threshold or for the 48-hour reference standard for PartoSure.
Stata® version 14.11 (StataCorp LP, College Station, TX, USA) software was used for all statistical analysis.
Graphs were made using Stata or Review Manager version 5.3 (Nordic Cochrane Centre, Copenhagen)
software.
Results of the systematic review
In this section, the results of the systematic review of PartoSure, Actim Partus and qfFN are presented.
Studies providing DTA data for one or more of these index tests are included (see Inclusion and exclusion
criteria for specific details on inclusion and exclusion criteria).
Overview of the quantity and quality of research available
The searches retrieved a total of 2619 unique titles and abstracts. A total of 2177 articles were excluded,
based on screening titles and abstracts. The remaining 442 articles were requested as full texts for more
in-depth screening.
Of the 442 articles retrieved as full texts, 415 were excluded. The primary reasons for exclusion were use
of an irrelevant test, typically qualitative fFN (n = 129), the study design (n = 59), that outcomes did not
match the review inclusion criteria (n = 31) or that the article was an abstract that both had insufficient
information to be included in the review and was unconnected to any of the included studies (n = 108).
Abstracts were included if they were connected (by reporting data from the same study) to a full-text
included study. The bibliographic details of studies retrieved as full papers and subsequently excluded,
along with the reasons for their exclusion, are detailed in Appendix 3. Additional tables (see Tables 28–30)
are provided in Appendix 3, listing all the citations provided by the industry to NICE along with whether or
not the citation was included, and, if not, the reason for exclusion. After screening relevant systematic
reviews (n = 11; see Appendix 3, Included systematic reviews), and forward and backward citations of the
included studies, no further new included studies were identified. Twenty studies from 31 citations met the
review inclusion criteria. The process of study selection is shown in Figure 2.
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Ongoing trials
A search of trial registries and company submissions identified seven ongoing trials that may be relevant to
this review of DTA. These trials are summarised in Table 2.
Four of the ongoing trials are based in the UK, two of which are planning to enrol > 1000 participants
(ISRCTN41598423, n = 2100, and Integrated Research Application System ID 111142, n = 1181). However,
it was not possible to include data from these ongoing trials in this review of test accuracy.
Description of the included studies
Characteristics of the included studies are summarised in Table 3. Two studies, Assessment of Perinatal
Outcome after Sustained Tocolysis in Early Labour (APOSTEL-1)42,43 and Hadzi-Lega et al.,44 assessed the
DTA of two different index tests in the same population: APOSTEL-142,43 assessed both Actim Partus and
qfFN whereas the study by Hadzi-Lega et al.44 assessed Actim Partus and PartoSure. APOSTEL-142,43 was
one of the larger studies (n = 350), conducted in 10 centres around the Netherlands, whereas the study by
Hadzi-Lega et al.44 was smaller (n = 57), from one centre in Macedonia.
A further 14 studies45–58 assessed the DTA for Actim Partus only. Three studies41,59–61 assessed PartoSure
only and one62 assessed qfFN only.
Records identified through
database searching
(n = 4767)
Additional records identified
through other sources
(n = 371)
Records after duplicates removed
(n = 2623)
Records screened
(n = 2623)
Full-text articles assessed
for eligibility
(n = 446)
Studies included in
quantitative synthesis
(n = 31, 20 studies
from 31 citations)
Records excluded
(n = 2177)
Full-text articles excluded,
with reasons
(n = 415)
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•  Abstract, n = 108
•  Comparator, n = 4
•  Design, n = 59
•  Language, n = 16
•  Outcome, n = 31
•  Population, n = 18
•  Systematic reviews, n = 11
•  Test, n = 129
•  Unobtainable, n = 39
FIGURE 2 Summary of the selection process.
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TABLE 2 Ongoing trials
Study Title Sponsor Status Location
Estimated
enrolment Test(s)
NCT01987024 Advantage of Detection of phIGFBP-1 to
Reduce Hospitalization Time for Stable
Patients With a Risk of Preterm Labour
Assistance Publique
Hôpitaux De Marseille
Unknown France 420 Actim Partus
NCT01868308 Screening To Obviate Preterm Birth (STOP) University of Pennsylvania Completed USA 568 fFN
NCT02853656 Time to Delivery of Preterm Birth Basildon and Thurrock
University Hospitals NHS
Foundation Trust
Currently recruiting UK 242 Actim Partus and fFN
NCT02904070 Interest of Placental Alpha-microglobulin-1
Detection Test to Assess Risk of Premature
Delivery in Reunion Island (PARTOSURE-OI)
Centre Hospitalier
Universitaire de La
Réunion
Currently recruiting Réunion Island,
France
300 PartoSure, Actim
Partus and fFN
ISRCTN41598423 Can a test of preterm labour (qfFN) help
diagnosis and clinical decision making?
(QUIDS and QUIDS-2)
HTA programme (UK) Currently recruiting UK 2100 PartoSure, Actim
Partus and fFN
IRAS ID 111142 Threatened preterm labour: a prospective
cohort study of a clinical risk assessment
tool and a qualitative exploration of
women’s experiences of risk assessment
and management (PETRA)
King’s College London Currently recruiting UK 1181 fFN
(Confidential information
has been removed)
(Confidential information
has been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
IRAS, Integrated Research Application System.
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TABLE 3 Study characteristics
Study (first
author/study name
and year)
Other tests
used
Number included
(number recruited)
Country
(number of
centres)
Definition of
preterm labour
symptoms
Weeks of
gestation
Dilatation
threshold for
exclusion Other exclusion criteria
Study assessing Actim Partus and qfFN
APOSTEL-1 (2016)42,43 Cervical length 350 (714) The Netherlands
(10)
Uterine contractions
(> 3/30 minutes),
abdominal pain,
back pain and vaginal
bleeding
24–34 > 3 cm Contraindications for tocolysis, Iatrogenic
deliveries and tocolytic treatment prior to
testing
Study assessing Actim Partus and PartoSure
Hadzi-Lega (2017)44 Cervical length 57 (72) Macedonia (1) Uterine contractions
and abdominal pain
22–34+6 > 3 cm Antepartum haemorrhage, cervical
cerclage and multiple gestations
Actim Partus
Abo El-Ezz (2014)45 N/A 57 (80) Kuwait (2) Uterine contractions
(≥ 8/hour), back pain,
pelvic pressure, vaginal
discharge and 50%
effacement
24–34 > 3 cm Cervical cerclage, chorioamnionitis,
fetal abnormalities, intrauterine growth
restriction, multiple gestations, placenta
praevia, prior cervical examination, sexual
intercourse in previous 24 hours, uterine
anomalies and vaginal bleeding
Altinkaya (2009)46 N/A 105 (NR) Turkey (1) Uterine contractions 24–34 ≥ 2 cm Fetal abnormalities, history of preterm
delivery, intrauterine growth restriction,
multiple gestations, preeclampsia,
smokers, uterine anomalies and vaginal
bleeding
Azlin (2010)47 Cervical length 51 (51) Malaysia (NR) Uterine contractions 24–36 ≥ 3 cm Abruptio placenta, cervical cerclage,
cervical incompetence, multiple
gestations and placenta praevia
Brik (2010)48 N/A 276 (325) Spain (1) Uterine contractions,
abdominal pain, back
pain, leaking of fluid
and other
24–34 > 3 cm Abruptio placenta, cervical cerclage, fetal
abnormalities, fetal distress and vaginal
bleeding (active labour)
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TABLE 3 Study characteristics (continued )
Study (first
author/study name
and year)
Other tests
used
Number included
(number recruited)
Country
(number of
centres)
Definition of
preterm labour
symptoms
Weeks of
gestation
Dilatation
threshold for
exclusion Other exclusion criteria
Cooper (2012)49 Qualitative fFN
(unclear which
test)
349 (366) Canada (2) Symptoms judged
by physician to be
indicative of labour
24+0 to
34+6
NR Antepartum haemorrhage and
chorioamnionitis (active labour)
Danti (2011)50 Cervical length 60 (102) Italy (1) Uterine contractions
(≥ 4/20 minutes)
24+0 to
32+6
> 3 cm Abruptio placenta, cervical cerclage,
fetal abnormalities, intrauterine growth
restriction, multiple gestations, placenta
praevia, preeclampsia, uterine anomalies
and vaginal bleeding
Eroglu (2007)51 QuikCheck fFN,
cervical length
51 (51) Turkey (1) Uterine contractions
(> 10/hour)
24–35 ≥ 3 cm Abruptio placenta, fetal abnormalities,
intrauterine growth restriction,
multiple gestations, placenta praevia,
preeclampsia, sexual intercourse in
previous 24 hours, uterine anomalies
and vaginal bleeding
Goyal (2016)52 Cervical length 60 (95) India (1) Uterine contractions
(> 4/20 minutes) and
abdominal pain
24–36 NR Fetal abnormalities, fetal growth
restrictions, preeclampsia, multiple
gestations and vaginal bleeding
Lembet (2002)53 N/A 36 (36) Turkey (1) Uterine contractions
(> 10/hour)
20–36 N/A Fetal abnormality, intrauterine growth
restriction, preeclampsia, multiple
gestations, uterine anomalies and vaginal
bleeding
Riboni (2011)54 fFN by ELISA 210 Italy (2) Uterine contractions
(> 10/hour)
24–34 > 2 cm Fetal abnormalities, multiple gestations,
placenta praevia, prior cervical
examination, sexual intercourse in
previous 24 hours, uterine anomalies and
vaginal bleeding
Tanir (2009)55 N/A 68 (121) Turkey (1) Uterine contractions
(> 4/20 minutes),
changes in cervix, back
pain and increased
discharge
24–37 ≥ 3 cm Asthma, cervical cerclage, diabetes
mellitus, digital examination in previous
24 hours, hyperthyroidism, multiple
gestations, preeclampsia, sexual
intercourse in previous 24 hours,
tocolytic treatment prior to testing,
vaginal bleeding and vaginal douche in
previous 24 hours
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Study (first
author/study name
and year)
Other tests
used
Number included
(number recruited)
Country
(number of
centres)
Definition of
preterm labour
symptoms
Weeks of
gestation
Dilatation
threshold for
exclusion Other exclusion criteria
Ting (2007)56 Qualitative fFN
(unclear which
test)
94 (108) Singapore (1) NR 24–34 ≥ 3 cm Cervical cerclage, chorioamnionitis, fetal
asphyxia, fetal abnormalities, intrauterine
growth restrictions, multiple gestations,
placenta praevia and preeclampsia
Tripathi (2016)57 QuikCheck fFN 468 (550) India (1) Uterine contractions
(> 1/10 minutes) and
labour pains
28+1 to
36+6
> 3 cm Blood-mixed cervical secretions,
diarrhoea, prepartum haemorrhage,
previous preterm delivery, sexual
intercourse in previous 24 hours, urinary
tract infection and vaginal leakage
Vishwekar (2017)58 N/A 30 (NR) India (1) Uterine contractions
and vaginal discharge
28–37 NR Blood-mixed cervical secretions, fetal
distress, hypertension and intrauterine
growth restrictions (active labour)
PartoSure
Bolotskikh (2017)59 Cervical length 99 (100) Russia (1) Uterine contractions,
abdominal pain, back
pain, pelvic pressure,
menstrual-like
cramping and
diarrhoea
22+0 to
36+6
> 3 cm Maternal age < 18 years, multiple
gestations, prior cervical examination,
placenta praevia, symptoms unrelated
to threatened preterm delivery (e.g.
trauma), tocolytic treatment prior to
testing and vaginal bleeding
Nikolova (2014/15)60,61 Cervical length,
QuikCheck fFN
203 (219) Macedonia and
Russia (2)
Uterine contractions,
abdominal pain and
pelvic pressure
20+0 to
36+6
> 3 cm Cervical cerclage, placenta praevia,
maternal age < 18 years and multiple
gestations
Werlen (2015)41 N/A 41 (42) France (1) Uterine contractions
and cervical changes
24–34 > 3 cm Blood-mixed cervical secretions, multiple
gestations and vaginal infection
qfFN
Bruijn (2016)62 Cervical length 455 (484) The
Netherlands,
Switzerland,
Belgium,
Germany and
Austria (10)
Uterine contractions
(> 3/30 minutes),
abdominal pain, back
pain and vaginal
bleeding
24–34 > 3 cm Contraindications for tocolysis, fetal
distress, iatrogenic deliveries, tocolytic
treatment prior to testing and triplet or
higher gestations
ELISA, enzyme-linked immunosorbent assay; N/A, not applicable; NR, not reported.
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For Actim Partus, study sizes ranged from 30 in Vishwekar et al.58 to 468 in Tripathi et al.57 and covered
the following countries: Kuwait,45 Turkey,46,51,53,55 Malaysia,47 Spain,48 Canada,49 Italy,50,54 India52,57,58 and
Singapore.56 The three studies assessing PartoSure were conducted in Russia,59 Macedonia60,61 and France41
and the study size ranged from 41 in Werlen et al.41 to 203 in Nikolova et al.61 Finally, the Bruijn study62
assessed qfFN only and recruited 455 participants from 10 centres across Austria, Belgium, Germany, the
Netherlands and Switzerland.
Key differences between studies
It was notable that the prevalence rates of preterm birth differed greatly between studies (see Tables 6
and 7). In addition, there were differences between studies in the mode of delivery for included women.
The participant inclusion/exclusion criteria also differed between studies. For example, although all studies
included women presenting with symptoms of preterm labour with intact membranes, the definition of
‘preterm’ (i.e. the number of weeks of gestation) differed between studies. The inclusion/exclusion criteria
of the studies also differed regarding the presenting symptoms of the women, the proportion of women
with singleton gestations, the risk status of included women, dilatation thresholds applied and other
specific exclusion criteria.
Differences between studies in prevalence of preterm birth
There was clear variation between studies regarding the prevalence of the reference standard (i.e. the
prevalence of preterm birth within 7 days and within 48 hours). Across all 20 studies, prevalence of preterm
birth within 7 days ranged from 1.7% [95% confidence interval (CI) 0.6% to 3.7%] in Cooper et al.49 to
73.3% (95% CI 60.3% to 83.9%) in Goyal et al.52 Both of these studies assessed the test accuracy of Actim
Partus. Therefore, the studies assessing Actim Partus had a larger range of prevalence (of preterm birth
within 7 days) than the studies assessing PartoSure and qualitative fFN. However, in the studies assessing
PartoSure, prevalence of preterm birth within 7 days still ranged widely (from 2.4%, 95% CI 0.1% to 12.9%
in Werlen et al.41 to 17.2%, 95% CI 12.3% to 23.2% in Nikolova et al.61). In the studies assessing qfFN,
prevalence of preterm birth within 7 days was slightly higher in APOSTEL-142,43 than in EUIFS62 (19.7%,
95% CI 15.7% to 24.3% vs. 10.5%, 95% CI 7.9% to 13.7%, respectively).
Seven studies provided DTA data for the index tests against preterm birth within 48 hours.41,48,52,53,56–58
Across these seven studies, the prevalence of preterm birth within 48 hours ranged from 2.4% (95% CI
0.1% to 12.9%) in Werlen et al.41 to 58.3% (95% CI 44.9% to 70.9%) in Goyal et al.52 The study by
Werlen et al.41 was the only study assessing PartoSure against preterm birth within 48 hours, with the
other six studies48,52,53,56–58 assessing Actim Partus. The lowest prevalence of preterm birth within 48 hours
within these six Actim Partus studies was 5.3% (95% CI 1.7% to 12.0%) in Ting et al.56
These differences in prevalence displayed between studies are probably attributable to differences in the
populations recruited into the studies (e.g. differences in gestational age and in presenting symptoms of
preterm labour; see Differences between studies in inclusion/exclusion criteria) and will also probably have
an impact on the DTA data presented in Results of quantitative data synthesis (test accuracy data) and the
generalisability of these data to the NHS in England.
Differences between studies in mode of delivery
It is important to know whether women who had non-spontaneous deliveries within the time frame of the
reference standard were included or excluded from the test accuracy data; if iatrogenic delivery takes place
within this time frame, it remains unclear whether or not a spontaneous delivery may have occurred, which
thus makes it impossible to accurately assess the reference standard in these women. Nine of the included
studies41,45,46,50–52,54,56,57 did not report the mode of delivery (i.e. whether or not birth was spontaneous, or
whether or not there were any planned caesarean sections or inductions).
The other 11 studies42–44,47–49,53,55,58–62 provided some data regarding mode of delivery (Table 4). Four of
these studies (APOSTEL-1,42,43 Hadzi-Lega et al.,44 EUIFS62 and Bolotskikh et al.59) reported that women who
had a non-spontaneous delivery within the time frame of the reference standard were excluded from the
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TABLE 4 Participant characteristics
Study (first
author/study name
and year) Participants (n)
Maternal age
(years), mean
(SD) [range]
Gestational age
at presentation
(weeks), mean
(SD) [range]
Multiple
gestations,
n (%)
BMI (kg/m2),
mean (SD)
Gravidity,
mean (SD) Parity, mean (SD)
Previous preterm
delivery, n (%)
Previous
miscarriage/
stillbirth, n (%) Mode of delivery, n (%)
Study assessing Actim Partus and qfFN
APOSTEL-142,43 350 29.9 (5.4) 29.0 (2.7) 71 (20) 23.1 (4.3) NR NR 79 (23) NR Non-spontaneous deliveries within
reference-standard time frame
excluded
Study assessing Actim Partus and PartoSure
Hadzi-Lega (2017)44 57 Median 27
[IQR 23.0–30.5]
Median 31
[IQR 28.8–32.4]
0 (0) NR NR NR NR NR Non-spontaneous deliveries within
reference-standard time frame
excluded
Actim Partus
Abo El-Ezz (2014)45 57 27.40 (6.1) 29.70 (2.5) 0 (0) NR NR 2.91 (NR) NR NR NR
Altinkaya (2009)46 105
a
24.52 (5.16) 29.63 (4.4) 0 (0) 24.1 (3.5) NR 0.65 (0.95) 0 (0) NR NR
Azlin (2010)47
phIGFBP-1 (+) 7 29.57 (3.99) 32.96 (3.07)b 0 (0) NR 2.43 (1.27) 1.00 (1.16) NR 0.43 (1.13) l Spontaneous: 36 (70.6)
l Elective caesarean section:
7 (13.7)
l Emergency caesarean section:
4 (7.8)
l Unknown: 4 (7.8)
phIGFBP-1 (–) 44 28.34 (4.32) 32.38 (2.64)
b
0 (0) NR 2.59 (1.59) 0.91 (0.96) NR 0.68 (1.25)
Brik (2010)48 276 29.4 (5.9)
[15–46]
29.9 (2.8)
[23–34]
0 (0) NR NR Nulliparous = 58.3% 26 (9.4) NR Unclear
Cooper (2012)49 349 29 (5.0)
[17–46]
Median 29+6
(4+6) [IQR 24–34]
20 (5.7)
c
NR NR Nulliparous = 43.3% 56 (16.1) NR l Spontaneous: 182 (52.1)
l Operative: 52 (14.9)
l Caesarean section: 115 (33.0)
Danti (2011)50 60
d
Median 31
[IQR 28–34]
Median 30.0
[IQR 28.7–31.4]
0 (0) NR NR Nulliparous = 63% NR NR NR
Eroglu (2007)51 51
a
27.6 (3.5) 29.5 (2.6) 0 (0) 22.6 (2.9) NR 0.4 (0.6) 2 (3.9) 2 (3.9) NR
Goyal (2016)52 60 29.92 (5.14) 32.84 (3.24) 0 (0) 23.61 (2.45) NR 0.9 (0.3) 18 (30) NR NR
Lembet (2002)53 36
a
28.4 (5.3) 31.3 (3.3) 0 (0) < 19.6, n = 7;
> 26, n= 29
2.2 (1.6) 0.7 (1.1) 7 (16) 3 (7) Unclear
Riboni (2011)54 210 28.7 (NR) 0 (0) NR NR NR NR NR
Delivering term 30.4 (5.6) 23.36 (3.99)
Delivering preterm 30.7 (5.1) 22.72 (3.7)
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TABLE 4 Participant characteristics (continued )
Study (first
author/study name
and year) Participants (n)
Maternal age
(years), mean
(SD) [range]
Gestational age
at presentation
(weeks), mean
(SD) [range]
Multiple
gestations,
n (%)
BMI (kg/m2),
mean (SD)
Gravidity,
mean (SD) Parity, mean (SD)
Previous preterm
delivery, n (%)
Previous
miscarriage/
stillbirth, n (%) Mode of delivery, n (%)
Tanir (2009)55
phIGFBP-1 (+)e 25 28.4 (4.6) 30.6 (3.5) 0 (0) 25.1 (3.5) 2.1 (1.3) 0.7 (0.3) NR 1.8 (0.8) l Caesarean section: 18 (72.0)f
l Vaginal: 16 (64)
g
phIGFBP-1 (–)
g
43 28.4 (5.3) 29.6 (2.3) 0 (0) 26.9 (4.4) 2.2 (1.3) 0.6 (0.4) NR 1.5 (0.5) l Caesarean section: 20 (46)
f
l Vaginal: 14 (33)
g
Ting (2007)56
phIGFBP-1 (+)e 28 27 30.5 0 (0) NR 2 0.5 NR NR NR
phIGFBP-1 (–)
g
66 27 32.2 0 (0) NR 2 1 NR NR
Tripathi, 201657 468 NR NR NR NR NR NR 0 (0) NR NR
Vishwekar 201758 25 [19–35] 2 (6.7) ‘Normal limits’ NR NR 4 (13.3) NR Unclear
phIGFBP-1 (+) 14 32
phIGFBP-1 (–) 16 32.5
PartoSure
Bolotskikh (2017)59 99 (100) Median 25
[IQR 23–38]
Median 32
[IQR 29–36]
0 (0) NR NR Nulliparous = 32% 15 (15) 27 (27) Non-spontaneous deliveries within
reference-standard time frame
excluded
Nikolova (2014 and
2015)60,61
203 Median 27
[range 18–43]
Median 32.0
[range
20.5–36.6]
0 (0) NR NR NR NR NR Patients with non-spontaneous
delivery excluded (n= 8); unclear
when these happened
Werlen (2015)41 41 27.6 (5.3)
[18–39]
29.5 (2.91)
[24–34]
0 (0) NR NR 0.54 (0.71) NR NR NR
qfFN
EUIFS62 455 29.5 (5.2) Median 29.6
[IQR 26.7–31.6]
67 (15) Median 24.5
(IQR 22.0–28.0)
(n= 429)
NR Nulliparous = 55% 72 (16) NR Non-spontaneous deliveries within
reference-standard time frame
excluded
IQR, interquartile range; NR, not reported; SD, standard deviation.
a Study group (symptomatic).
b Reported in paper as POA, assumed to mean presentation on admission for gestational weeks.
c Two participants; number of fetuses unknown.
d High-risk group: cervical length≤ 30mm.
e Actim Partus test positive.
f Data as reported in paper; however, values do not add up.
g Actim Partus test negative.
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test accuracy data. Women who had a non-spontaneous delivery outside the time frame of the reference
standard should not be excluded as these women would be considered to be reference-standard negatives
in any case (i.e. they did not deliver within 48 hours or within 7 days). In a further three studies (Vishwekar
et al.,58 Brik et al.48 and Nikolova et al.60,61), iatrogenic delivery was mentioned as a reason for exclusion,
but it is unclear how many of these deliveries took place within the time frame of the reference standard,
and in another study (Lembet et al.53) the number of iatrogenic deliveries could not be ascertained.
In three studies,47,49,55 the numbers of spontaneous/iatrogenic deliveries were reported, but no exclusion of
data from non-spontaneous deliveries was made. In the study by Azlin et al.,47 70.6% of women delivered
spontaneously, 7.8% underwent an emergency caesarean section and for a further 7.8% there were no
data available on mode of delivery. Although 13.7% of women delivered by a planned caesarean section,
it is unclear whether or not these took place within the time frame of the reference standard, and these
women were not excluded from the test accuracy data.47 In Cooper et al.,49 52.1% of women delivered
spontaneously, 14.9% had an operative delivery and 33.0% had a caesarean section, although, again,
it was unclear how many of these procedures were planned and how many took place within the time
frame of the reference standard. Finally, Tanir et al.55 report the proportion of women who delivered by
caesarean section or from vaginal delivery; however, these data do not appear to be correct (see Table 4).
Differences between studies in inclusion/exclusion criteria
There are several ways in which the participant inclusion/exclusion criteria differed between studies
(see Table 3). It is likely that many of these differences had an impact on the prevalence of preterm labour
and, thus, test accuracy data. However, insufficient data were provided to fully assess these relationships.
Gestational age Of the 20 included studies, 14 recruited women from 24 weeks’ gestation onwards
(see Table 3).41–43,45–52,54–56,62 In these 14 studies, the upper limit of gestation varied widely: eight studies
recruited women at gestation of up to 34 weeks,41–43,45,46,48,54,56,62 with the upper limit of gestation ranging
from 32+6 weeks (Danti et al.50) to 37 weeks (Tanir et al.55) in the remaining six studies.
Of the remaining six studies, four recruited women at an earlier gestation: two studies53,61 recruited women
from as early as 20 weeks’ gestation and two studies44,59 included women from 22 weeks’ gestation. Two of
these studies recruited women up until 36+6 weeks,59,61 one recruited women up until 36 weeks53 and the
other recruited women up until 34+6 weeks.44 The other two studies57,58 recruited women at a later gestation
(i.e. from 28 weeks’ gestation), with both recruiting up until 37 weeks (36+6 weeks for Tripathi et al.57).
None of the studies presented test accuracy data between different gestational cut-off points. It was not
possible, therefore, to make any within-study assessment, for any of the index tests, whether or not test
accuracy differed based on gestation.41–62
Presenting symptoms of preterm labour Other than stating that women had to be symptomatic,
all studies except for Ting et al.56 provided some further details about the presenting symptoms of preterm
labour. However, one further study (Cooper et al.49) added only that that ‘symptoms indicative of labour
were to be determined by a physician’.
All other studies reported uterine contractions as a necessary indicator of preterm labour.41–48,50–55,57–62
Ten studies additionally described the rate of uterine contractions necessary for inclusion: a rate of six
contractions per hour was reported by Tripathi et al.,57 Bruijn62 and APOSTEL-1,42,43 a rate of eight
contractions per hour was reported by Abo El-Ezz et al.,45 a rate of 10 contractions per hour was reported
by Eroglu et al.,51 Riboni et al.54 and Lembet et al.53 and a rate of 12 contractions per hour was reported by
Danti et al.,50 Goyal et al.52 and Tanir et al.55
Other commonly reported symptoms included in definitions of preterm labour were abdominal pain
(in seven studies42–44,48,52,59–62), back pain (in six studies42,43,45,48,55,59,62), pelvic pressure (in three studies45,59–61),
vaginal bleeding (in the APOSTEL-1 and Bruijn studies42,43,62) and vaginal discharge (in three studies45,55,58).
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Singleton/multiple pregnancies The majority of included studies were based on samples that only
included women with singleton pregnancies. However, based on the protocol amendment, four studies were
included that recruited women with multiple gestation pregnancies. One of these studies assessed two index
tests in the same population [APOSTEL-1 (qfFN and Actim Partus)] and 20% of the included pregnancies
were multiple pregnancies.42,43 Two of these studies assessed only Actim Partus, with one (Cooper et al.49)
having 6% of included pregnancies as multiple pregnancies and the other (Vishwekar et al.58) having 7% of
included pregnancies as multiple pregnancies. The final study that included multiple pregnancies (Bruijn62)
only assessed qfFN, and they made up 15% of the population. We are not aware of any published evidence
to suggest that multifetal pregnancies would alter the DTA of either qfFN or Actim Partus.
Risk status of participants Only one of the included studies (Bolotskikh et al.59) clearly reported the risk
status of included women (i.e. whether or not the women were at high or low risk for preterm labour
prior to the onset of symptoms). In this study, the population was described as high risk because 15% of
the participants had previously experienced preterm labour, 43% had mild preeclampsia and 51% were
previously hospitalised during the pregnancy.59 However, although none of the other studies explicitly
stated that the populations were at high risk of preterm labour, eight additional studies42,43,48,49,51–53,58,62
also recruited some women who had previously experienced preterm delivery (see Table 4). In addition,
two studies (APOSTEL-142,43 and Danti et al.50) restricted their population by conducting tests in women
presenting with a cervical length of < 30 mm. However, this high-risk status is associated with symptoms
at presentation rather than the women being high risk prior to the onset of symptoms.
Recruiting high-risk women would be expected to have an impact on the prevalence of preterm birth.
However, because almost all studies did not clearly report risk status, it is not possible to properly assess if
or how this had an impact on prevalence rates (and, therefore, test accuracy data).
Dilatation threshold and cervical length All studies except Cooper et al.,49 Goyal et al.,52 Lembet
et al.53 and Vishwekar et al.58 included a dilatation threshold for exclusion; typically, the threshold was
> 3 cm or ≥ 3 cm. However, Riboni et al.54 had a dilatation threshold of > 2 cm and Altinkaya et al.46
had a threshold of ≥ 2 cm.
Studies were not excluded on the basis of access to cervical length measurement (lack of access was unlikely
to be reported in studies). Indeed, studies that did not report the use of cervical length measurement did
not explicitly cite lack of access or discuss the suitability of cervical length measurement for the included
population. Cervical length measurement was conducted in nine of the included studies.42–44,47,50–52,59–62
In seven of these studies,44,47,51,52,59–62 no selection of women took place in accordance with cervical length
measurement, and, therefore, it is not expected that the women in these studies would substantively differ
from women who would not have access to cervical length measurement in clinical practice. However, in
the other two studies (APOSTEL-142,43 and Danti et al.50), all women included in final analyses of index test
data had a transvaginal cervical length measurement of ≤ 30 mm, which would probably increase the
prevalence of preterm birth in these studies. Both of these studies were assessing Actim Partus, with
APOSTEL-1 additionally assessing qfFN.42,43,50
Other exclusion criteria Other criteria for exclusion differed substantially between studies (see Table 3
for specific details). Across studies, exclusion criteria included abruptio placenta, antepartum haemorrhage,
contraindications for tocolysis, cervical cerclage, cervical incompetence, chorioamnionitis, diabetes mellitus,
diarrhoea, digital examination in the previous 24 hours, fetal asphyxia, fetal abnormalities, fetal distress,
history of preterm delivery, hypertension, hyperthyroidism, iatrogenic deliveries, intrauterine growth
restriction, maternal age of < 18 years, multiple gestations, placenta praevia, preeclampsia, prior cervical
examination, sexual intercourse in the previous 24 hours, smokers, symptoms unrelated to threatened
preterm delivery (e.g. trauma), tocolytic treatment prior to testing, urinary tract infection, uterine anomalies,
vaginal bleeding, vaginal douche in the previous 24 hours, vaginal infection and vaginal leakage.41–62
All exclusion criteria were reasonable in the context of the index tests under consideration (see Quality
appraisal summary).
ASSESSMENT OF TEST ACCURACY
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Summary of the reference standard
In all studies, the reference standard was preterm birth, within 48 hours and/or within 7 days.41–62
All 20 included studies evaluated the index tests against the 7-day reference standard.41–62 Six of the
Actim Partus studies48,52,53,56–58 and one PartoSure study41 also evaluated the index test against a 48-hour
reference standard. qfFN was not evaluated against the 48-hour reference standard.42,43,62
Summary of test administration
The manufacturers’ descriptions of the index tests and how they should be used are presented in Table 1.
The quantity and quality of reported details regarding how each test was performed within a study
varied considerably.
Actim Partus
In the 16 studies that used the Actim Partus test,43,45–58 the information provided on how the test was
administered typically followed the manufacturer’s guidance; however, there were some differences.
The reporting of detection-limit thresholds varied between studies, but it is likely that all studies used a
threshold of 10 µg/l: eight studies clearly reported a detection limit of 10 µg/ml.45,49,50,52–54,57,58 Two
studies46,51 reported that samples higher than 30 µg/l give ‘a strong positive result’. It is unclear in both of
these studies whether or not a weak positive at 10 µg/l would have been considered a positive result,
although this appears to be the case.46,51 One study48 states that a threshold of 30 µg/l was required for a
positive result, and that this shows as two blue lines on the dipstick, but this is incorrect (two blue lines
show at 10 µg/l). Finally, five studies41,43,44,47,55,56 did not report what detection limit they used; however,
given the qualitative nature of the test, it appears most likely that a 10-µg/l threshold was used. Indeed,
the manufacturer’s guidance indicates that a concentration of ≥ 10 µg/l in the cervical fluid causes a
positive Actim Partus test reaction result.
All studies report taking their sample from around the external cervical orifice or cervical os or as a cervical
specimen.43–58 However, two studies43,56 report that the sample was taken from the posterior fornix.
The instructions from the manufacturer state that the sample should be taken from the cervical os. Our
obstetric clinical experts have advised that samples taken from the posterior fornix would probably yield a
higher false-negative rate because the secretion samples differ between the two areas and concentrations
are likely to be weaker from the posterior fornix. A difference in secretion sample concentration between
cervical locations has been demonstrated by Kuhrt et al.,63 although using the qfFN test, it is likely that
Actim Partus would be affected in a similar manner.
The manufacturer’s instructions state that if the single (control) line does not appear then the test is invalid.
However, one study55 interpreted no visible lines as a positive test result. This was their way of dealing with
missing data owing to invalid results. This is unlikely to greatly alter results as only two tests from 68 results
were invalid.55 The remaining studies did not report details on how invalid tests were treated.
Two studies43,49 both froze their samples at –20 °C for future analysis. In APOSTEL-1,43 samples were
reported to have been transferred and stored at –80 °C within 6 months. It is unknown how long after the
transfer samples remained in storage before testing; however, it is likely that total storage time would have
exceeded 6 months.43 Likewise, in the study by Cooper et al.49 it is unclear how long the tests remained
frozen before testing. Both of these studies43,49 go on to describe that samples were thawed before the
Actim Partus test was run. This protocol differs from the manufacturer’s guidance (and, of course, clinical
practice), in which freezing a sample is not discussed in the instructions for use. We have received clinical
input from our obstetricians to suggest that freezing is unlikely to affect the sample’s integrity and,
therefore, is unlikely to have an impact on test accuracy.
PartoSure
All four studies assessing the PartoSure test appeared to conduct the test in a manner that was consistent
with the manufacturer’s guidance.41,44,59–61 However, Bolotskikh et al.59 did not specifically report that
samples were collected using a speculum.
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Fetal fibronectin
Of the two studies that used the qfFN test, one study (Bruijn62) appeared to conduct the test in accordance
with the manufacturer’s guidance. The other study (APOSTEL-142) froze the samples as reported in Studies
evaluating more than one index test. This is not in accordance with the manufacturer’s guidance, which
states that in order to avoid degradation of the analyte, frozen samples should be assayed within 3 months.
Time to test results
Based on the manufacturers’ instructions, the maximum time between taking the sample and receiving the
test results (including time for mixing in solvents, etc.) is approximately 6 minutes for Actim Partus and
PartoSure, and 12 minutes for qfFN. Some of the studies provided information within their methods relating
to the maximum time that test personnel had to wait before reading the result from the test. This was
always in accordance with the manufacturers’ guidance.
None of the 20 studies included in our review reported, in the study results, how long it took to conduct
the test and receive a result; therefore, no further data can be presented on this outcome.
Test failure rates
Only two studies (Goyal et al.52 and Tanir et al.55), both of which evaluated Actim Partus, reported information
about test failures: Goyal et al.52 reported that there were no invalid tests and Tanir et al.55 reported that there
were two cases in which the Actim Partus test failed to show any visible lines. For these two women, the test
result was not assigned as invalid and the tests were not re-run; they were instead assigned as positive Actim
Partus results.52,55 It was not clear whether these two women had a preterm delivery within 48 hours or within
7 days (i.e. whether they were assigned as true positive or false positive); therefore, it was not possible to
conduct sensitivity analyses when these two cases were assigned as negative test results.
Frozen samples
Following the protocol amendment to include studies using frozen samples, two additional studies
(APOSTEL-142 and Cooper et al.49) were included. Methodological details on freezing of the samples are
described in the previous sections Actim Partus and PartoSure, and are further discussed in Quality appraisal
of included studies. We have received clinical input from our obstetricians to suggest that freezing of the
sample is unlikely to affect the integrity of the sample, even if thawed outside the time frame suggested by
the manufacturer’s guidance, and is, therefore, unlikely to have a major impact on test accuracy. However,
it should be noted that we have no published data to verify this.
Description of included participants
Studies evaluating more than one index test
The APOSTEL-1 study, which evaluated both Actim Partus and qfFN in the same population, recruited
350 participants.42,43 The characteristics of these participants are reported in Table 4. To summarise, the
mean maternal age was 29.9 years [standard deviation (SD) 5.4 years] and the mean gestational age
at presentation was 29.0 weeks (SD 2.7 weeks). In this study,42,43 20% of the participants (n = 71) had
multiple gestations and 23% (n = 79) had previously delivered preterm.
The other study evaluating more than one index test in the same population was a much smaller
study: Hadzi-Lega et al.44 assessed both Actim Partus and PartoSure and recruited 57 participants. The
characteristics of these participants are also reported in Table 4. In this study,44 the median maternal age
was reported as 27 years [interquartile range (IQR) 23.0–30.5 years] and the median gestational age at
presentation was reported as 31 weeks (IQR 28.8–32.4 weeks).
Actim Partus
In the 16 Actim Partus studies (including APOSTEL-142,43 and Hadzi-Lega et al.44),42–44,57,58 sample sizes
ranged from 30 in Vishwekar et al.58 to 468 in Tripathi et al.57 Reported maternal ages ranged from a mean
of 24.5 years (SD 5.16 years) in Altinkaya et al.46 to a median of 31 years (IQR 28–34 years) in Danti et al.50
ASSESSMENT OF TEST ACCURACY
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Gestation ranged from a mean of 28.7 weeks (SD not reported) in Riboni et al.54 to 32.8 weeks
(SD 3.24 weeks) in Goyal et al.52 Further details describing the participant characteristics in each study
are given in Table 4.
Three43,49,58 of the 16 studies assessing Actim Partus included participants with multiple gestations (20%,
n = 71;43 6%, n = 20;49 and 7%, n = 258). Previous preterm delivery was reported in seven studies,43,48,49,51–53,58
and prevalence ranged from 3.9% (n = 2) in Eroglu et al.51 to 30% (n = 18) in Goyal et al.52
PartoSure
In the four PartoSure studies,41,44,59–61 sample sizes ranged from 41 in Werlen et al.41 to 203 in Nikolova et al.61
Reported maternal age ranged from a median of 25 years (IQR 23–38 years) in Bolotskikh et al.59 to a median
of 27 years in Nikolova et al.60,61 (range 18–43 years) and Hadzi-Lega et al.44 (IQR 23–30.5 years). Gestational
ages ranged from a mean of 29.5 weeks (SD 2.91 weeks) in Werlen et al.41 to a median of 32 weeks (range
20.5–36.6 weeks) in Nikolova et al.60,61 Further details describing the participant characteristics in each study
are given in Table 4.
Quantitative fetal fibronectin
In the two studies assessing qfFN (APOSTEL-142 and Bruijn62), sample sizes were 350 and 455, respectively.
Maternal age was similar in these two studies [mean 29.9 years (SD 5.4 years) in APOSTEL-142 and mean
29.5 years (SD 5.2 years) in Bruijn62], as was gestation [mean 29.0 weeks (SD 2.7 weeks) in APOSTEL-142 and
median 29.6 weeks (IQR 26.7–31.6 weeks) in Bruijn62]. The APOSTEL-1 study42 had a higher proportion of
multiple pregnancies than Bruijn62 [20% (n = 71) in APOSTEL-142 vs. 15% (n = 67) in Bruijn62]. Proportionally
more women had previously delivered preterm in APOSTEL-142 than in Bruijn62 [23% (n = 79) in APOSTEL-142
vs. 16% (n = 72) in Bruijn62]. Further details describing the participant characteristics in each study are given
in Table 4.
Summary of any treatments given
The index tests of interest are designed to be used before the reference standard (the occurrence of
preterm delivery within 48 hours and/or 7 days). For this reason, it is important to consider the use of
any treatments that might have an impact on the reference standard and, thus, the test accuracy results.
Whether or not a woman received treatment for symptoms of preterm labour varied substantially between
studies. This variability was based on (1) the standard treatment protocols used within each study and
(2) the test(s) used to initiate treatment within the study (e.g. Actim Partus, PartoSure or qfFN or another
test that is not being assessed as part of this review, such as transvaginal cervical length). Subsequently,
when treatment was given, the number of women receiving treatment was not always reported, particularly
with reference to the results of the diagnostic tests of interest. This means that in several cases it is difficult
to ascertain the extent to which treatments may have had an impact on the test accuracy results.
Studies evaluating more than one index test
Treatment decisions from the APOSTEL-1 trial42,43 were not based on the test results of Actim Partus or
qfFN alone. Instead, treatment decisions were based on the combined results of two tests not being
assessed in this review (cervical length measurement and qfFN with a threshold of 50 ng/ml). In addition, a
strict treatment protocol was not used; instead, recommendations were provided. Tocolytics (a choice from
nifedipine, indomethacin, Atosiban and ritodrine) were recommended for women with a cervical length of
< 10 mm but not for women with a cervical length of > 30 mm. Women with a cervical length between
10 mm and 30 mm and a positive fFN result were encouraged to receive tocolytics, whereas those with a
negative fFN result received tocolytics at the discretion of the advising clinician. Corticosteroids were
permitted at the clinician’s discretion. No data were provided on how many women received tocolytics
or corticosteroids.
Treatment decisions from the study by Hadzi-Lega et al.44 (a single-centre study assessing both Actim Partus
and PartoSure) followed the standard of care at the hospital. This included hospitalisation, discharge,
tocolytics (including beta-mimetics and calcium channel blockers) and corticosteroids (e.g. betamethasone).
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Thirty-eight of 57 women (67%) received corticosteroids, four of whom had a preterm birth within 7 days.
Thirty-eight of 57 women (67%) received tocolytics (note that not all patients who received corticosteroids
received tocolytics), six of whom had a preterm birth within 7 days. No details were provided for either of
the test results in correlation to treatment administration.44
Actim Partus
Sixteen studies assessed Actim Partus, two of which (APOSTEL-142,43 and Hadzi-Lega et al.44) also assessed
another index test and have been discussed previously (see Studies evaluating more than one index test).
The remaining 14 studies45–58 all report the use of tocolytics and most specify the type (typically Atosiban,
calcium channel blockers, nifedipine, ritodrine or magnesium sulphate). All of these studies except Azlin
et al.47 report the use of corticosteroids (either betamethasone or dexamethasone, when specified).
One study reports that cervical length measurements were available to managing clinicians and were used
to aid treatment decisions.50 Of the 60 patients in this study, 22 (37%) received tocolytics and 28 (47%)
received corticosteroids.
In another study,51 it is reported that patients were admitted to hospital based on frequency of contractions
and digital examination. In this study, women at > 34 weeks’ gestation did not receive any tocolytics or
corticosteroids. In total, 16 out of 51 patients (31%) received tocolytics, eight of whom had a positive
Actim Partus result; the study does not report the number of patients who received corticosteroids.51 In a
further four studies,53,54,57,58 treatment decisions were also guided by gestational age. In Lembet et al.53
patients at > 34 weeks’ gestation were not administered tocolytics, those at > 24 weeks’ gestation received
corticosteroids and those at < 28 weeks’ gestation received a repeat dose. In this study, 21 out of 36 patients
(58%) received tocolytics, eight of whom had a positive Actim Partus test result.53 In Riboni et al.,54 women
at < 34 weeks’ gestation received corticosteroids, and all patients received tocolytics. In the studies by Tripathi
et al.57 and Vishwekar et al.,58 women at < 34 weeks’ gestation received tocolytics and corticosteroids. The
studies by Riboni et al.,54 Tripathi et al.57 and Vishwekar et al.58 do not report the proportion of patients who
received these treatments (or the Actim Partus results of these patients).
Five studies state that treatment decisions were based on standard hospital protocol.47–49,52,56 In these
studies, it is largely unclear whether diagnostic tests, symptoms or maternal characteristics (e.g. gestation)
were used to guide decision-making. Four of these studies report details on the proportion of patients
receiving treatment. In the study by Azlin et al.,47 12 out of 51 patients (24%) received tocolytics (two of
whom had a positive Actim Partus result), but no details were reported regarding how many patients
received corticosteroids. In the study by Brik et al.,48 213 out of 276 patients (77%) received tocolytics
and 200 (73%) received corticosteroids. In the study by Cooper et al.,49 8 out of 349 patients received
tocolytics (2%) and 56 (16%) received corticosteroids. In the study by Goyal et al.,52 all patients received
tocolytics and the number receiving corticosteroids was unclear. The number of patients receiving tocolytics
or corticosteroids was not reported in Ting et al.56
The remaining three studies report limited detail regarding how treatment decisions were made.45,46,55
In the studies by Abo El-Ezz et al.45 and Altinkaya et al.,46 all patients were admitted to hospital. Abo El-Ezz
et al.45 report that all patients received tocolytics, and it is unclear how many patients received corticosteroids.
In the study by Altinkaya et al.,46 patients whose symptoms persisted received tocolytics, and all patients
were administered corticosteroids. Neither of these studies report details regarding the Actim Partus results
of those receiving treatment. In the study by Tanir et al.,55 63 out of 69 patients (93%) received tocolytic
therapy (23 of whom had a positive Actim Partus test result). The number of patients receiving corticosteroids
was not reported.55
PartoSure
Four studies assessed PartoSure, one of which44 also assessed another index test and has been discussed
previously (see Studies evaluating more than one index test).
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In one of the remaining three studies,59 tocolytics were given irrespective of test outcomes (all admitted
women were treated). In another study,41 treatment was at the discretion of the investigator in accordance
with the protocol of the department. Of the 41 women in this study, 13 received corticosteroids and
25 received tocolytics, but no details were provided for treatment administration in connection with the
PartoSure test results. In the remaining study,60,61 no treatment protocols were reported.
Quantitative fetal fibronectin
Two studies assessed qfFN, one of which (APOSTEL-142,43) also assessed another index test and has been
discussed previously (see Studies evaluating more than one index test).42–44
In the other study (Bruijn62), treatment with tocolytics and steroids was based on a combination of cervical
length and the qfFN result at a threshold of 50 ng/ml, neither of which are index tests in this review.
In addition, no data were provided on how many women received treatments.
Quality appraisal of included studies
Quality appraisal was conducted, using phase 3 of the QUADAS-2 tool,39 for all 20 studies. Phase 3 of the
QUADAS-2 tool contains four domains: patient selection, index tests, reference standard, and flow and
timing. The APOSTEL-1 study42,43 and the study by Hadzi-Lega et al.44 each assess two index tests (Actim
Partus and qfFN, and PartoSure and Actim Partus, respectively). For these two studies, the index test
domain was conducted separately for each test.
It is important to note that the QUADAS-239 tool assesses the likely risk of bias and not the presence or
magnitude of bias. Therefore, any rating of ‘high’ means that the risk of bias is high but does not mean
that there is a high degree of bias, or even that bias has been detected. The quality of the included studies
is discussed in the following sections, and a summary of the QUADAS-2 ratings is provided in Table 5.
Further details relating to patient selection, index tests, reference standard, and flow and timing can also
be found in Table 5.
Quality appraisal summary
All of the included studies were single-gate DTA studies rather than case–control studies. A key issue to
note is that only two studies (APOSTEL-142,43 and Hadzi-Lega et al.44) evaluated more than one index test in
the same population. Thus, only these two studies allow for a direct comparison between the index tests.
Any comparisons made between the tests based on the other studies will be subject to confounding
(i.e. owing to differences in the recruited populations, hospitals and other factors that may have an impact
on whether or not a woman is likely to have a preterm delivery).
Although all of the included studies recruited appropriate populations, in the majority of studies there was
a lack of clarity regarding recruitment procedures and so an assessment cannot be made regarding whether
or not the selection of women in these studies could have introduced bias. Indeed, only five studies, four
of which were Actim Partus studies47,48,50,58 and one of which was a PartoSure study,60,61 clearly reported
selection procedures.
In almost all of the studies, index tests were conducted in a manner that is consistent with clinical practice.
However, both the APOSTEL-1 study42,43 and the study by Cooper et al.49 used frozen samples, which
means that the index tests (Actim Partus in both studies and qfFN in APOSTEL-1) were interpreted after the
reference standard. Owing to the nature of the tests, this is unlikely to have much impact, although some
amount of bias cannot be completely ruled out. In addition, in APOSTEL-142,43 and the study by Ting et al.,56
samples were taken from the posterior fornix of the vagina rather than the external cervical os. This sampling
method is not compatible with the manufacturer’s guidance for the Actim Partus test.
Furthermore, although not likely to have a major impact on results, in several studies there is potential for
‘cross-contamination’ of results from one index test to another and/or from additional tests that are not part
of this review (e.g. cervical length measurement). There is also potential, in several studies, for the index test
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TABLE 5 Quality appraisal: QUADAS-239
Quality appraisal
questions
Test
Actim Partus
and fFN
a
Actim
Partus and
PartoSure
b
Actim Partus PartoSure fFN
APOSTEL-142,43
Hadzi-Lega
et al.44
(2017)
Abo El-Ezz
et al.45
(2014)
Altinkaya
et al.46
(2009)
Azlin
et al.47
(2010)
Brik
et al.48
(2010)
Cooper
et al.49
(2012)
Danti
et al.50
(2011)
Eroglu
et al.51
(2007)
Goyal
et al.52
(2016)
Lembet
et al.53
(2002)
Riboni
et al.54
(2011)
Tanir
et al.55
(2009)
Ting
et al.56
(2007)
Tripathi
et al.57
(2016)
Vishwekar
et al.58
(2017)
Bolotskikh
et al.59
(2017)
Nikolova
et al.60,61
(2014 and
2015)
Werlen
et al.41
(2015) Bruijn62
Patient selection
Was a
consecutive or
random sample
of patients
enrolled?
U U U U Y Y U Y U U U U U U U Y U Y U U
Was a
case–control
design
avoided?
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y
Did the
study avoid
inappropriate
exclusions?
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y
Could the
selection of
patients have
introduced
bias?
U U U U L L U L U U U U U U U L U L U U
Is there
concern that
the included
patients do not
match the
review
question?
L L L L L L L L L L L L L L L L L L L L
Index test 1
Were the index
test results
interpreted
without
knowledge of
the results of
the reference
standard?
U Y Y Y Y Y U Y Y Y Y Y Y Y Y Y Y Y Y Y
If a threshold
was used, was
it prespecified?
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y
A
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Quality appraisal
questions
Test
Actim Partus
and fFN
a
Actim
Partus and
PartoSure
b
Actim Partus PartoSure fFN
APOSTEL-142,43
Hadzi-Lega
et al.44
(2017)
Abo El-Ezz
et al.45
(2014)
Altinkaya
et al.46
(2009)
Azlin
et al.47
(2010)
Brik
et al.48
(2010)
Cooper
et al.49
(2012)
Danti
et al.50
(2011)
Eroglu
et al.51
(2007)
Goyal
et al.52
(2016)
Lembet
et al.53
(2002)
Riboni
et al.54
(2011)
Tanir
et al.55
(2009)
Ting
et al.56
(2007)
Tripathi
et al.57
(2016)
Vishwekar
et al.58
(2017)
Bolotskikh
et al.59
(2017)
Nikolova
et al.60,61
(2014 and
2015)
Werlen
et al.41
(2015) Bruijn62
Could the
conduct or
interpretation
of the index
test have
introduced
bias?
U L L L L L U L L L L L L L L L L L L L
Is there concern
that the index
test, its conduct,
or interpretation
differ from the
review question?
H
c
L L L L L L L L L L L L H
c
L L L L L L
Index test 2
Were the index
test results
interpreted
without
knowledge of
the results of
the reference
standard?
U Y N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
If a threshold
was used, was
it prespecified?
Y Y N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Could the
conduct or
interpretation
of the index
test have
introduced
bias?
U L N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Is there
concern that
the index test,
its conduct, or
interpretation
differ from
the review
question?
L L N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
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TABLE 5 Quality appraisal: QUADAS-239 (continued )
Quality appraisal
questions
Test
Actim Partus
and fFN
a
Actim
Partus and
PartoSure
b
Actim Partus PartoSure fFN
APOSTEL-142,43
Hadzi-Lega
et al.44
(2017)
Abo El-Ezz
et al.45
(2014)
Altinkaya
et al.46
(2009)
Azlin
et al.47
(2010)
Brik
et al.48
(2010)
Cooper
et al.49
(2012)
Danti
et al.50
(2011)
Eroglu
et al.51
(2007)
Goyal
et al.52
(2016)
Lembet
et al.53
(2002)
Riboni
et al.54
(2011)
Tanir
et al.55
(2009)
Ting
et al.56
(2007)
Tripathi
et al.57
(2016)
Vishwekar
et al.58
(2017)
Bolotskikh
et al.59
(2017)
Nikolova
et al.60,61
(2014 and
2015)
Werlen
et al.41
(2015) Bruijn62
Reference standard
Is the reference
standard likely
to correctly
classify the
target
condition?
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y
Were the
reference
standard
results
interpreted
without
knowledge of
the results of
the index test?
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Could the
reference
standard, its
conduct, or its
interpretation
have
introduced
bias?
L L L L L L L L L L L L L L L L L L L L
Is there
concern that
the target
condition as
defined by
the reference
standard does
not match
the review
question?
L L L L L L L L L L L L L L L L L L L L
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Quality appraisal
questions
Test
Actim Partus
and fFN
a
Actim
Partus and
PartoSure
b
Actim Partus PartoSure fFN
APOSTEL-142,43
Hadzi-Lega
et al.44
(2017)
Abo El-Ezz
et al.45
(2014)
Altinkaya
et al.46
(2009)
Azlin
et al.47
(2010)
Brik
et al.48
(2010)
Cooper
et al.49
(2012)
Danti
et al.50
(2011)
Eroglu
et al.51
(2007)
Goyal
et al.52
(2016)
Lembet
et al.53
(2002)
Riboni
et al.54
(2011)
Tanir
et al.55
(2009)
Ting
et al.56
(2007)
Tripathi
et al.57
(2016)
Vishwekar
et al.58
(2017)
Bolotskikh
et al.59
(2017)
Nikolova
et al.60,61
(2014 and
2015)
Werlen
et al.41
(2015) Bruijn62
Flow and timing
Was there an
appropriate
interval
between index
test(s) and
reference
standard?
N Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y
Did all patients
receive a
reference
standard?
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y
Did patients
receive the
same reference
standard?
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y
Were all
patients
included in the
analysis?
N N N U Y N Y Y Y N Y U Y N N Y Y N N N
Could the
patient
flow have
introduced
bias?
H H H U L H H L L H L U L H H L L H H H
H, high; L, low; N, no; N/A, not applicable; U, unknown; Y, yes.
a Index test 1 =Actim Partus, index test 2 = fFN.
b Index test 1 =Actim Partus, index test 2 = PartoSure.
c The samples were taken from the posterior fornix of the vagina rather than the external cervical os.
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results to have influenced the clinical management of patients; approximately half of the studies stated that
the clinicians involved in patient management were unaware of the index test results.42–44,49–51,53,55,56,60–62
Another point to note is that the index tests are designed to be used before the occurrence of the
reference standard, and this was the case in all but two studies (APOSTEL-142,43 and Cooper et al.49).
This may inflate false-positive results and deflate true-positive results through the use of tocolytics to
prevent the occurrence of the reference standard.
Ten of the studies41–45,48,52,56,57,60–62 were rated as being of high risk of bias regarding not including all
women in analyses. A high risk of bias does not equate to a high degree of bias, and this should be
considered here and for other QUADAS-2 items in which a high risk of bias rating has been given
(see Table 5).
Results of quantitative data synthesis (test accuracy data)
The 7-day delivery reference standard
Studies evaluating more than one index test
Two studies (APOSTEL-142,43 and Hadzi-Lega et al.44) reported test accuracy data on two index tests. Both
studies used only the 7-day (and not the 48-hour) delivery reference standard. The prevalence of preterm
birth within 7 days was 19.7% (95% CI 15.7% to 24.3%) in the APOSTEL-1 study42,43 and 10.5%
(95% CI 4.0% to 21.5%) in the study by Hadzi-Lega et al.44
The APOSTEL-1 study reports test accuracy from 350 women for both Actim Partus and qfFN (Table 6).42,43
The sensitivity and specificity for Actim Partus, against delivery within 7 days, were 78.3% (95% CI
66.7% to 87.3%) and 89.3% (95% CI 85.1% to 92.7%), respectively. As would be expected, in the qfFN
results from the APOSTEL-1 study, lowering the threshold for a positive test result increased sensitivity and
decreased specificity whereas elevating the threshold for a positive test result increased specificity and
decreased sensitivity (see Table 6). The qfFN sensitivity and specificity values that were most similar to
Actim Partus values for the APOSTEL-1 study were those provided at a threshold of 200 ng/ml, at which
sensitivity was 71.0% (95% CI 58.8% to 83.1%) and specificity was 83.6% (95% CI 78.8% to 87.8%).
With regard to the qfFN data from APOSTEL-1, the threshold with the highest PPV was 500 ng/ml (70.7%,
95% CI 54.5% to 83.9%) and the threshold with the lowest PPV was 10 ng/ml (28.9%, 95% CI 23.2%
to 35.3%). For Actim Partus the PPV of delivery within 7 days was 64.3% (95% CI 53.1% to 74.4%).
For qfFN, the highest NPV was at a threshold of 10 ng/ml (97.5%, 95% CI 93.0% to 99.5%) and the
lowest at a threshold of 500 ng/ml (87.1%, 95% CI 82.8% to 90.6%). For Actim Partus, NPV was 94.4%
(95% CI 90.9% to 96.8%). LRs, concordance and yield were also calculated for this study, and these
values are provided in Table 6.
The other study providing data on more than one index test in the same sample was the study by
Hadzi-Lega et al.,44 in which test accuracy data from 57 women were reported for both Actim Partus and
PartoSure (see Table 6). The sensitivity of both Actim Partus and PartoSure for delivery within 7 days was
83.3% (95% CI 35.9% to 99.6%), and specificity was higher for PartoSure (90.2%, 95% CI 78.6% to
96.7%) than for Actim Partus (76.5%, 95% CI 62.5% to 87.2%). In addition, PPV, LR+ and concordance
were higher for PartoSure than for Actim Partus, although the wide CIs, particularly for PPV, are notable.
LR– and NPV were similar for both tests and diagnostic yield was higher for Actim Partus than for
PartoSure. Specific values are given in Table 6.
Actim Partus
Results for Actim Partus against the 7-day delivery reference standard were provided by 16 studies (Figure 3,
and see Table 6). Across these studies, sensitivity ranged from 33.3% (95% CI 4.3% to 77.7%) in the study
by Cooper et al.49 to 94.7% (95% CI 89.9% to 97.7%) in the study by Tripathi et al.57 Specificity of Actim
Partus ranged from 50.0% (95% CI 24.7% to 75.3%) in the study by Goyal et al.52 to 93.5% (95% CI
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TABLE 6 Calculated diagnostic accuracy parameters against the 7-day reference standard
Study (first author/study
name and year) Participants (n)
Diagnostic accuracy (95% CI)
Sensitivity (%) Specificity (%) LR+ LR– PPV (%) NPV (%) Prevalence (%) Concordance Yield
Study assessing qfFN and Actim Partus
APOSTEL-1 (2016)42,43
fFN at 10 ng/ml 350 95.7
(87.8 to 99.1)
42.3
(36.5 to 48.4)
1.66
(1.48 to 1.86)
0.10
(0.03 to 0.31)
28.9
(23.2 to 35.3)
97.5
(93.0 to 99.5)
19.7
(15.7 to 24.3)
0.53
(0.48 to 0.58)
0.65
(0.60 to 0.70)
fFN at 200 ng/ml 350 71.0
(58.8 to 81.3)
83.6
(78.8 to 87.8)
4.34
(3.20 to 5.88)
0.35
(0.24 to 0.50)
51.6
(41.1 to 62.0)
92.2
(88.1 to 95.1)
19.7
(15.7 to 24.3)
0.81
(0.77 to 0.85)
0.27
(0.23 to 0.32)
fFN at 500 ng/ml 350 42.0
(30.2 to 54.5)
95.7
(92.7 to 97.8)
9.84
(5.30 to 18.28)
0.61
(0.49 to 0.74)
70.7
(54.5 to 83.9)
87.1
(82.8 to 90.6)
19.7
(15.7 to 24.3)
0.85
(0.81 to 0.89)
0.12
(0.09 to 0.16)
Actim Partus 350 78.3
(66.7 to 87.3)
89.3
(85.1 to 92.7)
7.33
(5.11 to 10.51)
0.24
(0.16 to 0.38)
64.3
(53.1 to 74.4)
94.4
(90.9 to 96.8)
19.7
(15.7 to 24.3)
0.87
(0.83 to 0.91)
0.24
(0.20 to 0.29)
Study assessing PartoSure and Actim Partus
Hadzi-Lega (2017)44
PartoSure 57 83.3
(35.9 to 99.6)
90.2
(78.6 to 96.7)
8.50
(3.43 to 21.03)
0.18
(0.03 to 1.11)
50.0
(18.7 to 81.3)
97.9
(88.7 to 99.9)
10.5
(4.0 to 21.5)
0.90
(0.79 to 0.96)
0.18
(0.09 to 0.30)
Actim Partus 57 83.3
(35.9 to 99.6)
76.5
(62.5 to 87.2)
3.54
(1.92 to 6.52)
0.22
(0.04 to 1.31)
29.3
(10.3 to 56.0)
97.5
(86.8 to 99.9)
10.5
(4.0 to 21.5)
0.77
(0.64 to 0.87)
0.30
(0.18 to 0.43)
Actim Partus
Abo El-Ezz (2014)45
Actim Partus 57 66.7
(47.2 to 82.7)
66.7
(46.0 to 83.5)
2.00
(1.11 to 3.61)
0.50
(0.28 to 0.89)
69.0
(49.2 to 84.7)
64.3
(44.1 to 81.4)
52.6
(39.0 to 66.0)
0.67
(0.53 to 0.79)
0.51
(0.37 to 0.64)
Altinkaya (2009)46
Actim Partus 105 64.3
(35.1 to 87.2)
82.4
(73.0 to 89.6)
3.66
(2.02 to 6.61)
0.43
(0.21 to 0.88)
36.0
(18.0 to 57.5)
93.8
(86.0 to 97.9)
13.3
(7.5 to 21.4)
0.80
(0.71 to 0.87)
0.24
(0.16 to 0.33)
Azlin (2010)47
Actim Partus 51 80.0
(28.4 to 99.5)
93.5
(82.1 to 98.6)
12.27
(3.77 to 39.86)
0.21
(0.04 to 1.24)
57.1
(18.4 to 90.1)
97.7
(88.0 to 99.9)
9.8
(3.3 to 21.4)
0.92
(0.81 to 0.98)
0.14
(0.06 to 0.26)
Brik (2010)48
Actim Partus 276 74.2
(55.4 to 88.1)
66.1
(59.8 to 72.0)
2.19
(1.67 to 2.87)
0.39
(0.21 to 0.71)
21.7
(14.3 to 30.8)
95.3
(90.9 to 97.9)
11.2
(7.8 to 15.6)
0.67
(0.61 to 0.73)
0.38
(0.33 to 0.44)
continued
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TABLE 6 Calculated diagnostic accuracy parameters against the 7-day reference standard (continued )
Study (first author/study
name and year) Participants (n)
Diagnostic accuracy (95% CI)
Sensitivity (%) Specificity (%) LR+ LR– PPV (%) NPV (%) Prevalence (%) Concordance Yield
Cooper (2012)49
Actim Partus 349 33.3
(4.3 to 77.7)
74.1
(69.1 to 78.6)
1.28
(0.41 to 4.04)
0.90
(0.51 to 1.59)
2.2
(0.3 to 7.7)
98.4
(96.1 to 99.6)
1.7
(0.6 to 3.7)
0.73
(0.68 to 0.78)
0.26
(0.22 to 0.31)
Danti (2011)50
Actim Partus 60 50.0
(6.8 to 93.2)
69.6
(55.9 to 81.2)
1.65
(0.57 to 4.74)
0.72
(0.27 to 1.94)
10.5
(1.3 to 33.1)
95.1
(83.5 to 99.4)
6.7
(1.8 to 16.2)
0.68
(0.55 to 0.80)
0.32
(0.20 to 0.45)
Eroglu (2007)51
Actim Partus 51 83.3
(35.9 to 99.6)
84.4
(70.5 to 93.5)
5.36
(2.48 to 11.56)
0.20
(0.03 to 1.19)
41.7
(15.2 to 72.3)
97.4
(86.5 to 99.9)
11.8
(4.4 to 23.9)
0.84
(0.71 to 0.93)
0.24
(0.13 to 0.38)
Goyal (2016)52
Actim Partus 60 59.1
(43.2 to 73.7)
50.0
(24.7 to 75.3)
1.18
(0.68 to 2.04)
0.82
(0.45 to 1.50)
76.5
(58.8 to 89.3)
30.8
(14.3 to 51.8)
73.3
(60.3 to 83.9)
0.57
(0.43 to 0.69)
0.57
(0.43 to 0.69)
Lembet (2002)53
Actim Partus 36 93.8
(69.8 to 99.8)
85.0
(62.1 to 96.8)
6.25
(2.19 to 17.88)
0.07
(0.01 to 0.49)
83.3
(58.6 to 96.4)
94.4
(72.7 to 99.9)
44.4
(27.9 to 61.9)
0.89
(0.74 to 0.97)
0.50
(0.33 to 0.67)
Riboni (2011)54
Actim Partus 210 50.0
(15.7 to 84.3)
83.7
(77.8 to 88.5)
3.06
(1.43 to 6.54)
0.60
(0.30 to 1.20)
10.8
(3.0 to 25.4)
97.7
(94.2 to 99.4)
3.8
(1.7 to 7.4)
0.82
(0.77 to 0.87)
0.18
(0.13 to 0.24)
Tanir (2009)55
Actim Partus 68 93.3
(68.1 to 99.8)
79.2
(65.9 to 89.2)
4.50
(2.61 to 7.74)
0.08
(0.01 to 0.56)
56.0
(34.9 to 75.6)
97.7
(87.7 to 99.9)
22.1
(12.9 to 33.8)
0.82
(0.71 to 0.91)
0.37
(0.25 to 0.49)
Ting (2007)56
Actim Partus 94 70.6
(44.0 to 89.7)
77.9
(67.0 to 87.6)
3.20
(1.90 to 5.38)
0.38
(0.18 to 0.80)
41.4
(23.5 to 61.1)
92.3
(83.0 to 97.5)
18.1
(10.9 to 27.4)
0.77
(0.67 to 0.85)
0.31
(0.22 to 0.41)
Tripathi (2016)57
Actim Partus 468 94.7
(89.9 to 97.7)
92.4
(88.9 to 95.1)
12.43
(8.45 to 18.30)
0.06
(0.03 to 0.11)
85.7
(79.5 to 90.6)
97.3
(94.8 to 98.8)
32.5
(28.3 to 37.0)
0.93
(0.91 to 0.95)
0.36
(0.32 to 0.41)
Vishwekar (2017)58
Actim Partus 30 72.2
(46.5 to 90.3)
90.9
(58.7 to 99.8)
7.94
(1.20 to 52.62)
0.31
(0.14 to 0.66)
92.9
(66.1 to 99.8)
66.7
(38.4 to 88.2)
62.1
(42.3 to 79.3)
0.79
(0.60 to 0.92)
0.48
(0.29 to 0.67)
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Study (first author/study
name and year) Participants (n)
Diagnostic accuracy (95% CI)
Sensitivity (%) Specificity (%) LR+ LR– PPV (%) NPV (%) Prevalence (%) Concordance Yield
PartoSure
Bolotskikh (2017)59
PartoSure 99 100.0
(73.5 to 100.0)
95.4
(88.6 to 98.7)
21.75
(8.35 to 56.64)
0.00
(N/A)
75.0
(47.6 to 92.7)
100.0
(95.7 to 100.0)
12.1
(6.4 to 20.2)
0.96
(0.90 to 0.99)
0.16
(0.10 to 0.25)
Nikolova
(2014 and 2015)60,61
PartoSure 203 80.0
(63.1 to 91.6)
94.6
(90.1 to 97.5)
14.93
(7.74 to 28.80)
0.21
(0.11 to 0.41)
75.7
(58.8 to 88.2)
95.8
(91.5 to 98.3)
17.2
(12.3 to 23.2)
0.92
(0.88 to 0.95)
0.18
(0.13 to 0.24)
Werlen (2015)41
PartoSure 41 0.0
(0.0 to 97.5)
97.5
(96.8 to 99.9)
0.00
(N/A)
1.03
(0.98 to 1.08)
0.0
(0.0 to 97.5)
97.5
(96.8 to 99.9)
2.4
(0.1 to 12.9)
0.95
(0.84 to 0.99)
0.02
(0.00 to 0.13)
qfFN
Bruijn (2016)62
fFN at 10 ng/ml 455 93.8
(82.8 to 98.7)
32.2
(27.7 to 37.0)
1.38
(1.25 to 1.53)
0.19
(0.06 to 0.59)
14.0
(10.4 to 18.3)
97.8
(93.6 to 99.5)
10.5
(7.9 to 13.7)
0.39
(0.34 to 0.43)
0.71
(0.66 to 0.75)
fFN at 200 ng/ml 455 70.8
(55.9 to 83.0)
78.6
(74.3 to 82.5)
3.31
(2.55 to 4.30)
0.37
(0.24 to 0.58)
28.1
(20.3 to 37.0)
95.8
(93.1 to 97.7)
10.5
(7.9 to 13.7)
0.78
(0.74 to 0.82)
0.27
(0.23 to 0.31)
fFN at 500 ng/ml 455 29.2
(17.0 to 44.1)
94.3
(91.6 to 96.4)
5.16
(2.85 to 9.34)
0.75
(0.63 to 0.90)
37.8
(22.5 to 55.2)
91.9
(88.8 to 94.3)
10.5
(7.9 to 13.7)
0.99
(0.84 to 0.90)
0.08
(0.06 to 0.11)
N/A, not applicable.
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82.1% to 98.6%) in the study by Azlin et al.47 The three studies with the lowest sensitivity were those by
Cooper et al.49 (33.3%, 95% CI 4.3% to 77.7%), Danti et al.50 (50%, 95% CI 6.8% to 93.2%) and Riboni
et al.54 (50%, 95% CI 15.7% to 84.3%). The prevalence reported in these studies was much lower [prevalence
ranging from 1.7% (95% CI 0.6% to 3.7%) to 6.7% (95% CI 1.8% to 16.2%)] than in all other studies
[prevalence ranging from 9.8% (95% CI 3.3% to 21.4%) to 73.3% (95% CI 60.3% to 83.9%)]. Indeed,
the large range of prevalence estimates across these studies is particularly noteworthy (see Differences
between studies in prevalence of preterm birth). Meanwhile, the three studies with the lowest specificities
were those by Goyal et al.54 (50%, 95% CI 24.7% to 75.3%), Brik et al.48 (66%, 95% CI 59.8% to 72.0%)
and Abo El-Ezz et al.45 (67%, 95% CI 46.0% to 83.5%). There were no obvious methodological or
participant characteristics in these studies to explain the differences, and, although two of these studies45,54
had high prevalence, the other48 did not.
A summary ROC plot for all 16 studies assessing Actim Partus against the 7-day delivery reference standard
is provided in Figure 3. Pooled analyses were undertaken for these data and provided a pooled sensitivity
of 77% (95% CI 68% to 83%) and a pooled specificity of 81% (95% CI 76% to 85%).
Data from these 16 Actim Partus studies were also used to calculate LR+, LR–, PPV, NPV, concordance and
yield. These values are provided in Table 6.
PartoSure
Results for PartoSure against the 7-day delivery reference standard were reported in four studies (Figure 4,
and see Table 6). Prevalence of preterm delivery within 7 days ranged from 2.4% (95% CI 0.1% to 12.9%)
in the study by Werlen et al.41 to 17.2% (95% CI 12.3% to 23.2%) in the study by Nikolova et al.61 These
four studies had wide-ranging sensitivity, from 0% (95% CI 0.0% to 97.5%) in the study by Werlen et al.41
to 100% (95% CI 73.5% to 100.0%) in the study by Bolotskikh et al.,59 whereas specificity was more
similar across studies, ranging from 90.2% (95% CI 78.6% to 96.7%) in the study by Hadzi-Lega et al.44 to
97.5% (95% CI 96.8% to 99.9%) in the study by Werlen et al.41 The low sensitivity in the study by Werlen
et al.41 is because, in the sample of 41 participants, only one tested (falsely) positive using the PartoSure test.
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FIGURE 3 The ROC plot for Actim Partus against the 7-day reference standard. HSROC, hierarchical summary
receiver-operating characteristic.
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Discounting this study, the sensitivity range would be 80% (95% CI 63.1% to 91.6%) in the study by
Nikolova et al.61 to 100% (95% CI 73.5% to 100.0%) in the study by Bolotskikh et al.59
A summary ROC plot for the four studies assessing PartoSure against the 7-day delivery reference standard
is provided in Figure 3. Pooled analyses were conducted for these data and provided a pooled sensitivity of
83% (95% CI 61% to 94%) and a pooled specificity of 95% (95% CI 89% to 98%).
Data from these four PartoSure studies were also used to calculate LR+, LR–, PPV, NPV, concordance and
yield. These values are provided in Table 6.
Quantitative fetal fibronectin
Results against the 7-day delivery reference standard for the two qfFN studies (Bruijn62 and APOSTEL-142,43),
at the three thresholds (10 ng/ml, 200 ng/ml and 500 ng/ml), are presented in Table 6. Prevalence of preterm
birth within the sample was lower in Bruijn62 (10.5%, 95% CI 7.9% to 13.7%) than in APOSTEL-142,43
(19.7%, 95% CI 15.7% to 24.3%). Bruijn62 presented with slightly lower (within 2%) sensitivity values than
APOSTEL-142,43 at both the 10-ng/ml and 200-ng/ml thresholds (see Table 6). At the 500-ng/ml threshold, the
sensitivity was much lower in Bruijn62 (29.2%, 95% CI 17.0% to 44.1%) than in APOSTEL-142,43 (42%, 95% CI
30.2% to 54.4%). Similarly, specificity values were slightly lower (within 5%) in Bruijn62 than in APOSTEL-142,43
at both the 200-ng/ml and 500-ng/ml thresholds, whereas at the 10-ng/ml threshold the specificity was much
lower (32.2%, 95% CI 27.7% to 37.0%) in Bruijn62 than in APOSTEL-142,43 (42.3%, 95% CI 36.5% to 48.4%).
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FIGURE 4 The ROC plot for PartoSure against the 7-day reference standard.
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Data from the two qfFN studies were also used to calculate LR+, LR–, PPV, NPV, concordance and yield.
These values are provided in Table 6.
The 48-hour delivery reference standard
Seven of the included studies also provided test accuracy data for the index tests against a 48-hour
preterm delivery reference standard. Six of these studies evaluated Actim Partus48,52,53,56–58 and one
evaluated PartoSure.41
Actim Partus
Across the six studies evaluating Actim Partus against the prevalence of preterm birth within 48 hours,48,52,53,56–58
the prevalence of preterm birth within 48 hours ranged from 5.3% (95% CI 1.7% to 12.0%) in the study by
Ting et al.56 to 58.3% (95% CI 44.9% to 70.9%) in the study by Goyal et al.52 Sensitivity ranged from 65.7%
(95% CI 47.8% to 80.9%) in the study by Goyal et al.52 to 100.0% (95% CI 47.8% to 100.0%) in the study
by Ting et al.56 Specificity ranged from 56.0% (95% CI 34.9% to 75.6%) in the study by Goyal et al.52 to
82.4% (95% CI 56.6% to 96.2%) in the study by Vishwekar et al.58
Specific sensitivity and specificity values for all six studies are given in Table 7, in which it can be seen that
the sensitivity and specificity of Actim Partus for the 48-hour reference standard were lowest in the studies
by Goyal et al.52 and Brik et al.48 compared with the other four studies,53,56–58 which seem more in line with
each other. There were no obvious methodological or participant characteristic differences in these studies
(other than that the women in the studies by Goyal et al.52 and Brik et al.48 were, on average, 1 year older
than those in the other studies). Brik et al.48 did present data for the number of women who received
tocolytics (77.2%), but the other five studies did not provide this information, so we cannot assess
whether this was particularly high or low in comparison.
A ROC plot for the six studies assessing Actim Partus against the 48-hour delivery reference standard is
provided in Figure 5. Pooled analyses were conducted for these data and provided a pooled sensitivity of
87% (95% CI 74% to 94%) and a pooled specificity of 73% (95% CI 62% to 82%).
In the six studies evaluating Actim Partus against the prevalence of preterm birth within 48 hours, the PPV
was lower in the studies by Brik et al.48 and Ting et al.56 [16.0% (95% CI 9.6% to 24.4%) and 17.9% (95% CI
6.1% to 36.9%), respectively] than in the other four studies [range 62.1% (95% CI 54.4% to 69.5%) to
78.6% (95% CI 49.2% to 95.3%)]. This is likely to be linked to the prevalence also being low in these two
studies (8.3%, 95% CI 5.4% to 12.2% in the study by Brik et al.48 and 5.3%, 95% CI 1.7% to 12.0% in the
study by Ting et al.56). Conversely, NPV was lowest in the study by Goyal et al.52 (53.8%, 95% CI 33.4% to
73.4%), with NPV in the other five studies ranging from 87.5% (95% CI 61.7% to 98.4%) in the study by
Vishwekar et al.58 to 100% (95% CI 94.6% to 100.0%) in the study by Ting et al.56 Looking at the diagnostic
yield, the study by Goyal et al.52 was the only study in which > 50% of the population had a positive Actim
Partus result (57%, 95% CI 43% to 69%); all other studies had a diagnostic yield of ≤ 50%. Data from these
six Actim Partus studies were also used to calculate LR+, LR– and concordance. These values are provided
in Table 7.
PartoSure
In the study evaluating PartoSure against the prevalence of preterm birth within 48 hours,41 prevalence of
preterm birth within 48 hours was lower (2.4%, 95% CI 0.1% to 12.9%) than in any of the Actim Partus
studies discussed in the previous section. Sensitivity was 0.0% (95% CI 0.0% to 97.5%) and specificity
was 97.5% (95% CI 86.8% to 99.9%); the total sample size was 41 and only one test result was positive
(a false positive).41 These data, along with calculated values for PPV, NPV, LR+, LR–, concordance and yield,
are given in Table 7.
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TABLE 7 Calculated diagnostic accuracy parameters against the 48-hour delivery reference standard
Study
(first author
and year) Participants (n)
Diagnostic accuracy (95% CI)
Sensitivity (%) Specificity (%) LR+ LR– PPV (%) NPV (%) Prevalence (%) Concordance Yield
Actim Partus
Brik (2010)48 276 73.9
(51.6 to 89.8)
64.8
(58.6 to 70.7)
2.10
(1.56 to 2.82)
0.40
(0.20 to 0.81)
16.0
(9.6 to 24.4)
96.5
(92.5 to 98.7)
8.3
(5.4 to 12.2)
0.66
(0.60 to 0.71)
0.38
(0.33 to 0.44)
Goyal (2016)52 60 65.7
(47.8 to 80.9)
56.0
(34.9 to 75.6)
1.49
(0.90 to 2.47)
0.61
(0.34 to 1.09)
67.6
(49.5 to 82.6)
53.8
(33.4 to 73.4)
58.3
(44.9 to 70.9)
0.62
(0.48 to 0.74)
0.57
(0.43 to 0.69)
Lembet (2002)53 36 93.3
(68.1 to 99.8)
81.0
(58.1 to 94.6)
4.90
(2.01 to 11.96)
0.08
(0.01 to 0.55)
77.8
(52.4 to 93.6)
94.4
(72.7 to 99.9)
41.7
(25.5 to 59.2)
0.86
(0.71 to 0.95)
0.50
(0.33 to 0.67)
Ting (2007)56 94 100.0
(47.8 to 100.0)
74.2
(63.8 to 82.9)
3.87
(2.72 to 5.50)
0.00
(N/A)
17.9
(6.1 to 36.9)
100.0
(94.6 to 100.0)
5.3
(1.7 to 12.0)
0.76
(0.66 to 0.84)
0.30
(0.21 to 0.40)
Tripathi (2016)57 468 95.5
(89.7 to 98.5)
82.1
(77.8 to 86.0)
5.34
(4.26 to 6.69)
0.06
(0.02 to 0.13)
62.1
(54.4 to 69.5)
98.3
(96.1 to 99.5)
23.5
(19.7 to 27.6)
0.85
(0.82 to 0.88)
0.36
(0.32 to 0.41)
Vishwekar (2017)58 30 84.6
(54.6 to 98.1)
82.4
(56.6 to 96.2)
4.79
(1.67 to 13.74)
0.19
(0.05 to 0.68)
78.6
(49.2 to 95.3)
87.5
(61.7 to 98.4)
43.3
(25.5 to 62.6)
0.83
(0.65 to 0.94)
0.47
(0.28 to 0.66)
PartoSure
Werlen (2015)41 41 0.0
(0.0 to 97.5)
97.5
(86.8 to 99.9)
0.00 (N/A) 1.03
(0.98 to 1.08)
0.0
(0.0 to 97.5)
97.5
(86.8 to 99.9)
2.4
(0.1 to 12.9)
0.95
(0.84 to 0.99)
0.02
(0.00 to 0.13)
N/A, not applicable.
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Summary
Diagnostic test accuracy data were sought in two ways:
1. a systematic review evaluating the test accuracy of: PartoSure, Actim Partus and qfFN at thresholds
other than 50 ng/ml
2. a non-systematic overview of the test accuracy evidence, based on studies from the systematic review
and supplemented with data from recent systematic reviews, of tests used in current clinical practice:
fFN at 50 ng/ml (qualitative or quantitative tests).
Data derived from the systematic review of diagnostic test accuracy
Included studies
Twenty studies met the systematic review inclusion criteria:
l Two ‘comparative’ studies (i.e. studies assessing more than one index test in the same population).
One of these (APOSTEL-142,43) included both Actim Partus and qfFN and the other (Hadzi-Lega et al.44)
included both Actim Partus and PartoSure.
l Fourteen studies assessing only Actim Partus.45–58
l Three studies assessing only PartoSure.41,59–61
l One study assessing only qfFN.62
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FIGURE 5 The ROC plot for Actim Partus against the 48-hour delivery reference standard.
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All 20 studies evaluated DTA against a reference standard of preterm delivery within 7 days.41–62 In seven
studies (six Actim Partus studies and one PartoSure study), test accuracy was also measured against a
reference standard of preterm delivery within 48 hours.41,48,52,53,56–58
In the studies assessing two index tests in the same sample, APOSTEL-142,43 and Hadzi-Lega et al.,44 sample sizes
were 350 and 57, respectively. Sample sizes in the other studies ranged from 30 to 468 for Actim Partus57,58
and from 41 to 203 for PartoSure,41,60,61 and the only study evaluating qfFN alone comprised 455 participants.62
In addition, seven ongoing trials were identified that may be relevant to this review question, including
four trials conducted in the UK (two of which aim to recruit > 1000 participants).
Heterogeneity between studies
There was substantial methodological, clinical and statistical heterogeneity between studies, including:
l The prevalence of preterm birth – prevalence of preterm delivery within 7 days ranged from 1.7%
(95% CI 0.6% to 3.7%) to 73.3% (95% CI 60.3% to 83.9%) and prevalence of preterm delivery within
48 hours ranged from 2.4% (95% CI 0.1% to 12.9%) to 58.3% (95% CI 44.9% to 70.9%).41,49,52
l Mode of delivery – four studies reported that women who had a non-spontaneous delivery within the
time frame of the reference standard were excluded from the test accuracy data,42–44,59,62 three further
studies mentioned iatrogenic delivery as a reason for exclusion, but it is unclear how many of these
deliveries took place within the time frame of the reference standard,48,58,60,61 and three studies report
the number of spontaneous/iatrogenic deliveries but include the data from these women.47,49,55 In the
remaining 10 studies, the mode of delivery was not clearly reported.41,45,46,50–54,56,57
l Gestation – the majority of included studies used 24 weeks as the lower limit for gestation at
enrolment,41–43,45–52,54–56,62 with the lower limit in the remaining six studies ranging from 20 to
28 weeks.44,53,57–61 The upper limit for gestation varied more between studies, ranging from 32.6 to
37 weeks.50,55,57,58 No studies reported test accuracy data stratified by gestation.
l Symptoms defined as indicative of preterm labour – all included studies state that women presented
with symptoms indicative of preterm labour, and all but one study provided further detail regarding
these symptoms.56 All other studies reported uterine contractions as a necessary indicator of preterm
labour;41–48,50–55,57–62 however, there was variation in the rate of uterine contractions necessary for
inclusion.42,43,45,50–55,57,62 Other symptoms of preterm labour varied between studies, covering abdominal
or back pain, pelvic pressure, vaginal bleeding and/or vaginal discharge.
l Multiple gestations – four studies included women with multifetal pregnancies.1,42,43,49,58,62 In these
studies, the proportion of study participants with multifetal pregnancies ranged from 6% to 20%.42,43,49
l Risk status – only one study clearly reports the risk status of participants.59 Heterogeneity of studies
regarding the risk status of women is, therefore, unclear.
l Dilatation threshold and cervical length – all but four studies included a dilatation threshold for
exclusion.49,52,53,58 Typically, the threshold was > 3 cm or ≥ 3 cm, but two studies had a lower threshold
(> 2 cm and ≥ 2 cm).46,54 In two studies, all included women had a transvaginal cervical length
measurement ≤ 30 mm.42,43,50
l Other more specific exclusion criteria also varied between studies (e.g. cervical cerclage, previous
tocolytic treatment, recent sexual intercourse, vaginal bleeding and prior cervical examination).
l Participant characteristics also differed between studies. These differences included average maternal
age, gestational age at presentation and history of preterm delivery.
Administration of index tests
Studies generally followed manufacturers’ guidance on how to administer index tests. Key differences in
how the tests were administered include:
l Two studies used frozen samples in their analysis.42,43,49 It is unclear how long samples were stored
before testing. This protocol is inconsistent with manufacturer guidance and clinical practice.
l One Actim Partus study included two failed tests (no visible lines) as positive test results.55
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l Two Actim Partus studies collected samples from the posterior fornix rather than from the external
cervical os.42,43,56
Provision of treatment
It should be noted that providing treatment (tocolytics and/or corticosteroids) may have an impact on the
occurrence of the reference standard (i.e. whether or not preterm delivery takes place), and this would
have an impact on the test accuracy data.
Whether or not a woman received treatment for symptoms of preterm labour varied substantially between
studies. Moreover, the number of women receiving treatment was not always reported, particularly with
reference to the results of the index tests.
This means that, in the included studies, it is difficult to ascertain the extent to which treatment may have
had an impact on the test accuracy results.
Quality appraisal
Phase 3 of the QUADAS-2 tool was used to evaluate the risk of bias and highlight concerns regarding
applicability. All studies were single-gate DTA studies, and issues regarding risk of bias and concerns
regarding applicability were minimal. However, the following key points were noted:
l Overall, there was a lack of detail regarding recruitment methods, with only five studies providing
clear details.47,48,50,58,60,61
l Two studies used frozen samples. Therefore, in these studies, the timing of the index tests was
inconsistent with clinical practice and assessors could have potentially been aware of the reference
standard (occurrence of preterm birth within 48 hours or within 7 days).42,43,49 There is also no clear
evidence regarding the likely impact of longer-term storage on the tests.
l In eight studies, there was lack of clarity regarding whether or not index test assessors were blinded to
the results of additional diagnostic tests (e.g. cervical length);42,43,50,51,54,56,57,60–62 however, owing to the
nature of the index tests, there is little scope for bias to exist in their interpretation.
l In two Actim Partus studies, samples were collected from the posterior fornix rather than the external
cervical os.42,43,56
l The lack of clarity regarding the administration of tocolytics, particularly in reference to test results,
precluded a thorough evaluation of the effect of treatment on test accuracy data.
Summary of the data available across the systematic review and overview
Table 8 summarises the results from the systematic review of DTA for the three index tests (PartoSure,
Actim Partus and qfFN).
TABLE 8 Summary of evidence and relative accuracy against the 7-day reference standard
Index tests Actim Partus PartoSure
qfFN at
10 ng/ml 200 ng/ml 500 ng/ml
Actim Partus NA
PartoSure No difference (Hadzi-Lega et al., 201744) NA
qfFN at
10 ng/ml Sensitivity of fFN superior, specificity
of Actim Partus superior (APOSTEL-142,43)
Indirect evidence only NA
200 ng/ml No difference (APOSTEL-142,43) Indirect evidence only NA
500 ng/ml Sensitivity of Actim Partus superior,
specificity of fFN superior (APOSTEL-142,43)
Indirect evidence only NA
NA, not applicable.
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As can be seen in Table 8, Actim Partus and PartoSure were assessed in the same sample in one study
(Hadzi-Lega et al.44) and Actim Partus and qfFN were assessed in the same sample in one other study
(APOSTEL-142–44). No studies were identified that assessed PartoSure and qfFN in the same sample.
As well as being assessed in the same sample as Actim Partus in the study by Hadzi-Lega et al.,44 PartoSure
was assessed in the same sample as the QuikCheck test in one study (Nikolova et al.61).
Summary of test accuracy data across the systematic review
Table 9 summarises the sensitivity and specificity data for the index tests in the systematic review of test
accuracy (PartoSure, Actim Partus and qfFN at thresholds other than 50 ng/ml).24
TABLE 9 Summary of test accuracy data from the systematic review
Index test Source
Test accuracy data (%) (95% CI)
Sensitivity Specificity
Test accuracy for the prediction of preterm delivery within 7 days
1. Studies assessing more than one index test
fFN at 10 ng/ml Bruijn et al. (APOSTEL-1)42,43 (n = 350) 95.7 (87.8 to 99.1) 42.3 (36.5 to 48.4)
fFN at 200 ng/ml Bruijn et al. (APOSTEL-1)42,43 (n = 350) 71.0 (58.8 to 81.3) 83.6 (78.8 to 87.8)
fFN at 500 ng/ml Bruijn et al. (APOSTEL-1)42,43 (n = 350) 42.0 (30.2 to 54.5) 95.7 (92.7 to 97.8)
Actim Partus Bruijn et al. (APOSTEL-1)42,43 (n = 350) 78.3 (66.7 to 87.3) 89.3 (85.1 to 92.7)
PartoSure Hadzi-Lega et al. (2017)44 (n = 57) 83.3 (35.9 to 99.6) 90.2 (78.6 to 96.7)
Actim Partus Hadzi-Lega et al. (2017)44 (n = 57) 83.3 (35.9 to 99.6) 76.5 (62.5 to 87.2)
2. Studies assessing a single index test
Actim Partus Pooled (16 studies) 77.0 (68.0 to 83.0) 81.0 (76.0 to 85.0)
Range (16 studies) 33.3 (4.3 to 77.7) to
94.7 (89.9 to 97.7)
50.0 (24.7 to 75.3) to
93.5 (82.1 to 98.6)
PartoSure Pooled (4 studies) 83.0 (61.0 to 94.0) 95.0 (89.0 to 98.0)
Range (4 studies) 0.0 (0.0 to 97.5) to
100.0 (73.5 to 100.0)
90.2 (78.6 to 96.7) to
97.5 (96.8 to 99.9)
fFN at 10 ng/ml Range (2 studies) 93.8 (82.8 to 98.7) to
95.7 (87.8 to 99.1)
32.2 (27.7 to 37.0) to
42.3 (36.5 to 48.4)
fFN at 200 ng/ml Range (2 studies) 70.8 (55.9 to 83.0) to
71.0 (58.8 to 81.3)
78.6 (74.3 to 82.5) to
83.6 (78.8 to 87.8)
fFN at 500 ng/ml Range (2 studies) 29.2 (17.0 to 44.1) to
42.0 (30.2 to 54.5)
94.3 (91.6 to 96.4) to
95.7 (92.7 to 97.8)
Test accuracy for the prediction of preterm delivery within 48 hours
3. Studies assessing a single index test
Actim Partus Pooled (6 studies) 87.0 (74.0 to 96.0) 73.0 (62.0 to 82.0)
Range (6 studies) 65.7 (47.8 to 80.9) to
100 (47.8 to 100.0)
56.0 (34.9 to 75.6) to
82.4 (56.6 to 96.2)
PartoSure Werlen et al.41 (2015) (n = 41) 0.0 (0.0 to 97.5) 97.5 (86.8 to 99.9)
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With regard to the reference standard of preterm delivery within 7 days:
l Data set 1 (see Table 9) reports test accuracy data obtained from the two studies that assess two index
tests (included in the systematic review).
l Data set 2 (see Table 9) reports the sensitivity and specificity values from all included studies (those
evaluating only one index test and those evaluating more than one index test); for all index tests,
data set 2 (see Table 9) reports the range of sensitivities and specificities across the individual studies.
Meta-analyses were conducted to calculate pooled sensitivity and specificity for the 16 studies assessing
Actim Partus and for the four studies assessing PartoSure. Meta-analyses were not conducted for qfFN
because only two studies of this test were included.
With regard to the reference standard of preterm delivery within 48 hours:
l Data set 3 (see Table 9) reports the range of sensitivities and specificities across the six Actim Partus
studies included in the systematic review and also reports the sensitivity and specificity derived from the
one PartoSure study providing test accuracy data against the 48-hour reference standard. For Actim
Partus, meta-analyses were conducted.
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Chapter 3 Assessment of clinical effectiveness
(end-to-end) studies
End-to-end studies investigate the clinical impact of conducting tests by following patients from testing,through treatment to final clinical outcomes. Randomised controlled trials (RCTs) provide the best-quality
end-to-end comparative evidence, providing a direct link between a testing strategy and the clinical
outcomes of interest. We conducted a systematic review of end-to-end studies, with a particular focus on
RCTs but also including other controlled study designs. This review was undertaken following the general
principles published by the University of York Centre for Reviews and Dissemination.37 The protocol was
registered on PROSPERO (reference number CRD42017072696).
Methods for reviewing effectiveness
Identification of studies
The same searches as for the review of diagnostic accuracy studies were conducted (see Chapter 2,
Identification of studies). In brief, these included searches of electronic databases (these were designed to
identify all studies assessing PartoSure, Actim Partus and qfFN), all systematic reviews identified by the
electronic searches, trial registries, Google Advanced Search, reference lists of included DTA studies,
studies citing the included DTA studies and industry submissions to NICE.
As with the review of DTA (see Chapter 2, Methods of the systematic review), screening for relevant
studies was in two stages (screening of titles and abstracts and then screening of papers obtained in full).
At both stages, screening was conducted concurrently with the screening for the review of test accuracy
studies and this was done independently by two reviewers (two of JVC, SD, MB and HC). Prespecified
inclusion and exclusion criteria were used (see Inclusion and exclusion criteria). Disagreements were
resolved by discussion.
Inclusion and exclusion criteria
Population
Regarding the population, inclusion criteria were the same as those for the review of test accuracy studies;
this includes the protocol amendment in which twin or multiple pregnancies could make up 20% of the
total population (see Chapter 2, Population).
Interventions
The interventions under consideration were identical to those in the review of test accuracy (i.e. PartoSure,
Actim Partus and qfFN; see Chapter 2, Index tests).
Comparators
Studies were eligible for inclusion if at least one of the interventions was compared with one or more of
the following comparators:
l one of the other interventions (with or without an assessment of clinical symptoms)
l the qfFN test used with a threshold of 50 ng/ml (with or without an assessment of clinical symptoms)
l a qualitative fFN test (with or without an assessment of clinical symptoms)
l clinical assessment of symptoms alone.
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Outcomes
In accordance with the NICE scope,12 eligible studies should have included one or more of the following
outcomes in order to be eligible for inclusion:
l perinatal mortality
l neonatal morbidity and mortality
l long-term health problems in the child
l maternal morbidity and mortality
l health-related quality of life
l anxiety associated with confidence in the test results
l number of women admitted to hospital
l number of re-presentations to hospital within 48 hours and 7 days
l number of women who have tocolytics/corticosteroids
l length of inpatient hospital stay
l number of transfers of pregnant women and neonates between hospitals
l time to delivery from presentation
l number of women treated with maternal corticosteroids appropriately (i.e. they deliver within 7 days
following treatment)
l number of women treated with maternal corticosteroids inappropriately (i.e. they do not deliver within
7 days following treatment)
l impact on neonatal intensive care resource planning
l gestational age at birth.
Studies that report data on costs only were not eligible for inclusion in the review of clinical effectiveness.
Study design
Randomised controlled trials were primarily sought for this review; however, other controlled designs
(prospective or retrospective) were also eligible for inclusion.
Other methods
Further aspects of the review methods (data extraction strategy, critical appraisal strategy and methods of
data synthesis) are not described as there were no included studies.
Results
Quantity and quality of research available
After screening 2623 items, no studies were identified that met the inclusion criteria for the review of clinical
effectiveness. This was because none of the studies compared the tests of interest with a comparator
regarding the clinical outcomes of interest; there were no studies identified in which some women received
one test and some received another and even in the studies identified in the test accuracy review, in which
women received more than one test (see Chapter 2, Summary), there was no clear indication that treatment
decisions were based on the results of one test for some women and based on the results of the other test
for other women. Indeed, these studies did not provide data on the clinical outcomes of interest.
Assessment of effectiveness
We were not able to draw any conclusions on the effectiveness of PartoSure, Actim Partus or fFN from the
systematic review of end-to-end studies.
It is important to consider that this review was looking for evidence from controlled study designs. For the
systematic review of clinical effectiveness, we did not look for evidence of clinical effectiveness from other
designs (e.g. uncontrolled pre–post studies). This decision was made because these designs may be too
open to bias to be worth including in a systematic review of end-to-end studies, even if they provide the
only available evidence.
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Summary
We were not able to draw any conclusions on the effectiveness of PartoSure, Actim Partus or qfFN from
the systematic review of end-to-end studies.
It is unlikely that we have missed major items of published literature; our broad searches were not restricted
by a study design filter and were focused on identifying all studies of the tests of interest. In order to identify
other (potentially unpublished) literature, and to reduce the likelihood of overlooking any relevant end-to-end
studies, web searches and searches of trial registries were conducted. We also considered conference
abstracts that were identified in the electronic searches, but from the limited information provided in these
abstracts it did not appear that any useful end-to-end data were available.
It is important to consider that this review was looking for evidence from controlled study designs and
did not look for evidence from other designs (e.g. uncontrolled pre–post studies). Therefore, it is worth
considering whether or not conducting controlled studies in this area can reasonably be expected. On
balance, it does not seem unreasonable to expect such studies to be conducted in this population; the
principal barrier to conducting a RCT would be the potential difficulty of recruiting participants during an
acute medical situation (e.g. the time needed to consent and randomise). However, this population and
these tests would also lend themselves well to a RCT design with regards the length of follow-up required
(for a number of key outcomes, the length of follow-up could be < 1 year).
Nevertheless, the decision to only include controlled studies was primarily based on the fact that
uncontrolled designs may be too open to bias to be worth including in a systematic review of end-to-end
studies, even if they provide the only available evidence. However, it should be noted that it may be
necessary for data from pre–post studies to be used in economic modelling (i.e. to parameterise a model
when this is the only available evidence) and these data may, therefore, be obtained from studies that
have not been selected via a systematic reviewing process.
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Chapter 4 Data informing the economic modelling
The systematic review produced limited DTA data (see Chapter 2) and no clinical effectiveness data(see Chapter 3) for populating an economic evaluation of diagnostic tests of interest. There was no
single DTA study that evaluated all three index tests, and only two studies (APOSTEL-142,43 and Hadzi-Lega
et al.44) compared at least two index tests. There is a high degree of heterogeneity between the reviewed
diagnostic accuracy studies in terms of prevalence of preterm birth, mode of delivery, gestational age,
definition (symptoms) of preterm labour (including dilatation threshold), multiple gestations, participant
characteristics and provision of treatments. In the light of this, comparisons among tests on the basis
of the results of the meta-analyses presented in Chapter 2 are likely to be biased because the studies
providing data for meta-analyses are very different both within and between the different tests. Therefore,
of the studies identified and reviewed in Chapter 2, only studies that presented results for at least two
different index tests in the same patient sample were used for the economic evaluation in Chapter 6. There
were two such studies: APOSTEL-1,42,43 which assessed both Actim Partus and fFN, and Hadzi-Lega et al.,44
which assessed Actim Partus and PartoSure. In addition, we excluded studies that investigated laboratory-
based enzyme-linked immunosorbent assay (ELISA) qualitative (at 50 ng/ml) fFN tests, as this technology
is no longer in use; thus, meta-analysis of the remaining four studies of Actim Partus versus qualitative
fFN42,43,51,56,57 provided the DTA results used in the economic evaluation. Details are presented in Chapter 6.
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Chapter 5 Systematic review of existing
cost-effectiveness evidence
The first part of this chapter presents the results of a systematic review of previous economic studies ofthe diagnostic test interventions. Owing to the limited evidence on economic evaluations evaluating
index tests, the review was extended to include economic evaluation studies of any test identified in our
systematic search of cost-effectiveness studies. The second part of this chapter presents a review of the
modelling structures used in previous evaluations of diagnostic tests for the diagnosis of preterm labour in
symptomatic women with intact membranes, identified by the same systematic search.
Methods for reviewing economic evaluation studies
Systematic review methods were used to identify previously published economic evaluations of the three
tests under consideration: PartoSure, Actim Partus and qfFN. The review was undertaken following the
general principles published by the University of York Centre for Reviews and Dissemination.37 The protocol
was registered on PROSPERO (reference number CRD42017072696).
Identification of studies
The methods followed those reported in Chapter 2, Methods of the systematic review, for study identification.
Studies were screened by two reviewers (RMM and JVC).
Inclusion and exclusion criteria
The population, index test and reference standard matched those reported in Chapter 2, Inclusion and
exclusion criteria, and the inclusion criteria include the protocol amendment that twin or multiple pregnancies
could make up 20% of the total population. However, for the review of economic evaluations, the criteria for
inclusion permitted studies that reported health-care costs of an index test without restriction in terms of the
design of the effectiveness study. In the following sections, any reference to exclusions owing to study design
mean economic study design (i.e. exclusion of studies that are not economic evaluations).
Data extraction strategy
Data were extracted by one reviewer (RMM) using standardised data extraction templates.
Critical appraisal strategy
The quality of the studies was assessed in detail by an experienced health economist (RMM) in accordance
with the criteria specified by the Consolidated Health Economic Evaluation Reporting Standards (CHEERS)
checklist.64 This represents a deviation from the study protocol, which stated that the Drummond and
Jefferson’s checklist would be used.65
Methods of data synthesis
Data were narratively reported. Methods and results were tabulated using the prices and currencies as
reported by the identified studies.
Results
Figure 6 shows the study flow diagram of this review. The electronic database search identified 2252
records after deduplication. All were screened on title and abstract. Of these 2252 records, 63 citations
were taken to full-text screening. One study met the inclusion criteria; it was a conference abstract67 of a
MSc dissertation.68 We contacted the authors and they provided a copy of the dissertation, which is the
basis for this review.
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Economic evaluation studies
The only study included in our review reported the management practice with the qualitative fFN test at
the preterm clinic of St Thomas’ Hospital in London. It also evaluated the hypothetical use of ACSs and
tocolysis with full compliance with the treatment protocol at different fFN thresholds (positive result of
≥ 10, ≥ 50, ≥ 200 and ≥ 500 ng/ml) provided by the Hologic, Inc. Rapid 10Q System against delivery
outcomes. Clinicians were blinded to the qfFN concentration ‘to prevent it influencing their management
based on the qualitative fFN test result’ (Table 10).67
The study reported the proportion of compliance with the qualitative fFN treatment protocol: 67% of
positive cases (35/51) and 6% of negative cases (16/252) were given ACS treatment. Two (6%) and
10 (29%) out of the 35 women who had a positive test result and were treated with ACS delivered within
7 days and before 37 weeks, respectively.
In addition, the study analysed the rate of compliance with the protocol of administering tocolysis treatment
to women with a positive test result. Only 14% of women (10/75) testing positive with qualitative fFN were
administered tocolytics, whereas 2% of women (6/282) testing negative received tocolytics. Of those patients
who tested positive and were given tocolytics, 1 out of 10 delivered within 7 days and 4 out of 10 delivered
before 37 weeks.
Records identified through
database searching
(n = 4767)
Additional records identified
through other sources
(n = 0)
Records after duplicates removed
(n = 2252)
Records screened
(n = 2252)
Records excluded
(n = 2189)
Full-text articles assessed
for eligibility
(n = 63)
Studies included in
quantitative synthesis
(n = 1, abstract)
Full-text articles excluded,
with reasons
(n = 62)
•  Abstract, n = 19
•  Design, n = 6
•  Population, n = 2
•  Systematic reviews, n = 2
•  Test, n = 25
•  Unobtainable, n = 8
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FIGURE 6 The PRISMA flow diagram for the economic evaluation review.66 © 2009 Moher et al.66 This is an open-
access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
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TABLE 10 The included cost-effectiveness study
Study (first author
and year) Population Setting Test/diagnostic strategy
Study
design n
Time
frame
Outcome and accuracy
test results (if available) Results Comments
Gibson (2013)
(dissertation)67,68
Subsample of EQUIPP:
high-risk
a
symptomatic
women aged ≥ 18 years
between 23+0 and 34+6
weeks’ gestation (GA
range suitable for ACS and
tocolysis administration).
Presenting symptom:
TPTL (contractions > 2 in
30 minutes) 15.2%;
abdominal pain 70.9% of
women; remaining 13.9%
presented with other
symptoms, such as
tightening and pelvic
pressure
Preterm Surveillance
Clinic at St Thomas’
Hospital in London
a. Management without fFN
testing (treat all)
b. Qualitative fFN protocol
in reality (less than full
compliance)
c. Full adherence to qualitative
fFN protocol
d. Modelled implementation of
qfFN at 10-, 50-, 200- and
500-ng/ml thresholds
e. Clinicians blinded to qfFN
results. Aim was to evaluate
whether or not qfFN could
add value to clinical
management
protocol
Prospective
cohort
ACS analyses: 306
Tocolysis analyses:
351
Until
delivery
SPTB < 34 weeks’
gestation and < 37 weeks’
gestation; delivery within
7 days and 14 days of
testing
Appropriate
management: the number
of symptomatic women
given the intervention,
NNT and number of cases
missed (spontaneous
delivery within the
specified time frame and
did not receive intervention)
Additional NNT to
successfully administer
steroids to one woman
within 7 days of testing
Figures not calculated
by the authors
The analysis of ACS also included
women who delivered within
24 hours of fFN testing as missed
cases, regardless of whether or
not they received ACS, because
of the evidence suggesting ACS
is ineffective in the reduction of
RDS when delivery occurs within
24 hours of treatment69
On the finding that the 500-ng/ml
threshold results in 12 fewer
women treated with ACS and one
missed case in need of treatment
relative to the 200-ng/ml threshold,
whereas no missed cases occur at
the 200-ng/ml vs. lower thresholds,
the authors concluded that the
optimal risk–benefit threshold
for ACS use is 200 ng/ml. The
corresponding analysis for tocolysis
led them to choose the 500-ng/ml
threshold to indicate its use
GA, gestational age; NNT, number needed to treat; PTB, preterm birth; RCOG, Royal College of Obstetricians and Gynaecologists; SPTB, spontaneous preterm birth; TPTL, threatened preterm labour.
a At least one of the following risk factors: history of previous PTB (< 37 weeks’ gestation)/second trimester loss (≥ 16 weeks’ gestation); short cervical length (< 25mm) measured on ultrasound scan at 18+0–27+6 weeks’ gestation; previous
cervical surgery. Exclusion criteria: congenital abnormality; sexual intercourse within 24 hours; blood-stained swab; previously administered steroids/tocolysis; symptomatic visit number ≥ 2.
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In the published abstract,67 results are presented for the number needed to prevent one case of RDS for
the ‘no-test and treat-all’ option and the 200 ng/ml fFN threshold option: 1540 and 80, respectively.
However, the methods used to obtain these numbers are not given in the abstract and no reference to
these results appears in the dissertation.68 However, the dissertation does provide detailed information on
some of the data required to calculate those numbers for the different diagnostic and treatment options,
in the form of numbers needed to successfully administer steroids to one woman delivering within 7 days
of testing (no test and treat all group, 77; 200 ng/ml fFN group, 9) and women delivered before receiving
a full steroids course (i.e. within 24 hours of testing; three in both cases).
Critique
Although the study by Gibson et al.67 did not aim to assess the cost-effectiveness of the different diagnostic
strategies, it did provide information with which to model the cost-effectiveness of the following two sets of
comparisons: (1) no test and treat all with steroids versus qualitative testing with fFN and treat those with
positive results, and (2) testing options investigated at the qfFN thresholds of 10, 50, 200 and 500 ng/ml.
Given the available data from the study, the costs per patient adequately treated with steroids (i.e. within
7 days) were calculated by the assessment group (AG) using the following formula (for the comparison
between no test and treating all with steroids):
Incremental cost per additional patient adequately treated
=fCACS−½CfFN + fFN+ × (CACS + CH) + fFNF− × (CACS + CH)g NNTA−NfFN
=fCACS−½CfFN + (fFN+ + fFNF− ) × (CACS + CH)g×NNT,
(7)
Where CACS = cost of steroids, CfFN = cost of fFN test, fFN+ = probability of a positive test result, CH = costs of
hospital admission, N = total sample size, NTA = number of mothers given ACS within 7 days and at least
1 day before delivery in the treat-all strategy, NfFN = number of mothers given ACS within 7 days and
at least 1 day before delivery in the testing strategy, fFNF– = probability of a false-negative test result and
NNT = number needed to treat to avoid one case of inadequate treatment without testing.
Thus the incremental cost per patient adequately treated is equal to the number needed to treat to avoid
one case of inadequate treatment without testing (NNT) multiplied by the incremental cost per patient
of treating all versus testing and treating positive cases. By combining the data from Gibson et al.67 with
treatment effectiveness data and cost and utility values used by previous models (e.g. NICE 2015,24
discussed below), we can obtain the incremental cost per case of RDS avoided, cost per life saved, and,
subject to the natural reservations about projecting long-term outcomes, cost per quality-adjusted life-year
(QALY) gained. The resulting formulae are:
Incremental cost per RDS case avoided = fCACS+CH – ½CfFN + (fFN+ + fFNF−) × (CACS + CH)g× NNTARRRDS , (8)
Incremental cost per IVH case avoided = fCACS+CH – ½CfFN+ (fFN++ fFNF−)×(CACS + CH)g× NNTARRIVH , (9)
Incremental cost per death avoided = fCACS+CH – ½CfFN + (fFN+ + fFNF−)× (CACS + CH)g× NNTARRDeath , (10)
Incremental cost per QALY gained = fCACS + CH – ½CfFN + (fFN+ + fFNF−)× (CACS + CH)g×
NNT
ARRDeathMaxQALY+ARRRDSDRDSDisuRDS +ARRIVHDIVHDisuIVH,
(11)
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where ARRRDS = the absolute risk reduction (i.e. the difference between the absolute probability with and
without appropriate ACS treatment administration) of RDS occurring, ARRIVH = the absolute risk reduction
of IVH occurring after steroid treatment, ARRDeath = the absolute overall death risk reduction (which includes
the reduction in death mediated through RDS and IVH), DIVH = the conditional probability of death in
neonates with IVH, DRDS = the conditional probability of death in neonates with RDS, DisuIVH = the QALY
loss from IVH and DisuRDS = the QALY loss from RDS.
By adopting the values in the NICE guideline model24 discussed below and summarised in Table 11,
one may calculate the relevant incremental cost-effectiveness measures using the diagnostic test results
reported by Gibson et al.67
These values result in an incremental cost per case of IVH avoided of £1,548,291, an incremental cost per
case of RDS avoided of £466,622, an incremental cost per death avoided of £473,967 and an incremental
cost per QALY gained of £20,942 with the ‘no-test and treat-all’ strategy relative to fFN. These figures do
not account for any negative effects of inappropriate use of steroids on the infant’s health, and, therefore,
may be considered a lower bound estimate.
Gibson et al.67 found that variation of the threshold from 10 to 50 to 200 ng/ml resulted in the same
number (two) of false-negative cases of women who delivered within 7 days of testing. In terms of
cost-effectiveness analysis, this finding means that qualitative testing using the 10 ng/ml and 50 ng/ml
thresholds is dominated by testing at the 200 ng/ml threshold because the latter results in lower resource
use for testing and hospital admissions than the lower threshold strategies. However, moving from the
200 ng/ml to the 500 ng/ml threshold resulted in one additional missed preterm birth case.67 Comparing
the qfFN test with the 200 versus the 500 ng/ml threshold, the AG calculates incremental costs per event
avoided of £221,115, £770,000 and £235,714 for the RDS, IVH and death outcomes, respectively. The
incremental cost per QALY is £10,415. Therefore, at the £20,000 NICE cost-effectiveness threshold,
the optimal, cost-effective diagnostic strategy is to use the qfFN with a threshold of 200 ng/ml.
TABLE 11 Model parameter values from the NICE guideline model24
Parameter Parameter definition Values Source
CACS Cost of full ACS course Included in cost of
hospital admission (CH)
NICE guideline 201524
CfFN Cost of fFN test £37.50 NICE guideline 201524
CH Cost of hospital admission £1050 NICE guideline 201524
fFN+ Marginal probability of positive fFN test result 0.18 Gibson et al.67
fFNF- Marginal probability of false-negative fFN test result 0.0082 Gibson et al.67
NNT Number needed to treat to avoid one inadequately
treated case
28.5 Gibson et al.67
ARRDeath Absolute risk reduction of death from treatment 0.049 NICE guideline 201524
ARRRDS Absolute risk reduction of RDS from treatment 0.052 NICE guideline 201524
ARRIVH Absolute risk reduction of IVH from treatment 0.015 NICE guideline 201524
DRDS Death risk from RDS 0.054 NICE guideline 201524
DIVH Death risk from IVH 0.300 NICE guideline 201524
MaxQALY Maximum lifetime QALYs without RDS or IVH 22.44 NICE guideline 201524
DisuRDS QALY loss from RDS 3.85 NICE guideline 201524
DisuIVH QALY loss from IVH 4.5 NICE guideline 201524
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It is evident from the small numbers of false-negative cases presented above that the findings from the
study by Gibson et al.67 are highly uncertain. This also highlights the need for evidence synthesis over
multiple studies in order to derive meaningful evidence.
We highlight that the above formulae (equations 7–11) allow for a separate treatment of the costs of hospital
admission and steroid treatment, in contrast to other models discussed below. This may be important
because diagnostic guidelines or protocols being used in some centres [e.g. Guy’s and St Thomas’ Hospital
(London)] suggest that the fFN threshold concentrations used by clinicians in the obstetrics department to
decide when to admit a patient may be different from those used by them for deciding when to administer
steroids. Therefore, the cost of treatment (i.e. the sum of steroid costs, CACS, and hospital costs, CH) may vary
across different qfFN thresholds.
Summary
One abstract was identified that investigated some measure of costs or cost-effectiveness of the interventions
of interest to this assessment. In this section, we have reviewed the abstract67 and corresponding dissertation68
that reported results in terms of the number needed to treat to achieve a desired neonatal outcome, and we
have shown how these data may be used in conjunction with the literature to derive useful information about
the cost-effectiveness of different thresholds for the qfFN test. We note that current treatment protocols in
some hospitals may allow for the use of different qfFN thresholds to decide whether or not to administer
steroids and admit to hospital.
Observational cost-minimisation studies
A set of studies was identified by one reviewer (RMM) in the systematic search of electronic bibliographic
databases that investigated the health-care costs of the comparator in this review: qualitative fFN testing
versus no test and treat all. These studies tended to date from 8 to 10 or more years ago and include
implementation evaluations. Although they are not relevant to our main study question (i.e. the evidence on
index tests), these studies provide some background evidence on the role of operational factors in the costs
and cost-effectiveness of interventions in routine practice. For details of these studies, see Appendix 4.
Model-based studies
We identified six different model structures presented in modelling studies of diagnostic interventions of
preterm labour.70–75 We describe these models as presented in their most recent applications found in the
published literature (Table 12). These are all decision tree models, which vary in four principal aspects. The
first is the type of study (cost-minimisation, cost-effectiveness and cost–utility analysis); the only cost–utility
model was that developed for the 2015 NICE guidelines24 by the Royal College of Obstetricians and
Gynaecologists (RCOG). The second aspect is the length of analytical horizon; some models measured
outcomes until delivery, thus assuming no differences beyond that landmark between diagnostic
strategies, whereas other models assessed outcomes until neonatal death or hospital discharge or in one
case extrapolated neonatal outcomes to lifetime. The third aspect is the obstetrician’s compliance, with
the model assuming perfect compliance with the treatment protocol based on the diagnostic test results
(i.e. all positive cases are treated and no negative cases are treated), as opposed to accounting for the
behavioural factors that reduce compliance with those protocols. The fourth characteristic is the treatment
being modelled. One model24 assumes that all positive cases are treated with tocolytics, whereas other
models base their modelling of neonatal health outcomes on the use of steroids independently of
tocolytic usage.
A detailed review of model-based studies can be found in Appendix 4. Here, we restrict discussion to a
single study, the 2015 NICE guidelines model,24 as this forms the basis for the independent economic
assessment model we develop in Chapter 6.
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TABLE 12 Modelling studies identified in the systematic review of cost-effectiveness evidence
Study (first author
and year) Population Perspective Setting
Test/diagnostic
strategy
Model
structure Time frame Effectiveness and cost parameters Type of study Comments
Deshpande (2013)70
Update of Honest
(2009)71
Threatened PTL NHS Hospital fFN and clinical
examination vs.
clinical examination
alone
Decision
tree
Before delivery l Steroids and tocolytics costs
l Admission costs (LOS)
l Hospital transfers
l Ultrasound scan
(after admission)
Cost-minimisation l Documents the use of steroids
and tocolytics from UK
diagnostic study data reported
by Dutta and Norman (2011)76
l Useful source of data on cost
parameters
l Does not include cost
of delivery
Chuck (2015)72 Threatened PTL or early
onset of delivery in
administrative databases
(inpatient and outpatient)
Alberta, Canada
Health
system
Hospital fFN vs. no fFN Decision
tree
Delivery l Test specificity and sensitivity
l Testing rates
l Admission rates after testing
l Transfers
l LOS
l Health-care costs
Cost-minimisation l Populated with data from
observational study (rates of
admission and transfers)
l The observational study found
that fFN increased transfers
and admissions
l Assumed no costs savings
from reductions of hospital
admissions for episodes with
false negative results, as costs
would only be delayed
Boyd (2011)73 Threatened PTL
(clinical diagnosis)
≥ 24 weeks’ gestation
UK
NHS Hospital fFN vs. no test Decision
tree
3 months post
birth or neonatal
hospital discharge
l Hospitalisations
l Transfers
l Health-care costs
l Neonatal morbidity
and mortality
Cost- effectiveness l fFN saved costs but had a
‘small but potentially
detrimental’ increase in
neonatal morbidity, and a
‘negligible increase in
mortality’
l It did not measure negative
effects of steroids use in false
positives. Only preterm infants
subject to morbidity are
exposed to mortality risk
Mozurkewich
(2000)74
Threatened PTL (regular
uterine contractions),
24 to 34 weeks’
gestation, intact
membranes, without
cervical dilatation ≥ 3 cm
USA
Third-party
payer
Tertiary
care unit
Rapid fFN vs. treat
all with steroids as
outputs
Decision
tree
Neonatal hospital
discharge or death
l Total cost = triage or
outpatient+ fFN
testing+ hospitalisation and
treatment+maternal
delivery+ neonatal care
l RDS
l Neonatal deaths
l Cost-effectiveness
l Cost per case of RDS/
neonatal death avoided
Maternal tocolytic side effects were
not measured. Assumed that
women having side effects
necessitating discontinuation of one
tocolytic would be given another
tocolytic if necessary. Thus,
maternal side effects would not be
related to the final probabilities of
RDS and neonatal death. Assumed
that infants with RDS receive
surfactant. It did not add costs for
maternal or neonatal transport
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TABLE 12 Modelling studies identified in the systematic review of cost-effectiveness evidence (continued )
Study (first author
and year) Population Perspective Setting
Test/diagnostic
strategy
Model
structure Time frame Effectiveness and cost parameters Type of study Comments
NICE (2015)24 Women with suspected
PTL and intact
membranes
England
NHS Hospital Treat all vs. test and
treat positive cases
Decision
tree
Lifetime of infant l QALYs
l Costs (tests, treatment,
maternal and neonatal
admissions, lifelong health care)
l Sensitivity and specificity of
SPTB within 7 days
l Mortality
l RDS
l IVH
Cost–utility What-if analysis accounted for
differences in costs and benefits by
gestation week. Assumed 100%
adherence to protocol for diagnosis
and treatment. Utilities of adverse
events were based on assumptions.
Long-term costs of adverse events
(IVH) were based on incorrect
calculations and questionable
assumptions
van Baaren (2017)75 Women with symptoms
of preterm labour,
a
intact membranes and
gestational ages of
24–34 weeks (APOSTEL-I)
The Netherlands
Societal Hospital Treat all vs. fFN Decision
tree
Neonatal death or
hospital discharge
l Proportion of patients treated,
perinatal death, composite of
adverse neonatal outcomes
(perinatal death, CLD, neonatal
sepsis, IVH > grade II,
periventricular leucomalacia
> grade I, and necrotising
enterocolitis)
l Costs (health care, medical
and non-medical transport
and indirect)
l Cost-effectiveness
l Cost per death avoided
l Cost per neonatal
adverse event avoided
Assumptions: full compliance with
diagnostic and treatment protocol.
Treatment was defined as
administration of tocolysis and
steroids, ‘combined with the
transfer of women to a perinatal
centre if they were currently in a
general hospital’. Preterm delivery
was defined as delivery within
7 days after presentation. It
distinguished between women who
deliver before 34 weeks’ gestation
and those who deliver after
34 weeks’ gestation
Accounted for different levels of
intensity of care (i.e. admission on
medium intensity, high intensity or
intensive care wards) and in-utero
transfers
CLD, chronic lung disease; LOS, length of stay; PTL, preterm labour; SPTB, spontaneous preterm birth.
a Contractions (more than three in 30 minutes), vaginal bleeding or abdominal or back pain.
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The National Institute for Health and Care Excellence 2015 guidelines model
The RCOG developed a decision-analytic model to inform the NICE 2015 guidelines24 on the diagnosis and
treatment of preterm labour and birth. The authors of this model concluded that the quality of the diagnostic
accuracy data was low for the different tests considered relevant at the time for women presenting with
symptoms of preterm labour (cervical length measurement by ultrasound scan, Actim Partus, qualitative fFN).
Consequently, they presented a ‘what-if’ analysis comparing the testing versus the no testing and treat-all
strategies, which consisted of identifying the levels of specificity and sensitivity at which a hypothetical test
became cost-effective in accordance with the NICE cost-effectiveness threshold of £20,000 per QALY gained.
Unlike previous analyses, the NICE evaluation accounted for the effect of gestational age on the trade-off
between sensitivity and specificity (i.e. costs of treating more patients unnecessarily versus missing patients
at high risk of neonatal adverse events, including death). This analysis set the cost of the test equal to that
of cervical length measurement, and found that testing was not cost-effective at gestations of < 30 weeks.
This served as the basis of the NICE recommendations about the use of testing to rule out preterm labour.
The NICE guidelines model structure is illustrated in Figure 7. In accordance with this model, the causal
pathway from diagnostic results to neonatal outcomes is mediated by tocolysis treatment, which can delay
premature delivery by ≥ 48 hours. This would generate a window of opportunity for appropriate steroid
administration (i.e. ≥ 24 hours and up to 7 days before delivery) and transfer to a tertiary hospital, thus
reducing the risk of RDS, IVH, and death. The risk reduction parameter values used in this model are based
on treatment effect estimates for calcium channel blockers versus placebo, from three separate network
meta-analyses of RCTs (one per model outcome) (NICE 2015).24 It is worth noting that two of these
treatment effect parameters, the odds ratio (OR) for death, 0.62 (95% CI 0.21 to 1.80), and the OR for
RDS, 0.81 (95% CI 0.50 to 1.34), are imprecisely estimated. The estimated OR for IVH was 0.40 (95% CI
0.21 to 0.74). None of these estimates used data from a direct head-to-head RCT. Furthermore, these
treatment effects were assumed to be constant across the gestation in the model (24 to 34 weeks), so that
the absolute risk reduction (ARR = relative risk × baseline risk) for the three types of event with tocolysis
varies by gestation only because the baseline (i.e. without tocolysis) risk declines with gestational age
(Figure 8 and see Table 11). IVH and RDS each contribute to the risk of neonatal mortality; the probability
of death is 0.300 conditional on the former and 0.054 conditional on the latter. Infants who did not
die following these adverse events would contribute additional costs and QALY losses over their
expected lifetime.
The analysis projected lifelong QALY values based on the neonatal adverse events. Infants who survived
the neonatal phase and were discharged home were assumed to have average expected QALYs that
varied with gestational age from 19.92 at 24 weeks to 22.61 at 34 weeks. These were calculated as the
gestational age-specific proportion of infants surviving the first year of life multiplied by the expected
QALYs of these infants, which, in turn, was equal to the life expectancy in England and Wales of 80 years
valued at the population norm health-state utility of 0.82 and discounted at an annual rate of 3.5%.77
Deaths in the first year of life were assumed to generate zero QALYs. In the event of RDS, an average QALY
loss would apply, arbitrarily set at 3.85 (based on RDS providing a slightly lower QALY loss than IVH).
The occurrence of IVH incurred an average QALY loss of 4.5, based on the assumption that the IVH would
incur the same quality-of-life loss as intracranial haemorrhage (ICH), which, in turn, was assumed to incur
one-third of the QALY loss of the cerebral palsy value reported by Cahill et al.78
The analysis accounted for the costs of tests, including test acquisition and staff time, drug treatment
[nifedipine at a loading dose of 40 mg and subsequent dose of 240 mg, at British National Formulary (BNF)
prices of £0.008 per 1 mg, from a 90-capsule pack of 10 mg] and administration (5 minutes of doctor and
5 minutes of nurse time) and downstream neonatal hospital costs of adverse events (RDS and IVH). The
downstream RDS costs were set at the NHS Reference Costs of neonatal intensive care unit (NICU) care
[British Association of Perinatal Medicine (BAPM) level 1] with extracorporeal life support/extracorporeal
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Women with suspected preterm
labour and intact membranes
Treat all
No diagnosis
Diagnostic test
Test positive
Test negative
No adverse event
No adverse event
Adverse event
Adverse event
Treat
No adverse event
No adverse event
Adverse event
Adverse event
Death
Death
Death
Death
Death
Death
Death
Death
Death
Death
Death
Survive
Survive
Survive
Survive
Survive
Survive
Survive
Survive
Death
RDS
IVH
IVH
IVH
IVH
RDS
RDS
RDS
FIGURE 7 The NICE 2015 guidelines model.24 Reproduced from: Royal College of Obstetricians NICE Guideline 25
Preterm Labour and Birth, London, ROCG, November 2015, with the permission of the Royal College of
Obstetricians and Gynaecologists.24
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membrane oxygenation, and the costs of IVH were assumed to be equal to the lifetime health-care costs
of ICH, which, in turn, were assumed to be equal to the health-care costs of severity grade III or grade IV
cerebral palsy.79 Regardless of how valid these clinical assumptions are, the cost of IVH appears to be
underestimated, as it was calculated with a higher discount rate than the 3.5% recommended by NICE,
and underweighted:
It was additionally assumed that Grade III and Grade IV ICH would be similar in cost to cerebral palsy.
A European paper80 estimated in year 2000 prices that the lifetime healthcare costs for cerebral palsy
using an annual discount rate of 5% was €66,155 for men and €65,288 [for women]. The mid-point
of this estimate was used and converted into GBP [Great British pounds] using an exchange rate of
£0.83 = €1 . . . It was then converted into 2011/12 prices using the HCHS (Hospital and Community
Health Service) Index. One study81 suggested that 30% of ICH is of severity Grade III and Grade IV and
therefore the cost of ICH was estimated as 0.3 × £79,000.
© NICE 2015.24 Preterm Labour and Birth. Available from www.nice.org.uk/guidance/ng25. All rights
reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in
England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE
accepts no responsibility for the use of its content in this product/publication
The parameter estimates for the different elements of cost appeared to be estimated in prices of different
years. Treatment costs were expressed in 2015 prices, costs of drug administration were in a price year
prior to 2014 and adverse events were in 2011/12 (IVH) and 2012/13 (RDS) prices. The long-term adverse
event cost of IVH was derived from a European study that reported results in 2000 euros,80 converted to
GBP (Great British pounds) using the exchange rate of £0.83 = €1.00 (the year this rate applied to was not
provided), and reflated to 2011/12 prices.
The key assumptions of the NICE guidelines model are summarised in Table 13. As in other models in this
literature, maternal outcomes are not measured. The model assumes full adherence to the diagnostic
protocol, thus abstracting from individual disparities in clinician behaviour. Critically, the model assumes
that all patients with positive test results are treated with tocolytics, which may not happen in routine
practice (Professor Andrew Shennan, King’s College London, 2017, personal communication). The model
does not explicitly account for the use and effect of corticosteroids, only implicitly within the treatment
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FIGURE 8 Baseline (without tocolytics) risks in the NICE guideline model. Reproduced from: Royal College of
Obstetricians NICE Guideline 25 Preterm Labour and Birth, London, ROCG, November 2015, with the permission of
the Royal College of Obstetricians and Gynaecologists.24
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effect estimates obtained from the network meta-analysis of tocolysis studies discussed previously in this
section. This feature makes the model less suitable for obtaining generalisable results for situations in
which the corticosteroids are used without tocolytic therapies. A major limitation of the analysis is the high
degree of uncertainty associated with the calculation of costs and QALYs, which were extrapolated to
lifetime values from neonatal morbidity outcomes. Thus, this model’s advantage in terms of producing
results in terms of QALYs for informing NICE decisions may have come at the cost of heroic assumptions
TABLE 13 Key assumptions in the NICE 2015 guidelines model24
Assumption Description Critique
The choice of diagnostic strategy has
no clinically and economically
significant effect on the mother
The clinical outcomes, costs and
QALYs associated with the mother are
not measured
Implicit is the view that the outcomes
of the mother are either irrelevant for
the policy-maker’s decision on how to
diagnose preterm labour
Full adherence to the diagnostic
protocol
All individuals testing positive are
admitted to hospital and given
treatment
Audit data from England found that
7% of patients testing fFN positive
were not admitted and 32% testing
fFN negative were admitted (Healthcare
Commission, 2008,82 and Hogg, Penney
and Carmichael, 200783)
The effects of diagnostic testing on
neonatal outcomes are mediated
through treatment with tocolytics
All individuals are treated with
tocolytics
Tocolytics is now being used
infrequently (Professor Andrew
Shennan, King’s College London, 2017,
personal communication)
Steroid use is not explicitly modelled
but implicit in the tocolytic treatment
effect values estimated from the
literature
Tocolytics may be given to postpone
delivery for at least 48 hours to
(1) allow in-utero transfers and/or
(2) treat with steroids
Some protocols on the use of qfFN
(e.g. London’s Guy’s and St Thomas’
NHS Foundation Trust) provide different
guidelines for the decision to admit and
the decision to treat with tocolytics and
to treat with steroids
The relative effect of tocolytics are
constant across gestational ages
Tocolysis reduces the risk of adverse
neonatal outcomes, including death,
at a constant proportion across
gestational ages
This is an untested assumption driven
by the available data
Neonatal morbidity outcomes are
measured in terms of RDS and IVH
RDS and IVH are two of the key
outcomes reported in the evaluation
literature on tocolytics treatment
The network meta-analysis evidence used
to populate the model parameters for
the treatment effects on these outcomes
is based entirely on indirect comparisons,
and the treatment effect estimates are
consistent with no effect (i.e 95%. OR
credible intervals cross the value of 1)
Neonatal mortality may occur through
the risk of death associated with RDS
or IVH or background risks that
decline with gestational age
The effect of tocolysis on neonatal
mortality is divided between an
indirect effect, operated through its
effect on RDS and IVH, and a direct
effect through other causes
The network meta-analysis evidence used
to populate the model parameters for the
treatment effects on this outcome was
based on no head-to-head data for the
comparison of tocolysis vs. no treatment,
and the treatment effect estimate is
consistent with no effect (i.e. 95% OR
credible interval crosses the value of 1)
The expected lifetime quality of life of
infants who survive the first year after
birth without RDS or IVH is the same
for full-term and preterm infants
Conditional on surviving the first
year of life and neonatal morbidity
outcomes, lifetime QALYs are
independent of gestational age at
birth
This assumption is questionable in the
light of evidence of long-term health
and behavioural problems associated
with preterm birth
The expected lifetime costs for
preterm and full-term infants who
survive the first year without IVH are
the same
Conditional on surviving the first year
of life and IVH occurrence, lifetime
costs are independent of gestational
age at birth
This assumption is questionable in the
light of evidence of long-term health
problems associated with preterm birth
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about the ability to predict lifetime costs and benefits from neonatal outcomes. In fact, the extrapolation
was inadequately calculated (by multiplying a life expectancy times a constant population norm) because it
did not account for the survival curve profile in population life tables and the varying utility with age,84 and
the utility norms were derived from a study that predates the time that EuroQol-5 Dimensions (EQ-5D)
scores were developed. It is unclear if by choosing to model treatment based on tocolysis as opposed to
steroids the model failed to account for outcomes in terms of other neonatal adverse events, such as
necrotising enterocolitis, sepsis and retinopathy. On the other hand, the model’s ability to account for
outcomes by gestation at presentation make this model the most relevant among those available for guiding
clinical decisions on individual patients, because other models did not produce results by length of gestation.
A summary of the main features of the model is provided using the CHEERS checklist64 in Table 14.
TABLE 14 The CHEERS checklist for the NICE guidelines model64
Item
Item
number Recommendation Reported details
Methods
Target population
and subgroups
1 Describe characteristics of the base-case
population and subgroups analysed,
including why they were chosen
Diagnosis of preterm labour in women
with intact membranes presenting with
symptoms suggestive of preterm labour
(Section 9.6, pp. 176–7, and Section 1.3,
p. 350, of NICE 2015 guideline24)
Setting and location 2 State relevant aspects of the system(s) in
which the decision(s) need(s) to be made
The model does not account for cost of
in utero transfers, thereby implicitly assuming
that women present to a level 3 hospital
Study perspective 3 Describe the perspective of the study and
relate this to the costs being evaluated
The NHS perspective was adopted.
Health-care costs are based on NHS
Reference Cost sources79 and costs of
medications are from BNF prices85
Comparators 4 Describe the interventions or strategies
being compared and why they were
chosen
It compared testing vs. no testing – treat
all vs. no test and no treat at different
gestational ages to derive the thresholds of
sensitivity and specificity that would make
testing cost-effective. This ‘what-if’
assessment was conducted in the light of
the low quality of DTA data
Time horizon 5 State the time horizon(s) over which
costs and consequences are being
evaluated and say why appropriate
Lifetime of child, based on imputed
long-term costs and QALYs on the basis of
neonatal adverse events. The lifetime
horizon is appropriate because neonatal
outcomes on which the choice of strategy
impact (respiratory and cognitive) have
long-term quality-of-life and resource-need
implications
Discount rate 6 Report the choice of discount rate(s)
used for costs and outcome(s) and say
why appropriate
3.5% for both costs and QALYs, as
recommended by the NICE reference case24
Choice of health
outcomes
7 Describe what outcomes were used
as the measure(s) of benefit in the
evaluation and their relevance for the
type of analysis undertaken
QALY. This combines morbidity and
mortality outcomes in a single index
measure for comparison across disease
areas, as required for informing NICE
decisions
continued
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TABLE 14 The CHEERS checklist for the NICE guidelines model64 (continued )
Item
Item
number Recommendation Reported details
Measurement of
effectiveness
8 Describe fully the methods used for the
identification of included studies and
synthesis of clinical data
The NICE guideline model24 was
systematically searched for studies of test
accuracy of biochemical test, cervical
length measurement by ultrasound scan
and clinical examination. However, it found
that the identified studies were of low
quality
The NICE guideline analysis24 updated a
systematic review comparing tocolytic
treatment classes using network
meta-analysis. This method allowed the
comparison of studies that were not
investigated directly in any RCT, thus
expanding the evidence base for informing
the analysis
Measurement
and valuation of
preference-based
outcomes
9 If applicable, describe the population and
methods used to elicit preferences for
outcomes
The expected QALYs at birth for an infant
without adverse neonatal events (RDS or
IVH) was calculated as the result of the life
expectancy at birth of 80 years in England
and Wales and this was multiplied by the
population utility norms of 0.82 (the details
of the citation given for this value, ‘Kind
1983’, could not be found). The disutility
associated with RDS was based on an
arbitrary assumption. The disutility associated
with IVH was based on one-third of the
utility loss from cerebral palsy
Estimating resources
and costs
10 Describe approaches and data sources
used to estimate resource use associated
with model health states. Describe
primary or secondary research methods
for valuing each resource item in terms
of its unit cost. Describe any adjustments
made to approximate to opportunity
costs
Included were the costs of tests, drug
treatment (at BNF prices) and administration
(doctor and nurse time) and downstream
neonatal hospital costs of adverse events
(RDS and IVH). The downstream RDS costs
were set at the NHS Reference Costs79 of
NICU care (BAPM level 1), and the costs of
IVH were assumed to be equal to the
lifetime health-care costs of ICH, which in
turn were assumed to be equal to the
health-care costs of severity grade III or IV
cerebral palsy. The calculations used in the
model appear to underestimate the long-
term costs of IVH
Currency, price date
and conversion
11 Report the dates of the estimated
resource quantities and unit costs.
Describe methods for adjusting
estimated unit costs to the year of
reported costs if necessary. Describe
methods for converting costs into a
common currency base and the
exchange rate
The parameter estimates for the different
elements of cost appeared to be estimated
in prices of different years: treatment costs
were expressed in 2015 prices, costs of
drug administration were in a price year
prior to 2014 and adverse events were in
2011/12 (IVH) and 2012/13 (RDS) prices.
The long-term adverse event cost (IVH)
was derived from a European study80
that reported results in Euros of 2010,
converted to GBP using an exchange rate
of 2014 and reflated them to 2011/12
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Discussion and further research
There is room for improvement in the parameter values used to populate the model, particularly in terms
of long-term disutility values of adverse events (IVH and RDS) and the health utility population norm used
for preterm survivors, which is outdated. Furthermore, the extrapolation of utility values does not account
for survival curves in life tables. In terms of costs, the quality of data collected for the NHS Reference
Costs79 of critical care BAPM levels 1–4 is low, as returns are based on the 2011 Healthcare Resource
Group (HRG) definition, which does not correspond with BAPM nursing requirements (Eleri Adams,
Oxford University Hospitals NHS Foundation Trust, 2017, personal communication). In 2016, a new HRG
classification was introduced to be more in line with BAPM requirements but this is not yet being used
for Reference Cost79 returns. In view of the lack of reliable data from NHS Reference Costs,79 we propose
that NHS tariffs for the four levels of care may be the best available estimates of true economic cost.
Furthermore, the costs of IVH were based on inappropriate calculations and data for another disease,
and systematic searching of the literature for better estimates of this cost parameter seems worthwhile.
TABLE 14 The CHEERS checklist for the NICE guidelines model64 (continued )
Item
Item
number Recommendation Reported details
Choice of model 12 Describe and give reasons for the specific
type of decision-analytic model used.
Providing a figure to show model
structure is strongly recommended
In line with prior modelling work, the NICE
guideline24 used a decision tree model,
with long-term QALY and costs pay-offs.
This is reasonable given the limited number
of neonatal outcome data on which to
base modelling of medium- to long-term
outcomes
Assumptions 13 Describe all structural or other
assumptions underpinning the decision-
analytic model
The model implies the assumption that the
mother is unaffected by the diagnostic
strategies (no maternal outcomes were
measured). It also assumed (1) full
adherence to the diagnostic protocol,
(2) that the effects of diagnostic testing on
neonatal outcomes are mediated through
treatment with tocolytics, (3) that steroid
use is not explicitly modelled but implicit in
the tocolytic treatment effect values
estimated from the literature, (4) that the
relative effects of tocolytics are constant
across gestational ages, (5) that neonatal
morbidity outcomes are measured in terms
of RDS and IVH and (6) conditional on
surviving the first year of life and neonatal
morbidity outcomes, lifetime QALYs are
independent of gestational age at birth
Analytic methods 14 Describe all analytic methods supporting
the evaluation. This could include
methods for dealing with skewed,
missing, or censored data; extrapolation
methods; methods for pooling data;
approaches to validate or make
adjustments (e.g. half-cycle corrections)
to a model; and methods for handling
population heterogeneity and uncertainty
Network meta-analysis was used to obtain
evidence of treatment effects of tocolytic
vs. no treatment on mortality and morbidity
(RDS and IVH) events. The model used no
long-term extrapolation; it simply projected
costs based on neonatal morbidity and
12-month infant survival after birth
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Other areas of uncertainty that deserve to be explored include:
l the mortality benefits of reducing the rate of false-negative cases for patients, who, depending on the
nature of the local hospital (i.e. a level 2/3 vs. a level 1 hospital), may be at increased risk of mortality if
birth takes place before 32 weeks’ gestation86
l accounting for differences in treatment costs of positive cases in accordance with the level of hospital
of presentation, owing to the costs of in utero transfers for very preterm pregnancies as well as their
repatriation to the local hospital after neonatal stabilisation
l accounting for compliance with the treatment protocol subsequent to diagnostic test findings.
In Chapter 6, we undertake these revisions to the NICE guideline model and populate them with the DTA
evidence from the systematic review in Chapter 2.
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Chapter 6 Independent economic assessment
Methods
This chapter presents a de novo evaluation of PartoSure, Actim Partus and fFN at thresholds other than
50 ng/ml, relative to fFN at 50 ng/ml as the comparator.
Model structure
In common with all previous studies (see Chapter 5), we used a decision tree to model the economic
evaluation of the diagnostic choice problem. As in the model supporting the 2015 NICE guidelines on
diagnosis and treatment of preterm labour,24 the only case that included both of these aspects of patient
management, our model includes an initial diagnostic phase followed by treatment and long-term
outcomes. Although our protocol stated the plan to use a decision tree model for the diagnostic phase
and another decision tree for the treatment phase, the available data did not allow us to populate the
decision tree for the treatment phase. Therefore, our model is a decision tree with lifetime costs and QALY
pay-offs. The model accounts for the costs incurred starting from the time women present to a maternity
hospital with symptoms suggestive of preterm labour, through hospital admission or discharge home, to
neonatal discharge or death in hospital. The health consequences to the offspring are measured in terms
of QALYs based on neonatal morbidity and mortality outcomes. The main features of our model are
that it:
l accounts for the costs and QALYs of the infant (as well as QALYs for the mother, in a scenario analysis)
l differentiates costs and benefits by gestational age
l distinguishes between hospital levels of designation – level 3 hospitals have NICUs providing all types
of care to the local population and care for the most severe infants transferred in utero or after birth,
level 2 hospitals or local neonatal units provide all types of neonatal care except long-term intensive
care and care for complex cases and level 1 hospitals provide specialised care for their local population,
stabilisation and non-invasive monitoring
l accounts for the costs and benefits of steroids and the costs of tocolysis and hospital transfer for
neonatal transfers
l determines long-term QALYs and costs by neonatal morbidity (RDS and IVH) and mortality outcomes.
The model builds on that used to inform the NICE 2015 guidelines24 on the diagnosis and treatment of
preterm labour, as the only prior model allowing for variation in health risks, and thus costs and benefits,
of inaccurate diagnosis by gestational age. By adopting this general structure, we are able to account for
the increasing neonatal health risks posed by an attending obstetrician’s failure to identify a woman in
preterm labour earlier in gestation. Unlike the NICE model, which assumed that the diagnosis of preterm
labour was intended to guide the decision of whether or not to administer tocolysis, we model the
treatment pathway following a diagnosis of preterm labour around the decision of whether or not to
treat with corticosteroids and/or admit to hospital or discharge home. This methodological variation in
our approach is motivated and informed by the very recent evidence quantifying the positive effects of
antenatal corticosteroid (ACS) administration for accelerating the maturation of the fetus’s lungs as a
function of the time of administration relative to delivery, the limited use of tocolysis reported in the
literature and the emerging consensus on its potential risks to the infant and side-effects to the
mother.30,33,34,87 For example, audit data for the period from September 2016 to May 2017 from the level 2
hospital in Exeter show that tocolysis was administered in only one out of nine patients (11%) presenting
with symptoms of preterm labour at 24–34 weeks with fFN of ≥ 50 ng/ml. In our analysis, we assume that
tocolysis is used only for all in utero transfers at gestational ages of < 28 weeks (see Results).
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Given the importance of the timing of ACS administration, the aim was to develop a model capable of
accounting for the different diagnostic test options’ capabilities to distinguish between those women likely
to deliver imminently following presentation and those who would deliver preterm in a week or later,
among presumptive cases of preterm labour. Despite our initial aim to explicitly model treatment
administration at intervals of < 2 days, 2–7 days and > 7 days before delivery, few studies of DTA reported
outcomes for the time-to-delivery interval of < 2 days (see Chapter 2, Results of the systematic review).
These intervals have been discussed in the literature as most relevant to ACS effectiveness, with 7 days
before delivery considered the earliest time for effective use of steroids in terms of fetal and neonatal
mortality and RDS.88,89 The latest evidence suggests that the effectiveness of ACSs in terms of mortality risk
reduction may be optimal within 2 days of delivery, and that it diminishes with time before delivery. This
observation also applies to the risk of RDS and IVH.33,87 Thus, we decided on the model structure illustrated
in Figure 9.
This structure shares the features of previous models of diagnosis and treatment and is determined by
(1) the available DTA data and (2) the latest evidence on the time window relative to delivery when
ACS treatment is most effective. The model assumes that the decision to admit and treat or transfer to
another hospital is driven by the test result (positive or negative). The model makes a distinction in terms
of effectiveness between diagnostic tests in accordance with their ability to correctly predict whether or
not a woman will deliver before term, and whether or not that will happen before or after 7 days.
In this model, the costs and health benefits of following one of at least two mutually exclusive courses of
action for managing a woman presenting with signs and symptoms of preterm labour are evaluated.
Figure 9 shows that a new test (PartoSure, Actim Partus and qfFN used qualitatively at thresholds other
than 50 ng/ml) or the no-test, treat-all strategy may be compared against the status quo of qualitative fFN
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FIGURE 9 The Peninsula Technology Assessment Group cost-effectiveness model structure of diagnosis and
treatment of women with symptoms of preterm labour. The dotted line indicates that the subsequent branch
structure after ‘fFN’ is identical to the structure shown for ‘New test’. New test is patient management in
accordance with one of the interventions or ‘index tests’. fFN is the comparator (admit and treat when fFN is
≥ 50 ng/ml) status quo. We also consider the no-test, treat-all comparator. Greek and Latin letters are parameters
populated with data from diagnostic accuracy test studies. π, pre-test probability of preterm birth in ≤ 7 days;
p, test sensitivity of PTB in ≤ 7 days; µ, pre-test probability of PTB; r, test specificity of PTB. PTB, preterm birth.
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(or qfFN used qualitatively at a 50 ng/ml threshold). The starting point of the model is when the decision
between diagnostic strategies is made, that is, immediately after clinical assessment of symptoms that have
not ruled out preterm labour. Thus, in the absence of further testing, all women would be admitted or
transferred to another hospital. A woman tested may deliver a preterm baby within 7 days of testing or
may deliver in more than 7 days from the time of testing; if the latter happens, birth may be preterm
(before 37 weeks’ gestation) or full term. Therefore, women may be classified in one of these three
subgroups in accordance with the time of delivery. Within each of these, the results of the new test will
determine how the patient is managed, and consequently the woman’s ability to benefit from ACS
treatment. Thus, if a woman tests positive, the obstetrician would be expected to treat her by admitting
her to the hospital and administering steroids (under fFN testing, in some hospitals women may be
admitted for observation above one threshold and admitted and administered steroids at another higher
threshold: we do not consider this case). The model distinguishes the type of hospital setting by level of
specialisation: if a woman attends a tertiary level hospital at < 28 weeks’ gestation and tests positive, she is
admitted into hospital, whereas if testing takes place at a lower-level hospital, she would be given tocolysis
(we assume that tocolysis is considered only for women undergoing in utero transfer at < 28 weeks’
gestation) and transferred to a level 3 hospital for her care. Women who test negative are sent home
without treatment; owing to a lack of any test-specific data on this parameter, we do not allow for partial
compliance with treatment guidelines in contrast with what is suggested in Figure 1. The same structure
is assumed for the status quo ‘fFN’ testing option with one and the same threshold for admission
and treatment.
In accordance with the model in Figure 9, a symptomatic woman who goes on to deliver within 7 days has
a positive test result with probability p (the sensitivity of the test) and a negative test result with probability
1 – p (the false-negative rate). Among women who deliver after 7 days, the probability of a positive test
result is equal to the false-positive rate (FPR), and the probability of a negative test result equals the test
specificity for delivery within 7 days of testing.
Some women have a positive test result, receive treatment and deliver after 7 days of testing, but before
37 weeks of gestation. In the base-case analysis, we assume that ACS produces no benefit when administered
> 7 days before preterm birth.88,89 In scenario analyses, these women are assumed to benefit from ACS,
but less so than those who are treated within 7 days of preterm delivery33,87 (we assume throughout that no
multiple courses of steroids are given, based on obstetricians’ advice on routine practice and the perceived
lack of proven benefit and risks to the neonate). The frequency of such cases is calculated as:
P(PTB > 7 days and + ve result) = (1 – ρ)×(1 – Specificity7d) – (1 – ρ37w)×(1 – r), (12)
where P(PTB > 7 days and +ve result) is the probability of having a positive test result and delivering
preterm > 7 days after testing, ρ is the incidence of delivery within 7 days, Specificity7d is the test specificity
for delivery within 7 days and r is the test specificity for delivery at < 37 weeks (i.e. the proportion of
women testing negative among those who deliver after 37 weeks), which has an incidence of ρ37w. Thus
the proportion of women who receive treatment more than 7 days before preterm birth (and, therefore,
derive partial benefit from ACSs) is equal to the difference between the FPR for delivery within ≤ 7 days
and the FPR for delivery is < 37 weeks, weighted by their respective incidences. The benefit from ACSs for
this group of women is also reduced by the fact that the baseline mortality and adverse event (IVH and RDS)
risk of preterm birth is lower, as the infant is delivered at a higher gestational age, than for mothers who
deliver within 7 days. We assume that delivery takes place at the midpoint between gestation at presentation
and 36 weeks.
Population
The population was defined as women presenting with symptoms of threatened preterm labour
(abdominal pain and contractions) with intact membranes between 24 and 36 weeks’ gestation for whom
a transvaginal ultrasound scan was not available or acceptable.
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Interventions and comparators
We evaluated the following diagnostic test strategies immediately following an initial clinical investigation
that had not ruled out preterm labour:
l testing with PartoSure
l testing with Actim Partus
l testing with qfFN at thresholds of 10, 200 and 500 ng/ml
l comparator testing with fFN at 50 ng/ml, from quantitative or qualitative versions of the test device
l treat all without testing (i.e. because clinical investigation could not attribute symptoms to other
causes, women are managed as presumptive cases of preterm labour).
These were the options for which evidence was available in the literature. Combinations of these options
were not considered, as they were not part of the NICE scope.
In addition, we explored the scenarios of evaluating (1) qualitative fFN in accordance with current treatment
protocols in Guy’s and St Thomas’ women’s hospital, where different thresholds are used to admit to
hospital (at 50 ng/ml) and treat with steroids (200 ng/ml), and (2) qfFN (qfFN) as observed at the level 2
maternity hospital in Exeter.90 These additional analyses are intended to reflect the spectrum of variation in
local current practice across the country.
Perspective, time horizon and discounting
The analysis adopted the perspective of the NHS and Personal Social Services. In accordance with the
requirements of the NICE methods guide, the time horizon is taken as the entire lifetime, and the projected
long-term health-care costs and utilities associated with avoiding an adverse neonatal outcome (death, RDS
and IVH) were measured.91 All previous models of diagnosis in preterm labour assumed much shorter time
horizons (up to neonatal death or discharge from hospital), except for the model informing the NICE 2015
guideline in this area24 (see Chapter 4 for a critique of these models). An annual discount rate of 3.5% for
costs and benefits was used, as set by NICE. We present results limited to neonatal death or discharge from
hospital in scenario analyses.
Model parameters
The model consists of two parts, the diagnostic phase and the treatment phase, each with a characteristic
set of parameters and sources of evidence. The diagnostic phase parameters are populated from diagnostic
accuracy studies of the interventions of interest, complemented by data on patient management, such as
admission rates conditional on test results, which are obtained from audit data or modelling studies. The
treatment phase is derived from large observational studies of the effects of steroids on neonatal health
outcomes and evidence synthesis of RCTs of ACS treatment. Cost estimates are obtained from detailed
costing studies in individual hospitals or routine national sources, and health-related quality-of-life utilities
have been obtained from observational and health-state preference elicitation studies.
Treatment effectiveness and extrapolation
Diagnostic test accuracy
We limit our analyses to evaluate the diagnostic tests assessed by individual comparative diagnostic
accuracy studies, as identified in Chapter 2. These studies are:
l APOSTEL-1, comparing Actim Partus with qualitative fFN at the 10, 50, 200 and 500 ng/ml thresholds
(Bruijn et al.42,43)
l a comparison of Actim Partus with PartoSure (Hadzi-Lega et al.44).
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Other studies were identified as providing relevant data but they were of lower quality than the data from
these two studies. One was a comparison of Actim Partus with fFN at 50 ng/ml.49 The study by Cooper et al.49
was the second largest of the three identified studies that compared Actim Partus with fFN at 50 ng/ml and
reported test accuracy data for delivery within 7 days and at < 37 weeks (see Chapter 2, Results of the systematic
review). However, as discussed in Chapter 2, it was unclear what version of the fFN test was used, but the ELISA
version of the qualitative fFN test, which is no longer used in clinical practice, was presumed to be used.
Therefore, we consider this study in scenario analyses, thus limiting the base-case analysis to include only
the APOSTEL-1 study, which evaluated a non-laboratory-based fFN test, and the study by Hadzi-Lega et al.44
In scenario analyses, we also evaluated the comparison of Actim Partus with fFN at 50 ng/ml (non-ELISA) tests
based on a meta-analysis of 7-day results reported by four comparative studies of these technologies.42,43,51,56,57
We did not consider this meta-analysis in the base case owing to the heterogeneity between the combined
studies, especially in terms of preterm birth rates, which probably drove their differences in test accuracy
results. Furthermore, the pooled results for each index test presented in Chapter 2, Results of quantitative data
synthesis (test accuracy data), were not considered in the economic analysis, because comparisons between
tests in terms of those results are probably confounded by the heterogeneity between the studies.
In addition, although it was excluded from the assessment of test accuracy section (see Chapter 2) because
it did not provide published test accuracy data within 7 days, we evaluated the diagnostic test considered
in the only UK study (Abbott et al.92) using data provided by the study authors for this review (Professor
Andrew Shennan, King’s College London, 2017, personal communication). This test was an assessment of
the Rapid fFN 10Q analyser (Hologic, Inc.) at the qualitative thresholds of 10, 50, 200 and 500 ng/ml.
Table 15 summarises the diagnostic test options compared in cost-effectiveness analyses, and the
diagnostic accuracy study sources used to populate the economic model.
The sensitivities and specificities used for these analyses are presented in Table 16. Two sets of accuracy
parameter values for each study were required for the model, one for predicting delivery within 7 days and
another predicting delivery before 37 weeks’ gestation. We could not obtain 37-week data for one of the
studies involving the comparison of fFN with Actim Partus (Bruijn et al.42,43). For this study, therefore, we
imputed specificity at 37 weeks from the corresponding 7-day specificity rate so as to obtain a 37-week FPR
aligned with the UK study of fFN and the Italian study of Actim Partus.54,92 Similarly, we imputed 37-week
sensitivity values for the analysis of Actim Partus versus fFN (50-ng/ml threshold) based on our meta-analysis
of 7-day accuracy data, using the Italian study data.54 We varied these values in sensitivity analyses.
TABLE 15 Diagnostic test options compared in cost-effectiveness analyses and their sources
Diagnostic test option
Comparator/
intervention
Base-case analysis Scenario analysis
APOSTEL-142,43
Hadzi-Lega
et al.44
Cooper
et al.49
Abbott
et al.92 Meta-analysis42,43,51,56,57
PartoSure Intervention ✓
Actim Partus Intervention ✓ ✓ ✓ ✓
Rapid fFN 10Q Cassette
Kit thresholds other than
50 ng/ml
Intervention ✓ ✓
fFN, threshold of 50 ng/ml Comparator ✓ ✓ ✓ ✓
No test, treat all Intervention ✓ ✓ ✓ ✓ ✓
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TABLE 16 Diagnostic accuracy values used in the Peninsula Technology Assessment Group model
Study (first author and year)
Delivery within 7 days
Delivery in
< 37 weeks
Diagnostic test N Sensitivity Specificity
Probability
distribution
sensitivity
[Beta(α,β)]
Probability
distribution
specificity
[Beta(α,β)] Specificity
Bruijn (2016)
(APOSTEL-1)42,43
fFN at 10 ng/ml 350 0.957 0.423 Beta(66,3) Beta(119,162) 0.458a
fFN at 50 ng/ml 350 0.913 0.648 Beta(63,6) Beta(182,99) 0.686b
fFN at 200 ng/ml 350 0.710 0.836 Beta(49,20) Beta(235,46) 0.866c
fFN at 500 ng/ml 350 0.420 0.957 Beta(29,40) Beta(269,12) 0.972d
Actim Partus 350 0.783 0.893 Beta(54,15) Beta(251,30) 0.929e
Hadzi-Lega (2017)44 PartoSure 57 0.833 0.902 Beta(5,1) Beta(39,12) 0.919f
Actim Partus 57 0.833 0.765 Beta(4,1) Beta(46,5) 0.764f
Cooper (2012)49 Actim Partus 349 0.333 0.741 Beta(2,4) Beta(254,89) 0.740
fFN at 50 ng/ml 349 0.333 0.898 Beta(2,4) Beta(256,29) 0.946
Abbott (2013)92 Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
information has
been removed
Confidential
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Study (first author and year)
Delivery within 7 days
Delivery in
< 37 weeks
Diagnostic test N Sensitivity Specificity
Probability
distribution
sensitivity
[Beta(α,β)]
Probability
distribution
specificity
[Beta(α,β)] Specificity
Meta-analysis by AG42,43,51,56,57 Actim Partus 963 0.832 0.879 Beta(150,30) Beta(689,94) 0.920e
fFN at 50 ng/ml 963 0.683 0.872 Beta(123,57) Beta(683,100) 0.909e
a Assumption: the FPR for delivery before 37 weeks was 6% lower than the FPR for delivery within 7 days of testing.
b Assumption: the FPR for delivery before 37 weeks was 11% lower than the FPR for delivery within 7 days of testing.
c Assumption: the FPR for delivery before 37 weeks was 18% lower than the FPR for delivery within 7 days of testing.
d Assumption: the FPR for delivery before 37 weeks was 35% lower than the FPR for delivery within 7 days of testing.
e 7-day FPR of test multiplied by ratio of FPR for delivery before 37 weeks relative to FPR for delivery in ≤ 7 days of corresponding test in Riboni et al.54
f Imputed: 7-day FPR of test multiplied by ratio of FPR for delivery before 37 weeks relative to FPR for delivery in ≤ 7 days of corresponding test in Cooper et al.49
Note
Further details are provided in Chapter 2, The 7-day delivery reference standard, and Table 6.
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Figure 10 depicts the differences in diagnostic accuracy parameters for predicting delivery within 7 days
across individual studies in Table 16 by index test and, for qfFN, by fFN threshold. The results from the
study by Cooper et al.,49 which compared Actim Partus with fFN at 50 ng/ml, are the two outlying points
at the bottom of the graph; as discussed in Chapter 2, it is unclear whether this study used a laboratory or
non-laboratory fFN test.49 Because none of the new tests appears to be superior in terms of both accuracy
measures, adopting any one of them implies a trade-off of specificity against sensitivity relative to fFN at
50 ng/ml. Not reflected in the figure is the extent of sampling uncertainty, which may be exemplified by
the case of the data for PartoSure, derived from a single study of 57 subjects.44
Background neonatal risks parameter values
Our model included underlying risks of neonatal mortality and adverse events in terms of RDS and IVH,
similar to the model that informed the NICE 2015 guidelines24 on preterm labour diagnosis and treatment,
but with data adjusted for steroid use in routine practice (Table 17 and Figure 11). We use the latest
estimates of baseline mortality risks by gestational age from the ONS.13 The risks of RDS and IVH were
derived from Medscape data compiled by Michael Ross (author; MD, MPH Distinguished Professor of
Obstetrics and Gynecology, University of California, Los Angeles, David Geffen School of Medicine;
Distinguished Professor, Department of Community Health Sciences, Fielding School of Public Health at
University of California at Los Angeles), which are available at https://emedicine.medscape.com/article/
260998-overview#a5 (accessed November 2017).
The baseline risk values in the model are intended to measure neonatal risks in the absence of ACS
treatment; thus, the values in Table 17 have been adjusted to subtract the effect of steroids use in routine
practice, using the formula:
Baseline risk =
Unadjusted risk
1 + PANS×(RRANS – 1)
, (13)
where ‘Unadjusted risk’ is the risk estimate as reported in the data source, PANS is the prevalence of ACS
use in routine practice, RRANS is the relative risk of mothers given ACSs relative to those not given ACSs
and ‘baseline risk’ is the adjusted risk estimate for each outcome and gestational age reported in Table 23.
The adjustment acknowledges the fact that the observed risk in the national statistics is a weighted
average of the risk of those who receive and do not receive ACSs, in which the weights are given by the
proportion of women receiving and not receiving ACSs. At the lowest extreme, the baseline risk will be
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FIGURE 10 Empirical summary ROC points across evaluated studies (7-day). These data (apart from those from
Abbot et al.92) come from test accuracy studies assessed in Chapter 2 and are therefore subject to the issues
discussed in relation to the quality of evidence (the implications of the quality of these data for the economic
conclusions are discussed in Chapter 9).
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TABLE 17 Baseline risk of neonatal adverse events
Gestational
age (weeks)
Adverse event
Death RDS IVH
Event
probability
Probability
distribution
[Beta(α,β)]
Event
probability
Probability
distribution
[Beta(α,β)]
Event
probability
Probability
distribution
[Beta(α,β)]
24 0.57 Beta(571,163) 0.70 Beta(408,326) 0.25 Beta(251,483)
25 0.44 Beta(480,244) 0.90 Beta(590,134) 0.30 Beta(309,415)
26 0.32 Beta(403,424) 0.93 Beta(695,132) 0.30 Beta(468,359)
27 0.24 Beta(362,537) 0.84 Beta(650,249) 0.16 Beta(280,619)
28 0.20 Beta(402,731) 0.65 Beta(650,483) 0.04 Beta(71,1062)
29 0.13 Beta(310,975) 0.62 Beta(818,467) 0.04 Beta(78,1207)
30 0.10 Beta(217,1368) 0.55 Beta(808,777) 0.02 Beta(59,1526)
31 0.08 Beta(318,1715) 0.37 Beta(776,1257) 0.02 Beta(60,1973)
32 0.05 Beta(236,2653) 0.28 Beta(771,2118) 0.01 Beta(40,2849)
33 0.04 Beta(320,3738) 0.34 Beta(1414,2644) 0.00 Beta(0,4058)
34 0.03 Beta(429,6368) 0.14 Beta(892,5905) 0.00 Beta(0,6797)
35 0.02 Beta(516,9518) 0.12 Beta(1128,8906) 0.00 Beta(0,10034)
36 0.01 Beta(547,19561) 0.07 Beta(1319,18789) 0.00 Beta(0,20108)
37 0.01 Beta(687,43773) 0.03 Beta(1458,43002) 0.00 Beta(0,44460)
Note
Source: UK stillbirth and neonatal mortality rates (ONS 201613) and US data from Medscape (https://emedicine.medscape.
com/article/260998-overview#a5; accessed November 2017). The adjusted analysis used data on ACS treatment effects
from Travers et al.93 and steroid use in routine practice from the Neonatal National Audit Programme.94
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FIGURE 11 Baseline risks of neonatal adverse events. Source: UK stillbirth and neonatal mortality rates (ONS 201613)
and rates of RDS and IVH in US data from Medscape (https://emedicine.medscape.com/article/260998-overview#a5;
accessed November 2017).
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equal to the unadjusted risk when no women are treated with ACSs or when ACSs have no effect on the
risk (i.e. RRANS = 1) and increases with ACS use and the effectiveness of ACSs to a maximum of 1/(1 – PANS)
multiplied by the unadjusted risk (i.e. when relative risk = 0). According to the National Neonatal Audit
Programme (NNAP),94 the most representative data source on ACS use in England, Scotland and Wales,
83% of mothers of babies born between 24 and 34 weeks’ gestation in 2013 (the year of our neonatal
mortality data) were given at least one dose of ACS. Because NNAP does not produce data by gestational
age, we assume such value applies to all gestational ages. We identified one study (by Travers et al.93) that
reports treatment effects of ACSs by gestational age (range 23 to 34 weeks) for death before discharge
and used that to derive RRANS (Grant95) for neonatal death in Table 23; we adopted the ACS treatment
effects on severe ICH by gestational age from the same source to approximate the RRANS for IVH. We could
not find estimates for ACS treatment effects on RDS by gestational age and, thus, assumed a constant
value of RRANS for this outcome, from the source described in Steroid treatment (Travers et al.93 report
treatment effects estimates for bronchopulmonary dysplasia, but the effects were so imprecisely estimated
that point estimates implied that the RRANS was > 1 for all but three gestational ages).
Because some IVH and RDS cases result in fatality, to calculate the number of infants who live to adulthood
with these conditions we follow the NICE 2015 guideline model24 and multiply the incidence of RDS and
IVH by 1 minus the probability of neonatal mortality among neonates with these events, which is assumed
to be constant across gestational ages. We searched the literature and identified a new source of data on
the probability of death related to IVH, which we adopted in our model.96 We found no new data on the
probability of neonatal death among RDS cases and, thus, used the value from the NICE guidelines,24 which
was obtained from US data for 2004 [Centers for Disease Control and Prevention (CDC) 200797]. The values
are 0.054 [beta(875,15393) in probabilistic sensitivity analyses] for RDS and 0.205 [beta(76,394)] for IVH.
Steroid treatment
In the model, women who test positive are treated with ANSs. In the scenarios in which women present
at level 1 or 2 maternity hospitals at < 28 weeks’ gestation, they also receive tocolysis and are transferred
in utero to a level 3 unit. The model does not account for any possible effects of tocolysis in terms of
delaying preterm delivery.
For our base-case analysis, we used treatment effects parameter values for ACS administration from results
reported by the Effective Perinatal Intensive Care in Europe (EPICE) study,33 a prospective cohort study
that collected data from 19 regions in 11 European countries in 2011 and 2012. This study was selected
as the largest and most representative source of data on ACS effectiveness in reducing neonatal mortality
and morbidity of very preterm infants by time to delivery. The EPICE study produced an analysis of the
association of administration-to-birth intervals with morbidity and mortality in 4594 infants born at
gestational ages of between 24 and 31 weeks. Given its large sample size, the study was able to analyse
the outcomes associated with corticosteroids given a few hours before birth relative to outcomes at longer
administration-to-birth intervals. The study concluded that ACSs may be effective even when administered
up to 3 hours before delivery, which was expected to reduce mortality relative to no ACS by 26%.33 The
authors reported that 77.9% of the 1111 women who received ACSs < 24 hours before delivery received
only one dose of ACS. Treatment effects on IVH were also derived from this source. For treatment effects
on RDS, we used data from the Cochrane Database Systematic Review of RCTs of the effectiveness of
ACSs relative to no treatment or placebo,34 which was also the source of values for sensitivity analyses. The
main findings from the Cochrane review are summarised in Table 18. Because subgroup analysis produced
no evidence that rupture of membrane status led to different rates of neonatal death, fetal death, RDS,
IVH or birthweight in infants exposed to corticosteroids, we decided to use the overall treatment effect
estimates in our model.
The effectiveness of steroids depends on the time from ANS administration to delivery. Table 19 displays
the treatment effect model parameter values for the base-case and sensitivity analysis, which reflect the
reduced effects of ACSs when given ≤ 7 days before birth.
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TABLE 18 Treatment effect of ACSs
Outcome Relative risk (95% CI) Source
Fetal mortality 0.98 (0.74 to 1.30) Meta-analysis; 6729 participants, 15 studies
Neonatal mortality 0.69 (0.59 to 0.81) Meta-analysis; 7188 participants, 22 studies
RDS 0.66 (0.56 to 0.77) Meta-analysis; 7764 participants, 28 studies
Moderate to severe RDS 0.59 (0.38 to 0.91) Meta-analysis; 1686 participants, 6 studies
IVH 0.55 (0.40 to 0.76) Meta-analysis; 6093 participants, 16 studies
Severe (grades 3 and 4) IVH 0.26 (0.11 to 0.60) Meta-analysis; 3438 participants, 6 studies
Chronic lung disease 0.86 (0.42 to 1.79) Meta-analysis; 818 participants, 6 studies
Data from Roberts et al.34
TABLE 19 Estimated effectiveness values of steroid treatment used in the model
Parameter
Base-case
value
Scenario
analyses
Probabilistic distribution
for sensitivity analysis
[log-normal (mean, SD)] Source
Treatment effects: neonatal mortality RR (95% CI)
ACS ≤ 7 days vs.
no ACS
0.5
(0.4 to 0.6)
0.69
(0.59 to 0.81)
Log-normal (0.50, 0.093) Base-case analysis: ACS 24 hours a
day, 7 days a week, adjusted estimate
from Table 2 in Norman et al.33
Scenario analysis: Cochrane review34
(did not distinguish by timing of ACS)
ACS > 7 days vs.
no ACS
1 0.7 (0.6 to 0.9)
0.69
(0.59 to 0.81)
Not varied: fixed at 1 Scenario analysis: Cochrane review34
and Norman et al.33
Treatment effects: RDS RR (95% CI)
ACS ≤ 7 days vs.
no ACS
1 0.66
(0.56 to 0.77)
Log-normal (0.66, 0.079) Base-case analysis: Cochrane review34
ACS > 7 days vs.
no ACS
1 0.66
(0.56 to 0.77)
Not varied: fixed at 1 Scenario analysis: Cochrane review
201734
Treatment effects: IVH RR (95% CI)
ACS ≤ 7 days vs.
no ACS
0.6
(0.5 to 0.9)
0.55
(0.40 to 0.76)
Log-normal (0.60, 0.207) Base-case analysis: ACS 24 hours a
day, 7 days a week, adjusted estimate
from Table 2 in Norman et al.33
Scenario analysis: Cochrane review34
ACS > 7 days vs.
no ACS
1 0.55
(0.40 to 0.76)
0.8
(0.6 to 1.2)
Not varied: fixed at 1 Scenario analysis: adjusted estimate
from Table 2 in Norman et al.,33
and Cochrane review34
Treatment effects: birthweight mean difference (g) (95% CI)
ACS ≤ 7 days vs.
no ACS
0 0 Not varied: fixed at 0 Assumption based on Roberts and
Dalziel32
ACS > 7 days vs.
no ACS
0 –147.0
(–292.0 to –2.0)
Not varied: fixed at 0 Base-case analysis: assumption based
on low quality of evidence in Roberts
and Dalziel32
Scenario analysis: WHO98 and Roberts
and Dalziel32
RR, relative risk.
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Health-related quality of life
We conducted a systematic search of the literature for utility values of neonatal outcomes in the model:
mortality, RDS and IVH. The details of the search strategy, identification and data extraction from the
identified studies are provided in Appendix 4, in which additional tables highlight the parameter values
used in the model. In this section, we summarise our findings.
Summary of identified studies
A total of 28 studies were identified from screening full texts as containing information useful for
obtaining or deriving utility parameters for the model, given the populations studied (i.e. either preterm
children or mothers). These studies are broadly summarised in Appendix 4.
Of these 28 studies, 24 assess the outcomes of children born preterm. The details of these studies are
summarised in Appendix 5, Table 39. Nine additional papers were cited as sources for utilities in some
of these studies. Parameter values from these additional papers are presented in Appendix 5, Table 40.
The remaining four papers assess the outcomes of mothers; these studies are summarised in Appendix 5,
Table 41.
Short Form questionnaire-36 items mapping and extraction of utilities
None of the studies that were found directly measured utilities based on the EQ-5D. However, various
mapping functions exist that allow Short Form questionnaire-36 items (SF-36)99 summary measures to be
converted into EQ-5D utilities.100 We made use of a mapping function obtained from Rowen et al.101 to
undertake this conversion, as it was deemed the most appropriate study based on regression variables and
the population sample used. A more detailed discussion of mapping studies can be found in Appendix 4.
Relevant studies for utilities of intraventricular haemorrhage and respiratory distress
syndrome and for mothers
Only one paper considers the quality of life for preterm children with IVH, separated into two severity
groups: level 0–2 IVH with no periventricular leukomalacia (PVL) and level 2–4 IVH with/without PVL.102
However, a suitable mapping to EQ-5D utility for the health-related quality-of-life measure used in this
paper could not be found.
Likewise, only one paper103 considers quality of life for preterm children with RDS. This study measures
SF-36 scores, but does not report them. We were unable to obtain the SF-36 data after contacting the
corresponding author.
The evidence on the quality of life of mothers of preterm children is sparse. Only two studies consider
mothers of preterm children specifically.104,105 The first is an abstract that reported only physical and mental
health SF-36 mean summary scores,104 and the second reported Maternal Postpartum Quality of Life
(MAPP-QOL) scores.105 Neither of these could be reliably mapped to EQ-5D utilities.
Couto et al.106 assessed the quality of life for mothers in Brazil who have had at least one of four previous
adverse pregnancy outcomes. Although preterm birth is one of the four outcomes that is an inclusion
criterion (along with early neonatal death, recurrent abortion and fetal death), we are not provided with
separate utilities for each outcome individually.
A more detailed discussion of all reviewed studies for the utilities of preterm survivors, IVH, RDS and mothers,
is provided in Appendix 4.
Utilities for reduced birthweight
In order to assess whether or not there is any quality-of-life impact from reduced birthweight as a result
of not receiving treatment, papers that were identified from title and abstract screening were searched
to find studies that contained both sufficient birthweight data and utility data. One study was identified,
and the author was able to provide the raw data on request.107
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A number of regression specifications were estimated using random-effects estimators, in order to find the
effects of birthweight on utility (see Appendix 5, Statistical analysis of the effects of birthweight on utility).
However, the coefficient estimates for birthweight and squared birthweight were not statistically significant
at the 5% level in any model. Furthermore, the simplest specification (including only birthweight and
squared birthweight) failed the LR test when compared with a specification that included gestational age,
sex and time dummies. Therefore, the analysis found insufficient evidence of a birthweight effect on utility,
and so we assumed that there is no utility loss from reduced birthweight alone. Further details of the
statistical analysis can be found in Appendix 5, Statistical analysis of the effects of birthweight on utility.
Utility parameters selected for the economic model
Based on the discussion in Appendix 4, utilities deemed the most appropriate base-case values are
reported in Table 20. Proxy utilities for RDS and IVH were obtained from the paper by Carroll and
Downs,108 which was the source for the study by Bastek et al.109
In practice, not all children with RDS go on to develop severe persistent asthma (the proxy for RDS used in
the model). Based on feedback from a neonatologist, we applied this proxy utility to 56% of all RDS cases.
This figure is from a UK-based study that found that 56% of children born extremely preterm had
abnormal baseline spirometry when they were 11 years old.110 The remaining 44% of RDS cases are
assumed to incur no additional QALY loss, relative to a preterm survivor.
For IVH, the proxy used (moderate cerebral palsy) is too severe for infants with IVH grades of below III.
On consultation with a clinical expert, long-term outcomes from IVH grades below III are thought to not
differ greatly from those of preterm survivors in general. Therefore, we apply the utility of moderate
cerebral palsy only to incidences of IVH that are at grade III or IV.
The utility for preterm survivors was obtained using mapped SF-36 scores.101 The utility computed from the UK
study111 was used for the base case, and the minimum and maximum utilities in the remaining papers were
selected to provide a range.112,113 This follows the principles outlined in the NICE technical support document.114
TABLE 20 Utilities selected for the economic model
Variable Subject Source Measure Utility Range
‘Severe’ RDS (severe persistent
asthma used as proxy)
Child Carroll and Downs108 TTO 0.85 0.84–0.86a
IVH grades III–IV (moderate
cerebral palsy used as proxy)
Child Carroll and Downs108
via Bastek et al.109
TTO 0.76 0.66–0.84b
Death Child Assumption. Upper bound
from Vandenbussche et al.115
SG (upper
bound only)
0 0–0.02
Preterm survivor Child Cooke111 SF-36c 0.879 0.846–0.901d
Mother with previous adverse
child outcome
Mother Couto et al.106 SF-36c 0.644 0.556–0.652e
Mother with no adverse child
outcome
Mother Couto et al.106 SF-36c 0.834 0.768–0.843e
SG, standard gamble; TTO, time trade-off.
a Range calculated as a 95% CI, based on the data from Carroll and Downs.108
b Range taken directly from the study by Bastek et al.109 These represent the minimum and maximum values found in their
literature search for these utilities.
c SF-36 means for the eight dimensions were mapped onto EQ-5D utilities using a quadratic model.101
d Range taken from two of the five studies reporting SF-36 scores (the minimum and maximum utilities reported among
the five studies).112,113
e Range is generated by generating a 95% CI for the eight SF-36 means, and mapping all lower bounds and all upper
bounds to EQ-5D using a linear model.101 These represent a wider estimate of the range than if a 95% CI was provided
for the EQ-5D measure directly.
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We also considered measuring the health-related quality-of-life outcomes of the mother. We identified
published evidence on longer term utility for mothers with previous adverse pregnancy or neonatal
outcomes from the study by Couto et al.106 This can be used as a proxy for mothers who have preterm
children who suffer an adverse outcome, with the caveat that it is likely to be an overestimate for infant
mortality and an underestimate for IVH or RDS. The lower (upper) bound for the two utilities imputed from
the study by Couto et al.106 is calculated by taking the lower (upper) value of the 95% CI for each of the
eight SF-36 dimensions and generating a mapped EQ-5D from this vector. This provides a relatively
pessimistic (wide) estimate of the range of utilities, which is desirable given the caveat attached to the
adverse outcome utility value.
Therefore, the utilities of mothers and infants were linked by the occurrence of neonatal mortality and
morbidity events both in deterministic and stochastic analyses. Further details on how discounted QALYs
were obtained from these utility values, and a comparison of these to the QALY values used in the NICE
guidelines model,24 can be found in Appendix 5, Quality-adjusted life-year calculations and comparison
with parameters used in the National Institute for Health and Care Excellence guidelines model. Details
may be found therein for the basis of assumptions such as the 1-year duration of mortality effects.
Summary of all child-related quality-adjusted life-year values used in the model
The base-case total discounted lifetime QALYs for children are summarised in Figure 12. For comparison,
total discounted lifetime QALYs calculated using the NICE guidelines method24 (i.e. without age and
survival adjustments across the lifespan) are denoted by dashed lines in Figure 12. As can be seen by
comparing these values, the NICE guidelines method for obtaining QALYs appears to:
l overestimate total QALYs for preterm survivors
l overestimate the QALY losses from RDS and IVH.
This illustrates that the NICE guideline method is likely to overestimate the benefits of treatment-intensive
options. It must be noted that this comparison of the two methods to extrapolating outcomes is
undertaken within the Peninsula Technology Assessment Group (PenTAG) model structure, which is based
on the effects of ACS treatment, as opposed to the original NICE model’s24 tocolytic-based mechanism
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FIGURE 12 Total lifetime QALYs for preterm children by gestational age and health state, using age and survival
adjustment (solid lines) and NICE’s unadjusted method24 (dashed lines). QALY losses in the graph are not scaled to
apply to only severe cases of RDS and IVH; this is to enable clearer visual comparison between the two QALY
calculation methods.
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of effect. Therefore, a comparison of the overestimation of QALY gains from treatment-intensive options
(e.g. treat all vs. qfFN) in the original NICE model24 is slightly smaller because, as discussed in Chapter 5 the
NICE model underestimated the benefits of treatment as it was based on tocolysis as opposed to ACSs.
Costs
The cost parameter values used in the model are presented in Table 21. The costs of the three tests include
the time involved in the costs of acquiring the test itself and the time required for a midwife to apply the
test. The costs of ACS injection and tocolysis treatment with Atosiban, as well as hospital admission and
in-utero transfer, were obtained from a published UK costing study conducted during 2009/10 in a London
university hospital.116 These costs were inflated to 2016 prices using the Health Care and Prices Index in the
Personal Social Services Research Unit’s publication of Unit Costs of Health and Social Care.117 The cost of
in-utero transfer in this study only includes the costs of the ambulance transfer service; to this, we added the
cost of arranging a transfer service and the cost of a midwife accompanying the baby during the transfer.
TABLE 21 Cost parameter values (2016 prices)
Cost parameter Unit cost (£) Definition, price-year and source
qfFN test 65 Based on 15 minutes of midwife time, with unit costs from Curtis and
Burns117
Costs of the test excluding VAT (typically £35) (request for information
from NICE to Hologic, Inc., 2017, personal communication from NICE).
Owing to lack of data, this figure does not include the cost of test failures
pIGFBP-1 35 Based on 10 minutes of midwife time, with unit costs from Curtis and
Burns117 and £15 cost of Medix test excluding VAT (request for
information from NICE to Alere Inc., 2017, personal communication from
Alere Inc.)
PAMG-1 52 Based on 10 minutes of midwife time, with unit costs from Curtis and
Burns.117 Cost of the test in the UK excluding VAT (request for information
from NICE to Parsagen Diagnostics Inc., 2017, personal communication
from Parsagen Diagnostics Inc.)
Maternal steroid injection 5 UCLH 2012 from Parisaei et al.116
Atosiban plus Atosiban
infusion equipment
362 Atosiban infusion equipment includes syringe pump, syringe and giving set
(Parisaei et al.116). Dosage or units of doses not given, nor does it include
costs of time to administer. Alternative values: BNF 2016, cost of solution
for 37.5 mg/5 ml of infusion Atosiban acetate concentrate for solution for
infusion vials, one vial costs £52.82 (hospital only) at maximum dose or
alternatively half the maximum adult dose in BNF 70 of 330.75 mg over
48 hours plus equipment cost (Parisaei et al.116)
Inpatient hospital 1325 Median length of hospital stay (2 days) multiplied by the cost of 24-hour
admission to hospital (Parisaei et al.116 based on data from Primary Care
Trust in London)
In-utero transfer 965 London Ambulance Service, 2012 (Parisaei et al.116). It includes 6 hours
(Gale et al.)118 of a modern matron’s time to arrange transfer [i.e. 6
multiplied by £62 (Curtis and Burns117)]
Long-term health-care costs
of IVH
114,648 Downstream health-care costs. NICE guideline 2015.24 These were
assumed to be equal to the cost of ICH, and that grade III and grade IV
ICH equals the cost of cerebral palsy. The calculation used by NICE 201524
seems to be wrong; we assume that the correct number is equal to
≥ £79,000, and use this number when all grades of IVH are considered
(alternatively, the assumption in the NICE 2015 guideline model24 that this
reflects 30% of the value for grade III–IV is used when considering severe
IVH only). The value assumes a life expectancy of 60 years and a discount
rate of 5% – this was adjusted using ONS 2014–16 life tables119 and for a
discount rate of 3.5%
continued
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The costs of adverse neonatal outcomes were derived from our analysis of the National Neonatal Research
Database, which contains selected data from the Badger.net neonatal electronic health records for the years
2014/15.124 In these data, the number of days spent at BAPM levels I–IV were applied to the respective HRG
tariffs for 2016. We used HRG reimbursement tariffs as opposed to the HRG Reference Costs on the advice
that the latter are unlikely to reflect actual resource use at the different levels of neonatal care, given the
common accounting practice of arbitrarily apportioning costs to the different levels of care by hospitals in
their HRG Reference Cost reports (Eleri Adams, personal communication). It was therefore thought that
HRG tariffs would better reflect the resource use in neonatal units, at least until the new HRG Reference
Costs for neonatal critical care become available.125
Unlike the economic analysis that informed the NICE 2015 guidelines24 on diagnosis and treatment of
preterm labour, our model accounts for the additional costs of saving a preterm neonatal life. There are
two offsetting effects on costs from saving the life of an infant. The cost per inpatient hospital day of an
infant who dies before discharge is likely to be greater than for a surviving infant; however, the length of
hospital stay of the surviving infant is much larger than for an infant that dies. Overall, the cost of the
length of hospital stay dominates and we estimate in national data (Badger)46 that saving a baby by means
of timely ACS treatment has the knock-on consequence of increasing neonatal hospital costs to the NHS
by £22,834. It is noteworthy that in a modelling study of the public sector costs of a preterm survivor up to
the age of 11 years, it is estimated that neonatal hospital costs account for ≈90% of the total.126
The costs of RDS and IVH were estimated from the Badger data set.120,121 In the data set available to us,
we did not have the information required to identify cases of IVH or RDS. We therefore estimated the
difference in cost between those receiving and those not receiving neonatal intensive care (BAPM level I),
after adjusting for gestational age, birthweight, sex, multiparous pregnancy, type of labour (spontaneous
vs. induced) and mode of delivery (vaginal vs. caesarean section), and assumed that the resulting estimate
was approximately equal to the cost of IVH or RDS in the model. We recognise that BAPM level I care can
also be for other causes, such as sepsis, necrotising enterocolitis and pulmonary haemorrhages, and may
TABLE 21 Cost parameter values (2016 prices) (continued )
Cost parameter Unit cost (£) Definition, price-year and source
Neonatal hospital costs of
preterm survivors discharged
home/to ward
32,435 PenTAG analysis of Badger data120,121 for infants born at gestational ages
of < 36 weeks in England and Wales in 2013/14 (n = 22,936). Includes
the costs of BAPM levels 1–5 (XA01Z, XA02Z, XA03Z, XA04Z and XA05Z)
at 2014/15 NHS tariffs. The mean overall length of stay (superspell) was
46 days (potential outcome without death)
Neonatal hospital costs of
RDS
5587 OLS-adjusted difference in neonatal hospital costs between infants with
and without days spent in BAPM level of care 1 in Badger 2014/15
data;120,121 valued at the national tariffs for BAPM levels 1–5 (XA01Z,
XA02Z, XA03Z, XA04Z and XA05Z) in 2014/15 prices. Alternative value:
downstream health-care costs; NHS Reference Costs 2011/12,79 XB01Z
Paediatric Critical Care, Intensive Care, ECMO/ECLS; NICE guideline
2015.24 Alternative value 2: Landry et al.,122 preterm hospitalisation cost:
2008 Canadian dollars; cost of medical and pharmaceutical services also
given. Adjusted using the HCHS indices and the purchasing power parities
to reflect the equivalent costs in the UK in Great British pounds in 2016.
The HCHS index for 1990/91 was calculated by taking the geometric
average yearly increase between 1988 and 2006
Additional neonatal hospital
costs: infant dies before
discharge
–22,834 Base case: neonatal hospital cost that would have been incurred by a
neonatal fatality had preterm child survived; calculated by AG from Badger
data.120,121 Alternative value: assumption of no costs, as in NICE 2015
guideline model.24 Alternative value 2: from Khan et al.123
HCHS, Hospital and Community Health Service; OLS, ordinary least squares; UCLH, University College London Hospitals.
Note
The costs were adjusted using the HCHS indices117 to reflect the equivalent prices in 2016.
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be for reasons as varied as nutrition, surgery, chest drains and congenital abnormalities. However, some of
these other causes may be affected by ACSs but are not amenable to be formally accounted for in our
model owing to a lack of evidence. To that extent, any bias that may result from this assumption may be
limited by the extent to which it compensates for those other unmeasured benefits of ACSs in our model.
Base-case analyses
In the base-case analysis, we consider the case of women presenting to a level 2 care hospital. This is
based on level 2 hospitals having the highest frequency of cases, given the mean gestational age at
presentation of 30 weeks. We set the prevalence rate of preterm birth within 7 days of testing at 3.0%
and the prevalence rate of preterm birth at < 37 weeks’ gestation at 12.1%.92 In order to derive the costs
and QALYs of PartoSure for comparison with fFN at 50 ng/ml (and other options in the full incremental
analyses), we conducted an indirect comparison whereby the incremental costs and QALYs of PartoSure
relative to fFN at 50 ng/ml based on the test accuracy data from the study by Hadzi-Lega et al.44 were
added to the costs and QALYs of Actim Partus based on the APOSTEL-1 data.42,43 Table 22 summarises the
main model assumptions.
Scenario analyses
We explore the following scenario analyses:
l alternative study sources of test accuracy data
l women presenting at tertiary-level unit hospitals
l limiting costs to the neonatal phase
l limiting costs to the diagnostic phase (until delivery)
l assuming that ACSs have (partial) benefits when administered earlier than 7 days before
preterm delivery
l excluding the neonatal hospital costs of infant death
l including mothers’ QALYs.
Probabilistic sensitivity analyses
We present probabilistic analyses using information on sampling uncertainty for test accuracy, costs and
utilities presented in Tables 16, 17 and 19. These analyses are presented in terms of the relative frequency
with which each diagnostic test option had the highest net monetary benefit of all competing options.127
Results
Because our results vary by length of gestation, we present details for the base case of a symptomatic
woman presenting at 30 weeks’ gestation (the average age on diagnostic accuracy studies) and general
results for longer (33 weeks) and shorter (26 weeks) gestation.
Base-case results
The base-case deterministic results are presented in Table 23. These are based on the preferred
comparative studies APOSTEL-142,43 and Hadzi-Lega et al.44 The base case considers women presenting at
30 weeks’ gestation to a level 2 hospital. Although all incremental cost-effectiveness ratios (ICERs) are
positive, they should be interpreted with caution because, other than ‘treat all’ and fFN of 10 ng/ml versus
fFN of 50 ng/ml, they represent a reduction in both costs and QALYs. Actim Partus results in £56,030 of
cost savings per QALY lost relative to fFN of 50 ng/ml, which are higher than those of fFN of 200 ng/ml
(£25,209) and fFN of 500 ng/ml (£17,025). The costs savings and QALY losses for PartoSure versus fFN of
50 ng/ml are the result of an indirect comparison between the studies by Bruijn et al.42,43 and Hadzi-Lega
et al.,44 because no included study directly compares these two tests. Subject to this caveat, PartoSure
would produce the same QALY loss but more cost savings than Actim Partus, relative to fFN of 50 ng/ml.
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TABLE 22 The PenTAG model specifications and assumptions
Model feature/parameter
Base-case model
specification/assumption Comment
Patient population Symptomatic women with intact
membranes presenting to a level 2
hospital, who have not been ruled for
preterm labour after clinical examination
Clinical examination is not a relevant
comparator for this population because it
precedes the starting point of the analysis
Scenario analyses consider women
presenting at level 1 and 2 hospitals
Time horizon Lifetime Scenario analyses limit the horizon to
delivery and alternatively to neonatal
hospital discharge
Diagnostic test protocol/
guideline
Complete adherence of treatment
decisions to results of diagnostic test
Differences in clinical
outcomes between test
options are the result of
differences in test sensitivity
Differences in true-positive rates result in
differences in neonatal mortality and
neonatal morbidity outcome (and costs)
through the timely use (within 7 days of
delivery) of ACSs. Maternity costs are
dependent on test sensitivity [i.e. false
negatives (i.e. delivering within 7 days
after a negative test result) are ‘missed’
(do not receive ACS)]
We vary this assumption in the scenario
analysis that limits the analytical horizon to
delivery, so that neonatal outcomes and
costs are assumed to be the same across
strategies and the only difference is in
terms of maternity costs (i.e. differences
depend only on test specificity)
Adverse events included
neonatal mortality and
morbidity
Outcomes considered are neonatal death,
RDS and IVH
This is in line with the previous model
informing the NICE guidelines on preterm
labour diagnosis and treatment (NICE 201524)
Neonatal mortality results in
net savings to the NHS
Saving a neonatal life through accurate
diagnosis and timely ACS treatment, has
the consequence of increasing NHS costs,
because the infant saved stays longer in
neonatal hospital (although at a slightly
less intensive average level of care per day)
In scenario analyses, we explore the impact
on results of assuming that saving a child
does not incur additional costs
ACSs are effective only if given
within 7 days of delivery
Infants born more than 7 days after
testing positive do not benefit from ACSs
In scenario analysis, we allow for partial
benefit from ACSs for those testing
positive and given ACS earlier than 7 days
before preterm birth (i.e. at < 37 weeks)
In utero transfers are only
required for women
presenting to a level 1/2
hospital at < 28 weeks’
gestation
Transfer to a tertiary hospital This is in line with NICE guidelines24
Tocolysis Only used for in utero transfers; no
consequences on clinical effects, only on
costs
This is intended to reflect emerging
consensus about the benefit–risk profile of
tocolysis
Long-term costs Only included those associated with IVH In line with the model informing the NICE
2015 guideline24 of preterm labour
diagnosis and treatment
Long-term quality of life Assumed that those who survive
beyond 1 year of life achieve the average
long-term quality of life in the general
population, regardless of preterm birth
status
In line with the model informing the NICE
2015 guideline24 of preterm labour
diagnosis and treatment; plausibility
supported with clinical experts’ opinion
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Table 24 shows the base-case results as a full incremental analysis. The rows of the table are ordered
from the most to the least effective testing option in terms of total QALYs. Incremental costs, QALYs and
cost-effectiveness for each test are shown in comparison with the following option in the table; for example,
fFN at 50 ng/ml is immediately above Actim Partus in the QALY ranking, but has lower costs than this test
and therefore dominates it. The relevant ICER of fFN at 50 ng/ml is, therefore, the ICER calculated relative to
PartoSure (i.e. £81,922; see Table 23). A graphical depiction of these results is presented in Figure 13.
Table 25 breaks down the base-case results shown in Table 23 in terms of their component discounted
costs and QALYs. It should be noted, as in Table 23, that the cost saving per QALY loss for PartoSure
versus fFN at 50 ng/ml is the result of an indirect comparison via Actim Partus. More specifically, the
relative differences between PartoSure and Actim Partus obtained using the study by Hadzi-Lega et al.44
were applied to the results for Actim Partus using the study by Bruijn et al.,42,43 and then compared with
fFN at 50 ng/ml.
The ICERs for women presenting at 26 weeks’ gestation and 33 weeks’ gestation at a level 2 hospital are
provided in Appendix 6.
Tornado analysis
For the tornado analysis, the parameter base-case values were increased and decreased by 20% (the upper
and the lower variations, respectively) and the ICERs versus the comparator of fFN at 50 ng/ml were
plotted, with the intersection of the vertical and the horizontal axes at the ICER base case. The tornado
plots for each of the interventions in the Bruijn et al.43 (APOSTEL-1) study and the Hadzi-Lega et al.44 study
are presented here and in Appendix 6.
TABLE 23 Summary of ICERs for women presenting at 30 weeks’ gestation (at a level 2 hospital)
Test
Total
costs
Total
QALYs
Base-case results
vs. treat all vs. fFN at 50 ng/ml
Incremental
costs
Incremental
QALYs
ICER
(per QALY)
Incremental
costs
Incremental
QALYs
ICER
(per QALY)
Actim Partusa £4891 22.010 –£1116 –0.010 £108,319b –£346 –0.006 £56,030b
PartoSurec £4731d 22.010c –£1110 –0.008 £140,587b –£506 –0.006 £81,922b
Treat all £6007 22.020 £0 0 – £770 0.004 £186,754
fFNa
10 ng/ml £5526 22.018 –£481 –0.002 £233,241b £289 0.002 £140,267
50 ng/ml £5237 22.016 –£770 –0.004 £186,754b £0 0 –
200 ng/ml £4995 22.006 –£1012 –0.014 £73,673b –£242 –0.010 £25,209b
500 ng/ml £4840 21.992 –£1167 –0.027 £42,485b –£398 –0.023 £17,025b
a Bruijn et al.42,43
b The ICER represents the south-west quadrant in cost-effectiveness (i.e. a reduction in both costs and QALYs).
c Hadzi-Lega et al.44 for comparison with treat all, indirect comparison between Bruijn et al.42,43 and Hadzi-Lega et al.44
for comparison with fFN at 50 ng/ml (Bruijn et al.42,43 was used as the reference study in this case).
d Inferred total cost and QALYs for PartoSure were obtained by applying relative differences vs. Actim Partus found using
Hadzi-Lega et al.44 to Bruijn et al.42,43
Note
Green text denotes ratios in which the difference in cost and the difference in benefit (QALYs) are both negative relative to
the reference test option.
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FIGURE 13 Incremental costs and benefits of index tests against comparator (fFN at 50 ng/ml).
TABLE 24 Fully incremental analysis of ICERs for women presenting at 30 weeks’ gestation at a level 2 hospital
Test Total costs Total QALYs
Base-case results vs. next option in the QALY ranking
Incremental
costs
Incremental
QALYs ICER
Treat all (test none) £6007 22.020 £481 0.002 £233,241
fFN at 10 ng/mla £5526 22.018 £289 0.002 £140,267
fFN at 50 ng/mla £5237 22.016 £346 0.006 £81,922b
Actim Partusa £4891 22.010 £160 0.000 Dominated by PartoSure
PartoSurec £4731d 22.010d –£264 0.003 Dominates fFN at 200 ng/ml
and fFN at 500 ng/ml
fFN at 200 ng/mla £4995 22.006 £155 0.014 £11,296 (dominated by PartoSure)
fFN at 500 ng/mla £4840 21.992 – – – (dominated by PartoSure)
a Bruijn et al.42,43
b Calculated relative to PartoSure, which dominates Actim Partus.
c Hadzi-Lega et al.44 for comparison with treat all, indirect comparison between Bruijn et al.42,43 and Hadzi-Lega et al.44
for comparison with fFN at 50 ng/ml (Bruijn et al.42,43 was used as the reference study in this case).
d Inferred total cost and QALYs for PartoSure were obtained by applying relative differences vs. Actim Partus found using
Hadzi-Lega et al.44 to Bruijn et al.42,43
Notes
Options have been ranked from most to least effective (in terms of QALYs). ICERs are relative to the next most effective
option (i.e. the test in the row immediately below).
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The tornado plot for PartoSure (imputed) versus fFN at 50 ng/ml is shown in Figure 14. The remainder can
be found in Appendix 6 (see Figures 19–23). There is a consistent pattern across all comparisons. The results
are sensitive to the health-related quality of life (state utility) of preterm survivors. Much less influential are
the cost of hospital admission, the prevalence of preterm birth within 7 days, the effectiveness of steroid
treatment and the baseline mortality risks. Other parameter values appear to have no discernible influence
on the results.
TABLE 25 Breakdown of base-case results (discounted costs and QALYs)
Cost and benefit
components
Base-case results
Treat all
Bruijn et al.42,43 (APOSTEL-1)
Indirect
comparisona
fFN at
10 ng/ml
fFN at
50 ng/ml
fFN at
200 ng/ml
fFN at
500 ng/ml
Actim
Partus PartoSure
Discounted costs (£)
Diagnosis 0 66 66 66 66 35 52
Treatment 5 3 2 1 0 1 0
Hospital admission 1325 781 493 250 95 177 1
In-utero transfer 0 0 0 0 0 0 0
Neonatal IVH 4006 4008 4010 4018 4030 4015 4015
Neonatal RDS 624 624 625 627 630 626 626
Neonatal deathb 47 45 43 33 20 36 36
Total 6007 5526 5237 4995 4840 4891 4731
Incremental costs
(vs. fFN at 50 ng/ml)
770 289 Reference –242 –398 –346 –506
Discounted QALYs
Surviving neonate
without morbidity
22.00 22.00 22.00 22.00 22.00 22.00 22.00
Infant morbidity
due to IVH
–0.02 –0.02 –0.02 –0.02 –0.02 –0.02 –0.02
Infant morbidity
due to RDS
–0.00 –0.00 –0.00 –0.00 –0.00 –0.00 –0.00
Infant mortality
avoidance
0.04 0.04 0.04 0.03 0.02 0.03 0.03
Total 22.020 22.018 22.016 22.006 21.992 22.010 22.010
Incremental QALYs
(vs. fFN at 50 ng/ml)
0.004 0.002 Reference –0.010 –0.023 –0.006 –0.006
ICER vs. fFN at 50 ng/ml (£) 186,754 140,267 Reference 25,209b 17,025c 56,030c 81,922c
a Costs and QALYs are inferred values computed via an indirect comparison between the Hadzi-Lega et al.44 and Bruijn
et al.42,43 studies.
b These are the neonatal hospital costs associated with those infants saved by steroid treatment.
c The ICER represents the south-west quadrant in cost-effectiveness (i.e. a reduction in both costs and QALYs).
Note
Green text denotes ratios in which the difference in cost and the difference in benefit (QALYs) are both negative relative to
the reference test option.
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Probabilistic sensitivity analyses
At a willingness to pay per QALY threshold of £20,000, Actim Partus has a probability of being cost-effective
of 14%, 21% and 21% for women presenting at gestational ages of 33, 30 and 26 weeks, respectively
(Figure 15, and see Appendix 6, Figures 24 and 25). PartoSure has probabilities of being cost-effective of 83%,
76% and 75% for women presenting at gestation of 33, 30 and 26 weeks, respectively, but these values are
based on indirect comparison and have a lower strength of evidence than for other diagnostic options.
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FIGURE 15 Probabilistic analysis: women presenting at 30 weeks’ gestation. The highest net monetary benefit is for
a gestational age at presentation of 30 weeks.
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FIGURE 14 Tornado diagram for model parameters with the most influential variation in value: PartoSure.
PTB, preterm birth; RR, risk ratio.
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The treat-all option has a probability of being cost-effective of 0% at a willingness to pay per QALY threshold
of £20,000 for all women, and becomes the option with the highest likelihood of being cost-effective for
women presenting at 26 weeks’ gestation only at a willingness to pay per QALY threshold of > £180,000.
Scenario analyses
Alternative diagnostic accuracy data
Using the DTA results of the study by Cooper et al.,49 which did not include PartoSure, suggests that the
fFN at 50 ng/ml test provides lower costs with equal health benefit when compared with Actim Partus.
The option of treating all women compared with fFN at 50 ng/ml yields an ICER of £34,508 per QALY.
(Confidential information has been removed.) (See Appendix 6, Table 56.)
When the diagnostic accuracy data from the meta-analysis of the four studies that compared Actim Partus
with fFN at 50 ng/ml were used,42,43,51,56,57 Actim Partus was dominant over fFN at 50 ng/ml as it resulted in
cost savings of £41 per woman and health benefits of 0.01 more QALYs per woman. The treat-all option
increased costs and QALYs and resulted in an ICER of £70,468.
Other scenarios
Including the negative impact on QALY outcomes, the effect of an infant’s death on mothers (which is
assumed to last for 10 years) favours options that involve more use of ACS treatment. That is, in Table 26
(and see Appendix 6, Tables 63 and 64), the ICER for treat all and fFN at 10 ng/ml under the column ‘with
maternal QALYs for 10 years’ is lower than in the ‘base case’ column. When we limit the analytical horizon
to the time of delivery, the assessment becomes in effect a cost-minimisation analysis because our model
does not account for health-related quality-of-life outcomes of the mother during the antenatal period.
In this scenario, among women presenting at a gestational age of 30 weeks, PartoSure is the least costly
option, with a £507 reduction in costs per woman, followed by fFN at 500 ng/ml (£400 reduction in costs
per woman) and Actim Partus (£347 reduction in costs per woman). As discussed previously, the values for
PartoSure need to be considered with caution.
When we allow for partial benefits of ACSs given earlier than 7 days before birth, the ICERs for fFN at
10 ng/ml and treat all are £24,420 and £41,625, respectively, among women presenting at 30 weeks’
gestation; as for the rest, only PartoSure results in savings per QALY lost of > £20,000 relative to fFN at
50 ng/ml (see Table 26). Further details on the analyses of women presenting at a gestational age of
26 weeks are presented in Appendix 6, Tables 54–56. Detailed results for women presenting at 33 weeks’
gestation are presented in Appendix 6, Tables 57–59. Tornado analyses of these gestational age groups
are presented in Appendix 6, Additional deterministic sensitivity analyses, their associated probabilistic
sensitivity analyses are presented in Appendix 6, Additional probabilistic sensitivity analyses, and other
scenarios are presented in Appendix 6, Scenario analyses.
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TABLE 26 Incremental cost-effectiveness ratios vs. fFN at 50 ng/ml
Option
ICERs by scenario (£)
Base case
Presentation
at 26 weeks’
gestation
Presentation
at 33 weeks’
gestation
With
maternal
QALYs for
10 years
Limiting the
analysis to
delivery
(additional
cost only)
Limiting the
analysis to the
first year after
birth
ACS earlier than
7 days before
preterm delivery
has partial benefits
Excluding
additional
neonatal
hospital costs
of death
Women
presenting
at a level 3
hospital
Applying
costs and
disutilities
of AEs to
all AEs
Treat all 186,754 128,939 323,093 111,813 770 4,930,356 41,625 185,771 186,754 175,158
fFN
10 ng/mla 140,267 92,845 242,716 74,564 289 3,704,141 24,420 139,284 140,267 131,558
200 ng/mla 25,209b 16,541b 43,781b 18,968b –243 669,219b 9728b 24,226b 25,209b 23,664b
500 ng/mla 17,025b 11,476b 29,631b 13,347b –400 453,340b 7428b 16,042b 17,025b 15,968b
Actim Partusa 56,030b 35,364b 97,069b 38,200b –347 1,482,175b 16,662b 55,046b 56,030b 52,551b
PartoSurec 81,922b 53,446b 141,838b 81,893b –507 2,165,156b 128,506b 80,939b 81,922b 76,836b
AE, adverse event.
a Bruijn et al.42,43
b The ICER represents the south-west quadrant in cost-effectiveness (i.e. a reduction in both costs and QALYs).
c Indirect comparison between the studies by Bruijn et al.42,43 and Hadzi-Lega et al.44 (Bruijn et al.42,43 was used as the reference study in this case).
Note
Green text denotes ratios in which the difference in cost and the difference in benefit (QALYs) are both negative relative to the reference test option.
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Chapter 7 Assessment of factors relevant to the
NHS and other parties
l The practical considerations when conducting these tests, highlighted to us by our advising
obstetricians, were:
¢ The qfFN swab can be collected at an appropriate time (e.g. when a woman is being examined)
and, if the clinician decides it is best to ‘wait and see’ for a few hours, the sample can be stored.
Using the pack to collect the sample is free; it is only when the cassette is opened to run the test
that a cost is incurred by the hospital.
¢ Manufacturing guidance from Actim Partus suggests that the swab should be collected from
the cervical os. Visualising the cervix can sometimes be difficult; therefore, it may not always be
practical to take the sample from the cervical os as advised.
l Some of these tests have a dual purpose because they can be used for other indications (e.g. women
with multifetal pregnancies, women with ruptured membranes and women not presenting with
symptoms). Our population is not representative of the whole population of women presenting with
threatened preterm labour. However, it is recognised that treatment of these other populations may
involve different management strategies.
l It is highlighted that new diagnostic test options for diagnosing preterm labour and predicting preterm
birth are likely to have spillover and feedback effects between maternity and neonatal care services.
A proper evaluation of the potential impact of these tests would therefore need to account for the
possibilities offered in the context of more integrated networks of maternity and neonatal services.
l There are potential implications of adopting new biochemical tests on neonatal unit workload and
service planning.
l Health-care service and travel needs and costs are borne by patients and relatives owing to changes in
in utero transfer policy resulting from new tests. This includes the effect on the likelihood that a very
preterm infant is born in a hospital with an inadequate level of specialisation, and the cost and health
consequences associated with postnatal transfers.
l There are effects on resource use in other parts of the public services (e.g. educational services) associated
with improvements in preterm birth survival rates and avoidance of neonatal long-term morbidity.
l There are long-term parental and societal economic impacts.
l There are equity implications of changes in hospital admissions across rural and urban areas.
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Chapter 8 Patient and public involvement
Patient and public involvement was not conducted for this project. This research project was part ofthe NICE Diagnostics Assessment programme in which, from the publication of the scope in week 12,
there were 24 weeks in which to prepare the entire report. Regrettably, it was not logistical nor feasible
to recruit and prepare for and report patient and public involvement in this project within the permitted
time frame. Patients and the public were involved in the NICE Diagnostic Advisory Committee meetings,
in which recommendations based on this report were made.
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Chapter 9 Discussion
Review of test accuracy evidence
This is the first review to systematically review the biomarker tests Actim Partus, PartoSure and qfFN
(at thresholds other than 50 ng/ml) together.
A summary of the key findings from the systematic review of test accuracy evidence can be found in
Chapter 2, Summary. In brief, 20 included studies evaluated an index test against the 7-day reference
standard41–62 and seven studies evaluated an index test against a 48-hour reference standard.41,48,52,53,56–58
There was sufficient evidence for pooling the test accuracy data for Actim Partus and PartoSure only
against the 7-day reference standard and Actim Partus only against the 48-hour reference standard.
However, owing to the substantial methodological, clinical and statistical heterogeneity between studies
and large 95% prediction regions (Actim Partus against the 7-day reference standard) and wide 95% CIs
(PartoSure against the 7-day reference standard and Actim Partus against the 48-hour reference standard),
there are considerable uncertainties surrounding the validity of these results.
The studies that offered the greatest certainty when looking to compare test accuracy results were those
that assessed two or more different tests within the same population. We identified two such studies:
APOSTEL-142,43 (2016; assessing Actim Partus and qfFN) and the study by Hadzi-Lega et al.44 (2017;
assessing Actim Partus and PartoSure). No studies assessing qfFN and PartoSure within the same
population were identified by our review. From APOSTEL-1, the sensitivity was superior for qfFN at the
thresholds of 10 and 50 ng/ml compared with Actim Partus, whereas Actim Partus had a superior
sensitivity compared with qfFN at the 200-ng/ml and 500-ng/ml thresholds. Specificity was superior using
Actim Partus compared with qfFN at the thresholds of 10, 50 and 200 ng/ml but not against the threshold
of 500 ng/ml. From the study by Hadzi-Lega et al.,44 the sensitivities were the same for PartoSure and
Actim Partus, whereas the specificity was superior using PartoSure. However, the CIs for all sensitivity and
specificity data from the two tests assessed within these two studies overlapped considerably (all data
available in Table 9).
When looking at the ranges of results for individual tests across studies, substantial heterogeneity between
the studies is clearly apparent. For Actim Partus against the 7-day reference standard (16 studies), the study
with the best overall sensitivity and specificity results was that by Tripathi et al.57 [sensitivity 94.7% (95% CI
89.9% to 97.7%) and specificity 92.4% (95% CI 88.% to 95.1%)], whereas Cooper et al.49 reported the
worst sensitivity [33.3% (95% CI 4.3% to 77.7%)] and specificity [74.1% (95% CI 69.1% to 78.6%)]. These
are two of the three largest studies identified in our review (Tripathi et al.,57 n = 468; Cooper et al.,49 n = 349).
For PartoSure against the 7-day reference standard (four studies), the study with the best overall sensitivity
and specificity results was that by Bolotskikh and Borisova59 (2017) [sensitivity 100.0% (95% CI 73.5% to
100.0%) and specificity 95.4% (95% CI 88.6% to 98.7%)], whereas Werlen et al.41 reported the worst
sensitivity [0.0% (95% CI 0.0% to 97.5%)] and specificity [97.5% (95% CI 96.8% to 99.9%)]. The low
sensitivity from the study by Werlen et al.41 is attributable to only one woman delivering preterm (within
7 days) and her testing (falsely) negative within the study sample of size 41. If discounting the results from the
study by Werlen et al.,41 the next study reporting the worst overall sensitivity and specificity results was that
by Nikolova et al.60,61 (2015) [sensitivity 80.0% (95% CI 63.1% to 91.6%) and specificity 94.6% (95% CI
90.1% to 97.5%)]. The fFN at a threshold of 10 ng/ml (two studies) had a sensitivity range of 93.8% (95% CI
82.8% to 98.7%) to 95.7% (95% CI 87.8% to 99.1%) and a specificity range of 32.2% (95% CI 27.7% to
37.0%) to 42.3% (95% CI 36.5% to 48.4%). At a threshold of 200 ng/ml, fFN had had a sensitivity range of
70.8% (95% CI 55.9% to 83.0%) to 71.0% (95% CI 58.8% to 81.3%) and a specificity range of 78.6%
(95% CI 74.3% to 82.5%) to 83.6% (95% CI 78.8% to 87.8%). At a threshold of 500 ng/ml, fFN had a
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sensitivity range of 29.2% (95% CI 17.0% to 44.1%) to 42.0% (95% CI 30.2% to 54.5%) and a specificity
range of 94.3% (95% CI 91.6% to 96.4%) to 95.7% (95% CI 92.7% to 97.8%). Looking at these data,
given the large ranges between studies assessing the same test and the wide CIs, it would be premature to
attempt to deduce which test was superior to the 7-day reference standard.
We were able to assess Actim Partus and PartoSure only against the 48-hour reference standard because no
studies were identified for qfFN. From the single PartoSure study (Werlen et al.41), the sensitivity was 0.0%
(95% CI 0.0% to 97.5%) and specificity was 97.5% (95% CI 86.8% to 99.9%); the total sample size was
41 and only one test result was positive (a false positive). From the six Actim Partus studies, the data could be
pooled; however, the same heterogeneity issues as with studies against the 7-day reference standard were
relevant here too. Looking at Actim Partus against the 48-hour reference standard (six studies), the study
with the best overall sensitivity and specificity results was that by Tripathi et al.57 [sensitivity 95.5% (95% CI
89.7% to 98.5%) and specificity 82.1% (95% CI 77.8% to 86.0%)], whereas Goyal et al.52 reported the
worst sensitivity [65.7% (95% CI 47.8% to 80.9%)] and specificity [56.0% (95% CI 34.9% to 75.6%)].
Given that we identified only a single study for PartoSure and the wide range of test accuracy data between
the study reporting the best and worst results for Actim Partus, it would be premature to attempt to deduce
which test was superior to the 48-hour reference standard.
We identified two relatively recent systematic reviews128,129 that assessed fFN at a threshold of 50 ng/ml
(i.e. current practice). Both of these reviews suffered from similar heterogeneity issues as our review and
their summary ROC plots displayed large 95% prediction regions. The pooled sensitivities for the reviews
by Boots et al.129 and Sanchez-Ramos et al.128 were 75% (95% CI 69% to 80%) and 76.1% (95% CI
69.1% to 81.9%), respectively, and the specificities were 79% (95% CI 76% to 83%) and 81.9% (95% CI
78.9% to 84.5%), respectively.
Both the study’s heterogeneity and the uncertainty about the true accuracy of the index tests inevitably
compromise the report’s ability to firmly conclude whether or not the accuracy of the index tests is better
than current practice.
Strengths
The strengths of this systematic review are that it was conducted by an independent, experienced research
team using the latest evidence and working to a prespecified protocol (PROSPERO CRD42017072696) that
follows a robust methodology.
The search strategy was devised by a dedicated information specialist. The strategy did not restrict by study
design and included both forward and backward citation chasing, web searching and cross-checking with
studies provided by the companies. The studies were independently screened by two reviewers, with data
extraction and quality appraisal conducted by one reviewer and checked by a second.
Weaknesses
The primary weakness of the review of test accuracy was the substantial methodological and clinical
heterogeneity between included studies. There was considerable heterogeneity in the following areas:
prevalence of preterm birth, mode of delivery, gestational age, definition (symptoms) of preterm labour
(including dilatation threshold), inclusion of multiple gestations, participant characteristics and provision of
treatments. As a consequence, the reported accuracies of individual tests varied widely, and hence the CIs
in the pooled analyses are also wide. Subsequently, we have limited confidence in the mean pooled test
accuracy results.
A limitation to our review was the lack of published studies in which two or more index tests were
administered to the same population. Such studies allow us to have more confidence in any differences
between the accuracy results of the tests as differences would not be attributable to population or study
design. Only two studies, APOSTEL-142,43 (2016) and Hadzi-Lega et al.44 (2017), assessed the DTA of two
different index tests in the same population; APOSTEL-142,43 assessed both Actim Partus and qfFN and
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
98
Hadzi-Lega et al.44 assessed Actim Partus and PartoSure. We did not identify any studies in which all three
tests were used in the same population.
Our review was also limited by the lower number of published studies for qfFN (two studies) and PartoSure
(four studies) than for Actim Partus (16 studies) against the 7-day reference standard. In addition, fewer
studies published data against the 48-hour reference standard, with only seven studies being identified
(six for Actim Partus and one for PartoSure). Meta-analysis of test accuracy data requires a minimum of
four studies; therefore, the scope for meta-analysis was restricted. We are aware of three studies published
after our searches were run that assessed PartoSure (Wing et al.,130 Lofti et al.131 and Melchor et al.132) and
(confidential information has been removed). We also identified seven relevant ongoing trials, four of
which are UK based, of which two plan to enrol > 1000 participants. Personal communications with trial
organisers (Dr Sarah Stock, University of Edinburgh, 2017, and Professor Andrew Shennan, King’s College
London, 2017) indicated that data from the two large UK trials (QUIDS/QUIDS-2 assessing PartoSure, Actim
Partus and qfFN and PETRA assessing qfFN) were expected in 2018. There is the potential, should our
analyses be re-run using the data from these trials, that the estimates of relative test accuracy may change.
The scope issued by NICE12 asked for an assessment of test accuracy of qfFN at thresholds other than
50 ng/ml. Our capabilities to look at different thresholds was limited by those reported in the published
studies. The two qfFN studies both used thresholds of 10, 50, 200 and 500 ng/ml. Without access to the
individual patient data, we were unable to assess any other thresholds.
Owing to the paucity of published test accuracy studies, we made two protocol amendments. The first was
to include women with multiple gestations (up to 20% of the total population). Without this amendment,
there would have been no includable qfFN studies. The second was to include studies in which testing
was not carried out in line with clinical practice (i.e. the samples were frozen and analysed at a later date).
Without this amendment, we would have had only one includable qfFN study (Bruijn et al.62).
Dependent on how the data were reported in each study, we were required to conduct some data
manipulations. Most studies reported the raw true-positive, true-negative, false-positive and false-negative
data, enabling us to calculate additional test accuracy statistics, such as sensitivity, specificity, PPV and NPV.
However, four studies48,54,56,57 reported only sensitivity, specificity, PPV and NPV. We back-calculated from
these statistics to derive the true-positive, true-negative, false-positive and false-negative values, which were
required in our review. All the raw data as reported in the published studies are available in Appendix 3
(see Tables 33 and 34).
Our review limited included studies to those published in the English language. This may be considered a
limitation; however, a systematic review assessing the bias of excluding studies that were not in the English
language found no evidence of bias but that there may have been an impact on precision.133 Our review
did include a French study (Werlen et al.41), as a certified translation was received from the manufacturer
(Parsagen Diagnostics Inc.).
Areas of uncertainty
There is considerable uncertainty surrounding the generalisability of the studies to the UK population.
Most specifically, none of the included studies was conducted in the UK. In addition, the prevalence rates
of preterm birth in our included studies ranged from 2% to 73%. UK prevalence is approximately 8%.
These differences in prevalence between studies are probably attributable to the differences in the
populations recruited into the studies (e.g. differences in gestational age, in presenting symptoms of
preterm labour and in recruitment of high- or low-risk women). It is likely that the prevalence of preterm
birth will have an impact on the DTA data presented in Chapter 2, Results of quantitative data synthesis
(test accuracy data).134 Indeed, Leeflang et al.134 explored how sensitivity and specificity vary with disease
prevalence, and suggested using prevalence as a guide when selecting studies that most closely match
the situation under assessment.
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Our ongoing trial searches identified four relevant ongoing UK trials, two of which are very large
(> 1000 participants) and their results are anticipated to be published in 2018 (PETRA and QUIDS).
There is some uncertainty around whether or not the studies included in the review will be representative
of women who do not (or cannot) have access to cervical length measurement. No studies were identified
that were specifically based on such a population; the majority of studies did not mention access to
cervical length measurement, seven studies used (but did not select participants based on) cervical length
measurement and two studies only included women with a transvaginal cervical length measurement
of ≤ 30 mm. It is in these final two studies (APOSTEL-142,43 and Danti et al.50) in which there is most
uncertainty; selection based on cervical length measurement would probably increase the prevalence of
preterm birth in these studies. However, given that 15 of the 20 included studies had a prevalence rate
of < 25% and both studies had a prevalence of < 25% (APOSTEL-1,42,43 19.7%; Danti et al.,50 6.7%), it is
unlikely that these criteria had an impact on prevalence rates.
There was also uncertainty around whether or not any management strategies (e.g. treatments) would
incorrectly inflate false-positive rates. As described in Chapter 2, Summary of any treatments given, the
types of treatments offered to women in threatened preterm labour differed between each study, as did
the level of detail describing what and who received the treatments. More often than not, the treatment
options were at the clinician’s discretion. It is most likely that the tocolytic treatments would have the
biggest impact on incorrectly inflating the false-positive rate, as their purpose is to delay delivery.
It is understood that clinicians would use the results of these tests in combination with other clinical
information to make clinical decisions. A mobile application called QUIPP is used in local clinical practice to
assist with decision-making. The QUIPP app generates a risk score from the following information: whether
or not the mother is symptomatic, number of fetuses, gestation in weeks and days, qfFN value and/or
cervical length measurement. In our review, we did not consider combining test results with such clinical
data, because no studies were identified that assessed this combination.
We also acknowledge four studies of PartoSure and quantitative/qualitative fFN that have been recently
published or are due to be published. These studies were published after our searches were run and
consequently were not eligible for the review. The studies are:
l Wing et al.130 (2017), n = 796 – PartoSure and fFN at 50 ng/ml
l Lofti et al.131 (2017), n = 132 – PartoSure
l Melchor et al.132 (2017), n = 420 – PartoSure and fFN at 50 ng/ml
l (confidential information has been removed).
Review of clinical effectiveness evidence
No studies were identified that met the inclusion criteria of this review.
Strengths
The review was conducted by an experienced research team and the conducted searches were very
sensitive as no study design filters were used. All citations were screened by at least two members of the
review team. The review team worked to a prespecified prospective protocol.
Weaknesses
The review focused on published literature indexed by bibliographic databases, meaning that grey
literature was not identified. The searches were conducted in July 2017, so it is possible that studies have
been published and indexed subsequently that have not been identified.
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Areas of uncertainty
Because no studies were identified for inclusion, we were unable to assess whether or not using these
biomarker tests for predicting preterm labour is clinically effective (i.e. whether or not they would improve
health outcomes).
Review of cost-effectiveness evidence
Only one conference abstract was identified that was relevant to our cost-effectiveness review.66
Strengths
Our review was able to highlight the major developments in methodological practice. Studies have evolved
from evaluating only the cost differences of diagnostic strategies, so that competing options were selected
solely on the basis of their ability to rule out cases of unnecessary treatment and admission, to evaluating
the neonatal health implications of missing the rare cases of true preterm labour. A clear finding from the
review was the limited information that most previous economic analyses provide for guiding decision-
making. With one exception (the model that informed the 2015 NICE guidelines24 on diagnosis and
treatment of preterm labour), the previous studies do not account for the gestational age gradient in
neonatal mortality and morbidity risk exposure and its consequences for cost-effectiveness.
Furthermore, previous models did not account for the variation in costs and benefits of diagnostic testing
across hospital settings.
Our results also highlight the need to account for the neonatal hospital cost implications of saving a
preterm infant, which no previous study has addressed.
Our analysis also suggests that, since the 2015 NICE guidelines24 on preterm labour diagnosis and
treatment, the evidence on the risk–benefit profile for tocolysis and steroids has changed. Tocolysis is now
used sparingly, whereas the importance of providing steroids within 2 days of preterm delivery has gained
consensus, especially following articles published in 2017. Unlike the NICE guidelines model, which used
tocolysis as the mediator of improved diagnosis and clinical effectiveness in terms of neonatal mortality and
morbidity, cost-effectiveness analysis should be considered with reference to the timing of corticosteroid
administration. Despite the 2015 NICE guideline recommendation that women presenting with symptoms
of preterm labour at < 30 weeks’ gestation should be admitted to hospital without testing, current practice
has not followed this recommendation. Instead, the fFN and Actim Partus tests are commonly used to guide
admission and treatment decisions in women as early as 22 weeks’ gestation. The qualitative fFN test that
previously produced a binary result has now been replaced with a test that provides a concentration level.
Clinicians are using the new test in more flexible ways than the older binary test, in some cases applying
different thresholds for admission and steroid treatment. This warrants new analysis that takes into account
the emerging evidence and updated testing practices.
Weaknesses
We focused on economic studies in symptomatic women with intact membranes, and did not cover
studies of asymptomatic women, which might have provided important relevant evidence on utilities,
costs, epidemiological parameters and modelling methods. For example, we learned that the only study
measuring generic health-related quality of life for outcomes of mothers (EQ-5D utilities) was a RCT in
asymptomatic women [the OPPITIMUM (dOes Progesterone Prophylaxis To prevent preterm labour IMprove
oUtcoMe) trial by Norman et al.135 in 2016]. We contacted the authors to request utility data, but these
were not yet available to external researchers to the trial.
At the time of writing, there is no published full economic evaluation of new index tests. The existing
studies have addressed only the question of the cost-effectiveness of testing versus no testing. We are
aware that there is a research article being prepared for publication on the basis of the QUIDDS project that
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evaluates the use of qfFN in 1500 individuals across the UK (Dr Sarah Stock, University of Edinburgh, 2017,
personal communication). This will constitute the largest known economic study to date on a biochemical
test in the population of interest to this review, and will enable the investigation of key outcomes for clinical
effectiveness, such as the ability to predict delivery within 2 days of presentation with symptoms suggestive
of preterm labour. Previous diagnostic studies of fFN tests have provided limited data on such outcomes.
In terms of methodological economic evaluation practice, older studies evaluating the at-the-time standard
practice of treating all symptomatic women assumed that the economic value of diagnostic testing
depended solely on a test’s ability to rule out cases in which patients were not in preterm labour or likely
to deliver within 7 days. More recent studies have extended the analysis from a purely cost-minimisation
framework to a cost-effectiveness framework, by recognising that, however few false-negative cases may
be missed by testing, they are placed at a risk relative to the treat-all alternative management option, so
that there is a trade-off between cost savings and increased risks to life and quality of life for a few cases
with testing. The model that informed the 2015 NICE guideline24 on diagnosis and treatment of preterm
labour represented a methodological advance in that it explicitly recognised that such trade-offs varied by
gestational age and were more favourable to testing at older gestational ages.
Since the 2015 NICE guidelines24 on the topic, new evidence has emerged on the value of timely use of
ACSs, which may still confer benefits on the neonate if given within 1 day of delivery and have a maximum
benefit when given between 1 and 2 days of delivery. However, existing models are ill suited to account
for this emerging evidence as few diagnostic studies are large enough to include sufficient numbers to
measure such outcomes reliably. Current clinical guidelines and recommendations maintain that steroids
need to be given within 7 days of delivery to be effective, although empirical findings published in 2017
by separate independent groups of researchers suggest residual beneficial effects when steroids are given
more than 7 days before delivery.34,35,94 On the other hand, existing studies have not accounted for the
risks posed to the neonate by ACSs in terms of birthweight, despite the common perception by health
professionals of the importance of these risks as manifested through the existing tendency to not give
repeated courses of ACSs to women who do not deliver within 7 days of an initial course.
Finally, although the screening was carried out by two reviewers, the data extraction and critical appraisal
were conducted by only one. This may increase the risk of bias associated with the findings of this review.
Areas of uncertainty
Our review could not inform the cost-effectiveness of PartoSure, Actim Partus and fFN. The only evidence
available was found for fFN in an unpublished study (a MSc dissertation68), which suggests that fFN at a
threshold of 50 ng/ml for treatment and hospital admission may be an inefficient use of NHS resources and
that restricting treatment and admission by raising the threshold to 200 ng/ml may be cost-effective. These
findings were derived by the AG from the number needed to test to adequately treat a woman with steroids,
as reported by the unpublished study of fFN, using a decision tree model and costs and utilities as used by
the NICE 2015 guideline model.24 In view of the limitations of the unpublished model highlighted previously,
it is unclear whether or not these findings are robust to sampling and structural model uncertainty.
Key areas of structural uncertainty include the maintained assumption in the NICE model24 that false
negatives (i.e. those who test negative but deliver within 7 days of testing) miss treatment and, therefore,
are placed at increased risk of neonatal death and of experiencing adverse chronic events including RDS
and IVH. In fact, some of those ‘missed’ cases are likely to return to the maternity hospital and receive
ACSs closer to delivery, thus, paradoxically deriving more benefit from the treatment than if they had been
detected in the first place. Another key unknown is the effect of accounting for neonatal costs on the
results, because previous studies have ignored the costs associated with neonatal deaths and have used
low-quality data on costs of neonatal morbidity. Better quality data on neonatal hospital costs (length of
stay at different levels of care) are available for the UK from the National Neonatal Research Database.124
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Independent economic assessment
In order to address some of the key limitations in the evidence base, primarily the lack of any evidence
on the cost-effectiveness of the index tests in question, we developed a de novo model. The model
incorporates the main elements of existing published models, in which a decision tree is used to evaluate the
costs of the diagnostic phase until delivery, and is linked to data on neonatal outcomes and hospital costs that
are mediated by ACS use, which is, in turn, contingent on diagnostic test results. Following the practice in
the model that informed the 2015 NICE guideline on the topic,24 we extrapolated costs and quality-adjusted
life-years to the lifetime of the infant to account for the lasting cost and health-related quality-of-life
consequences of neonatal IVH, and the quality of life of infants who survive the first year after birth.
Our analysis compared all index tests (PartoSure, Actim Partus and qfFN at thresholds other than 50 ng/ml)
with the comparators (fFN at 50 ng/ml and no testing and treating all) based on the best available diagnostic
accuracy evidence for the tests. This turned out to be from the two available studies that compared at least
two index tests in the same patient sample (Bruijn et al.42,43 and Hadzi-Lega et al.44). One study compared
qfFN with Actim Partus in a group of women from the Netherlands (n = 350),42,43 and the other compared
Actim Partus with PartoSure in a group of women from Macedonia (n = 37).44 Thus, we presented an
economic evaluation of those two comparisons and also of the indirect comparison of PartoSure with fFN
via Actim Partus as the common treatment to both studies, and included the no-testing treat-all and fFN at
50 ng/ml comparators using the data from the Dutch study.
In women presenting at 30 weeks’ gestation, PartoSure was cheaper and had the same effectiveness
as Actim Partus, which, in turn, saved costs at the expense of inferior health outcomes (fewer QALYs)
relative to fFN at 50 ng/ml. ‘No testing treat all’ and fFN at 10 ng/ml had ICERs of > £100,000 relative to fFN
at 50 ng/ml, and fFN at 200 ng/ml and fFN at 500 ng/ml each produced less cost savings per unit of QALY
lost relative to fFN at 50 ng/ml than Actim Partus. Probabilistic sensitivity analysis shows that the willingness
to pay per QALY would need to be > £100,000 for a test other than PartoSure to become the option most
likely to be cost-effective. Similar results apply to women presenting at different gestational ages.
It must be noted that these results are based on two studies from non-UK populations. This is important
because diagnostic accuracy results may vary with the prevalence rate and the only UK study (n = 299;
Abbott et al.92) reported a 7-day prevalence rate of 3%, compared with 19.7% (n = 350; APOSTEL-1,
Bruijn et al.42,43) and 10.5% (n = 57; Hadzi-Lega et al.44) reported by the studies used in the base-case
economic analysis. Subject to this strong caveat, our result that Actim Partus saves more costs per QALY
lost relative to fFN at 50 ng/ml than qfFN at 200 ng/ml and 500 ng/ml is robust to different assumptions.
The only scenario when this result did not apply was when we used data from a Canadian study (Cooper
et al.49); however, this appears to have used a qualitative fFN test technology that is no longer in use.
In contrast to the results reported by the economic analysis that informed the 2015 NICE guidelines on
preterm labour diagnosis and treatment,24 we found that the policy of not testing and treating all women
presenting at ≤ 30 weeks of gestation had ICERs well above the £20,000-per-QALY-gained level. There are
important differences between our model and that used by NICE, primarily in terms of the test accuracy
data used, which were not available to NICE at the time, and the fact that in our model the mechanism
from test results to clinical outcomes operated through the use of ACSs. NICE assumed that the benefits
were accrued through the use of tocolysis and populated its treatment effectiveness parameters from
neonatal outcomes reported by RCTs of tocolytics, whereas we populated treatment effectiveness with
the latest evidence on steroids effectiveness. There were also differences in terms of the measured costs,
because we included the costs to the NHS generated by infants whose lives were saved by ACS use,
which NICE assumed to be zero. Although we used the same source of national statistics on neonatal and
adverse event mortality data, we used more recent data than NICE. On the other hand, we adjusted the
baseline risk values derived from those data for the fact that ACSs are now highly prevalent, with 83%
of preterm infants born in the UK being given at least one ACS dose; the model used by NICE did not
adjust for such prevalent use of ACS and, thus, may have underestimated the QALY benefits from
treatment-intensive options.
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Strengths
We provide new evidence on the cost-effectiveness of new and existing diagnostic tests in use in the NHS.
We model the costs and benefits of diagnostic testing on the basis of recent evidence on the optimal
time-to-delivery intervals for effective ACS administration in terms of neonatal mortality and morbidity
(RDS and IVH). Furthermore, we adopted the best modelling practice in the field and introduced some
innovations by accounting for:
l gestational age
l hospital setting (level 1, 2 or 3)
l costs of in utero transfers at very preterm gestation
l neonatal hospital costs of saving a preterm infant
l long-term QALYs and costs of additional preterm birth survivors with and without adverse events
(RDS and IVH)
l mothers’ QALYs (in exploratory analysis).
We also conducted extensive scenario analysis and probabilistic analysis to reflect sampling uncertainty in
model parameter values.
Weaknesses
We were unable to consider multipurpose uses of some of the tests (i.e. relevant for other indications). In
our analysis, we did not account for the effect of costs of any deals offered by suppliers for the purchasing
of combinations of diagnostic tests or in bulk over a hospital network.
The scope of our analysis is limited by the fact that we do not consider diagnostic strategies involving
combinations of tests. The population was defined as women for whom a transvaginal ultrasound scan
was not indicated or who were attending maternity hospitals in which it was unavailable.
We had to approximate the neonatal hospital costs of RDS and IVH, assuming that they are the same and
equal to the additional neonatal hospital costs incurred by infants who were admitted to BAPM level 1
care (this led to costs similar to those used by the NICE 2015 guideline model24).
Critically, the evidence on accuracy was limited to two comparative studies, one of which may be considered
too small (n = 57) to reliably detect differences between index tests; in fact, the study found PartoSure and
Actim Partus to have the same sensitivity, which in our model determines clinical effectiveness. Therefore, our
findings must be considered with caution and point to the need to conduct further research before drawing
any conclusions on the relative cost-effectiveness of Actim Partus and PartoSure. On firmer ground are the
findings that, relative to fFN at 50 ng/ml, Actim Partus produced larger savings per QALY lost than fFN at
200 ng/ml and fFN at 500 ng/ml, whereas ‘treat all’ and fFN at 10 ng/ml had ICERs above the £80,000 mark
in women presenting at 24–34 weeks’ gestation; these results are based on diagnostic accuracy data from
one study42,43 in 350 women. However, it must be noted that our results were based on the assumption that
the overall test accuracy reported in these studies is the same across gestational ages, owing to a lack of data
by length of gestation.
It is worth noting that the only UK diagnostic study was a non-comparative study of qfFN, in which fFN at
200 ng/ml and at 500 ng/ml resulted in the same sensitivity as that of fFN at 50 ng/ml. This was considered
in scenario analyses, and fully incremental analysis suggests that lowering the fFN threshold for diagnosing
preterm labour from 500 to 200 ng/ml has an ICER of < £20,000, whereas lowering it from 200 to 50 ng/ml
has an ICER of > £20,000.
There is an absolute lack of evidence on the outcomes of the status quo diagnostic test, qfFN, in routine
practice. Our analysis was largely based on the modelling of the strict adherence to local hospitals’
treatment guidelines with fFN. We were able to obtain audit data on treatment practice over 6 months
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(2016–17) in a local level 2 hospital (n = 75); however, this is too small an administrative sample to draw
definitive conclusions.
A methodological limitation of our analysis is the working assumption that false-negative cases miss
treatment altogether with the associated increased exposure to risks of neonatal mortality and morbidity.
It may be argued that at least some false negatives may actually end up benefiting from being ‘missed’
because they may deliver between 2 and 7 days and, therefore, as an unintended consequence get the
chance to return before delivery and closer to the target optimal window for ACS administration of 1 to
2 days before delivery.33 Thus, many if not most false negatives may possibly end up having the same clinical
outcomes as true positives. This would appear to justify applying a simpler modelling approach that focused
only on costs (i.e. cost-minimisation analysis) or perhaps on 48-hour as opposed to 7-day diagnostic outcomes.
Given the limited existing data and large sample sizes required to measure 48-hour diagnostic outcomes, the
cost-minimisation analysis may seem the only practicable alternative and we conducted scenario analyses that
limited the analytical horizon to the time of delivery, effectively providing a cost-minimisation analysis of the
decision problem of interest (i.e. because we do not measure any clinical outcomes for the diagnostic phase).
This scenario analysis also favoured Actim Partus and suggested that PartoSure may be cost-effective subject
to the strong caveat discussed previously. Another argument in support of cost minimisation is provided by
the perceived harm of multiple courses of ACSs; in this case, the key diagnostic outcome measure for clinical
effectiveness would be the FPR because not only would it result in ineffective use of ACSs to start with but it
would measure the extent to which women were precluded from any use of ACSs and thus exposed to the
risk of adverse neonatal health outcomes. This suggests that the cost-minimisation analysis may be thought of
as a conservative alternative scenario to the base case.
We found no reliable data to account for the side effects of ACSs in terms of birthweight. The only source
of data on long-term quality-of-life outcomes by birthweight that we identified was from a Canadian study
by Saigal et al.,107 which involved measured quality-of-life outcomes in 286 extremely low-birthweight
survivors at adolescence and young and mature adulthood. Our analysis showed that data produced no
detectable relationship between birthweight and quality of life, which may be attributed to the sample
being too small to reliably measure long-term outcome differences by gestational age at birth.
There was little evidence on quality-of-life outcomes of mothers, and we could conduct only some
exploratory analysis of results including such evidence. Another limitation is that costs and utility values
were independent of gestational age at birth; for example, we assumed that, provided a preterm infant
survives until their first birthday, they will experience the same long-term quality of life as in the average
population. Owing to a lack of data on the quality-of-life effects of IVH, we had to use utility values from
other patient populations (i.e. individuals with ICH).
The mapping algorithm that we used to derive EQ-5D utility values from SF-36 produced predicted EQ-5D
utilities that were consistently higher than (overpredicted) actual EQ-5D utilities for more severe EQ-5D
states;101 however, this prediction error is large only for health-state utilities of < 0.25. The lowest mapped
utility we consider is 0.64, which was for mothers, and not used in base-case analysis. The only mapped
utilities included in the base case were for preterm survivors, and these were all > 0.8. Therefore, although
there is certainly a limitation with the mapping function, we do not believe that the limitation is a concern
given the ranges of utility values we deal with in this review.
Areas of uncertainty
There is a high degree of uncertainty associated with the costs and health benefits of PartoSure relative to
other tests, as we had access to only one comparative study of this test, which involved < 100 individuals.
A study of this size is unlikely to provide reliable results on diagnostic accuracy on delivery outcomes at
48 hours and 7 days. The uncertainty of our findings is compounded by the lack of a study of all relevant
tests in the same patient sample, which led us to resort to indirect comparisons using a common
comparator (i.e. Actim Partus) approach.
DOI: 10.3310/hta23130 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 13
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Varley-Campbell et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of
Southampton Science Park, Southampton SO16 7NS, UK.
105
More generally, as discussed previously, the ability to predict delivery within 48 hours has become critical,
given recent evidence on the importance of good neonatal outcomes of administering ACSs within such a
short period before birth. In addition to prediction within 7 days, we aimed to differentiate in our model
for the ability of a test to predict delivery within 48 hours but we abandoned that analysis owing to a lack
of the required data for the great majority of studies. Further DTA studies in preterm labour should be
undertaken with sufficiently large samples to measure and report diagnostic outcomes for the within
48 hours delivery end point in addition to the conventional 7-day outcomes.
Given the importance of this element for the cost-effectiveness of diagnostic options, further research is
warranted to produce the data required to calculate more precise measures of long-term QALYs gained
by saving a neonatal life, which distinguishes by the gestational age at birth. Furthermore, evidence is
required on the long-term implications of birthweight reductions on quality of life, so that an adequate
picture of the implications of the benefit–risk profile of ACSs may be accounted for in economic assessments.
There is a high degree of heterogeneity in the evidence on DTA, as illustrated by the very different
prevalence of preterm birth between the largest comparative study (APOSTEL-1,42,43 20% delivery within
7 days) and the UK study (Abbott et al.,92 3% delivery within 7 days), which is not explained by the former
study’s inclusion and the latter’s exclusion of non-spontaneous preterm births. More obvious differences in
the selection of patients for study participation is also a problem, as highlighted by the high preterm birth
prevalence in one of the four available studies comparing Actim Partus and fFN at 50 ng/ml,57 which, by
including patients at gestational ages of 28–36 weeks, rather than the more common 24- to 34-week
range, led to a 7-day prevalence of preterm birth of 32.5% versus 19.7% in the largest comparative study
of these tests (APOSTEL-1) (see Chapter 2, Differences between studies in mode of delivery).
We did not conduct a value-of-information analysis because, as with any model of intervention at birth,
there is a degree of structural uncertainty associated with the need to extrapolate from neonatal to lifetime
outcomes that would render parameter uncertainty meaningless. Thus, probabilistic sensitivity analysis
needs to be considered as exploratory and value of information could not be considered reliable in
informing research priorities.
Some of the uncertainties discussed previously may be addressed by the findings of two large (> 1000
participants) ongoing trials of the predictive utility of qfFN (PETRA) and qfFN, PartoSure and Actim Partus
(QUIDS 2) in the UK. Until these new data become available, the value of PartoSure is unlikely to be
settled. This and other studies may also address a key issue of uncertainty in our analysis, namely whether
or not the use of the new tests do affect routine patient management. Our model was limited by the lack
of these data and the consequently simplifying assumption that mothers were treated in strict accordance
with the test results, which we know does not happen with the current status quo test (fFN at 50 ng/ml).
Other relevant factors
In these analyses, we have not allowed for the complicated treatment protocols and guidelines that
have been implemented in some hospitals whereby, for example, some women may be admitted with a
concentration level above one fFN threshold but not given ACSs unless that level is above another, higher,
threshold. This type of more complicated decision algorithm may work to optimise the status quo, but may
more reasonably be evaluated using actual data on its operation and results rather than, as has been done
here, modelled on the assumption of full adherence.
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Chapter 10 Conclusions
A lthough evidence was identified relating to the test accuracy of the three biomarker tests, there wastoo much uncertainty in the results to be able to draw any clear conclusions on the relative accuracies
of the tests. With the imminent publication of relevant UK-based data from large studies, it may be
advisable to wait for these data to be published.
We identified no trials that followed patients from testing to ultimate health outcomes. Therefore, we
found no direct evidence on whether or not the use of the biomarker tests for predicting preterm labour
led to improved health outcomes. Instead, we used modelling for this purpose.
The limited evidence from DTA studies in patient populations from non-UK countries suggests that Actim
Partus may result in a discounted QALY loss of 0.006 per women tested but reduces discounted health
care costs by > £30,000 per QALY lost relative to the status quo (the qfFN at 50 ng/ml test). This ratio
of savings per QALY lost is larger than that achieved by other options that restrict treatment relative to
standard practice (qfFN at 50 ng/ml) (i.e. qfFN at 200 ng/ml and qfFN at 500 ng/ml). In contrast, options
that increase access to treatment (i.e. qfFN at 10 ng/ml and the policy of no testing and treat all) increase
QALYs and costs and have ICERs in excess of £100,000 relative to qfFN at 50 ng/ml. As for PartoSure, the
evidence is inconclusive owing to the small number of patients in the only comparative study of the test.
These findings warrant reconsideration in the light of forthcoming evidence from large ongoing diagnostic
studies of these tests in UK populations. Our results suggest that the current NICE-recommended policy
of treating all symptomatic women presenting at < 30 weeks’ gestation without testing may not be
cost-effective.
Suggested research priorities
The primary research priority would be for DTA studies to assess more than one of the index tests within
the same trial. Given the practical limitations of comparative studies in this area, a feasible study would
give all new tests to the same mothers and compare diagnostic accuracy results with those of the local
standard practice. This would allow for a more robust comparison between tests, because population
differences between trials would not be an issue. It is probable that these types of studies are currently
under way, because some of the index tests are, comparatively speaking, in their infancy of use and
to date have been predominantly compared with older (qualitative fFN) or not commonly used (cervical
length) tests. We are aware of four ongoing comparative studies, three in the UK and one in France.
The publication of these studies will greatly help us compare the DTA between the tests, given that the
sample population and hospital treatment protocols will be standardised.
New diagnostic studies involving larger samples are required to investigate the differences in available tests
in terms of test accuracy outcomes defined relative to delivery within 48 days of testing. Few previous
studies have reported these outcomes, which is probably a reflection of the fact that they have included
very small samples to reliably measure such outcomes. The importance of this question is highlighted by
the emerging evidence documenting the first 48 hours as the target window to optimise ACS treatment.
Studies that follow mothers and babies from testing through to final health outcomes are required. Ideally,
such studies would also compare tests. The available evidence includes only observational before-and-after
studies of changes in local practice from a policy of managing women in accordance with no testing (treat all)
to one based on the results of fFN at 50-ng/ml testing. Similar evidence may be obtained by taking advantage
of variation in practice across the UK, where one of fFN or Actim Partus may be used routinely.
More evidence is required about the side effects of ACS treatment. Despite the perceived risks of steroids
in terms of neonatal outcomes, there is little evidence on the effects of inappropriate use of the treatment.
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There is practically no evidence on the mothers’ health-related quality-of-life outcomes after diagnostic
testing for preterm labour, both before and after birth and over the long term. Observational studies
may be able to provide some of these data, particularly in relation to long-term outcomes, using existing
representative surveys of birth cohorts.
Improving on the costs of cognitive, respiratory and intestinal neonatal adverse events is also warranted,
using electronic records from the Badger data set,120,121 such as that extracted by the National Neonatal
Research Database. This would allow the more precise assessment of the costs to the NHS from key
neonatal outcomes affected by diagnostic testing.
CONCLUSIONS
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Appendix 1 Literature search strategies
Database searches
MEDLINE
Host: Ovid.
Data parameters: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid
MEDLINE(R) Daily, Ovid MEDLINE and Versions(R).
Date range searched: inception to 24 July 2017.
Date searched: 24 July 2017.
Searcher: Chris Cooper.
Search checked by: Jo Varley-Campbell.
Hits: 916.
Search strategy
1. (PartoSure or Parto Sure or PartoSureR or Parto SureR).ti,ab,kw. (3)
2. ((Placental alpha adj5 test$) or PAMG-1).ti,ab,kw. (44)
3. (Actim Partus or Actim PartusR or “insulin-like growth factor-binding protein 1 test” or phIGFBP-1 or
(IGFBP-1 adj5 test$)).ti,ab,kw. (103)
4. (((Fetal or foetal) adj5 fibronectin$) or fFN).ti,ab,kw. (787)
5. 1 or 2 or 3 or 4 (916)
Notes: not applicable.
File name: PartoSure MEDLINE 916 RIS.txt
EMBASE
Host: Ovid.
Data parameters: 1974 to 21 July 2017.
Date range searched: inception to 24 July 2017.
Date searched: 24 July 2017.
Searcher: Chris Cooper.
Search checked by: Jo Varley-Campbell.
Hits: 1270.
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Search strategy
1. (PartoSure or Parto Sure or PartoSureR or Parto SureR).ti,ab,kw. (13)
2. ((Placental alpha adj5 test$) or PAMG-1).ti,ab,kw. (75)
3. (Actim Partus or Actim PartusR or “insulin-like growth factor-binding protein 1 test” or phIGFBP-1 or
(IGFBP-1 adj5 test$)).ti,ab,kw. or *actim partus test/ (158)
4. (((Fetal or foetal) adj5 fibronectin$) or fFN).ti,ab,kw. (1080)
5. 1 or 2 or 3 or 4 (1270)
Notes: not applicable.
File name: PartoSure Embase 1270 RIS.
The Cochrane Library (Cochrane Database of Systematic Reviews, Cochrane Central
Register of Controlled Trials, Database of Abstracts of Reviews of Effects, Health
Technology Assessment and NHS Economic Evaluation Database)
Host: Wiley Interface.
Data parameters: (CDSR: issue 7 of 12, July 2017; DARE: issue 2 of 4, April 2015; CENTRAL: issue 6 of 12,
June 2017; HTA issue 4 of 4, October 2016; and NHS EED issue 2 of 4, April 2015).
Date range searched: inception to 24 July 2017.
Date searched: 24 July 2017.
Searcher: Chris Cooper.
Search checked by: Jo Varley-Campbell.
Hits: 159 [note: 164 hits were identified. 159 study records were downloaded and five records from the
methods register (3) and Cochrane groups register (2) were not downloaded (totalling 164). NHS EED and
DARE were searched as an archive because they have not been updated since 2015]: CDSR 36, DARE 13,
CENTRAL 91, HTA 14 and NHS EED 5.
Search strategy
#1 (PartoSure or Parto Sure or PartoSureR or Parto SureR) (17)
#2 ((Placental alpha near/5 test*) or (PAMG-1)) (15)
#3 (Actim Partus or Actim PartusR or “insulin-like growth factor-binding protein 1 test” or phIGFBP-1 or
(IGFBP-1 near/5 test*)) (13)
#4 (((Fetal or foetal) near/5 fibronectin*) or fFN) (125)
#5 #1 or #2 or #3 or #4 (164)
BioSciences Information Service
Host: Clarivate Analytics.
Data parameters: 1969–2017.
Date range searched: inception to 24 July 2017.
Date searched: 24 July 2017.
Searcher: Chris Cooper.
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Search checked by: Jo Varley-Campbell.
Hits: 806.
Search strategy
(PartoSure or Parto Sure or PartoSureR or Parto SureR) (2)
((Placental alpha near/6 test*) or (PAMG-1)) (25)
(Actim Partus or Actim PartusR or “insulin-like growth factor-binding protein 1 test” or phIGFBP-1 or
(IGFBP-1 near/6 test*)) (80)
(((Fetal or foetal) near/6 fibronectin*) or fFN) (716)
Notes: not applicable.
File name: PartoSure BIOSIS 806 RIS.
Web of Science
Host: Clarivate Analytics.
Data parameters: 1900–2017.
Date range searched: inception to 24 July 2017.
Date searched: 24 July 2017.
Searcher: Chris Cooper.
Search checked by: Jo Varley-Campbell.
Hits: 1358.
Search strategy
(PartoSure or Parto Sure or PartoSureR or Parto SureR) (3)
((Placental alpha near/6 test*) or (PAMG-1)) (45)
(Actim Partus or Actim PartusR or “insulin-like growth factor-binding protein 1 test” or phIGFBP-1 or
(IGFBP-1 near/6 test*)) (124)
(((Fetal or foetal) near/6 fibronectin*) or fFN) (1226)
Notes: not applicable.
File name: PartoSure WoS 1358 RIS.
Cumulative Index to Nursing and Allied Health Literature
Host: EBSCOhost.
Data parameters: 1937–2017.
Date range searched: inception to 24 July 2017.
Date searched: 24 July 2017.
Searcher: Chris Cooper.
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Search checked by: Jo Varley-Campbell.
Hits: 258.
Search strategy
(PartoSure or Parto Sure or PartoSureR or Parto SureR) (4)
((Placental alpha N6 test*) or (PAMG-1)) (22)
(Actim Partus or Actim PartusR or “insulin-like growth factor-binding protein 1 test” or phIGFBP-1 or
(IGFBP-1 N6 test*)) (25)
(((Fetal or foetal) N6 fibronectin*) or fFN) (221)
Notes: not applicable.
File name: PartoSure CINAHL 258 RIS.
Trial registry searching
Date range searched: inception to 29 August 2017.
Date searched: 29 August 2017.
Searcher: Sophie Dodman.
ClinicalTrials.gov (https://clinicaltrials.gov/ct2/home)
Search terms, enumerated as four different searches:
1. Parto Sure
2. Actim Partus
3. Fetal fibronectin
4. Foetal fibronectin
ISRCTN (www.isrctn.com/editAdvancedSearch)
1. Parto Sure
2. Actim Partus
3. Fetal fibronectin
4. Foetal fibronectin
Web searching
Date searched: 17 September 2017.
Searcher: Chris Cooper.
The first 50 pages were searched in each instance.
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Google
Search strategy
1. PartoSure
2. PartoSure filetype:pdf
3. “Actim Partus”
4. “Actim Partus” filetype:pdf
5. “Fetal fibronectin”
6. “Fetal fibronectin” filetype:pdf
Utilities database searches
Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations,
Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present
Date range searched: inception to 11 September 2017.
Date searched: 11 September 2017.
Search strategy
# Searches Results
1 exp Obstetric Labor, Premature/ 23,638
2 ((Pre term or preterm or premature or early or immature) adj5 (labo?r or birth$ or childbirth$ or deliver$
or partu$ or baby or babies or child$ or infant$ or toddler$ or postnatal or neonatal)).ti,ab,ot,hw.
188,755
3 (PROM or PPROM or PROM or PTB).ti,ab,ot. 7439
4 ((Short$ or reduced or multiple) adj4 gestation$).ti,ab,ot. 4711
5 (low$ adj3 birth weight).ti,ab,kw. 26,742
6 1 or 2 or 3 or 4 or 5 210,020
7 (euroqol or euro qol or eq5d or eq 5d or EQ-5D or EQ-5D-Y or EQ-5D-5L).ti,ab,kw. 7897
8 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).ti,ab,kw. 1831
9 (sf10 or sf 10 or short form 10 or shortform 10 or sf ten or sften or shortform ten or short form
ten).ti,ab,kw.
102
10 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve of sftwelve or shortform twelve or short form
twelve).ti,ab,kw.
4702
11 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short
form sixteen).ti,ab,kw.
28
12 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty of sftwenty or shortform twenty of short
form twenty).ti,ab,kw.
390
13 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirstysix or
shortform thirty six or short form thirty six or short form thirtysix or short form thirty six).ti,ab,kw.
22,677
14 (health utilities index$ or (hui or hui1 or hui2 or hui3 or hui4 or hui-4 or hui-1 or hui-2 or hui-3)).ti,ab,kw. 1483
15 (“time trade off” or “time tradeoff” or TTO).ti,ab,kw. 1668
16 standard gamble$.ti,ab,kw. 849
17 (QWB or “quality of wellbeing” or “quality of well being” or “quality of well-being” or (index adj3
wellbeing)).ti,ab,kw.
570
18 "discrete choice".ti,ab,kw. 1359
19 (AQoL or “Assessment of Quality of Life”).ti,ab,kw. 1679
20 (HYE or HYES or health$1 year$1 equivalent$1).ti,ab,kw. 79
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# Searches Results
21 ((quality adj2 life) or HRQoL or HRQL or QoL or (quality adjusted or adjusted life year$) or QALY* or qald$
or QTIME$ or qale$ or qtime$ or daly*).ti,ab,kw. or Quality of life/ or Quality adjusted life years/
287,614
22 (health state or health status).ti,ab,kw. or Health status/ or Health status indicators/ 127,992
23 Value of Life/ 5752
24 ((utilit$ or disutilit$) adj3 (health$ or score$1 or scoring or valu$ or measur$ or evaluat$ or scale$1 or
instrument$1 or weight or weights or weighting or information or data or unit or units or life or estimat$
or elicit$ or disease$ or mean or cost$ or expenditure$1 or gain or gains or loss or losses or lost or
analysis or index$ or indices or overall or reported or calculat$ or range$ or increment$ or state or states
or status)).ti,ab,kw.
29,499
25 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 422,994
26 (Parental Stressor Scale or PSS:NICU or Edinburgh Postpartum Depression Scale or EPDS or Spielberger
State-Trait Anxiety Inventory or STAI or “Family Adaptability and Cohesion Evaluation Scale II” or FACES II
or “The Impact of Bronchiolitis Hospitalization Questionnaire” or IBHQ or “Preschool Children Quality of
Life Questionnaire” or TNO AZL or TAPQOL or “Pediatric Quality of Life Inventory” or “Child Health
Questionnaire” or CHQ or “The Preterm Birth Experience and Satisfaction Scale”).ti,ab,kw.
6377
27 25 or 26 427,211
28 6 and 27 4129
29 limit 28 to english language 3700
EMBASE
Date range searched: 1974 to 8 September 2017.
Date searched: 11 September 2017.
Search strategy
# Searches Results
1 exp Obstetric Labor, Premature/ 40,189
2 ((Pre term or preterm or premature or early or immature) adj5 (labo?r or birth$ or childbirth$ or deliver$
or partu$ or baby or babies or child$ or infant$ or toddler$ or postnatal or neonatal)).ti,ab,ot,hw.
208,972
3 (PROM or PPROM or PROM or PTB).ti,ab,ot. 10,995
4 ((Short$ or reduced or multiple) adj4 gestation$).ti,ab,ot. 6592
5 (low$ adj3 birth weight).ti,ab,kw. 33,872
6 1 or 2 or 3 or 4 or 5 238,680
7 (euroqol or euro qol or eq5d or eq 5d or EQ-5D or EQ-5D-Y or EQ-5D-5L).ti,ab,kw. 13,620
8 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).ti,ab,kw. 1929
9 (sf10 or sf 10 or short form 10 or shortform 10 or sf ten or sften or shortform ten or short form
ten).ti,ab,kw.
149
10 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve of sftwelve or shortform twelve or short form
twelve).ti,ab,kw.
7188
11 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short
form sixteen).ti,ab,kw.
47
12 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty of sftwenty or shortform twenty of short
form twenty).ti,ab,kw.
381
13 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirstysix or
shortform thirty six or short form thirty six or short form thirtysix or short form thirty six).ti,ab,kw.
33,894
14 (health utilities index$ or (hui or hui1 or hui2 or hui3 or hui4 or hui-4 or hui-1 or hui-2 or hui-3)).ti,ab,kw. 2047
15 (“time trade off” or “time tradeoff” or TTO).ti,ab,kw. 2242
16 standard gamble$.ti,ab,kw. 992
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# Searches Results
17 (QWB or “quality of wellbeing” or “quality of well being” or “quality of well-being” or (index adj3
wellbeing)).ti,ab,kw.
680
18 "discrete choice".ti,ab,kw. 1938
19 (AQoL or “Assessment of Quality of Life”).ti,ab,kw. 2465
20 (HYE or HYES or health$1 year$1 equivalent$1).ti,ab,kw. 135
21 ((quality adj2 life) or HRQoL or HRQL or QoL or (quality adjusted or adjusted life year$) or QALY* or qald$
or QTIME$ or qale$ or qtime$ or daly*).ti,ab,kw. or Quality of life/ or Quality adjusted life years/
464,722
22 (health state or health status).ti,ab,kw. or Health status/ or Health status indicators/ 136,100
23 Value of Life/ 124,596
24 ((utilit$ or disutilit$) adj3 (health$ or score$1 or scoring or valu$ or measur$ or evaluat$ or scale$1 or
instrument$1 or weight or weights or weighting or information or data or unit or units or life or estimat$
or elicit$ or disease$ or mean or cost$ or expenditure$1 or gain or gains or loss or losses or lost or
analysis or index$ or indices or overall or reported or calculat$ or range$ or increment$ or state or states
or status)).ti,ab,kw.
42,607
25 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 726,333
26 (Parental Stressor Scale or PSS:NICU or Edinburgh Postpartum Depression Scale or EPDS or Spielberger
State-Trait Anxiety Inventory or STAI or “Family Adaptability and Cohesion Evaluation Scale II” or FACES II
or “The Impact of Bronchiolitis Hospitalization Questionnaire” or IBHQ or “Preschool Children Quality of
Life Questionnaire” or TNO AZL or TAPQOL or “Pediatric Quality of Life Inventory” or “Child Health
Questionnaire” or CHQ or “The Preterm Birth Experience and Satisfaction Scale”).ti,ab,kw.
9565
27 25 or 26 732,723
28 6 and 27 8472
29 limit 28 to english language 7634
NHS Economic Evaluation Database, Issue 2 of 4
Date range searched: inception to April 2015.
Date searched: April 2015.
Date run: 11 September 2017.
Search strategy
#1 MeSH descriptor: [Obstetric Labor, Premature] explode all trees (1317)
#2 ((Pre term or preterm or premature or early or immature) near/3 (labor or labour or birth* or childbirth*
or deliver* or partu* or baby or babies or child* or infant* or toddler* or postnatal or neonatal)) (15,146)
#3 (PROM or PPROM or PROM or PTB) (775)
#4 ((Short* or reduced or multiple) near/4 gestation*) ((Short* or reduced or multiple) near/4
gestation*) (563)
#5 (low* near/3 birth weight) (low* near/3 birth weight) (4485)
#6 #1 or #2 or #3 or #4 or #5 (17,627)
NHS EEDs, n = 250.
The School of Health and Related Research Health Utilities Database was hand-searched.
DOI: 10.3310/hta23130 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 13
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Varley-Campbell et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of
Southampton Science Park, Southampton SO16 7NS, UK.
129
Adverse events database searches
MEDLINE
Date searched: September 2017.
Search strategy
1. exp Obstetric Labor, Premature/
2. ((Pre term or preterm or premature or early or immature) adj5 (labo?r or birth$ or childbirth$ or deliver$ or partu$ or
baby or babies or child$ or infant$ or toddler$ or postnatal or neonatal)).ti,ab,ot,hw.
3. (PROM or PPROM or PROM or PTB).ti,ab,ot.
4. ((Short$ or reduced or multiple) adj4 gestation$).ti,ab,ot.
5. (low$ adj3 birth weight).ti,ab,kw.
6. 1 or 2 or 3 or 4 or 5
7. (cost$ or healthcare utilisation or healthcare utilization or expend$ or price$ or pricing or budget$ or value$).ti,ab,kw.
8. ((neonat$ or newborn$) and (mortality or death)).ti,ab,kw.
9. respiratory distress syndrome.ti,ab,kw.
10. intraventricular haemorrhage.ti,ab,kw.
11. 8 or 9 or 10
12. 6 and 7 and 11
13. limit 15 to english language
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Appendix 2 Additional details for quality
appraisal for the diagnostic test accuracy review
Patient selection
All included studies were single-gate DTA studies, and thus avoided the use of a case–control design (i.e. there
were no studies that selected a group of women who had delivered preterm and a group of control group
women who did not deliver preterm).41–62 In addition, all included studies avoided inappropriate exclusion
of participants in terms of their participant inclusion and exclusion criteria. However, only 5 of the 20
included studies47,48,50,58,60,61 were rated as having a low risk of bias due to patient selection (four assessing
Actim Partus and one assessing PartoSure). These studies reported that eligible women were enrolled into
the study consecutively.47,48,50,58,60,61 For the remaining 15 studies, it was unclear whether or not patient
selection could have introduced bias because it was unclear whether a consecutive or random sample of
participants was recruited.
For all studies included in the review, there were no concerns about whether or not the included
participants matched the review question (see Table 5). However, it should be reiterated that in two
studies (APOSTEL-142,43 and Danti et al.50), all women included in the final analyses of index test data had a
transvaginal cervical length measurement of ≤ 30 mm, which would probably increase the prevalence of
preterm birth in these studies.
Index tests
Two of the included studies enable a direct comparison between two of the index tests of interest, by
evaluating both index tests in the same population: the APOSTEL-1 study42,43 evaluated both Actim Partus and
qfFN and the study by Hadzi-Lega et al.44 evaluated both Actim Partus and PartoSure. The other 18 studies
all evaluated only one of the index tests of interest, with three of the studies evaluating only PartoSure,41,59–61
the Bruijn study only evaluating qfFN62 and the remaining 14 studies evaluating only Actim Partus.
In all studies included in the review, except for the APOSTEL-1 study42,43 and the study by Cooper et al.,49
the risk that the conduct and interpretation of the test could have introduced bias was rated as low
(see Table 5). This is because all studies either clearly reported prespecified thresholds for the test (qfFN) or
used a test with a standardised threshold (Actim Partus or PartoSure), and owing to the timing of the tests,
all studies other than APOSTEL-142,43 and the study by Cooper et al.49 interpreted the index tests without
knowledge of the reference standard (the tests were conducted before the occurrence of preterm birth).
In both the APOSTEL-1 study and the study by Cooper et al.,49 frozen samples were used (see Chapter 2,
Frozen samples). In both studies, although samples were collected prior to the assessment of the reference
standard, the index tests (Actim Partus and qfFN in APOSTEL-142,43 and Actim Partus in Cooper et al.49)
were interpreted after the assessment of the reference standard. For these index tests, it is unclear whether
or not these interpretations were made blind to whether or not preterm birth had occurred.42,43,49 It should
be noted, however, that this is unlikely to lead to a high risk of bias for either test because there is limited
need for any subjective interpretation of the test results.
Although not covered by QUADAS-2, it should also be considered, in the studies assessing more than one
test (APOSTEL-142,43 and that by Hadzi-Lega et al.44) and in those that included a clinical assessment or a
test not included in this review (e.g. transvaginal cervical length), whether clinicians were blinded to
this information when interpreting the index test. This is to mitigate any ‘cross-contamination’ of test
results (i.e. bias in the interpretation of the test owing to prior knowledge from another test or other
clinical information).
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Even though, as previously mentioned, there is limited scope for bias to occur in the interpretation of any
of the index test results, it should be noted that the qfFN test does not require any subjective judgement
of the test result, whereas both the Actim Partus and PartoSure tests require some judgement (albeit
limited). In the use of the Actim Partus test, the potential for bias when interpreting results is still greater
than for the qfFN test when no subjective interpretation is required. For this reason, in the APOSTEL-1
study, the Actim Partus test was conducted before the qfFN test.42,43 However, additional tests were also
carried out in the APOSTEL-1 study (qualitative fFN and cervical length measurement) and these were
conducted before the index tests; it is unclear whether or not the index tests were interpreted blind to the
results from the qualitative fFN test or the cervical length measurement. It is therefore unclear whether or
not any ‘cross-contamination’ of results may have taken place between the two tests, although, again,
owing to the nature of the tests the scope for such bias is very limited. In the study by Hadzi-Lega et al.,44
in which both the PartoSure and Actim Partus tests were conducted, it was unclear which test was carried
out first, or indeed whether or not the tests were carried out in a predetermined order.44 The authors do
state that the reader of the index tests was blind to the results of ultrasound and digital examinations, and
this would mitigate any ‘cross-contamination’, however limited, between these assessments and the index
test results.
In four of the remaining studies, three assessing Actim Partus47,49,52 and one assessing PartoSure,59
it was reported that the index test was interpreted blind to the results of transvaginal cervical length
measurements47,49,52 or qualitative fFN.59 In the studies by Azlin et al.,47 Bolotskikh et al.59 and Goyal et al.,52
this was because the cervical length measurement was conducted after the index test and in the study
by Cooper et al.59 it was stated that the Actim Partus test was conducted blind to the qualitative fFN
measurement. In an additional study,48 it was stated that the sample was collected before the cervical
length measurement and that the Actim Partus test was conducted immediately, so it is likely that the
index test was interpreted before the cervical length measurement. In a further seven studies,50,51,54,56,57,60–62
additional tests or assessments (qualitative fFN and/or cervical length measurement) were reported, but it
was unclear whether or not the index tests were interpreted blind to the results of these additional tests.
In the remaining six studies,41,45,46,53,55,58 there was no reported use of other tests or clinical assessments.
In all of the studies included in the review, except for the APOSTEL-1 study42,43 and the study by Ting
et al.,56 there were no concerns that the conduct or interpretation of either of the index tests was different
from the review question (see Table 5). However, in APOSTEL-142,43 and the study by Ting et al.,56 the test
was conducted in a way that may have had an impact on the results because samples were taken from the
posterior fornix of the vagina rather than the external cervical os.
Reference standard
In all of the included studies, the reference standard was whether or not preterm birth took place within
48 hours and/or within 7 days.41–62 For this reason, the reference standard and the target condition were
identical. Similarly, there were no concerns (in any of the studies) that the target condition, as defined by
the reference standard (preterm birth), did not match the review question (see Table 5).
In addition, because the reference standard was the occurrence of preterm birth rather than a diagnostic
test, no assessment was made regarding whether or not the reference standard results were interpreted
without knowledge of the results of the index test (i.e. because the reference standard was not something
that involved interpretation). For this reason, there were no concerns in any of the included studies regarding
whether the reference standard, its conduct or its interpretation could have introduced bias (see Table 5).
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Flow and timing
Of course, in all of the included studies, all participants ‘received’ a reference standard.41–62 Because the
reference standard was the occurrence or otherwise of preterm delivery by 48 hours and/or by 7 days,
this was the same for all participants in all of the included studies (see Table 5).
It is important to note that because the index tests in this review (PartoSure, Actim Partus and qfFN) are
designed to be conducted before the occurrence of the reference standard, this in itself may introduce bias
(through the use of treatments to prevent the occurrence of the reference standard). It is likely that use of
tocolytics, although indicated, may inflate false-positive results and deflate true-positive results.
For all but two of the included studies (APOSTEL-142,43 and Cooper et al.49), the timing of the index test was
as per the manufacturers’ instructions. For both of these studies, the timing of the index tests may have
introduced bias because frozen samples were used and it is unclear when the samples were thawed and
used.42,43,49 However, this is unlikely to have had a large impact on the test results (see Chapter 2, Frozen
samples, for further details).
Related to this, and outside the core QUADAS-2 questions, we also assessed blinding of clinical staff to the
results of the index test. Awareness of test results may necessarily influence treatment decisions, but may
also lead to unintentional differences between those with positive and negative test results in the way in
which a patient is managed. On the other hand, when treatment decisions are influenced by a test other
than the index test, it may not be possible to ascertain from the literature whether or not index test positives
and negatives received different patterns of clinical management. In fact, only two of the included studies
reported that the managing clinicians were aware of the test results (Azlin et al.47 and Riboni et al.54),
although in the study by Riboni et al.54 it was stated that clinical management was not altered by this
knowledge. In six of the studies,42–44,49,50,60–62 it was reported that clinical management personnel were
unaware of the index tests (management was based on qualitative fFN results and/or cervical length). In four
of the studies,51,53,55,56 clinical management personnel were blinded to the results of all tests reported in the
study and, therefore, it was unclear on what basis clinical decisions were made. In the remaining eight
studies,41,45,46,48,52,57–59 it was not clearly reported whether or not clinical personnel were blinded to the index
test results.
Regarding missing data, it was clear that in 10 of the included studies41–45,48,52,56,57,60–62 some of the
participants were excluded from the analysis (see Table 5). This may lead to bias because it was not clear
from the study reports whether or not the women who were not included systematically differed from
those whose data were analysed. In fact, only eight studies47,49–51,53,55,58,59 clearly specify that data were
analysed from all participants who received tests, although it should be noted that, in the study by
Tanir et al.,55 two participants with failed tests were coded as test positives.
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Appendix 3 Supplementary citations and data
Included systematic reviews
Corabian P. The Actim™ Partus versus the TLiIQ® System as rapid response tests to aid in diagnosing
preterm labour in symptomatic women (Structured abstract). Health Technol Assess 2008;(4).
URL: http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32008100231/frame.html
(accessed September 2017).
Corabian P, Guo B, Chojecki D, Wodinski L, Wanke M, Nguyen T, Chuck A. Post policy implementation
review (PPIR) of rapid fetal fibronectin testing for preterm labour in Alberta (Structured abstract). Health
Technol Assess 2015;(4). URL: http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32015001020/
frame.html (accessed September 2017).
Conde-Agudelo A, Romero R. Cervical phosphorylated insulin-like growth factor binding protein-1 test for
the prediction of preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol 2016;214:57–73.
https://doi.org/10.1016/j.ajog.2015.06.060
Honest H, Bachmann LM, Gupta JK, Kleijnen J, Khan KS. Accuracy of cervicovaginal fetal fibronectin test in
predicting risk of spontaneous preterm birth: systematic review. BMJ 2002;325:301.
Leitich H, Kaider A. Fetal fibronectin – how useful is it in the prediction of preterm birth? BJOG
2003;110(Suppl. 20):66–70.
Lucaroni F, Morciano L, Rizzo G, D’Antonio F, Buonuomo E, Palombi L, et al. Biomarkers for predicting
spontaneous preterm birth: an umbrella systematic review. J Matern Fetal Neonatal Med 2017;31:1–9.
Menon R, Torloni MR, Voltolini C, Torricelli M, Merialdi M, Betrán AP, et al. Biomarkers of spontaneous
preterm birth: an overview of the literature in the last four decades. Reprod Sci 2011;18:1046–70.
https://doi.org/10.1177/1933719111415548
Sanchez-Ramos L, Delke I, Kaunitz A. Cervico-vaginal fetal fibronectin as a short-term predictor of preterm
birth in symptomatic patients: A meta-analysis of diagnostic accuracy. Am J Obstet Gynecol 2007;197:S198-S.
Sanchez-Ramos L, Delke I, Zamora J, Kaunitz AM. Fetal fibronectin as a short-term predictor of preterm
birth in symptomatic patients: a meta-analysis. Obstet Gynecol 2009;114:631–40. https://doi.org/10.1097/
AOG.0b013e3181b47217
Smith V, Devane D, Begley CM, Clarke M, Higgins S. A systematic review and quality assessment of
systematic reviews of fetal fibronectin and transvaginal length for predicting preterm birth. Eur J Obstet
Gynecol Reprod Biol 2007;133:134–42.
Vis JY, Wilms FF, Oudijk MA, Bossuyt PM, van der Post JA, Grobman WA, Mol BW. Why were the results
of randomized trials on the clinical utility of fetal fibronectin negative? A systematic review of their study
designs. Am J Perinatol 2011;28:145–50. https://doi.org/10.1055/s-0030-1263297
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Hezelgrave NL, Abbott DS, Radford SK, Seed PT, Girling JC, Filmer J, et al.
Quantitative Fetal Fibronectin at 18 Weeks of Gestation to Predict Preterm
Birth in Asymptomatic High-Risk Women. Obstet Gynecol 2016;127:255–63.
https://doi.org/10.1097/AOG.0000000000001240
Population Asymptomatic population
Jwala S, Tran TL, Terenna C, McGregor A, Andrel J, Leiby BE, et al. Evaluation
of additive effect of quantitative fetal fibronectin to cervical length for
prediction of spontaneous preterm birth among asymptomatic low-risk
women. Acta Obstet Gynecol Scand 2016;95:948–55. https://doi.org/10.1111/
aogs.12907
Population Asymptomatic population
Kuhrt K, Hezelgrave N, Foster C, Seed PT, Shennan AH. Development and
validation of a tool incorporating quantitative fetal fibronectin to predict
spontaneous preterm birth in symptomatic women. Ultrasound Obstet Gynecol
2016;47:210–16. https://doi.org/10.1002/uog.14894
Comparator Outcome at 14 days
Kuhrt K, Smout E, Hezelgrave N, Seed PT, Carter J, Shennan AH. Development
and validation of a tool incorporating cervical length and quantitative fetal
fibronectin to predict spontaneous preterm birth in asymptomatic high-risk
women. Ultrasound Obstet Gynecol 2016;47:104–9. https://doi.org/10.1002/
uog.14865
Population Asymptomatic population
Kuhrt K, Unwin C, Hezelgrave N, Seed P, Shennan A. Endocervical and high
vaginal quantitative fetal fibronectin in predicting preterm birth. J Matern Fetal
Neonatal Med 2014;27:1576–9. https://doi.org/10.3109/14767058.2013.
870550
Population Asymptomatic population
Kurtzman J, Chandiramani M, Briley A, Poston L, Das A, Shennan A.
Quantitative fetal fibronectin screening in asymptomatic high-risk patients and
the spectrum of risk for recurrent preterm delivery. Am J Obstet Gynecol
2009;200:263.e1–6. https://doi.org/10.1016/j.ajog.2009.01.018
Population Asymptomatic population
Lu GC, Goldenberg RL, Cliver SP, Kreaden US, Andrews WW. Vaginal fetal
fibronectin levels and spontaneous preterm birth in symptomatic women.
Obstet Gynecol 2001;97:225–8
Study
design
ELISA test
McLaren JS, Hezelgrave NL, Ayubi H, Seed PT, Shennan AH. Prediction of
spontaneous preterm birth using quantitative fetal fibronectin after recent
sexual intercourse. Am J Obstet Gynecol 2015;212:89.e1–5. https://doi.org/
10.1016/j.ajog.2014.06.055
Population Asymptomatic population
Min J, Watson HA, Hezelgrave NL, Seed PT, Shennan AH. Ability of a preterm
surveillance clinic to triage risk of preterm birth: a prospective cohort study.
Ultrasound Obstet Gynecol 2016;48:38–42. https://doi.org/10.1002/
uog.15925
Population Asymptomatic population
Ridout A, Carter J, Shennan A. Clinical utility of quantitative fetal fibronectin in
preterm labour. BJOG 2016;123:1972. https://doi.org/10.1111/1471-0528.13850
Study
design
Letter
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Citation
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Ross GN, Ridout AE, Shennan AH. Optimal clinical risk prediction can be
achieved by combining quantitative fetal fibronectin and cervical length, and
avoiding thresholds. Acta Obstet Gynecol Scand 2016;95:956. https://doi.org/
10.1111/aogs.12922
Study
design
Letter
Schindhelm RK, Hoogenberg J, de Vos MT, Tegelaers FP. Analytical
performance of quantitative fetal fibronectin assay. Ultrasound Obstet Gynecol
2016;47:127. https://doi.org/10.1002/uog.15824
Study
design
Letter
van der Krogt L, Hezelgrave NL, Seed PT, Shennan AH. Prediction of
spontaneous preterm birth using fetal fibronectin in women with a low-lying
placenta. J Matern Fetal Neonatal Med 2017;30:313–16. https://doi.org/
10.3109/14767058.2016.1171837
Population Asymptomatic population
Vandermolen BI, Hezelgrave NL, Smout EM, Abbott DS, Seed PT, Shennan AH.
Quantitative fetal fibronectin and cervical length to predict preterm birth in
asymptomatic women with previous cervical surgery. Am J Obstet Gynecol
2016;215:480.e1–480.e10. https://doi.org/10.1016/j.ajog.2016.05.020
Population Asymptomatic population
Watson HA, Carter J, Seed PT, Tribe RM, Shennan AH. The QUIPP app: a safe
alternative to a treat-all strategy for threatened preterm labour. Ultrasound
Obstet Gynecol 2017;50:342–6
Abstract Use of telephone
application
Zhou MX, Zhou J, Bao Y, Chen YQ, Cai C. Evaluation of the ability of cervical
length and fetal fibronectin measurement to predict preterm delivery in
asymptomatic women with risk factors. J Matern Fetal Neonatal Med
2015;28:153–7. https://doi.org/10.3109/14767058.2014.909801
Population Asymptomatic population
TABLE 30 Parsagen Diagnostics Inc. (PartoSure) submitted citations
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Bolotskikh V, Borisova V. Combined value of placental alpha microglobulin-1
detection and cervical length via transvaginal ultrasound in the diagnosis
of preterm labor in symptomatic patients. J Obstet Gynaecol Res
2017;43:1263–9. https://doi.org/10.1111/jog.13366
Included
Echebiri NC, McDoom MM, Aalto M, Pullen J, Doyle NM. Placental
alpha-microglobulin-1 and combined traditional diagnostic test: a cost–benefit
analysis. Am J Obstet Gynecol 2014;123:3S-S
Population Ruptured membranes
Echebiri NC, McDoom MM, Pullen JA, Aalto MM, Patel NN, Doyle NM.
Placental alpha-microglobulin-1 and combined traditional diagnostic test: a
cost-benefit analysis. Am J Obstet Gynecol 2015;212:77.e1–10. https://doi.org/
10.1016/j.ajog.2014.07.028
Population Ruptured membranes
Fatkullin I, Akhmetgaliev A, Matveeva E, Seeger S. Utilization of a novel
biomarker test (PARTOSURE PAMG-1) to reduce the length of stay in patients
with threatened preterm labor and a short cervix. J Matern Fetal Neonatal Med
2016;29(Suppl. 1):283
Abstract Not enough information
Hadzi-Lega M, Maier JT, Helmer H, Hellmeyer L, Markova AD, Poposka A.
Comparison of PAMG-1 and phIGFBP-1 tests for the prediction of preterm
delivery in patients with preterm labor. Open J Obstet Gynecol 2017;7:358–68
Included
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Heverhagen A. Placental alpha microglobulin-1 in combination with
transvaginal ultrasound for prediction of preterm birth. J Perinat Med
2015;43(Suppl. 1):240
Abstract Not enough information
Konoplyannikov A, Lysyuk I, Sokolyan A, Pipia N, Apresyan S, Karasova A, et al.
PAMG-1 biomarker test (PARTOSURE) in combination with transvaginal
ultrasound for improved assessment of spontaneous preterm birth in
patients with threatened preterm labor. J Matern Fetal Neonatal Med
2016;29(Suppl. 1):278
Abstract Not enough information
Lotfi G, Faraz S, Al Swalhee N, Nasir R, Somini S, Abdeldayem R, et al.
Evaluation of PAMG-1 for the prediction of preterm birth in patients
symptomatic of preterm labour. J Perinat Med 2015;43(Suppl. 1):250
Abstract Not enough information
Lou YY, Ajay B. Is PartoSure effective in assessing preterm birth? BJOG
2016;123(Suppl. 2):89
Abstract Not enough information
Ravi M, Beljorie M, El Masry K. Evaluation of the quantitative fetal fibronectin
test And PartoSure™ (placental alpha microglobulin-1 [PAMG-1]) for the
prediction of spontaneous preterm birth (SPTB) in patients with signs and
symptoms suggestive of preterm labor. Journal of Pediatric and Neonatal
Individualized Medicine 2017;6:ABS50
Abstract Not enough information
Nikolova T, Bayev O, Nikolova N, Di Renzo GC. Evaluation of a novel placental
alpha microglobulin-1 (PAMG-1) test to predict spontaneous preterm delivery.
J Perinat Med 2014;42:473–7. https://doi.org/10.1515/jpm-2013-0234
Included
Nikolova T, Bayev O, Nikolova N, Di Renzo GC. Comparison of a novel test
for placental alpha microglobulin-1 with fetal fibronectin and cervical length
measurement for the prediction of imminent spontaneous preterm delivery in
patients with threatened preterm labor. J Perinat Med 2015;43:395–402.
https://doi.org/10.1515/jpm-2014-0300
Included
Nikolova T, Uotila J, Nikolova N, Borisova VY, Bolotskikh VM. 16: Do PAMG-1
or phIGFBP-1 biomarkers improve the prediction of imminent spontaneous
preterm delivery in PTL symptomatic women with non-obvious cervical length
(CL)? Am J Obstet Gynecol 2017;216:S11–12
Abstract Not enough information
Melchor JC, Navas H, Marcos M, Iza A, de Diego M, Rando D, Burgos J.
Retrospective Analysis on the Efficacy of the PAMG-1 Test and the Fetal
Fibronectin Test in Assessing Preterm Birth in Symptomatic Women Attending
an Emergency Obstetric Unit. Conference: 1st World Congress on Maternal
Fetal Neonatal Medicine. London, April 2017
Abstract Not enough information
Van Holsbeke C, Dam K, Staelens A, Mesens T, Corremans A. Comparison
of the fetal fibronectin (Rapid fFN) and placental alpha microglobulin-1
(PartoSure) tests for predicting imminent spontaneous preterm birth.
Ultrasound Obstet Gynecol 2016;48:84
Abstract Not enough information
Wing D, Haeri S, Silber A, Roth C, Echebiri N, Franco A, Pappas L, et al.
PAMG-1 (PARTOSURE™) vs. fFN to Assess Risk of Preterm Delivery in
Symptomatic Women. Conference: KU Medical Centre/UC Irvine Health
Institute. PartoSure GA Analysis
Abstract Not enough information
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TABLE 31 Studies excluded at full-text review, with reasons
Citation
Reason for
exclusion
Caroline VH, Annick C. Comparison of the fetal fibronectin (rapid FFN) and placental alpha microglobulin-1
(partosure) tests for predicting imminent spontaneous preterm birth in patients with threatened preterm
labor. J Perinat Med Conference: 12th World Congress of Perinatal Medicine 2015;43(no pagination)
Abstract
Desjardins PR, Dansereau J, Hoag GN. Comparing the clinical effectiveness of Fetal Fibronectin and
IGFBP-1 measurements in cervico-vaginal secretions, in predicting preterm deliveries. Clinical Chemistry
2008;54:A39–40
Abstract
Ehsanipoor RM, Swank M, Jwa SC, Wing DA, Tarabulsi G, Blakemore KJ. Placental alpha-microglobulin-1
in vaginal secretions as a predictor of preterm birth in women with evidence of preterm labor. Reprod Sci
2014;1:155A
Abstract
Fatkullin I, Akhmetgaliev A, Matveeva E, Seeger S. Utilization of a novel biomarker test (PARTOSURE PAMG-1)
to reduce the length of stay in patients with threatened preterm labor and a short cervix. J Matern Fetal
Neonatal Med 2016;29:283
Abstract
Grobman W, Welshman E, Calhoun E. Does fetal fibronectin use in the diagnosis of preterm labor affect
physician behavior and health care costs? A randomized trial. Am J Obstet Gynecol 2002;187(Suppl. 6):S80
Abstract
Grobman WA, Welshman EE, Calhoun EA, Ramsey PS. Fetal fibronectin results did not reduce medical
resource use for women with preterm uterine contractions. Evidence-based Obstetrics and Gynecology
2005;7:118–9
Abstract
Hansen W, Lowe M, Zimmerman B. Effect of the fetal fibronectin assay on preterm labor management.
Am J Obstet Gynecol 2001;185(Suppl. 6):S136. URL: http://onlinelibrary.wiley.com/o/cochrane/clcentral/
articles/596/CN-00387596/frame.html (accessed September 2017)
Abstract
Heverhagen A. Placental alphamicroglobulin-1 in combination with transvaginal ultrasound for prediction of
preterm birth. J Perinat Med Conference: 12th World Congress of Perinatal Medicine 2015;43(no pagination)
Abstract
Heverhagen A, Baumann M, Raio L, Surbek D. Placental alpha-microglobulin-1 in combination with
transvaginal ultrasound for prediction of preterm birth. Am J Obstet Gynecol 2015;212(Suppl. 1):S81
Abstract
Heverhagen A, Muller M, Schleussner E, Deruelle P, Raio L, Surbek D. The prediction of preterm birth
using placental alpha-microglobulin-1 in combination with transvaginal ultrasound. Reprod Sci
2016;1:131A–2A
Abstract
Hillman-Cooper C, Ghag K, Dempsey A, Denbow M, Lopez Bernal A. Actim Partus-the first year at
St. Michael’s Hospital, Bristol. Arch Dis Child Fetal Neonatal Ed 2014;99:A158–9
Abstract
Holmgren C, Lacoursiere DY, Esplin MS. Clinical predictors of a false negative fetal fibronectin (FFN).
Am J Obstet Gynecol 2007;197:S204-S
Abstract
Kang JH, Lee SE, Park C-W, Jun JK, Romero R, Yoon BH. Cervical fetal fibronectin: An index of
intra-amniotic inflammation, histologic chorioamnionitis and impending preterm delivery in patients with
preterm labor and intact membranes. Am J Obstet Gynecol 2007;197(Suppl. 6):S47
Abstract
Karunakaran B, Berry J, Parasuraman R. Can we raise the threshold for negative fetal fibronectin result?
Arch Dis Child Fetal Neonatal Ed 2012;97:A89
Abstract
Konoplyannikov A, Lysyuk I, Sokolyan A, Pipia N, Apresyan S, Karasova A. PAMG-1 biomarker
test (PARTOSURE) in combination with transvaginal ultrasound for improved assessment of spontaneous
preterm birth in patients with threatened preterm labor. J Matern Fetal Neonatal Med Conference: 25th
European Congress of Perinatal Medicine, the Netherlands 2016;29:278. URL: http://onlinelibrary.wiley.
com/o/cochrane/clcentral/articles/387/CN-01214387/frame.html (accessed September 2017)
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Kuhnert M. Individual management of preterm labour by using rapid fetal fibronectintesta. J Matern Fetal
Neonatal Med 2014;27:392–3
Abstract
Kung RWK, Northridge R, Nicoll AE. Fetal fibronectin (FFN) and iatrogenic pre-term birth. Arch Dis Child
Fetal Neonatal Ed 2012;97:A80–1
Abstract
Lawin-O’Brien A, Jesner O, Biswas C. Evaluation of fetal fibronectin testing, subsequent management and
outcomes in a London teaching hospital. Arch Dis Child Fetal Neonatal Ed 2014;99:A119
Abstract
Lega MH. Prediction of preterm delivery in patients in preterm labor. J Perinat Med Conference:
12th World Congress of Perinatal Medicine 2015;43(no pagination)
Abstract
Lotfi G, Faraz S, Al Swalhee N, Nasir R, Somini S, Abdeldayem R, et al. Evaluation of PAMG-1 for the
prediction of preterm birth in patients symptomatic of preterm labor. J Perinat Med Conference:
12th World Congress of Perinatal Medicine 2015;43(no pagination)
Abstract
Lou YY, Ajay B. Is PartoSure effective in assessing preterm birth? BJOG 2016;123:89 Abstract
Mahavarker S, Osman MW, Ten-Hof J. Phosphorylated insulin-like growth factor binding protein-1
(ACTIM PARTUS) testing in management of threatened preterm labour. Arch Dis Child Fetal Neonatal Ed
2012;97:A99–100
Abstract
Nikolova N, Nikolova T, Jovchevski S, Micevska M. Phosphorylated insulin-like growth factor binding
protein-1 in the prediction of preterm delivery in patients with preterm labor. J Matern Fetal Neonatal Med
2016;29:56
Abstract
Nikolova N, Nikolova T, Jovchevski S, Micevska M, Nikolovski S. A comparison between the
phosphorylated insulin-like growth factor binding protein-1 and the cervical length in prediction of
sampling to delivery time in patients with preterm labor. J Matern Fetal Neonatal Med 2016;29:56
Abstract
Nikolova T, Uotila J, Nikolova N, Borisova V, Bolotskikh V. Do PAMG-1 or phIGFBP-1 biomarkers improve
the prediction of imminent spontaneous preterm delivery in PTL symptomatic women with non-obvious
cervical length (CL)? Am J Obstet Gynecol Conference: 37th annual meeting of the society for maternal-
fetal medicine: the pregnancy meeting United States 2017;216(Suppl. 1):S11–2. URL: http://onlinelibrary.
wiley.com/o/cochrane/clcentral/articles/156/CN-01304156/frame.html (accessed September 2017)
Abstract
Northridge R, Liu H, Youssef R, Nicoll AE. Predicting pre-term birth using fetal fibronectin (FFN) in
Ninewells Hospital, Dundee. Arch Dis Child Fetal Neonatal Ed 2011;96:Fa69
Abstract
Ponnusamy V, Farrer K. Impact of antenatal tests on acute in-utero transfers. Arch Dis Child Fetal Neonatal
Ed 2012;97:A87
Abstract
Radford S, Costa F, Junior E, Sheehan P. Clinical application of quantitative fetal fibronectin for the prediction of
preterm birth in symptomatic women. BJOG: Conference: RCOG World Congress 2016, UK 2016;123:158–9.
URL: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/043/CN-01179043/frame.html
(accessed September 2017)
Abstract
Randhawa TS, Kwek K. Assessment of the predictive value of phosphorylated insulinlike growth factor
binding protein-1 for preterm delivery. J Matern Fetal Neonatal Med 2010;23:294
Abstract
Spyroulis C, Tsitlakidis C. Prospective study of the Actim Partus test to predict preterm delivery between
24–34 weeks of gestation in Glan Clwyd Hospital. Period of study between August 2014–February 2015.
BJOG 2016;123:8
Abstract
Thandayathany V, Yassin MAJM, Omar MH, Ismail NAM, Tamil AM, Kampan NC. Fetal fibronectin rapid
test versus phosphorylated insulin-like growth factor-1 (phIGFBP-1) as bedside test kits for prediction of
preterm delivery in the clinical setting. BJOG 2012;119:5
Abstract
Van Holsbeke C, Dam K, Staelens A, Mesens T, Corremans A. OP11.04: Comparison of the fetal
fibronectin (Rapid fFN) and placental alpha microglobulin-1 (PartoSure) tests for predicting imminent
spontaneous preterm birth. Ultrasound Obstet Gynecol 2016;48:84
Abstract
Sophie W, Tiphaine B, Celine C, Aurelie DB. Preterm labor: Reliability of the partosure test before and
after digital and transvaginal ultrasound examinations. J Perinat Med Conference: 12th World Congress of
Perinatal Medicine 2015;43(no pagination)
Abstract
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Bare T, Mitre A, Shahinaj R, Bakiri F. Fetal fibronectin and cericometry in patients at increased risk for premature
birth. J Perinat Med Conference: 12th World Congress of Perinatal Medicine 2015;43(no pagination)
Abstract
Benson J, Ghidini A, Landy H, Gilo N, Drassinower D, Poggi S. Fetal fibronectin for evaluation of preterm
labor in the setting of cervical cerclage. Am J Obstet Gynecol 2009;201:S68–S9
Abstract
Berghella V, Hayes E, Visintine J, Baxter JK. Fetal fibronectin testing for reducing the risk of preterm birth.
Cochrane Database Syst Rev 2008;4:CD006843. https://doi.org/10.1002/14651858.CD006843.pub2
Abstract
Burrus DR, Ernest JM, Veille JC. Efficacy of four markers of preterm labor (PTL) at predicting preterm delivery
(PTD) in a population presenting with contractions and cervical change. Am J Obstet Gynecol 1995;172:405
Abstract
Burrus DR, Ernest JM, Veille JC. Efficacy of four markers of preterm labor (PTL) at predicting latency (LAT)
in a population receiving tocolytic therapy. Am J Obstet Gynecol 1995;172:405
Abstract
Goepfert AR, Network NM. The preterm prediction study: Quantitative fetal fibronectin (FFN) values and
the prediction of spontaneous preterm birth (SPTB). Am J Obstet Gynecol 1997;176:S52
Abstract
Goldenberg RL. Vaginal fetal fibronectin (V-fFN) levels at 8–22 weeks and subsequent spontaneous
preterm birth (SPB). Am J Obstet Gynecol 2000;182:S32
Abstract
Greenhagen JB, Van Wagoner J, Dudley D, Hunter C, Mitchell M, Casal D, et al. The value of fetal
fibronectin as a predictor of preterm delivery in low risk women. Am J Obstet Gynecol 1996;174:471
Abstract
Grover CM. Use of the fetal fibronectin assay to avert unnecessary hospitalization and bedrest in patients
with preterm labor symptoms: a cost analysis. Prim Care Update Ob Gyns 1998;5:178–9
Abstract
Hadzi-Lega M, Daneva Markova A, Micevska M, Atanasovska Bosku A, Gjirevski V. Cervical length and
phosphorilated insulin like growth factor binding protein-1 as a predictors of spontaneus preterm delivery
in symptomatic women. J Matern Fetal Neonatal Med 2014;27:399
Abstract
Hedriana HL, Bliss MC, Gilbert WM. Implementation of fetal fibronectin (FFN) testing in a large private
practice hospital is safe and effective for the diagnosis and management of preterm labor (PTL).
Am J Obstet Gynecol 2005;193:S52-S
Abstract
Henrich W. Cervicometry and fibronectin role. J Matern Fetal Neonatal Med 2010;23:39 Abstract
Hillman-Cooper C, Denbow M, Lopez Bernal A. Identification and quantification of maternal plasma
proteins that predict preterm labour. BJOG 2013;120:160–1
Abstract
Hillman-Cooper CS, Denbow M, Bernal AL. Identification and quantification of maternal plasma proteins
that predict preterm labour. Endocrine Reviews Conference: 95th Annual Meeting and Expo of the
Endocrine Society, ENDO 2013;34(Suppl. 1)
Abstract
Hong J-S, Yoon BH, Romero R, Shim S-S, Sohn Y-K, Park C-W, et al. Patients with a positive cervical
fetal fibronectin followed by a negative test have a reduced likelihood of spontaneous preterm delivery.
Am J Obstet Gynecol 2003;189(Suppl. 6):S173
Abstract
Iriye B, Hancock J, Wold S, Huang W, Gorski L, Hancock L. Fetal fibronectin (fFN) testing in symptomatic
patients for preterm labor and McDonald cerclage. Am J Obstet Gynecol 2004;191:S111-S
Abstract
Joffe G. The use & cost benefit of fetal fibronectin testing in an integrated health care system. Clinical Chemistry
1999;45:S32–S3
Abstract
Kay S, McKie L, Ajoku K, Roberts N. Fetal fibronectin testing in a district general hospital setting – Are we
changing our management of women with symptomatic preterm labour? BJOG 2015;122:186
Abstract
Khizar SBK, Vallabu S. How to introduce a new service in clinical practice. BJOG 2013;120:96 Abstract
Kiefer D, Keeler S, Rust O, Demishev M, Muscat J, Bornstein E, et al. Is fetal fibronectin (FFN) a marker of
intra-amniotic inflammation in patients with midtrimester short cervix? Am J Obstet Gynecol 2009;201:S60-S
Abstract
Knee A, Belisle E, Markenson G, Malshe A, Plevyak M, Bsat F, et al. Do pregnancies complicated by
preterm births with a negative fetal fibronectin screen have different characteristics compared to those
that have positive fibronectin results? Am J Obstet Gynecol 2011;204:S190-S
Abstract
continued
DOI: 10.3310/hta23130 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 13
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Varley-Campbell et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of
Southampton Science Park, Southampton SO16 7NS, UK.
147
TABLE 31 Studies excluded at full-text review, with reasons (continued )
Citation
Reason for
exclusion
Knight B, Smith H, Tregarthen A, Lapointe J, Shennan A, Taylor MJO, et al. Quantitative fetal fibronectin as a
predictor of time to delivery in women undergoing induction of labour: a pilot study. BJOG 2016;123:E5-E
Abstract
Kreaden U, Sheldon L, Lockhart T, Paulson M, Shorter S, Martinez R, et al. Natural distribution of fetal
fibronectin (fFN) among symptomatic and asymptomatic pregnant women. Clinical Chemistry 1999;45:A86–7
Abstract
Krems J, McGregor J, Hastings C, Hanson J. Fetal fibronectin in cervical secretions: An aid for predicting
delivery in women at high risk from preterm delivery. Am J Obstet Gynecol 1995;172:406
Abstract
Kuhrt K, Seed P, Smout E, Hezelgrave N, Shennan A. The development and validation of a new tool to
predict spontaneous preterm birth in high-risk women using quantitative fetal fibronectin and cervical
length. BJOG 2013;120:14–15
Abstract
Kurtzman J, Chandiramani M, Riley A, Poston L, Das A, Shennan A. Quantitative fetal fibronectin
screening at 24 weeks delineates the risk of spontaneous preterm delivery in asymptomatic patients with a
prior history of preterm premature rupture of membranes (PPROM). Am J Obstet Gynecol 2009;1:S227
Abstract
Kurtzman J, Jimenez-Solis G, Rosalesortiz S, Martinez-Alvarez O, Das A, Antonio AMJ. Cervical length
significantly modifies the risk of preterm delivery in low risk patients with symptomatic preterm labor and
a positive fetal fibronectin. Am J Obstet Gynecol 2008;199:S212-S
Abstract
Levine LD, Romero JA, Pappas H, Weber AL, Elovitz MA. A prospective blinded cohort study evaluating
fetal fibronectin and cervical length in predicting preterm birth in symptomatic women. Am J Obstet
Gynecol 2016;214:S441–2
Abstract
Luzzi V, Hankins K, Gronowski AM. Accuracy of the rapid fetal fibronectin TLi system in predicting preterm
delivery. Clin Chem 2003;49:501–2
Abstract
Maharajan P, Elliot J, Thampi P. Efficacy of fibronectin and its impact on the use of atosiban-cost implication.
Arch Dis Child Fetal Neonatal Ed 2012;97:A92
Abstract
Mancuso M, Biggio J, Owen J. Fetal fibronectin and latency period in women with arrested preterm labor.
Am J Obstet Gynecol 2013;208:S221-S
Abstract
Mateus J, Pereira L, Baxter J, Berghella V, Cheku B, Tolosa JE. Fetal fibronectin compared to cervical
dilation in clinical practice. Am J Obstet Gynecol 2003;189:S165-S
Abstract
McKenna DS, Chung K, Shubert P, Iams JD. The effect of digital examination on the expression of fetal
fibronectin. Am J Obstet Gynecol 1998;178:S188
Abstract
Merriam A, Sciscione A, Daniel L. A prospective evaluation of the effectiveness of vaginal fetal fibronectin
to predict preterm birth in women with symptoms of preterm labor in the outpatient setting. Am J Obstet
Gynecol 2014;210:S224-S
Abstract
Mogami H, Kondo E, Fujita K, Chigusa Y, Nishimura F, Ujita M, et al. Fetal fibronectin is a pathogenic
factor of preterm PROM and preterm birth. Placenta 2013;34:A4-A
Abstract
Morrison JC, Naefi RWI, Botti JJ, Katz M, Belluomini JM. Uterine activity and fetal fibronectin are
independent and combined predictors of spontaneous preterm birth. Am J Obstet Gynecol 1995;172:406
Abstract
Muller A, McCullough M, Obican S, Norton H, Carter J, Gonzalez-Quintero VH. ‘false’ positive fetal
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Raw rest accuracy data as reported in the papers
TABLE 32 The DTA values for prediction of delivery within 48 hours
Study (first author
and year) N
True
positive
False
positive
True
negative
False
negative Sensitivity (%) Specificity (%) PPV (%) NPV (%) +LR (95% CI) –LR (95% CI)
Actim Partus
Brik (2010)48 276 NR NR NR NR 73.7 64.9 16.1 96.4 2.10
(1.52 to 2.91)
0.41
(0.19 to 0.87)
Goyal (2016)52 60 23 11 14 12 NR NR NR NR NR NR
Lembet (2002)53 36 14 4 17 1 93.3 81 77.8 94.4 4.9
(2.0 to 11.9)
0.08
(0.01 to 0.50)
Ting (2007)56 94 NR NR NR NR 100 74 18 100 NR NR
Tripathi (2016)57 468 NR NR NR NR 95.4 82.2 61.7 98.3 NR NR
aVishwekar (2017)58 30 11 3 14 2 73.3 64.3 68.8 69.2 NR NR
PartoSure
Werlen (2015)41 41 0 1 39 1 NR NR NR NR NR NR
NR, not reported.
a One patient with a negative result absconded so delivery details could not be obtained.
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TABLE 33 The DTA values for prediction of delivery within 7 days
Study (first author and year) and test N
True
positive
False
positive
True
negative
False
negative
Sensitivity, n/N
(%) [95% CI]
Specificity, n/N
(%) [95% CI]
PPV, n/N (%)
[95% CI]
NPV, n/N (%)
[95% CI] +LR (95% CI) –LR (95% CI)
Bruijn (2016) (APOSTEL-1)42,43
fFN at < 10 ng/ml 350 66 162 119 3 NR NR NR NR NR NR
fFN at < 200 ng/ml 49 46 235 20 NR NR NR NR NR NR
fFN at < 500 ng/ml 29 12 269 40 NR NR NR NR NR NR
Actim Partus 54 30 251 15 (78.3) (89.3) (64.3) (94.4) NR NR
Hadzi-Lega (2017)44
Actim Partus 57 5 12 39 1 5/6 (83)
[35.88 to 99.58]
39/51 (76)
[62.51 to 87.21]
5/17 (29)
[10.31 to 55.96]
39/40 (98)
[86.84 to 99.94]
NR NR
PartoSure 5 5 46 1 5/6 (83)
[35.88 to 99.58]
46/51 (90)
[78.59 to 96.74]
5/10 (50)
[18.71 to 81.29]
46/47 (98)
[88.71 to 99.95]
NR NR
Abo El-Ezz (2014)45
Actim Partus 57 20 9 18 10 NR NR NR NR NR NR
Altinkaya (2009)46
Actim Partus 105 9 16 75 5 NR NR NR NR NR NR
Azlin (2010)47
Actim Partus 51 4 3 43 1 (80.0) (93.5) (57.1) (97.7) NR NR
Brik (2010)48
Actim Partus 276 NR NR NR NR 73.1 66.2 21.8 95 2.16
[1.60 to 2.92]
0.41
[0.21 to 0.78]
Cooper (2012)49
Actim Partus 349 2 89 254 4 2/6 (33)
[0.00 to 0.71]
254/343 (74)
[0.69 to 0.79]
2/91 (2)
[0.00 to 0.05]
254/258 (98)
[0.97 to 1.00]
1.28
[0.41 to 4.04]
0.90
[0.51 to 1.59]
Danti (2011)50
Actim Partus 60 2 17 39 2 (50) [7 to 93] (70) [56 to 81] (11) [1 to 33] (95) [83 to 99] 1.65
[0.57 to 4.74]
0.72
[0.27 to 1.94]
Eroglu (2007)51
Actim Partus 51 5 7 38 1 (83.3) (84.4) (41.7) (97.4) 5.36
[2.3 to 12.2]
0.20
[0.01 to 0.7]
Goyal (2016)52
Actim Partus 60 26 8 8 18 NR NR NR NR NR NR
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TABLE 33 The DTA values for prediction of delivery within 7 days (continued )
Study (first author and year) and test N
True
positive
False
positive
True
negative
False
negative
Sensitivity, n/N
(%) [95% CI]
Specificity, n/N
(%) [95% CI]
PPV, n/N (%)
[95% CI]
NPV, n/N (%)
[95% CI] +LR (95% CI) –LR (95% CI)
Lembet (2002)53
Actim Partus 36 15 3 17 1 (93.8) (85) (83.3) (94.1) 6.2
[2.2 to 17.8]
0.07
[0.01 to 0.5]
Riboni (2011)54
Actim Partus 210 NR NR NR NR (50) (83.7) (10.8) (97.7) NR NR
aTanir (2009)55
Actim Partus 68 14 11 42 1 14/15 (93.3) 42/53 (79.2) 14/25 (56) 42/43 (97.6) 4.4
[2.1 to 5.2]
0.8
[0.4 to 0.9]
Ting (2007)56
Actim Partus 94 NR NR NR NR (69) (78) (39) (92) NR NR
Tripathi (2016)57
Actim Partus 468 NR NR NR NR (94.7) (92.4) (85.6) (97.3) NR NR
bVishwekar (2017)58
Actim Partus 30 13 1 10 5 (68.4) (90) (92.9) (60) NR NR
Bolotskikh (2017)59
PartoSure 99 12 4 83 0 12/12 (100)
[74 to 100]
83/87 (95)
[89 to 99]
12/16 (75)
[48 to 93]
83/83 (100)
[96 to 100]
NR NR
Nikolova (2015)61
PartoSure 203 28 9 159 7 28/35 (80)
[63.1 to 91.6]
159/168 (95)
[90.1 to 97.5]
28/37 (76)
[58.8 to 88.2]
159/166 (96)
[91.5 to 98.3]
NR NR
Werlen (2015)41
PartoSure 41 0 1 39 1 (0) [0.0 to 9.75] (97.5)
[86.8 to 99.9]
(0) [0.0 to 97.5] (97.5)
[86.8 to 99.9]
NR NR
Bruijn (2016) (Bruijn)62
fFN at < 10 ng/ml 455 45 276 131 3 NR NR NR NR NR NR
fFN at < 200 ng/ml 455 34 87 320 14 NR NR NR NR NR NR
fFN at < 500 ng/ml 455 14 23 384 34 NR NR NR NR NR NR
NR, not reported.
a ‘When there were no visible lines, which was observed in two cases, a new sample was not taken. These patients were assigned test positive.’
b One patient with a negative result absconded so delivery details could not be obtained.
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Appendix 4 Additional information on existing
cost-effectiveness studies
Further detail on observational cost-minimisation studies
The study by Abenhaim et al.136 describes the cost implications for the addition of Rapid fFN to clinical
examination in a tertiary university hospital in Montreal, Canada. The diagnostic protocol of clinical
evaluation of women presenting with symptoms of threatened preterm labour followed by fFN testing in
pregnant women without a confirmed (i.e. cervix dilated > 3 cm in presence of contraction) or ruled out
(cervix was closed and uneffaced and monitoring revealed no palpable or measured contractions) preterm
labour diagnosis by clinical examination was compared with clinical examination alone.
This study evaluated fFN in a setting in which cervical length measurement has not been incorporated
as part of the assessment of patients presenting to a labour and delivery unit with preterm contractions.
The fFN group was a prospective cohort of 116 pregnant women, of whom 36 were tested for fFN. Three
patients had a positive test result, of whom one delivered within 7 days after admission (33% PPV) and the
other two were eventually discharged from hospital without delivery. Thirty-three pregnant women had a
negative test result, none of whom delivered within 2 weeks (100% NPV); however, three of these women
(9%) were admitted to hospital. The latter finding is one of the major strengths of this study, given the
paucity of evidence on the effect of testing on patient management in this area.
The authors136 acknowledged the absence of pharmaceutical and radiological and laboratory costs as a
limitation of their study. In this regard, the study does not provide evidence on the proportion of women
who were adequately managed with corticosteroid treatment (i.e. within 7 days of delivery) or, indeed,
on the overall proportion of preterm deliveries including those beyond 2 weeks after testing. The authors
also state that fFN was overused during the study period, thus preventing an accurate assessment of the
proportion of women who would have required additional evaluation if testing had been unavailable.
A US study137 compared the number of hospital admissions in the year after the adoption of a laboratory-
based fFN protocol with the baseline 12-month period in a single provider and its tertiary referral centre,
covering the period from July 1995 to June 1997. The protocol specified that those with a negative test
result should be asked to return 2 weeks later for re-examination and testing. Adopting fFN reduced the
percentage of admissions from 28.1% to 17%, the mean number of preterm labour admissions per
patient from 1.8 to 1.6 (p = 0.002) and the proportion of patients with tocolytic therapy from 10% to
7.9% (p = 0.030). This study also reported neonatal outcomes (i.e. percentage of NICU admissions, median
days of NICU length of stay, ventilation duration and percentage of steroid administration among infants
admitted to NICU), but these were not reported in a manner useful to our purposes. In any case, the fFN
testing protocol in this study is outdated because it was based on a laboratory assay (as opposed to the
Rapid fFN test commonly used these days) and required mothers testing negative to return 2 weeks later
for fFN retesting.
Other studies with relevant outcomes
Berghella and Saccone138 systematically reviewed the RCT evidence on fFN and found that it resulted in an
increasing trend towards admission to NICU (risk ratio 2.48, 95% CI 0.96 to 6.46) relative to clinical examination
alone (blinded to fFN results), which had a 7.45% prevalence across the two RCTs reporting this outcome.76,139
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Detailed review of individual models
Cost-minimisation studies
A decision analysis was used by Chuck and Nguyen72 to evaluate the health system costs following the
adoption of fFN testing in Alberta, Canada, in January 2008. Their evaluation used observational data
from inpatient and outpatient administrative medical records covering the period from April 2002 to
March 2013. It linked data from the provincial laboratory system to determine the proportion of patients
presenting with signs and symptoms of preterm labour that resulted in admissions, hospital transfers,
preterm birth (< 37 weeks) with false labour and fFN testing.
The study analysed the proportion of transfers between those who received fFN and those who did
not from a lower level unit to a tertiary care unit. The rate of admissions was also analysed using the
outpatient administrative data. The inpatient data were used to analyse the length of stay.
The model divided the episodes of pregnant women presenting with signs and symptoms of preterm
labour between true preterm labour episodes and episodes of patients who did not deliver before
37 weeks (Figure 16). For each of these subgroups, the decision between conducting the Rapid fFN test
and not conducting the test was evaluated. The model was populated with parameter values from logistic
regression including maternal and patient management characteristics covariates. The main model
parameters for our purposes are summarised in Table 34.
Chuck and Nguyen72 estimated that the introduction of fFN led to an extra 27 ambulance transfers, one
fewer hospital admission and 143 more hospital days for women who were not in labour, relative to what
would have happened had testing not been done, during the 2008–13 period of observation. There were
69 more ambulance transfers and an additional 1379 days in hospital among women in premature labour.
The costs of these health-care resources and the additional testing led to an overall increase in costs of US$4M.
One limitation of Chuck and Nguyen’s72 study is that it was a retrospective study that relied on administrative
coding data to identify cases of preterm labour and preterm birth, which is likely to render estimates of
‘real-world’ test accuracy performance unreliable. Another limitation, also acknowledged by the authors, is in
their omission of the costs and benefits associated with fFN testing from additional false negatives and true
positives mediated through the increases in the proportion of patients born in tertiary care units. Furthermore,
the major limitation of this study from our perspective is the lack of assessment of health outcomes.
Signs and
symptoms of
preterm
labour
Preterm labour
fFN test
fFN test
+
Transfer/admission
Sent home
Sent home
Sent home
Transfer/admission
Transfer/admission
No test
No test
–
No preterm labour
Costs
Costs
Costs
Costs
Costs
Costs
FIGURE 16 Decision tree of fFN testing strategy in Chuck and Nguyen.72 Dotted lines denote the same tree
structure as described for the preterm labour branch in the tree.
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The strengths of the study are found in its documenting of patient management consequent on test results,
particularly in relation to transfers from lower level to tertiary units, and hospital admissions.
A UK study also modelled the cost difference between fFN plus clinical examination with clinical examination
alone based on signs and symptoms.70 Costs were measured for the time of hospital observation up to
delivery, as the evaluated test strategies were assumed by the authors to not differ in their neonatal costs and
consequences. The model was populated with values for hospital admission rates, incidence of tocolysis use
and incidence of steroid use from a UK RCT (data reported by Dutta and Norman76) (Table 35). In terms of
costs, the analysis used an activity-weighted average length of stay of NHS Reference Costs HRG NZ07 and
NZ08 (for short and long stay), and the rate of hospital transfers and the proportion of tocolysis administered
intravenously were assumed to be the same across arms, as was the number of ultrasound scans per admission
(n = 1).79 Owing to a lack of data, the price of a fFN pathology-based test was used in this study instead of the
intended Rapid fFN test, and prices for tocolysis and steroids were obtained from BNF sources85 and doses from
the guidelines of the Royal College for Obstetricians and Gynaecologists.140,141 The costs of hospital transfer and
the cost of ultrasound scan (HRG 501OU) were obtained from NHS Reference Costs.79 The study found that
TABLE 34 Parameter values in Chuck and Nguyen72
Parameter
Parameter values
Source
Inpatient database Outpatient database
Estimate 95% CI Estimate 95% CI
Not in preterm labour
Transfers
Positive test results 0.32 0.26 to 0.39 0.14 0.11 to 0.18 Chuck and Nguyen72
Probability of transfer if not tested 0.06 0.05 to 0.07 0.03 0.02 to 0.04
OR positive vs. not tested (OR+) 2.22 1.38 to 3.57 10.81 3.96 to 19.51
OR negative vs. not tested (OR–) 0.78 0.51 to 1.19 1.53 0.81 to 2.88
OR positive vs. negative 2.85 N/A 7.06 N/A Calculations by
AG = OR+/OR–
Hospital admissions
Positive test results UA UA 0.11 0.09 to 0.12
Probability of admission not tested UA UA 0.11 0.10 to 0.11
OR positive vs. not tested (OR+) UA UA 5.38 3.65 to 7.95
OR negative vs. not tested (OR–) UA UA 0.47 0.37 to 0.60
OR positive vs. negative UA UA 11.44 N/A
In preterm labour
Positive test results 0.41 0.35 to 0.46 0.31 0.28 to 0.34 Chuck and Nguyen72
Probability of transfer if not tested 0.06 0.05 to 0.07 0.22 0.21 to 0.23
OR positive vs. not tested (OR+) 7.45 3.89 to 14.27 3.68 2.55 to 5.31
OR negative vs. not tested (OR–) 1.91 1.11 to 3.29 1.26 0.96 to 1.66
OR positive vs. negative 3.90 N/A 2.92 N/A Calculations by
AG = OR+/OR–
Hospital admissions UA UA Not reported Not reported Model assumes that
no cost savings are
realised
N/A, not applicable; UA, unavailable.
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the Rapid fFN strategy saved hospital costs that were partly offset by an increase in diagnostic test costs,
resulting in an overall saving of £23.88 per patient in health-care costs to the NHS.
Cost-effectiveness studies
Boyd et al.73 designed a decision tree model with the aim of informing the design of a non-inferiority RCT142
of fFN that included measuring cost-effectiveness neonatal outcomes from the NHS perspective. The model
measured the benefits of accurately diagnosing preterm birth with fFN and treating with steroids and the
costs of false-negative test results in terms of neonatal mortality and morbidity. These were measured
relative to the status quo at the time, which was clinical examination and an ‘admit all approach’.73 Unlike
other models in this field, the authors of this model assigned a < 100% admission probability (93%) given
positive test results, based on UK audit data.83,143 They also adopted a 90% probability of admission in the
clinical-examination-only arm, as a best guess assumption (Table 36). The model included the costs of
TABLE 35 Model parameter values in Deshpande et al.70
Parameter Value Standard error Source
Admission rate with fFN (positive) 1.00 Not applicable (value
fixed by assumption)
Reproduction from
Dutta and Norman76
by Deshpande et al.70
Incidence of tocolysis with fFN (positive) 0.286 = (0.286 × 0.714/7)0.5
Incidence of steroids with fFN (positive) 0.714 = (0.714 × 0.286/7)0.5
Transfer from hospital with fFN (positive) 0.167 = (0.167 × 0.833/6)0.5
Admission rate with fFN (negative) 0.324 = (0.324 × 0.676/37)0.5
Incidence of tocolysis with fFN (negative) 0.027 = (0.027 × 0.973/37)0.5
Incidence of steroids with fFN (negative) 0.297 = (0.297 × 0.703/37)0.5
Transfer from hospital with fFN (negative) 0.056 = (0.056 × 0.944/36)0.5
TABLE 36 Key parameters from Boyd et al.73
Model parameter Value Source and comments
Probability of preterm birth 0.20 Probability of PTB among TPL population in ORACLE II (Kenyon et al.144);
however, the figure is not found in the source
Probability of preterm morbidity 0.244 Admission to neonatal intensive care or specialised care (equivalent to BAPM
level 1–3) in ORACLE II (Kenyon et al.144)
Steroid risk reduction 0.54 Relative risk preterm morbidity reduction (i.e. admission to intensive care or
specialised care) with steroids (Roberts and Dalziel32)
Probability of death 0.0257 Probability of death in preterm births (ISD 2008145)
Probability of hospital admission
with fFN (positive)
0.93 Audit data (HC 200882 and Hogg, Penney and Carmichael 200783)
Probability of hospital admission
with fFN (negative)
0.33 Audit data (HC 200882 and Hogg, Penney and Carmichael 200783)
Probability of admission with
clinical examination strategy
0.90 Assumption
Risk of hospital transfer 0.35 Risk of transfer of admitted women to another hospital (Macintyre-Beon
et al. 2007146)
Cost of hospital admission £1068 Maternity inpatient cost per stay (average 2.2 days) including drug or treatment
Cost of hospital transfer £1000 Cost to the NHS of transfer between different hospital CLUs. Value is based
on assumption
CLU, consultant-led unit; PTB, preterm birth; TPL, threatened preterm labour.
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hospital transfers, in addition to those of hospitalisations. On the other hand, it omitted outcomes in terms
of inadequate steroid use (i.e. outside the 48-hour to 7-day window before delivery) owing to false-positive
test results (Boyd et al.73). Furthermore, the model does not account for variation in costs and benefits by
gestational age, thus ignoring the dramatically different implications of missing a premature birth, for
example under 28 weeks versus older gestational ages. Furthermore, it did not measure negative effects
of steroids use in false-positive cases and assumed that only preterm infants who received intensive or
specialised care, 24% (in the ORACLE II RCT, Kenyon et al.144), are exposed to mortality risks. The study
conclusions were that fFN saved costs but had a ‘small but potentially detrimental’ increase in neonatal
morbidity and a ‘negligible increase in mortality’.73
A US evaluation of the Rapid fFN and the traditional fFN (treat all with tocolysis and steroids for 24 hours
while awaiting the test results) found that the former was more costly and led to more RDS cases and
more deaths than the latter.74 The study compared these strategies with the strategy of treating all
pregnant women with steroids as outpatients, which had an incremental cost per RDS avoided of US
$433,000 and a cost per neonatal life saved of US$1,300,000, using 1999 prices. A novel feature of this
evaluation was its account of adequate corticosteroid administration in the causal chain from testing to
neonatal outcomes, through explicit modelling of preterm birth within 48 hours of testing (Figure 17).
The model was specified by (1) estimating the probability of premature delivery (before 37 weeks),
(2) estimating the probability of delivery within 48 hours of testing among those who are destined to
deliver prematurely and (3) estimating the effectiveness of tocolysis in delaying delivery beyond 48 hours
and applying these estimates to the baseline probability of delivery within 48 hours. Tocolysis was assumed
to not affect the probability of preterm delivery, and the model accounted for the reduced effects of
tocolysis owing to 24-hour treatment as opposed to a 48-hour treatment course. The sensitivity and
specificity of Rapid fFN in predicting preterm birth were used to populate the model. Relevant parameters
from this analysis are presented in Table 37.
The major contribution of this study was the evaluation of diagnostic effects on neonatal outcomes
and the role in these of tocolytic and steroidal treatment. The study measured costs of test administration,
hospitalisation and treatment, maternal cost of delivery and neonatal hospitalisation costs until death or
discharge. Although the study was designed to evaluate cost-effectiveness in a tertiary care unit, and
consequently did not measure the costs of transfer in utero or acute neonatal transfers, the costs of antenatal
Death
≤ 48 hours after test
< 48 hours after test
> 48 hours after test
> 48 hours after test
RDS
Survive
No RDS
Death
RDS
Survive
No RDS
Death
RDS
Survive
No RDS
Death
RDS
Survive
No RDS
Preterm birth
Term birth
fFN +
(treat)
fFN –
(do not treat)
Preterm birth
Term birth
Test with
Rapid fFN
FIGURE 17 Model of Rapid fFN testing from Mozurkewich et al.74
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transfers of women presenting with threatened preterm labour to a lower care unit would be straightforward
to incorporate in this model. A limitation of this analysis was assuming that all patients having positive test
results would be admitted and treated with tocolytics and steroids and that all of those testing negative
would be sent home. In practice, some women testing negative may be admitted owing to considerations
other than the detection of fFN and, less frequently, some women testing positive may be discharged.73
A model for the Netherlands used information on treatment effects of tocolytic and steroid administration
from the APOSTEL-II study150 and diagnostic accuracy from APOSTEL-I,151 reviewed in Chapter 2, to evaluate
qualitative fFN, against a treat-all strategy.75 The economic evaluation was undertaken from a societal
perspective in different settings, including general hospitals and tertiary care hospitals. Accordingly,
costs of transfer borne by the health system and patients varied depending on the level of the hospital of
presentation. Indirect costs of productivity losses were also measured. The model measured perinatal death
and adverse neonatal outcomes as a composite measure (including perinatal death, chronic lung disease,
neonatal sepsis, IVH above grade II, periventricular leucomalacia above grade I and necrotising enterocolitis).
The model separately measured the outcomes of infants born within 7 days of testing, after 7 days and
before 34 weeks and after 34 weeks of gestation (Figure 18) to account for the varying effectiveness of
treatment (corticosteroids) with time to delivery. Costs and benefits were measured up to neonatal hospital
discharge or death and results were presented in terms of incremental cost per neonatal adverse event
avoided and cost per neonatal death avoided. The authors justified their choice of time horizon on the basis
that a lack of data made projections highly uncertain. Key model parameters are presented in Table 38.
TABLE 37 Effectiveness parameters based on Mozurkewich et al.74
Parameter Value Range Source
Probability of preterm birth 0.50 0.20–0.71 Gyetvai et al.147 and Moutquin et al.148
Baseline proportion of premature deliveries delivered
within 48 hours
0.5 0.2–0.8 Moutquin et al.148
Effectiveness of tocolytics for delay of birth of < 48 hours 0.44 0.18–0.62 Gyetvai et al.147
Fractional decrease in effectiveness of tocolytics with
short-term treatment
0.5 0.2–0.8 Authors’ assumption (arbitrary owing
to lack of data)
Probability of RDS 0.23 0.07–0.67 Crowley et al.149
Effectiveness of optimal corticosteroids in preventing RDS 0.65 0.54–0.74
Fractional decrease in effectiveness of corticosteroids with
suboptimal treatment
0.36 0–0.80
Baseline probability of neonatal death 0.11 0–0.26
Effectiveness of corticosteroids in preventing death 0.34 0.24–0.52
Fractional decrease in effectiveness of corticosteroids in
preventing death with suboptimal treatment
0.65 0.5–0.9 Authors’ assumption (based on the
evidence of Crowley et al.149 on
reduced effectiveness in terms of RDS)
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
174
Signs of PTD
Strategy 1
Strategy 2
No PTD < 7 days
PTD < 7 days
< 34 weeks
≥ 34 weeks
Test(s) indicate high
risk – treatment
Test(s) indicate high
risk – treatment
Test(s) indicate low
risk – no treatment
Test(s) indicate low
risk – no treatment
Death
Death
Survive
Survive
Death
Survive
Death
Survive
Morbidity
Healthy
Morbidity
Healthy
Morbidity
Healthy
Morbidity
Healthy
(same branch structure as for < 34 weeks)
(same branch structure as for strategy 1)
FIGURE 18 Model of fFN diagnostic testing in van Baaren et al.75 PTD, preterm delivery. Dotted line denotes the
same tree structure as described for the strategy 1 branch in the tree.
TABLE 38 Effectiveness parameters based on van Baaren et al.75
Parameter Value Range Source
Probability of preterm delivery within 7 days of
presentation
0.14 0.12–0.17 APOSTEL-I151 and van Baaren et al.152
Preterm delivery > 7 days post testing and
< 34 weeks’ gestation
0.10 0.08–0.13 APOSTEL-I151 and van Baaren et al.152
fFN positive in PTB within 7 days 0.90 0.82–0.94 APOSTEL-I151 and van Baaren et al.152
fFN positive in PTB > 7 days 0.61 0.49–0.72 APOSTEL-I151 and van Baaren et al.152
fFN positive in birth ≥ 34 weeks’ gestation 0.37 0.33–0.41 APOSTEL-I151 and van Baaren et al.152
Perinatal death with ACSs in PTB within 7 days 0.05 0.02–0.10 APOSTEL-II151 and Roos et al.150
Perinatal death with ACSs in PTB after 7 days 0.04 0.02–0.08 APOSTEL-II151 and Roos et al.150
Perinatal death in births ≥ 34 weeks’ gestation 0.01 0.00–0.02 APOSTEL-II151 and Roos et al.150
Severe adverse neonatal outcomesa with ACSs
in PTB within 7 days
0.29 0.22–0.38 APOSTEL-II151 and Roos et al.150
Severe adverse neonatal outcomesa with ACSs
in PTB after 7 days
0.19 0.14–0.26 APOSTEL-II151 and Roos et al.150
Severe adverse neonatal outcomes- in births
≥ 34 weeks’ gestation
0.01 0.00–0.02 APOSTEL-II151 and Roos et al.150
RR of perinatal death with corticosteroids 0.77 0.67–0.89 Roberts and Dalziel32
RR of severe adverse neonatal outcomea with
corticosteroids within 7 daysb
0.59 0.41–0.88 Roberts and Dalziel32
PTB, preterm birth; RR, risk reduction.
a Composite of IVH above grade II, chronic lung disease, PVL above grade I, necrotising enterocolitis, neonatal sepsis and
perinatal mortality.
b The reporting of these parameters in van Baaren et al.152 appears inconsistent, as no RR is presented for adverse
neonatal events with corticosteroids in PTB (< 34 weeks) after 7 days.
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Appendix 5 Supplementary discussion and tables
for the systematic review and selection of utilities
Quality-of-life outcomes for preterm children
Studies concerning the quality-of-life outcomes of preterm children are summarised in Table 39. Of the
24 papers shortlisted, seven were deemed as lower priority, because they either use non-standard measures
of quality of life or do not report their quality-of-life figures in a usable format. One study does not report
SF-36 mean scores apart from in the form of a graph.153 A second study measures but does not report any
SF-36 scores.103 Four studies use quality-of-life measures that do not have mapping functions that allow for
conversion to utilities.102,154–156 Finally, another study measures utilities for 140 15- to 16-year-olds that had a
gestational age pf < 29 weeks using the Health Utilities Index version 3 (HUI3);157 however, this was only an
abstract, and it did not report any values.
Of the remaining 17 papers (authors marked as bold in Table 39),103,110,114,161–167,170–175 12 provide direct
measures of utility.110,161,164–167,170–175 Seven of these studies use a version of the HUI.158–164 One of these
studies is a systematic review of quality of life and also reports utilities drawn from other sources.161
Three studies from Finland use the 17D measure.165–167 Five studies reported means and SDs for the SF-36
measure of health-related quality of life.111–113,168,169 The remaining two studies are modelling papers that
make use of utilities drawn from other sources.109,170
Many studies in Table 39 that were model based cited sources for the utilities they used. These source
papers were collated and are summarised in Table 40. The majority of these studies used either the HUI2
domains, which had been converted into a utility using a multiattribute health status utility function,171
or a direct utility measure based on standard gamble. The study by Carroll and Downs108 and some of the
studies reported in Tengs and Wallace172 also used time trade-off methods of utility elicitation.
Quality-of-life outcomes for mothers
Studies concerning the quality-of-life outcomes for mothers are summarised in Table 41. Of these four
studies, one was not used because its measure of quality of life cannot be mapped into a utility value.105
The remaining three studies report summary scores for the SF-36.104,106,173
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TABLE 39 Summary of papers from the systematic search, with information on quality of life for preterm children
Study (first
author and
year) Population Sample size Country QoL measure Parameters provided Comments
Bastek (2012)109 Preterm children with
34 weeks ≤GA < 36 weeks
N/A (literature review) USA (although
utilities obtained
from other studies)
Standard gamble and
time trade-off methods
used in source paper
Utilities for acute respiratory
disease; chronic respiratory
disease; neurodevelopmental
delay in childhood; death in
childhood
These utilities originate from
two sources.108,115 Utilities for
moderate persistent asthma and
moderate cerebral palsy were
used as proxies for RDS and
adverse neurodevelopment,
respectively
Båtsvik (2015)112 GA ≤ 28 weeks or BW
≤ 1000 g; assessed at mean
age of 24 weeks; with/
without severe disability
43 preterm + 43 control Norway SF-36 SF-36 dimension means
Baumgardt
(2012)153
Preterm with BW < 1250 g;
surveyed at median age of
23 weeks
52 preterm + 75 control Switzerland SF-36 SF-36 dimension means plotted
but not explicitly provided
Scores are also separated by sex
Beaudoin
(2013)103
Preterm with BPD; with RDS;
with no respiratory
complications
426 with BPD+ 852
RDS/preterm/term
Canada SF-36 version 2 SF-36 results not reported
Berbis (2012)154 Gestational age between
24 and 32 weeks; assessed
at age 6–10 years
82 France VSP-A VSP-A subscale means reported
in paper, but would need to be
combined to form a utility
Preterm children are compared
with French population norms
Bianco (2011)155 GA ≤ 29 weeks and/or BW
≤ 1500 g; treated/not treated
with surfactant; assessed at
18 months
89 preterm with
surfactant+ 61 preterm,
no surfactant + 145 term
Italy TAPQOL TAPQOL of children treated/not
treated with surfactant
Abstract only
A
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Study (first
author and
year) Population Sample size Country QoL measure Parameters provided Comments
Cooke (2004)111 Preterm VLBW infants,
assessed at age 19–22 years
(mean 20)
79 preterm + 71 term UK SF-36 SF-36 dimension means
reported for both males and
females
The paper also reports additional
information on social/behavioural
outcomes, depression and
physical size
Dalziel et al.
(2007)168
Preterm and term children,
assessed at age 31 years
126 preterm+ 66 term New Zealand SF-36 SF-36 dimension means
Einerson
(2016)170
N/A – paper presents a
cost-effectiveness model for
cervical length screening
N/A – see source paper
information in Table 40
USA (although
utilities obtained
from other studies)
Standard gamble and
time trade-off methods
used in source papers
Utilities for neonatal death;
severe neonatal morbidity;
healthy neonate
Utilities for death and
morbidity obtained from three
sources.115,172,174 It is not clear
exactly which figures have been
used, or how they may have
been combined
Feingold
(2002)102
BW < 1501 g and GA
< 33 weeks, assessed
at age 18–19 years
43 IVH 0–2, no
cysts+ 10 IVH 3–4
and/or cysts
USA HRQoL from CDC Means of four dimensions of
HRQoL reported, separated into
two IVH severity level groups
(0–2, no PVL; and 3–4, with/
without PVL)
Unclear how to derive utilities
from the HRQoL means
Gray (2007)157 GA < 29 weeks, assessed at
age 15–16 years
140 preterm+ 108
control
UK HUI3 No figures provided Abstract only – relative
differences are reported but not
absolute utilities
Husby (2016)169 Preterm with BW ≤ 1500 g,
assessed at age 23 years
35 preterm + 37 control Norway SF-36 SF-36 dimension means
provided for those VLBW
children without cerebral palsy
or low IQs, as well as those
with one or more of the above
Additional results find lower risk
of alcohol abuse, 5 times higher
likelihood of depression, and
poorer motor skills
Ketharanathan
(2011)156
32 weeks ≤GA < 36 weeks,
assessed at preschool age
(2–5 years)
218 responders The Netherlands TAPQOL TAPQOL dimension means
are provided
Unclear how to derive utilities
from the TAPQOL means. Study
also reports prevalence of various
behavioural problems
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TABLE 39 Summary of papers from the systematic search, with information on quality of life for preterm children (continued )
Study (first
author and
year) Population Sample size Country QoL measure Parameters provided Comments
Korvenranta
(2010)165
GA < 32 weeks or BW
< 1501 g, assessed at age 4
1752 Finland Utilities derived from
17D166
Implied utilities provided for
survivors (QALYs/4). These
include survival utilities for
different gestational ages;
seizures; cerebral palsy; visual
problems; hearing problems;
obstructive airway diseases
QALYs were calculated for
4 years in the paper by defining
a HRQoL score for each day of
life then multiplying by number
of days alive
Lehtonen
(2011)167
GA < 32 weeks or BW
< 1501 g, assessed at age
5 years
568 preterm+ 173
control
Finland Utilities derived from
17D166
Implied utilities (QALYs/5) for
preterm/VLBW infants
compared with controls
Being born in a level III hospital
increased median QALYs by
0.03/5 = 0.006, relative to a
level II hospital
Lund (2012)113 Preterm with BW ≤ 1500 g,
and another group SGA.
Assessment at age 20 years
43 VLBW+ 55 SGA+ 73
control
Norway SF-36 SF-36 dimension means
provided for each group
Many other cognitive and
behavioural measures also
reported
Petrou (2009)158 20 weeks ≤GA < 25 weeks,
assessed at age 11 years
(EPICure study)
190 preterm+ 141
control
UK and Ireland HUI3 HUI3 multiattribute utilities
provided for gestational ages
up to 25 weeks, as well as
controls
Utility score for GA ≤ 23 weeks
based on a sample of only 19
HUI3 scores were converted into
multiattribute utilities using
methods from two studies175,176
Rautava
(2009)166
BW ≤ 1500 g or GA
< 32 weeks, assessed
at age 5
588 preterm+ 176
control
Finland 17D Figures identical to those used
in Lehtonen et al.167
Additional utility provided for
live-born VLBW infants
Being born in a level III hospital
(relative to a level II hospital)
increased the mean QALYs by
0.5/5 = 0.1
Roberts
(2013)159
GA < 28 weeks or BW
< 1000 g, assessed at age 18
194 preterm+ 148
control
Australia HUI3 and SF-36 HUI3 scores for preterm and
controls. SF-36 dimension
scores also provided, but only
medians
It is not clear whether or not the
HUI3 score reported here is
computed in the same way as
the multiattribute score in
Petrou et al.158
van Lunenburg
(2013)160
GA < 32 weeks or BW
< 1500 g, assessed at ages
19 and 28 (POPS cohort)
314 The Netherlands HUI3 HUI3 multiattribute utility given
at age 19 years, and at 28 years
Multiple imputation values
are based on an algorithm
(multivariate imputation by
chained equations) that
incorporates information from
respondents to interpolate
missing data values
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Study (first
author and
year) Population Sample size Country QoL measure Parameters provided Comments
Verrips (2008)161 BW ≤ 1000 g included from
three separate cohorts,
assessed at age 12–16 years
150 (Canada), 65
(Germany), 126
(the Netherlands)
Germany, Canada,
the Netherlands
HUI3 HUI3 multiattribute utility for
ELBW in Canada, Germany
and the Netherlands
Utility function based on Furlong
et al.176
Wolke (2016)162 ELBW (Canada), VP or VLBW
(Germany, the Netherlands),
assessed at adolescence
(12–16 years), early
adulthood (19–26 years) and
adulthood (> 26 years)
169 (Canada), 91
(Germany), 140
(the Netherlands)
Germany, Canada,
the Netherlands
HUI3 HUI3 utilities reported for three
life stages for Canada, Germany
and the Netherlands
Canada also includes utilities
with/without neurosensory
impairment
Summary of utilities from
multiple studies. Dutch study
had a different cohort at
adolescence, but the same
cohort was measured at both
early adulthood and adulthood
Wolke (2013)163 BW < 1500 g or GA
< 32 weeks, assessed
at age 13 years
260 preterm+ 282
control
Germany HUI3 HUI3 multiattribute utilities for
VP/VLBW infants and controls,
reported by both parents and
children
Paper also reports other social
and cognitive characteristics. In
particular, mean IQ in VP/VLBW
infants = 92, versus 101 in
full-term controls
Another group of VP/VLBW
infants who could not report
their own utility had a parent-
reported value of 0.18, but only
based on a small sample (n = 12)
Zwicker
(2008)164
VLBW or preterm N/A – see Table 40
for source paper
information
Multiple, but utility
sources all from
Canada
HUI2 and standard
gamble
Utilities for preterm and control
children at school age,
adolescence and young
adulthood
Study is a systematic review of
QoL scores from other studies.
Utility scores reported are from
multiple studies177–181
17-dimensional Health-related Quality of Life; BPD, bronchopulmonary dysplasia; BW, birthweight; ELBW, extremely low birthweight; GA, gestational age; HRQoL, health-related quality of life;
IQ, intelligence quotient; POPS, Project On Preterm and Small for gestational age infants; QoL, quality of life; SGA, small for gestational age; TAPQOL, TNO-AZL Preschool children Quality of Life;
VLBW, very low birthweight; VP, very premature; VSP-A, Vécu et Santé Perçue des Adolescents.
Note
Green shading represents studies that did not provide any appropriate quality-of-life utility measures.
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TABLE 40 Secondary sources for utilities (referenced by papers found in the systematic search)
Study (first author
and year) Sample Country Utility measure Utilities reported Comments
Carroll (2009)108 4016 (> 18 years, had at
least 1 child)
USA Standard gamble and time
trade-off
Utilities for 30 medical states
provided (including perfect health)
Implicitly uses Von Neumann–Morgenstern
expected utility assumptions. Both
elicitation methods assume risk neutrality
Pham (2003)174 180 (90 postnatal,
59 midwives, 31 medical
staff)
Australia Standard gamble Perfect health; jaundice requiring
phototherapy; admission to neonatal
nursery; shoulder dystocia; nerve
palsy; transient neurological
symptoms; permanent neurological
sequelae; perinatal death
Health outcomes do not seem relevant to
current model. Mothers of premature
babies were excluded from the study
Saigal (1994)177 156 ELBW + 145 controls Canada HUI2 transformed using a MAHS
utility function
Utilities are provided for different
attribute score combinations on a
six-dimension quality-of-life scale,
for children at age 8 years
Originally excluded in full-text screening as
it focused on low birthweight only
Utilities provided are for a combination of
subjective health states, and do not
correspond to any particular condition
Saigal (1994)178 156 ELBW + 145 controls Canada HUI2 transformed using a MAHS
utility function
Study identifies unique health states
required to classify the ELBW and
control children, but does not report
utilities explicitly
This study appears to be supplemental to
the previous study in this table, rather
than providing new utility data
Saigal (1996)179 141 ELBW + 145 controls Canada HUI2 (actual and for hypothetical
states), standard gamble
Mean utilities for age 12–16 years
reported, for own health states as
well as four hypothetical scenarios
Sensitivity analysis results also provided.
Provides average utility for ELBW, but not
for specific medical conditions in isolation
Saigal (2000)180 149 (parents of ELBW) +
126 (parents of controls)
Canada HUI2 (actual states), visual
analogue scale and standard
gamble (hypothetical states)
Parental perspectives of child’s
(12–16 years) utility, and
perspectives for four hypothetical
scenarios
Originally excluded in full-text screening as
it focused on low birthweight only. Data
for child’s impression exists, so parent’s
assessment may be unnecessary
Saigal (2006)181 143 ELBW + 130 controls Canada Standard gamble (quality of life,
and hypothetical states)
Utilities for young adults (≈23 years)
with/without neurosensory
impairments
Originally excluded in full-text screening as
it focused on low birthweight only
Results of sensitivity analyses also provided
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Study (first author
and year) Sample Country Utility measure Utilities reported Comments
Tengs (2000)172 154 (studies reviewed) Multiple 51% of studies used direct
elicitation, 32% estimated, 17%
health status instruments
1000 health states reported.
Relevant utilities are outcomes from
various degrees of low birthweight,
at different levels of severity
Paper is a review of studies containing
original quality of life estimates for 1000
health states. Would need to refer to
original studies to critique individual
utilities
Vandenbussche
(1999)115
42 (12 obstetricians,
15 pregnant women,
15 mothers)
The
Netherlands
Standard gamble Four health states: healthy child;
transient neurological symptoms;
permanent neurological symptoms;
neonatal death. Each outcome has
three utilities depending on type of
birth
Sample size is split into pregnant women,
mothers and obstetricians. This does not
consider longer term outcomes reported
by preterm survivors
ELBW, extremely low birthweight; MAHS, multiattribute health status.
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TABLE 41 Summary of papers on quality of life for mothers
Study (first author
and year) Population Sample size Country QoL measure Parameters provided Comments
Alemdaroglu
(2009)104
Mothers of LBW, premature
children with/without ICH or IVH
24 (12 with ICH/IVH children,
12 without)
Turkey SF-36 QoL for mothers of
children with and without
ICH/IVH
Only abstract available, no
further details of SF-36
dimensions. Sample size
very small
Couto (2009)106 Pregnant women with a history
of one or more of the following:
recurrent abortion, fetal death,
preterm birth, early neonatal
death
120 prior adverse
outcomes + 120 controls
Brazil SF-36 SF-36 dimension means May not be as relevant for
mothers who are not likely
to have more children
Coyle (2011)173 Random sample of mothers of
students in each of four different
age groups (< 5, 5–10, 11–13,
14–18 years)
234 USA SF-36 v2 SF-36 dimension means Also provides mean SF-36
measures for mothers after
splitting them into three
age groups
Hill (2007)105 Mothers of preterm, near-term
and term children. Assessed 7
and 21 days post delivery
184 (37 preterm, 59 near
term, 88 term)
USA MAPP-QOL QoL for preterm, near-term
and term, evaluated 1 and
3 weeks after birth
Mean scores for additional
subdimensions also
reported. Unclear how to
convert this measure to a
utility
LBW, low birthweight; QoL, quality of life.
Note
Green shading represents studies that did not provide suitable quality-of-life information for the PenTAG model.
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Summary tables containing raw and mapped utilities from all relevant studies identified in the systematic
review of utilities
TABLE 42 Summary of utilities for preterm children
Study (first author and year) Population Measure Variable Utility
Bastek (2012)109 34 weeks ≤GA < 36 weeks Standard gamble, TTO Acute respiratory disease 0.87
Chronic respiratory disease 0.88
Neurodevelopmental delay 0.76
Death 0.01
Båtsvik (2015)112 GA ≤ 28 weeks or BW ≤ 1000 g;
43 preterm + 43 control
SF-36 (assessed at mean age of 24 years) Severe disability 0.763
Healthy 0.846
Cooke (2004)111 Preterm (VLBW) infants;
79 preterm + 71 control
SF-36 (assessed at age 19–22 years) All preterm 0.879
Male 0.907
Female 0.856
Dalziel (2007)168 Preterm and term children;
126 preterm + 66 control
SF-36 (assessed at age 31 years) All preterm 0.887
Einerson (2016)170 Preterm survivors Standard gamble, TTO Neonatal death 0
Severe neonatal morbidity 0.55
Healthy neonate 1
Husby (2016)169 Preterm with BW ≤ 1500 g;
35 preterm + 37 control
SF-36 (assessed at age 23 years) All preterm 0.857
VLBW with no cerebral palsy, and not
with low IQ
0.891
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TABLE 42 Summary of utilities for preterm children (continued )
Study (first author and year) Population Measure Variable Utility
Korvenranta (2010)165 GA < 32 weeks or BW < 1501 g; n = 1752 17D (assessed at age 4 years) None of the studied morbidities 0.9475
23 weeks’ GA 0.9025
24–25 weeks’ GA 0.9075
26–27 weeks’ GA 0.9175
28–29 weeks’ GA 0.9275
30–31 weeks’ GA 0.94
≥ 32 weeks’ GA 0.9425
Seizures 0.9675
Cerebral palsy 0.9225
Visual disorder 0.875
Other ophthalmologic problems 0.9375
Hearing loss 0.8825
Obstructive airway diseases 0.91
Two or more of the above morbidities 0.87
Lehtonen (2011)167 and
Rautava (2009)166
GA < 32 weeks or BW < 1501 g;
568 preterm + 173 control
17D (assessed at age 5 years) All preterm 0.92 (median)
0.72 (mean)
Live-born 0.94 (median)
0.82 (mean)
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Study (first author and year) Population Measure Variable Utility
Lund (2012)113 Preterm with BW ≤ 1500 g, and SGA;
43 VLBW + 55 SGA + 73 control
SF-36 (assessed at age 20 years) All preterm 0.901
SGA 0.888
Petrou (2009)158 20 weeks ≤GA < 25 weeks;
190 preterm + 141 control
HUI3 (assessed at age 11 years) All preterm 0.789
≤ 23 weeks 0.772
24 weeks 0.717
25 weeks 0.83
Roberts (2013)159 GA < 28 weeks or BW < 1000 g;
194 preterm + 148 control
HUI3 (assessed at age 18 years) All preterm 0.93
van Lunenburg (2013)160 GA < 32 weeks or BW < 1500 g; n = 314 HUI3 Age 19 years (assessed) 0.89
Age 19 years (multiple imputation) 0.83
Age 28 years (assessed) 0.88
Age 28 years (multiple imputation) 0.85
Verrips (2008)161 BW ≤ 1000 g; 150 (Canada),
65 (Germany), 126 (the Netherlands)
HUI3 (assessed at 12–16 years) Canada 0.76
Germany 0.752
The Netherlands 0.868
Wolke (2016)162 ELBW (Canada, n = 169); VP or VLBW
(Germany n = 91, the Netherlands n = 140)
HUI3, assessed at adolescence (12–16 years),
early adulthood (19–26 years), adulthood
(> 26 years)
Canada, all preterm 0.79 (12–16 years)
0.79 (19–26 years)
0.73 (> 26 years)
ELBW without neurosensory
impairment (Canada)
0.83 (12–16 years)
0.83 (19–26 years)
0.77 (> 26 years)
ELBW with neurosensory impairment
(Canada)
0.68 (12–16 years)
0.65 (19–26 years)
0.60 (> 26 years)
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TABLE 42 Summary of utilities for preterm children (continued )
Study (first author and year) Population Measure Variable Utility
Germany, all preterm 0.82 (12–16 years)
0.82 (19–26 years)
The Netherlands, assessed 0.87 (12–16 years)
0.89 (19–26 years)
0.88 (> 26 years)
The Netherlands, imputed 0.83 (19–26 years)
0.85 (> 26 years)
Wolke (2013)163 GA < 32 weeks or BW < 1500 g;
260 preterm + 282 control
HUI3 (assessed at age 13 years) Parent reported 0.88
Child self-reported 0.84
Zwicker (2008)164 VLBW or preterm HUI2 and standard gamble School-age 0.82
Adolescents (study 1) 0.87
Adolescents (study 2) 0.91
Young adults 0.85
ELBW, extremely low birthweight; GA, gestational age; SGA, small for gestational age; TTO, time trade-off; VLBW, very low birthweight; VP, very premature.
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TABLE 43 Summary of utilities from secondary sources cited by studies found in the systematic search
Study (first author and year) Population Measure Variable Utilities
Carroll (2009)108 4016 (parent assessment of
child’s health)
Standard gamble and time
trade-off
Mild persistent asthma 0.90 (SG); 0.91 (TTO)
Mild intermittent asthma 0.91 (SG); 0.91 (TTO)
Moderate persistent asthma 0.88 (SG); 0.91 (TTO)
Severe persistent asthma 0.83 (SG); 0.85 (TTO)
Mild cerebral palsy 0.87 (SG); 0.88 (TTO)
10-day ICU hospitalisation 0.87 (SG); 0.91 (TTO)
Mild seizure disorder 0.85 (SG); 0.86 (TTO)
Moderate seizure disorder 0.84 (SG); 0.83 (TTO)
Mild mental retardation 0.84 (SG); 0.83 (TTO)
Moderate cerebral palsy 0.76 (SG); 0.76 (TTO)
Severe seizure disorder 0.70 (SG); 0.71 (TTO)
Severe cerebral palsy 0.60 (SG); 0.55 (TTO)
Severe mental retardation 0.59 (SG); 0.51 (TTO)
Pham (2003)174 180 (90 postnatal, 59 midwives,
31 medical staff)
Standard gamble, median scores Admission to neonatal nursery 0.99 (mothers); 0.95 (midwives);
0.99 (medical staff)
Transient neurological symptoms 0.95 (mothers); 0.90 (midwives);
0.95 (medical staff)
Permanent neurological sequelae 0.50 (mothers); 0.50 (midwives);
0.50 (medical staff)
Saigal (1994)177 156 ELBW + 145 controls HUI2 transformed using a MAHS
utility function
All ELBW infants 0.82 (mean); 0.88 (median)
Saigal (1996)179 141 ELBW + 145 controls Standard gamble (chance board) All ELBW infants 0.87 (mean); 1.00 (median)
Saigal (2000)180 149 (parents of ELBW) + 126
(parents of controls)
Standard gamble (chance board) All ELBW infants (parental
assessments)
0.91 (mean); 1.0 (median)
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TABLE 43 Summary of utilities from secondary sources cited by studies found in the systematic search (continued )
Study (first author and year) Population Measure Variable Utilities
Saigal et al. (2006)181 149 (parents of ELBW) + 126
(parents of controls)
Standard gamble All ELBW infants 0.85 (mean, ELBW);
0.95 (median, ELBW)
ELBW infants with neurosensory
impairments
0.85
ELBW infants without neurosensory
impairments
0.85
Tengs and Wallace (2000)172 140 experts Standard gamble Cerebrovascular disease, intracranial
aneurysm, good but incomplete
recovery, normal life with minor
neurological and psychological
deficits
0.85
Cerebrovascular disease, intracranial
aneurysm, moderate disability,
independent daily living
0.63
Cerebrovascular disease, intracranial
aneurysm, persistent vegetative
state, unresponsive and speechless
until death after acute brain damage
0.08
Cerebrovascular disease, intracranial
aneurysm, severe disability,
dependent on others for daily
support owing to mental and/or
physical disability
0.26
156 patient proxies HUI ELBW infants (501–1000 g),
assessed at age 8 years
0.82
24 patients Standard gamble Lung disease, chronic (e.g. chronic
bronchitis, emphysema, cystic
fibrosis, on waiting list for
transplant)
0.65
Lung disease, chronic (e.g. chronic
bronchitis, emphysema, cystic
fibrosis, transplant)
0.8
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Study (first author and year) Population Measure Variable Utilities
Vandenbussche et al. (1999)115 42 (12 obstetricians,
15 pregnant women,
15 mothers)
Standard gamble, median
utilities
Healthy child, spontaneous birth 1
Transient neurological symptoms,
spontaneous birth
0.99
Permanent neurological symptoms,
spontaneous birth
0.5 (pregnant women);
0.35 (mothers); 0.05 (obstetricians)
Neonatal death, spontaneous birth 0.01 (pregnant women, mothers);
0.23 (obstetricians)
ELBW, extremely low birth weight; ICU, intensive care unit; MAHS, multiattribute health status; TTO, time trade-off.
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Short Form questionnaire-36 items mapping and extraction of utilities
Although none of the studies that were found directly measured utilities based on the EQ-5D, various
mapping functions exist that allow SF-36 summary measures to be converted into EQ-5D utilities. The
EQ-5D is NICE’s preferred measure of quality of life.114 The University of Oxford Health Economics Research
Centre maintains a database of such mapping studies.183 The latest version was last updated in May 2016.
Two studies from this database were shortlisted, owing to their use of a more general sample of the
population and a large sample size. The first uses UK data (n = 25,783) and a generalised least squares (GLS)
approach to estimate a mapping function to the EQ-5D.101 They show that this provides a more accurate
prediction of EQ-5D utility than using ordinary least squares (OLS) estimates. Although censored models
were also estimated, these are problematic to use owing to their non-linearity. Because only mean SF-36
data are provided in the papers included after screening, and given that the mean is a linear operator,
it would not be possible to generate predictions without bias in censored mapping models. However,
given that the studies provided SDs for their SF-36 summary scores, one can use mean-aggregated data to
predict EQ-5D using the quadratic version of their GLS mapping model. (The study also includes a version
of the model with full interaction terms. However, this was not used as it provided only an incremental
improvement in fit, while introducing bias. This is owing to the assumption required that covariances
between SF-36 dimension means are 0, given that the studies that report SF-36 means did not, in general,
report a full variance–covariance matrix.) This version of the model was preferred to the linear model when
appropriate, as it provided an improved R2 value (0.70 for the quadratic model, 0.67 for the linear model)
and less than or equal mean squared errors everywhere outside the range of 0–0.499.101
The second mapping study is not preferred to the first as it uses a smaller, Korean sample (n = 1660) to
generate model estimates, which may be less representative of the UK population.182 However, it includes
a simple linear model (estimated using OLS) that generates EQ-5D utility from the physical health and
mental health summary scores that are sometimes reported from SF-36 data. This model (R2 = 0.6366, root
square mean error = 0.16) was used to predict EQ-5D scores from the single study that reported outcomes
for mothers of children with and without IVH or ICH, because this study did not report mean scores for
each of the eight SF-36 dimensions.104
TABLE 44 Mapped utilities for the quality of life of mothers
Study (first
author and
year) Population n Measure Variable Utilities
Alemdaroglu
(2015)104
Mothers of LBW infants,
premature children with/
without ICH or IVH
12 SF-36 (physical
and mental
summary only)
Mothers of children with ICH/IVH 1.021a
12 Mothers of children without ICH/IVH 1.016a
Couto (2009)106 Pregnant women with a
history of one or more of the
following: recurrent abortion,
fetal death, preterm birth,
early neonatal death
120 SF-36 Pregnant women with previous
adverse pregnancy outcomes
0.644
120 Control mothers 0.834
Coyle (2011)173 Random sample of mothers
of students in each of
four different age groups
(< 5, 5–10, 11–13,
14–18 years)
234 SF-36 version 2 All mothers 0.640
69 Mothers aged 25–34 years 0.529b
110 Mothers aged 35–44 years 0.525b
40 Mothers aged 45–54 years 0.532b
LBW, low birthweight.
a These mapped utilities are greater than 1, suggesting that the mapping function is extrapolating too far outside the
domain of the original sample used by Kim et al.182
b Utility mapped using a linear model (rather than quadratic), because SDs were not reported for the input SF-36 mean scores.
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These SF-36-to-EQ-5D mapped utilities are tabulated in this appendix, along with the other relevant
utilities extracted directly from papers (where available) as follows: Table 42 contains all relevant utilities
from studies of preterm children, Table 43 contains all relevant utilities from studies that were identified as
secondary sources of utility data and Table 44 contains all relevant utilities from the studies of mothers.
Study discussion
Studies of preterm children
The majority of the studies identified utilities (either directly or via the SF-36) for children born preterm or
at a reduced birthweight, at various stages of life. Of these, only two studies used a UK/Ireland-based
population.111,158
Two studies provide utilities for children born at different gestational ages.158,165 Petrou et al.158 only study
children born between the gestational ages of 20 and 25 weeks, but assess utility using the HUI3 at
11 years of age in a UK and Ireland population. Korvenranta et al.165 study Finnish children at 4 years of age,
but provide utilities using the 17D measure for all gestational ages of preterm birth from 23 weeks onwards.
The largest studies are from Finland, and all three make use of the 17D quality-of-life measure.165–167
These studies report QALYs rather than utilities, but because they are computed linearly, implied utilities
are derived by dividing the QALY value by the overall time horizon (4 years in Korvenranta et al.,165 5 years
in Lehtonen et al.167). No mapping studies from the 17D to the EQ-5D were found in the current University
of Oxford Health Economics Research Centre database.183 A Google Scholar search for the term ‘17D
EQ-5D’ was undertaken, but no mapping studies between the two were found.
Only one paper considers the quality of life for preterm children with IVH, separated into two severity
groups: level 0–2 IVH with no PVL and level 2–4 IVH with/without PVL.102 The health-related quality-of-life
measure they used, developed by the CDC, does not have a suitable mapping to EQ-5D utility. However,
those with more severe IVH do, in most cases, report a significantly lower quality of life at age 18–19 years.
Likewise, only one paper considers quality of life for preterm children with RDS. The authors measure,
but do not provide, SF-36 scores in their paper.103 However, they do explain that there was no significant
difference in SF-36 means between different groups of children, when assessed as adults. This study is
discussed further in Utilities for respiratory distress syndrome.
Although other studies do not measure quality of life for children with IVH or RDS, some do make use of
related utility measures as proxies for these conditions. The best example of this109 identifies utilities (originally
derived from two other studies108,115) for acute/chronic respiratory disease, and neurodevelopmental delay.
The utilities from the study by Carroll and Downs108 are considered particularly reliable, as they are the result of
using both the standard gamble and the time trade-off methods of elicitation for 4016 US parent (or guardian)
assessments of a child’s hypothetical health state.108 The utilities from this paper are used by Bastek et al.109 for
their model of ACSs, a treatment which is relevant to the economic model devised for this report. This study is
discussed further in Utilities for respiratory distress syndrome and Utilities for intraventricular haemorrhage.
We received a forthcoming paper in confidence after contacting Dr Stavros Petrou (University of Warwick,
2017, personal communication), a health economist who has previously studied childhood outcomes.184 This
study includes a meta-analysis of utilities for preterm birth, as well as for other complications that may be
related to RDS and IVH. This may provide more reliable quality-of-life estimates than selecting one study alone,
but has the disadvantage of only providing utilities classified into more general health states than those found
in individual studies. For example, they provide a weighted average utility score for chronic lower respiratory
disease and for combined disorders of the respiratory system, but not specific utilities for RDS. In addition,
there are no average utilities for children born preterm measured by EQ-5D or SF-36/SF-6D. Finally, this study
excluded papers with a mean or median assessment age of > 18 years, which may be problematic when
extrapolating over the entire lifespan.
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Studies of mothers
The quality of evidence on the quality of life of mothers of preterm children is low. Only two studies consider
mothers of preterm children specifically.104,105 The first is an abstract that reports only physical and mental
health SF-36 mean summary scores. It is taken from a small Turkish sample of 24 mothers (12 who have
low-birthweight preterm children with ICH or IVH and 12 who have low-birthweight preterm children
without ICH or IVH), which may not be representative of mothers in the UK. Furthermore, given that the
mapping function (derived from subjects in Korea) applicable to physical and mental summary SF-36 scores
used OLS,182 it yields utilities of > 1 (see Table 44) when applied to the data from Alemdaroglu et al.104
Hence, we are not able to use this paper to generate appropriate utilities for the economic model.
The second study reported MAPP-QOL scores for mothers in the USA.105 This study could not be mapped
into utilities, and only provides quality of life for mothers of preterm, near-term and term children 1 and
3 weeks postpartum. However, it does not contain information on mothers of preterm children with adverse
birth conditions. Likewise, the utility mapped from the SF-36 means of a random sample of US mothers by
Coyle173 could have been considered as a baseline for the quality of life of mothers whose children do not
experience adverse health outcomes, but there is no corresponding quality-of-life information for mothers
of children who have adverse health outcomes. Therefore, neither of these studies provide usable utilities
for the economic model.
The final study of mothers, by Couto et al.,106 captures the quality of life of mothers in Brazil who have
had at least one of four previous adverse pregnancy outcomes. Although preterm birth is one of the
four outcomes that is an inclusion criterion (along with early neonatal death, recurrent abortion and fetal
death), we are not provided with separate utilities for each outcome individually. The death outcomes are
likely to skew the utility measure lower than if only mothers with a history of preterm birth were included
in the population. It may be useful to treat this utility as a proxy for any adverse outcomes resulting from
preterm labour, with the caveat that the utility would be an underestimate for mothers of preterm children
who develop conditions but do not die and an overestimate for mothers of preterm children who die.
A recent study (that was not included in the shortlist) suggests that whether a child is born very preterm
or not may not have much of an effect on longer term parent quality of life.185 We also consulted with
Professor Dieter Wolke (University of Warwick, 2017, personal communication), an expert on the outcomes
of preterm and low birthweight children, on this matter. He confirmed that, on the whole, data on the
outcomes of parents with preterm children is very limited.
Utilities for respiratory distress syndrome
There is only one study identified that measured quality-of-life outcomes for preterm children with RDS.103
The study compares four groups of subjects:
1. born preterm (gestational age < 37 weeks) who developed bronchopulmonary dysplasia without infant RDS
2. born preterm with RDS but no subsequent bronchopulmonary dysplasia
3. born preterm without respiratory complications
4. born at term without respiratory complications.
The study uses a Canadian sample to whom questionnaires were administered containing the SF-36
version 2 via post. A total of 233 of the responses were from preterm individuals with RDS, measured
at a mean age of 20.04 years. However, SF-36 scores were not reported in the paper. The corresponding
author was contacted to request these data, but was unable to provide it. The study claims that
health-related quality of life did not differ between the four groups studied.
In their modelling study for ACSs, Bastek et al.109 utilise proxy utilities for acute and chronic respiratory disease.
They argue that a utility value for a 10-day intensive care unit (ICU) admission was an acceptable proxy for
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acute respiratory disease, because infants with RDS are managed in NICUs. The utility corresponding to this
outcome is 0.87.108 In Table 43, we see that Carroll and Downs108 obtained this utility using the standard
gamble method. Because NICE uses the UK time trade-off value set to obtain utilities from the EQ-5D, time
trade-off utilities obtained by Carroll and Downs108 are preferred to those obtained by standard gamble.114
In the study by Carroll and Downs,108 the time trade-off utility for 10-day ICU admission is 0.91.
Bastek et al.109 report a utility for chronic respiratory disease of 0.88, which was taken from the study by
Carroll and Downs108 as the utility of moderate persistent asthma. In Table 43, we see that this utility was
obtained using the standard gamble method. The time trade-off equivalent from the study by Carroll and
Downs108 is 0.91. However, given that this utility is higher than the value used for preterm survivors, we
opted to use the utility for severe persistent asthma from the study by Carroll and Downs.108 This is 0.85,
as elicited using the time trade-off method.
Utilities for intraventricular haemorrhage
As discussed in Study discussion, only one study measured quality-of-life outcomes for children with IVH
specifically.102 This study uses four health-related quality-of-life questions from the CDC. One of these is
measured on a 5-point scale, while the remaining three ask for a number of days over the past 30 days
that a particular health state (e.g. poor mental health) was not good. There is no clear mapping for these
measures to provide a single measure of utility.
Therefore, the study by Bastek et al.109 again provides the best available estimate of a utility value. They
use the utility for moderate cerebral palsy from the study by Carroll and Downs108 as a proxy for adverse
neurodevelopment. In Table 43, we see that this utility of 0.76 is identical for both the standard gamble
and time trade-off methods of elicitation.
Utilities for preterm survivors
The NICE-preferred measure of health-related quality of life in adults is the EQ-5D;114 however, given that
we do not have any such data, the second-best option is to use SF-36 scores mapped onto the EQ-5D.
Five studies provide utilities for children that were obtained from mapping the SF-36 mean dimension scores
onto the EQ-5D.111–113,168,169 Although many other studies provide utilities using the HUI and 17D, these
measures are less desirable than the mapped SF-36 for populating a NICE reference case analysis. In addition,
the SF-36 studies, on average, measured outcomes later in life than the 17D or HUI studies, suggesting that
the utilities obtained from these studies would be more relevant when extrapolated across the lifespan.
Three of these five studies are Norwegian.112,113,169 One study restricts its population to gestation of
≤ 28 weeks or a birthweight of ≤ 1000 g.112 This appears too limiting to capture the outcomes of all
preterm children. The other two studies consider a more generous birthweight range of ≤ 1500 g, but
have small preterm sample sizes of 35113 and 43.169
Of the remaining two studies, one has SF-36 measures for a very low-birthweight sample of 79 participants
from the UK (assessed between ages 19 and 22 years).111 The other uses a larger sample of 126 preterm
children from New Zealand (assessed at age 31 years) whose mothers were participants in the Auckland
Steroid Trial.168 Of these individuals, 21 had RDS in infancy, which may lead to a small downwards bias in
the quality-of-life scores, although it is possible that this bias had been diminished by the time the
participants were assessed.
In summary, the five studies that report SF-36 quality-of-life scores provide mapped EQ-5D utilities that can
be used for preterm survivors. The studies that used the 17D or HUI measures were seen as less desirable,
as they cannot be mapped in a straightforward way to EQ-5D utilities.
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Statistical analysis of the effects of birthweight on utility
In order to determine whether or not it was necessary to incorporate a utility reduction for lower birthweight,
regression analysis was carried out on a data set obtained from one of the authors of a Canadian study.107
The data contained utility, as measured by HUI3, assessed at three life stages (adolescence, young adulthood
and mature adulthood). Along with this, we were supplied with data on birthweight, sex and gestational age.
Data from 290 individuals were provided, although some had missing sex information and many participants
did not respond in all three life stages. The mean birthweight in the sample was 2047.9 g (minimum =
560 g, maximum = 4734 g) and the mean gestational age was 33.2 weeks (minimum = 23 weeks,
maximum = 40 weeks).
A random-effects GLS panel data estimator was used to estimate the following general model (the ‘between’
estimator was also used, but results are not reported as they did not differ substantially from the GLS estimates,
and because random-effects GLS is a more efficient estimator in general):
uit = α + βBi + γXi + θDt + νi + ϵit, (14)
where u = utility, B = a vector containing birthweight and squared birthweight, X = a vector containing sex
and gestational age, D = a vector of time dummies, ν = an unobservable fixed effect and ε = the
idiosyncratic error term. Table 45 shows the estimates of five different model specifications.
TABLE 45 Random-effects GLS estimates of utility on birthweight
Explanatory variable
Dependent variable: utility (HUI3)
(1) (2) (3) (4) (5)
Birthweight (g) 9 × 10–5 9.07 × 10–5* 0.00011 0.00011 0.0000292
(4.96 × 10–5) (4.96 × 10–5) (9.06 × 10–5) (9.05 × 10–5) (2.20 × 10–5)
Birthweight squared –1.08 × 10–8 –1.11 × 10–8 –1.4 × 10–8 –1.4 × 10–8
(1.10 × 10–8) (1.10 × 10–8) (1.52 × 10–8) (1.52 × 10–8)
Young adult 0.00196 0.00216
(0.0144) (0.0145)
Mature adult –0.0531*** –0.0517*** –0.0528***
(0.0167) (0.0167) (0.0149)
Gestational age (weeks) –0.0015 –0.0014 0.00246
(0.00605) (0.00605) (0.00436)
Male 0.0463** 0.0440** 0.0446**
(0.0198) (0.0198) (0.0198)
Constant 0.705*** 0.716*** 0.711*** 0.721*** 0.676***
(0.0397) (0.0403) (0.116) (0.116) (0.105)
Observations 714 714 713 713 713
Number of individuals 287 287 286 286 286
*p < 0.1, **p < 0.05, ***p < 0.01.
Note
Standard errors are in brackets.
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The coefficient for birthweight squared was not significantly different from 0 in any of the five specifications.
Specification (5) was performed as a result of removing the non-significant young adult dummy and the
squared birthweight variable from (4) in order to compare model fit. A LR test comparing these two models
[these had to be re-estimated using maximum likelihood estimation (MLE) in order to obtain the log-likelihoods
necessary to calculate the LR test statistic; the parameter estimates were identical when using MLE and GLS]
resulted in a χ2 statistic of 0.9 (p = 0.6368). Therefore, there is insufficient evidence for a quadratic relationship
between birthweight and utility. As shown in (5), the marginal impact of a 150-g reduction in birthweight is a
utility reduction of 0.004.
The linear birthweight coefficient was significantly different from 0 at the 10% level only in specifications in
which sex and gestational age were not included. In order to test whether or not the simple specification
(1) is equally as valid as (4), another LR test was conducted. The test statistic of 18.16 (p = 0.0011) suggests
that we should reject that specification (1) is equally as suitable as specification (4).
We also ran preliminary non-parametric (local polynomial) regressions that are consistent with the findings
just described. These results suggest that the sample size available for analysis is too small to detect a
small, if existent at all, effect of birthweight on utility, as measured by the HUI3 instrument.
Based on this analysis, we conclude that there is insufficient evidence of a strong enough birthweight
effect on utility to warrant inclusion in the economic model.
Quality-adjusted life-year calculations and comparison with parameters
used in the National Institute for Health and Care Excellence
guidelines model
Preterm survivors
National Institute for Health and Care Excellence guidelines
The model used for tocolytic treatment in the 2015 NICE guidelines for preterm labour24 provides utilities
for preterm survivors through the gestational age range of 24 to 34 weeks. The assumption made was that
those surviving to the age of 1 year would live for 80 years (based on life expectancy in 2015 in England and
Wales) at a utility value of 0.82 per year (based on a UK population norm) [the NICE guidelines state that
this norm was established in either 1982 or 1983 (two different years are stated at different places in the
evidence report24); therefore, it is somewhat outdated]. This was then discounted by the standard rate of
3.5% and multiplied by the probability of survival at each gestational age. Therefore, the utility of preterm
survivors in the guideline model was not based on data specifically from individuals born preterm.
Peninsula Technology Assessment Group model
In contrast, the utility selected for our model is based on the mapped SF-36 score of preterm survivors
assessed between ages 19 and 22 years.111 The range is generated by taking the minimum and maximum
mapped SF-36 values out of four other SF-36 follow-up studies of preterm individuals, assessed at a similar
point in the life cycle (from 20 to 31 years of age).112,113,168,169
Rather than assuming fixed life expectancy, our model uses ONS 2014–16 life tables119 for survival. These
are multiplied by baseline population utilities for each age, which are derived from a regression equation
by Ara and Brazier.84 These baseline utilities account for the natural decline in health-related quality of life
with ageing. Some extrapolation was necessary at the beginning and end of the life horizon, as the life
tables cover the age range 0–100, and the Ara and Brazier84 regression equation was obtained by fitting
to data with an age range of 16–98 years. Finally, the utilities for each health state from Table 20 are
multiplied to these baseline utilities at each age.
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The probabilities of survival after 1 year at each gestational age were obtained from 2013 ONS data186
for England and Wales. These were applied to the resulting overall discounted sum of utilities over the
lifetime to obtain total QALYs. Our method improves on that of the 2015 NICE guidelines model24 by
taking population ageing and survival into account, while preserving NICE’s use of survival probabilities by
gestational age. Alternative QALY values were also calculated by excluding the population ageing effect,
and assuming a fixed life expectancy, in order to provide QALYs that use the same methodology as the
NICE guidelines, but with updated health-state utilities.
Two studies were found using data from Sweden, which reported hazard ratios for preterm children.187,188
Both of these studies showed a very small increase in mortality until 5 years of age, and negligible
increases in mortality beyond 5 years. Because of this, we did not apply additional adjustments to the
survival probabilities from preterm birth after 1 year.
Table 46 summarises the base-case total QALYs for preterm survivors by gestational age.
Intraventricular haemorrhage and respiratory distress syndrome
The 2015 NICE guidelines model24 for tocolytic treatment assumes a ‘dummy value’ for the lifetime QALY
loss from RDS, owing to its variable prognosis. This value was chosen to be marginally lower than the
lifetime QALY loss from IVH. The economic model in the study by Bastek et al.109 uses a 10-day ICU stay as
a proxy for RDS, but also provides a proxy for chronic respiratory disease as being the utility of moderate
persistent asthma. The original time trade-off values for these parameters from the study by Carroll and
Downs108 are identical at 0.91. However, this value is higher than the mapped utility of preterm survivors
found in the literature. Therefore, we opted to use the utility of severe persistent asthma from the study by
Carroll and Downs108 as a proxy for the lifetime effects of RDS (0.85).
TABLE 46 Total discounted QALYs for preterm survivors, by gestational age
Gestational age
(weeks)
Probability that
infant survives the
first year (based on
ONS 2015 data)186
Weighted
discounted QALYs
using age and
survival adjustments
Weighted
discounted QALYs
using NICE method
(=maximum
QALYs × probability
of infant being alive
after the first year)
Weighted
discounted QALY
used in 2015
NICE guidelines
24 0.5934 13.23 14.44 19.92
25 0.7621 16.99 18.55 20.89
26 0.8289 18.48 20.17 21.27
27 0.8917 19.88 21.70 21.69
28 0.9120 20.33 22.19 22.18
29 0.9544 21.27 23.23 22.44
30 0.9679 21.57 23.55 22.61
31 0.9733 21.69 23.69 22.52
32 0.9833 21.92 23.93 22.53
33 0.9870 22.00 24.02 22.58
34 0.9904 22.08 24.10 22.61
35 0.9916 22.10 24.13 N/A
36 0.9955 22.19 24.23 N/A
N/A, not applicable.
Note
The NICE guidelines model24 stops at 34 weeks’ gestational age, and therefore no NICE QALYs are reported for the
35-week and 36-week gestational ages.
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The QALY loss from IVH of 4.5 in the guidelines model was based on the value for ICH, which was
assumed to be one-third of the QALY loss from moderate to severe cerebral palsy.78 The source for the
health-state utility on which this QALY loss was derived appears to have been obtained from Pham and
Crowther174 as the utility of permanent neurological sequelae, assessed by antenatal or emergency
midwives.174 However, a very small sample size of 14 was used to elicit this result.
In comparison, the proxy of moderate cerebral palsy used in the study by Bastek et al.109 for IVH was
obtained from the study by Carroll and Downs.108 This appears to be a more reliable source, given that the
time trade-off elicitation task was conducted on a much larger (and more relevant) sample of 4016 parents.
The same age and survival adjustment methodology was used to compute the discounted total QALYs
over the lifetime for children with RDS and IVH as with preterm survivors. Table 47 summarises the total
QALY loss from RDS and IVH (relative to a preterm survivor). It should be noted that these values imply the
assumption of no effect of IVH and RDS on survival after the first year.
Mothers
In common with all other previous models of preterm labour, the NICE guidelines model24 does not account
for the health-related quality of life of mothers of preterm children after adverse outcomes. Although data
are extremely limited, we use the utility mapped from the SF-36 scores reported by Couto et al.106 of
mothers that have had previous adverse pregnancy outcomes as a proxy for the utility for a mother after
infant mortality in the model to conduct exploratory scenario analyses. We consider two scenarios. First,
the mother suffers the adverse pregnancy outcome utility for her remaining lifetime. Second, the mother
suffers the adverse pregnancy outcome utility for 10 years and then reverts to the utility for mothers with
no previous adverse pregnancy outcomes. ONS 2015186 data state that the mean age of mothers at birth is
30 years, and this is echoed by findings in Chapter 2. This is used as the starting age from which to compute
QALYs for mothers.
It has been previously discussed that this utility is too broad to capture a mother’s utility for each individual
child outcome accurately. However, it does allow us to contrast the potential average disutility for a
mother who loses her child.
TABLE 47 Total discounted QALY loss for RDS and IVH as used in the economic model
Outcome PenTAG base case NICE guidelines24 value
RDS (applied to all cases) 0.74 3.85
RDS (applied to 56% of cases) 0.41 2.16 (inferred)
IVH (applied to all grades) 3.02 4.50
IVH (applied to grades III and IV – 30% of cases) 0.91 1.35 (inferred)
TABLE 48 Total discounted QALYs for mothers (assuming age at birth of 30 years)
Outcome Lifetime QALYs
Child dies (applied for lifetime) 13.45
Child dies (applied for 10 years following birth) 15.94
Child survives 17.42
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Appendix 6 Additional cost-effectiveness results
Women presenting at 26 weeks’ gestation (at a level 2 hospital)
As noted previously, ICERs should be interpreted with caution because, other than ‘treat all’ and fFN at
10 ng/ml versus fFN at 50 ng/ml, they represent a reduction in both costs and QALYs. Incremental costs
and QALYs for PartoSure versus fFN at 50 ng/ml are the result of an indirect comparison between the
studies by Bruijn et al.42,43 and Hadzi-Lega et al.,44 because no included study directly compares these two
tests. As for the case of women presenting at 30 weeks’ gestation, Actim Partus results in £35,364 of cost
savings per QALY lost relative to fFN at 50 ng/ml, which are higher than those of fFN at 200 ng/ml
(£16,541) or fFN at 500 ng/ml (£11,476). Based on indirect comparison, PartoSure appears to offer the
same QALY loss as but higher cost savings than Actim Partus, relative to fFN at 50 ng/ml.
Full incremental analyses are presented in Table 50 and detailed costs and QALYs are presented in Table 51.
Note that diagnostic options involving wider use of treatment have become more attractive for this group
of women than for women presenting at later gestation (e.g. ICER for treat all in Table 49, £128,939,
is lower than that in Table 23, £186,754).
TABLE 49 Summary of ICERs for women presenting at 26 weeks’ gestation (level 2 hospital)
Test
Total
costs (£)
Total
QALYs
Vs. treat all Vs. fFN at 50 ng/ml
Incremental
costs (£)
Incremental
QALYs
ICER (£)
(per QALY)
Incremental
costs (£)
Incremental
QALYs
ICER (£)
(per QALY)
Actim
Partusa
15,263 21.619 –2259 –0.031 72,794b –658 –0.019 35,364b
PartoSurec 14,926d 21.619d –2266 –0.024 95,252b –995 –0.019 53,446b
Treat all 17,522 21.650 0 0 – 1600 0.012 128,939
fFN at
10 ng/mla
16,498 21.643 –1024 –0.006 165,033b 576 0.006 92,845
fFN at
50 ng/mla
15,921 21.637 –1600 –0.012 128,939b 0 0 –
fFN at
200 ng/mla
15,442 21.608 –2080 –0.041 50,260b –479 –0.029 16,541b
fFN at
500 ng/mla
15,114 21.567 –2408 –0.070 29,095b –807 –0.070 11,476b
a Bruijn et al.42,43
b The ICER represents the south-west quadrant in cost-effectiveness (i.e. a reduction in both costs and QALYs).
c Total costs and QALYs for PartoSure were obtained by applying the differences in these outcomes between PartoSure
and Actim Partus reported in Hadzi Lega et al.45 to corresponding results for Actim Partus reported by Brujin et al.43,44
d Inferred total cost and QALYs for PartoSure obtained by applying relative differences vs. Actim Partus found using
Hadzi-Lega et al.44 to Bruijn et al.42,43
Note
Green text denotes ratios in which the difference in cost and the difference in benefit (QALYs) are both negative relative to
the reference test option.
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TABLE 50 Fully incremental analysis of ICERs for women presenting at 26 weeks’ gestation (level 2 hospital)
Test Total costs (£) Total QALYs
Vs. next option in the QALY ranking
Incremental
costs (£)
Incremental
QALYs ICER (£)
Treat all (test none) 17,522 21.650 1024 0.006 165,033
fFN at 10 ng/mla 16,498 21.643 576 0.006 92,845
fFN at 50 ng/mla 15,921 21.637 658 0.019 53,446b
Actim Partusa 15,263 21.619 337 0.000 Dominated by PartoSure
PartoSurec 14,926d 21.619d –516 0.010 Dominates fFN at 200 ng/ml
and fFN at 500 ng/ml
fFN at 200 ng/mla 15,442 21.608 328 0.041 7930
fFN at 500 ng/mla 15,114 21.567 – – – (dominated by PartoSure)
a Bruijn et al.42,43
b Calculated relative to PartoSure, which dominates Actim Partus.
c Total costs and QALYs for PartoSure were obtained by applying the differences in these outcomes between PartoSure
and Actim Partus reported in Hadzi Lega et al.45 to corresponding results for Actim Partus reported by Brujin et al.43,44
d Calculated relative to PartoSure, which dominates Actim Partus.
Notes
Options have been ranked from most to least effective (in terms of QALYs). ICERs are relative to the next most effective
option (i.e. the test in the row immediately below).
TABLE 51 Breakdown of discounted costs and QALYs for women presenting at 26 weeks’ gestation
Costs and QALYs Treat all
Bruijn et al.42,43 (APOSTEL-1)
Indirect
comparisona
fFN at
Actim
Partus PartoSure10 ng/ml 50 ng/ml 200 ng/ml 500 ng/ml
Discounted costs (£)
Diagnosis 0 66 66 66 66 35 52
Treatment 367 216 136 69 0 49 0
Hospital admission 1325 781 493 250 95 177 1
In-utero transfer 965 569 359 182 69 129 1
Neonatal IVH 5232 5235 5237 5248 5264 5244 5244
Neonatal RDS 9467 9473 9480 9509 9552 9499 9499
Neonatal deathb 166 158 151 118 70 130 130
Total 17,522 16,498 15,921 15,442 15,114 15,263 14,926
Incremental costs
(vs. fFN at 50 ng/ml)
1600 576 Reference –479 –807 –658 –995
Discounted QALYs
Surviving neonate without
morbidity
21.55 21.55 21.55 21.55 21.55 21.55 21.55
Infant morbidity due to IVH –0.03 –0.03 –0.03 –0.03 –0.03 –0.03 –0.03
Infant morbidity due to RDS –0.01 –0.01 –0.01 –0.01 –0.01 –0.01 –0.01
Infant mortality avoidance 0.13 0.13 0.12 0.10 0.06 0.10 0.10
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Women presenting at 33 weeks’ gestation (at a level 2 hospital)
Results that are qualitatively similar to those described before for women presenting at 26 and 30 weeks’
gestation were found for women presenting at 33 weeks’ gestation. At £97,069, Actim Partus saves more costs
per QALY lost relative to fFN at 50 ng/ml than fFN at 200 ng/ml (£43,781) and fFN at 500 ng/ml (£29,631), and
treat all and fFN at 10 ng/ml both have incremental costs per QALY gained that are > £200,000. Based on
indirect comparison, PartoSure appears to dominate Actim Partus as it results in the same number of QALYs
and lower costs. Table 52 presents the summary results for each test relative to the comparators, Table 53
presents the fully incremental analyses and Table 54 presents the detailed costs and QALY elements.
TABLE 52 Summary of ICERs for women presenting at 33 weeks’ gestation (level 2 hospital)
Test
Total
costs
(£)
Total
QALYs
Vs. treat all Vs. fFN at 50 ng/ml
Incremental
costs (£)
Incremental
QALYs
ICER (£)
(per QALY)
Incremental
costs (£)
Incremental
QALYs
ICER (£)
(per QALY)
Actim Partusa 2716 22.096 –1117 –0.006 187,479b –347 –0.004 97,069b
PartoSurec 2556d 22.096d –1111 –0.005 243,269b –507 –0.004 141,838b
Treat all 3833 22.102 0 0 – 770 0.002 323,093
fFN at
10 ng/mla 3352 22.101 –481 –0.001 403,469b 289 0.001 242,716
50 ng/mla 3063 22.100 –770 –0.002 323,093b 0 0 –
200 ng/mla 2820 22.094 –1013 –0.008 127,575b –243 –0.006 43,781b
500 ng/mla 2663 22.086 –1170 –0.016 73,650b –400 –0.014 29,631b
a Bruijn et al.42,43
b ICER represents the south-west quadrant in cost-effectiveness (i.e. a reduction in both costs and QALYs).
c Total costs and QALYs for PartoSure were obtained by applying the differences in these outcomes between PartoSure
and Actim Partus reported in Hadzi Lega et al.45 to corresponding results for Actim Partus reported by Brujin et al.43,44
d Inferred total cost and QALYs for PartoSure obtained by applying relative differences vs. Actim Partus found using
Hadzi-Lega et al.44 to Bruijn et al.42,43
Note
Green text denotes ratios in which the difference in cost and the difference in benefit (QALYs) are both negative relative to
the reference test option.
TABLE 51 Breakdown of discounted costs and QALYs for women presenting at 26 weeks’ gestation (continued )
Costs and QALYs Treat all
Bruijn et al.42,43 (APOSTEL-1)
Indirect
comparisona
fFN at
Actim
Partus PartoSure10 ng/ml 50 ng/ml 200 ng/ml 500 ng/ml
Total 21.650 21.643 21.637 21.608 21.567 21.619 21.619
Incremental QALYs
(vs. fFN at 50 ng/ml)
0.012 0.006 Reference –0.029 –0.070 –0.019 –0.019
ICER vs. fFN at 50 ng/ml 128,939 92,845 Reference 16,541c 11,476c 35,364c 53,446c
a Costs and QALYs are inferred values computed via an indirect comparison between the Hadzi-Lega et al.44 and Bruijn
et al.42,43 studies.
b These are the neonatal hospital costs associated with those infants saved by steroid treatment.
c ICER represents the south-west quadrant in cost-effectiveness (i.e. a reduction in both costs and QALYs).
Note
Green text denotes ratios in which the difference in cost and the difference in benefit (QALYs) are both negative relative to
the reference test option.
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TABLE 53 Fully incremental analysis of ICERs for women presenting at 33 weeks’ gestation (level 2 hospital)
Test
Total
costs (£)
Total
QALYs
Vs. next option in the QALY ranking
Incremental
costs (£)
Incremental
QALYs ICER (£)
Treat all (test none) 3833 22.102 481 0.001 403,469
fFN at 10 ng/mla 3352 22.101 289 0.001 242,716
fFN at 50 ng/mla 3063 22.100 347 0.004 141,838b
Actim Partusa 2716 22.096 160 0.000 Dominated by PartoSure
PartoSurec 2556d 22.096d –264 0.002 Dominates fFN at 200 ng/ml and
fFN at 500 ng/ml
fFN at 200 ng/mla 2820 22.094 157 0.008 19,725 (dominated by PartoSure)
fFN at 500 ng/mla 2663 22.086 – – – (dominated by PartoSure)
a Bruijn et al.42,43
b Calculated relative to PartoSure, which dominates Actim Partus.
c Total costs and QALYs for PartoSure were obtained by applying the differences in these outcomes between PartoSure
and Actim Partus reported in Hadzi Lega et al.45 to corresponding results for Actim Partus reported by Brujin et al.43,44
d Inferred total cost and QALYs for PartoSure obtained by applying relative differences vs. Actim Partus found using
Hadzi-Lega et al.44 to Bruijn et al.42,43
Notes
Options have been ranked from most to least effective (in terms of QALYs). ICERs are relative to the next most effective
option (i.e. the test in the row immediately below).
TABLE 54 Breakdown of discounted costs and QALYs for women presenting at 33 weeks’ gestation
Costs and QALYs Treat all
Bruijn et al.42,43 (APOSTEL-1)
Indirect
comparisona
fFN at
Actim
Partus PartoSure10 ng/ml 50 ng/ml 200 ng/ml 500 ng/ml
Discounted costs (£)
Diagnosis 0 66 66 66 66 35 52
Treatment 5 3 2 1 0 1 0
Hospital admission 1325 781 493 250 95 177 1
In-utero transfer 0 0 0 0 0 0 0
Neonatal IVH 2477 2478 2479 2484 2492 2482 2482
Neonatal RDS 0 0 0 0 0 0 0
Neonatal deathb 26 25 24 19 11 21 21
Total 3833 3352 3063 2820 2663 2716 2556
Incremental costs
(vs. fFN at 50 ng/ml)
770 289 Reference –243 –400 –347 –507
Discounted QALYs
Surviving neonate
without morbidity
22.09 22.09 22.09 22.09 22.09 22.09 22.09
Infant morbidity due to
IVH
–0.01 –0.01 –0.01 –0.01 –0.01 –0.01 –0.01
Infant morbidity due to
RDS
–0.00 –0.00 –0.00 –0.00 –0.00 –0.00 –0.00
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Full incremental analyses are presented in Table 53 and detailed costs and QALYs are presented in Table 54.
Diagnostic options involving wider use of treatment have become less attractive for this group of women
than for women presenting at earlier gestation (e.g. ICER for treat all in Table 52, £323,093, is higher than
those in Table 49, £128,939, and Table 23, £186,754.
Additional deterministic sensitivity analyses
Treat all vs. fFN at 50 ng/ml
Long-term cost of IVH
Cost of hospital admission
Cost of hospital transfer
Neonatal hospital costs RDS
Costs of saving the life of a PTB
ACS RR mortality
ACS RR IVH
ACS RR RDS
Baseline mortality risk
Baseline RDS risk
Baseline IVH risk
Cost of qfFN test
Cost of pIGFBP-1 test
Cost of PartoSure
PTB within 7 days
Utility of preterm survivors
Proportion of severe IVH cases
ICER (£1000 per QALY)
Lower variation
Upper variation
£0 £50 £100 £150 £200 £250 £300 £350 £400 £450
ICERs from
FIGURE 19 Tornado diagram of most influential model parameter values: treat all. PTB, preterm birth; RR, risk ratio.
TABLE 54 Breakdown of discounted costs and QALYs for women presenting at 33 weeks’ gestation (continued )
Costs and QALYs Treat all
Bruijn et al.42,43 (APOSTEL-1)
Indirect
comparisona
fFN at
Actim
Partus PartoSure10 ng/ml 50 ng/ml 200 ng/ml 500 ng/ml
Loss of infant mortality 0.03 0.02 0.02 0.02 0.01 0.02 0.02
Total 22.102 22.101 22.100 22.094 22.086 22.096 22.096
Incremental QALYs
(vs. fFN at 50 ng/ml)
0.002 0.001 Reference –0.006 –0.014 –0.004 –0.004
ICER vs. fFN at 50 ng/ml 323,093 242,716 – 43,781c 29,631c 97,069c 141,838c
a Costs and QALYs are inferred values computed via an indirect comparison between the Hadzi-Lega et al.44 and Bruijn
et al.42,43 studies.
b These are the neonatal hospital costs associated with those infants saved by steroid treatment.
c The ICER represents the south-west quadrant in cost-effectiveness (i.e. a reduction in both costs and QALYs).
Note
Green text denotes ratios in which the difference in cost and the difference in benefit (QALYs) are both negative relative to
the reference test option.
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fFN at 10 ng/ml vs. fFN at 50 ng/ml
Long-term cost of IVH
Cost of hospital admission
Cost of hospital transfer
Neonatal hospital costs RDS
Costs of saving the life of a PTB
ACS RR mortality
ACS RR IVH
ACS RR RDS
Baseline mortality risk
Baseline RDS risk
Baseline IVH risk
Cost of qfFN test
Cost of pIGFBP-1 test
Cost of PartoSure
PTB within 7 days
Utility of preterm survivors
Proportion of severe IVH cases
ICER (£1000 per QALY)
Lower variation
Upper variation
£0 £50 £100 £150 £200 £250 £300 £350
ICERs from
FIGURE 20 Tornado diagram of most influential model parameter values: fFN at 10 ng/ml. PTB, preterm birth;
RR, risk ratio.
fFN at 200 ng/ml vs. fFN at 50 ng/ml
Long-term cost of IVH
Cost of hospital admission
Cost of hospital transfer
Neonatal hospital costs RDS
Costs of saving the life of a PTB
ACS RR mortality
ACS RR IVH
ACS RR RDS
Baseline mortality risk
Baseline RDS risk
Baseline IVH risk
Cost of qfFN test
Cost of pIGFBP-1 test
Cost of PartoSure
PTB within 7 days
Utility of preterm survivors
Proportion of severe IVH cases
ICER (£1000 per QALY)
Lower variation
Upper variation
£0 £10 £20 £30 £40 £50 £60
ICERs from
FIGURE 21 Tornado diagram of most influential model parameter values: fFN at 200 ng/ml. PTB, preterm birth;
RR, risk ratio.
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fFN at 500 ng/ml vs. fFN at 50 ng/ml
Long-term cost of IVH
Cost of hospital admission
Cost of hospital transfer
Neonatal hospital costs RDS
Costs of saving the life of a PTB
ACS RR mortality
ACS RR IVH
ACS RR RDS
Baseline mortality risk
Baseline RDS risk
Baseline IVH risk
Cost of qfFN test
Cost of pIGFBP-1 test
Cost of PartoSure
PTB within 7 days
Utility of preterm survivors
Proportion of severe IVH cases
ICER (£1000 per QALY)
Lower variation
Upper variation
£0 £10 £20 £30 £40
ICERs from
FIGURE 22 Tornado diagram of most influential model parameter values: fFN at 500 ng/ml. PTB, preterm birth;
RR, risk ratio.
Actim Partus vs. fFN at 50 ng/ml
Long-term cost of IVH
Cost of hospital admission
Cost of hospital transfer
Neonatal hospital costs RDS
Costs of saving the life of a PTB
ACS RR mortality
ACS RR IVH
ACS RR RDS
Baseline mortality risk
Baseline RDS risk
Baseline IVH risk
Cost of qfFN test
Cost of pIGFBP-1 test
Cost of PartoSure
PTB within 7 days
Utility of preterm survivors
Proportion of severe IVH cases
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FIGURE 23 Tornado diagram of most influential model parameter values: Actim Partus. PTB, preterm birth;
RR, risk ratio.
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Additional probabilistic sensitivity analyses
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FIGURE 24 Probabilistic analysis: women presenting at 33 weeks’ gestation. The highest net monetary benefit is for a gestational age at presentation of 33 weeks.
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FIGURE 25 Probabilistic analysis: women presenting at 26 weeks’ gestation. The highest net monetary benefit is for a gestational age at presentation of 26 weeks.
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Scenario analyses
TABLE 55 Results for Actim Partus and no testing vs. fFN at 50 ng/ml using data from Cooper et al.49 for women
presenting at 30 weeks’ gestation (level 2 hospital)
Outcome
Cooper et al.49
Treat all Actim Partus fFN at 50 ng/ml
Discounted costs (£)
Diagnosis 0 35 66
Medication 5 1 1
Admission 1325 373 171
Transfer 0 0 0
IVH 4006 4034 4034
RDS 624 630 630
Neonatal death 47 16 16
Total 6007 5090 4917
Incremental costs vs. fFN at 50 ng/ml 1090 173
Discounted QALYs
Baseline without morbidity 22.00 22.00 22.00
IVH –0.02 –0.02 –0.02
RDS –0.00 –0.00 –0.00
Infant mortality 0.04 0.01 0.01
Total 22.02 21.99 21.99
Incremental QALYs vs. fFN at 50 ng/ml 0.03 0.00
ICER vs. fFN at 50 ng/ml £34,508 Dominated –
TABLE 56 Results for fFN (various thresholds) vs. fFN at 50 ng/ml using data from Abbott et al.92 for women
presenting at 30 weeks’ gestation (level 2 hospital)
Outcome
Abbott et al.92
Treat all
fFN at
10 ng/ml 200 ng/ml 500 ng/ml 50 ng/ml
Discounted costs
Diagnosis (Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
Medication (Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
Admission (Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
continued
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TABLE 56 Results for fFN (various thresholds) vs. fFN at 50 ng/ml using data from Abbott et al.92 for women
presenting at 30 weeks’ gestation (level 2 hospital) (continued )
Outcome
Abbott et al.92
Treat all
fFN at
10 ng/ml 200 ng/ml 500 ng/ml 50 ng/ml
Transfer (Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
RDS (Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
IVH (Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
Neonatal death (Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
Total (Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
Incremental costs vs. fFN
at 50 ng/ml
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
Discounted QALYs
Baseline without
morbidity
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
RDS (Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
IVH (Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
Infant mortality (Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
Total (Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
Incremental QALYs vs.
fFN at 50 ng/ml
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
ICER vs. fFN at 50 ng/ml (Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
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Table 58 shows results for women presenting at a gestational age of 26 weeks and Table 59 shows results
for women presenting at a gestational age of 33 weeks. Results are similar to those for women presenting
at 30 weeks. One main exception is that Actim Partus saves £24,532 in health-care costs per QALY lost
among women with a gestational age of 33 weeks.
For women presenting at 26 weeks, excluding the neonatal hospitalisation costs associated with saving an
infant’s life by timely administration of ACSs has the effect of halving the ICERs relative to fFN at 50 ng/ml.
Therefore, this favours the treatment-intensive options treat all and fFN at 10 ng/ml, which now have an
ICER of £61,791 and £46,358, respectively. Other options are favoured by the change, but all now save
< £20,000 per QALY lost relative to fFN at 50 ng/ml. The exception is PartoSure, which saves £26,988 per
QALY lost.
TABLE 57 Results for no testing and Actim Partus vs. fFN at 50 ng/ml using data from meta-analysis for women
presenting at 30 weeks’ gestation (level 2 hospital)
Outcome
Meta-analysis42,43,51,56,57
Treat all Actim Partus fFN at 50 ng/ml
Discounted costs (£)
Diagnosis 0 35 66
Medication 5 1 1
Admission 1325 195 204
Transfer 0 0 0
IVH 4006 4013 4019
RDS 624 626 627
Neonatal death 47 39 32
Total 6007 4908 4949
Incremental costs vs. fFN at 50 ng/ml 1058 –41
Discounted QALYs
Baseline without morbidity 22.00 22.00 22.00
IVH –0.02 –0.02 –0.02
RDS –0.00 –0.00 –0.00
Infant mortality 0.04 0.04 0.03
Mother 0.00 0.00 0.00
Total 22.02 22.01 22.00
Incremental costs vs. fFN at 50 ng/ml 0.02 0.01
ICER (relative to fFN at 50 ng/ml) £70,468 Dominant –
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TABLE 58 Incremental cost-effectiveness ratios vs. fFN at 50 ng/ml for women presenting at 26 weeks’ gestation (level 2 hospital)
Option
ICERs (£)
Base
case
With
maternal
QALYs for
10 years
Limiting the
analysis to delivery
(additional cost
only)
Limiting the
analysis to first
year after birth
ANSs earlier than 7 days
before preterm delivery
has partial benefits
Excluding
additional neonatal
hospital costs of
death
Women
presenting at
a level 3
hospital
Applying costs
and disutilities of
AEs to all AEs
Treat all 128,939 72,006 1603 3,422,534 41,153 127,779 61,791 117,174
fFN at
10 ng/mla 92,845 45,524 578 2,470,464 23,957 91,685 46,358 84,373
200 ng/mla 16,541b 11,916b –486 457,751b 8557b 15,381b 8161b 15,032b
500 ng/mla 11,476b 8660b –824 324,143b 6576b 10,316b 5444b 10,429b
Actim Partusa 35,364b 22,807b –663 954,254b 14,629b 34,204b 18,392b 32,137b
PartoSurec 53,446b 53,424b –1000 1,431,224b 68,857b 52,287b 26,988b 48,570b
AE, adverse event.
a Bruijn et al.42,43
b The ICER represents the south-west quadrant in cost-effectiveness (i.e. a reduction in both costs and QALYs).
c Indirect comparison between Bruijn et al.42,43 and Hadzi-Lega et al.44 (Bruijn et al.42,43 was used as the reference study in this case).
Note
Green text denotes ratios in which the difference in cost and the difference in benefit (QALYs) are both negative relative to the reference test option.
A
PPEN
D
IX
6
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
212
TABLE 59 Incremental cost-effectiveness ratios vs. fFN at 50 ng/ml for women presenting at 33 weeks’ gestation (level 2 hospital)
Option
ICERs (£)
Base
case
With
maternal
QALYs for
10 years
Limiting the
analysis to delivery
(additional cost
only)
Limiting the
analysis to first
year after birth
ACSs earlier than 7 days
before preterm delivery
has partial benefits
Excluding
additional neonatal
hospital costs of
death
Women
presenting at
a level 3
hospital
Applying costs
and disutilities of
AEs to all AEs
Treat all 323,093 194,770 770 8,522,367 59,091 322,126 323,093 306,507
fFN at
10 ng/mla 242,716 130,060 289 6,402,235 34,621 241,750 242,716 230,256
200 ng/mla 43,781b 33,081b –243 1,154,838b 14,902b 42,815b 43,781b 41,534b
500 ng/mla 29,631b 23,314b –400 781,581b 11,654b 28,664b 29,631b 28,110b
Actim Partusa 97,069b 66,541b –347 2,560,443b 24,532b 96,103b 97,069b 92,086b
PartoSurec 141,838b 141,788b –507 3,741,321b 267,481b 140,871b 141,838b 134,556b
AE, adverse event.
a Bruijn et al.42,43
b The ICER represents the south-west quadrant in cost-effectiveness (i.e. a reduction in both costs and QALYs).
c Indirect comparison between Bruijn et al.42,43 and Hadzi-Lega et al.44 (Bruijn et al.42,43 was used as the reference study in this case).
Note
Green text denotes ratios in which the difference in cost and the difference in benefit (QALYs) are both negative relative to the reference test option.
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TABLE 60 Summary of ICERs for a woman presenting at 30 weeks’ gestation (level 2 hospital), including QALY
losses to the mother for 10 years in case of infant mortality
Test
Total
costs (£)
Total
QALYs
Vs. treat all Vs. fFN at 50 ng/ml
Incremental
costs (£)
Incremental
QALYs
ICER (£)
(per QALY)
Incremental
costs (£)
Incremental
QALYs
ICER (£)
(per QALY)
Actim Partusa 4891 22.016 –1116 –0.016 69,968c –346 –0.009 38,200c
PartoSureb 4731d 22.019d –1110 –0.013 88,385c –506 –0.006 81,893c
fFN at
10 ng/mla 5526 22.029 –481 –0.003 159,831c 289 0.004 74,564
50 ng/mla 5237 22.025 –770 –0.007 111,813c 0 0.000 –
200 ng/mla 4995 22.012 –1012 –0.020 51,469c –242 –0.013 18,968c
500 ng/mla 4840 21.995 –1167 –0.037 31,829c –398 –0.030 13,347c
a Bruijn et al.42,43
b Hadzi-Lega et al.44 for comparison with treat all, indirect comparison between Bruijn et al.42,43 and Hadzi-Lega et al.44
for comparison with fFN at 50 ng/ml (Bruijn et al.42,43 was used as the reference study in this case).
c The ICER represents the south-west quadrant in cost-effectiveness (i.e. a reduction in both costs and QALYs).
d Total costs and QALYs for PartoSure were obtained by applying the differences in these outcomes between PartoSure
and Actim Partus reported in Hadzi Lega et al.45 to corresponding results for Actim Partus reported by Brujin et al.43,44
Note
Green text denotes ratios in which the difference in cost and the difference in benefit (QALYs) are both negative relative to
the reference test option.
TABLE 61 Summary of ICERs for a woman presenting at 30 weeks’ gestation (level 2 hospital), including lifetime
QALY losses to the mother in case of infant mortality
Test
Total
costs (£)
Total
QALYs
Vs. treat all Vs. fFN at 50 ng/ml
Incremental
costs (£)
Incremental
QALYs
ICER (£)
(per QALY)
Incremental
costs (£)
Incremental
QALYs
ICER (£)
(per QALY)
Actim Partusa 4891 22.027 –1116 –0.025 43,954d –346 –0.014 24,936d
PartoSureb 4731c 22.035c –1110 –0.020 54,536d –506 –0.006 81,844d
fFN at
10 ng/mla 5526 22.048 –481 –0.005 104,731d 289 0.007 41,820
50 ng/mla 5237 22.041 –770 –0.011 66,923d 0 0.000 –
200 ng/mla 4995 22.023 –1012 –0.030 34,226d –242 –0.018 13,416d
500 ng/mla 4840 22.000 –1167 –0.052 22,426d –398 –0.041 9806d
a Bruijn et al.42,43
b Hadzi-Lega et al.44 for comparison with treat all, indirect comparison between Bruijn et al.42,43 and Hadzi-Lega et al.44
for comparison with fFN at 50 ng/ml (Bruijn et al.42,43 was used as the reference study in this case).
c Total costs and QALYs for PartoSure were obtained by applying the differences in these outcomes between PartoSure
and Actim Partus reported in Hadzi Lega et al.45 to corresponding results for Actim Partus reported by Brujin et al.43,44
d The ICER represents the south-west quadrant in cost-effectiveness (i.e. a reduction in both costs and QALYs).
Note
Green text denotes ratios in which the difference in cost and the difference in benefit (QALYs) are both negative relative to
the reference test option.
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Appendix 7 Additional diagnostic test accuracy
data on cervical length
Methods of the overview
In addition to the systematic review described in Chapter 2, Methods of the systematic review, an overview
of studies that assess the DTA of at least one of the index tests (PartoSure, Actim Partus and qfFN), in
addition to a qualitative fFN test, qfFN at 50 ng/ml and/or transvaginal cervical length measurement, was
provided because these are the tests currently recommended by NICE guidance.24
These data were extracted, when available, from the studies included in the systematic review of PartoSure,
Actim Partus and qfFN (see Chapter 2, Results of the systematic review). For this reason, studies included in
the systematic review that also provided test accuracy data for a qualitative fFN test, qfFN at 50 ng/ml and/or
transvaginal cervical length measurement, were included in this overview. Test accuracy data for qualitative
fFN, qfFN at 50 ng/ml and/or transvaginal cervical length measurement were extracted, tabulated and
analysed following the same methods and principles described in Chapter 2, Methods of the systematic
review, although only sensitivity, specificity, PPV and NPV are summarised (and no meta-analyses were
conducted). These test accuracy data are compared (in tables and text) with the test accuracy data for
PartoSure, Actim Partus and qfFN, obtained from the same studies.
It should be noted that, because only ‘comparative’ DTA studies are summarised (i.e. studies providing data
for both an index test and one or more of qualitative fFN, qfFN at 50 ng/ml and/or transvaginal cervical
length measurement), this summary does not systematically cover the full breadth of DTA evidence on these
additional tests. [These studies are not comparative in the strictest sense, rather they evaluate more than
one test within the same population (but do not directly compare the tests). This applies throughout this
appendix.] In order to ensure that the test accuracy data for qualitative fFN, qfFN at 50 ng/ml and/or
transvaginal cervical length measurement included here are largely representative of all data available for
these tests, recent systematic reviews of DTA studies for these tests were sought and assessed.
Results of the overview: fetal fibronectin
In this section, we present an overview of studies that assess the DTA of at least one of the index tests
(PartoSure, Actim Partus and qfFN), in addition to a qualitative fFN test and/or qfFN at 50-ng/ml test.
In a similar manner, a further overview incorporating cervical length is given in Appendix 2.
The reasons for presenting these additional data are twofold. First, fFN at 50 ng/ml is recommended in the NICE
guidelines for current practice.24 Second, these tests are also comparators in our review of clinical effectiveness
(end-to-end studies) but no such studies were found (see Chapter 3). However, it is important to highlight here
that, because fFN at 50 ng/ml was not an index test in the test accuracy review, the data are presented for
information only and do not form part of the systematic review of test accuracy. Nevertheless, only data
presented in those studies that were included in the systematic review are included in this overview. Owing to
this, these data are not exhaustive of all data available for qualitative fFN or qfFN at 50 ng/ml (because several
studies only reporting such data would have been excluded from the systematic review). To ensure that the
data presented here are similar to the wider available evidence, we also identified, for comparison, recent
systematic reviews of test accuracy data for qualitative fFN or qfFN at 50 ng/ml.
In this overview, DTA data, against a reference standard of preterm birth within 7 days, are provided for
fFN, at a threshold of 50 ng/ml (qualitative or quantitative test). These data are presented in Chapter 2,
Results of the systematic review, together with test accuracy data for index tests from the same studies
(i.e. data from index tests produced for the systematic review of PartoSure, Actim Partus and qfFN at
thresholds other than 50 ng/ml).
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TABLE 62 Test accuracy results (against preterm birth within 7 days) for index tests, cervical length measurement
and fFN at 50 ng/ml
Study (study
name/first author
and year) and test
Number of
participants
Test accuracy results (%) (95% CI)
Sensitivity Specificity PPV NPV
Azlin (2010)47
CL < 25mm 51 80.0 (28.4 to 99.5) 71.7 (56.5 to 84.0) 23.5 (6.8 to 49.9) 97.1 (84.7 to 99.9)
Actim Partus 51 80.0 (28.4 to 99.5) 93.5 (82.1 to 98.6) 57.1 (18.4 to 90.1) 97.7 (88.0 to 99.9)
Bolotskikh (2017)59
CL < 15mma 99 33.3 (9.9 to 65.1) 98.9 (93.8 to 100.0) 80.0 (28.4 to 99.5) 91.5 (83.9 to 96.3)
PartoSure 99 100.0 (73.5 to 100.0) 95.4 (88.6 to 98.7) 75.0 (47.6 to 92.7) 100.0 (95.7 to 100.0)
APOSTEL-1 (2016)42,43
CL < 15mma 350 72.5 (60.4 to 82.5) 83.3 (78.4 to 87.4) 51.5 (41.2 to 61.8) 92.5 (88.5 to 95.4)
fFN at 10 ng/ml 350 95.7 (87.8 to 99.1) 42.3 (36.5 to 48.4) 28.9 (23.2 to 35.3) 97.5 (93.0 to 99.5)
fFN at 50 ng/mlb 350 91.3 (82.0 to 96.7) 64.8 (58.9 to 70.3) 38.9 (31.3 to 46.9) 96.8 (93.2 to 98.8)
fFN at 200 ng/ml 350 71.0 (58.8 to 81.3) 83.6 (78.8 to 87.8) 51.6 (41.1 to 62.0) 92.2 (88.1 to 95.1)
fFN at 500 ng/ml 350 42.0 (30.2 to 54.5) 95.7 (92.7 to 97.8) 70.7 (54.5 to 83.9) 87.1 (82.8 to 90.6)
Actim Partus 350 78.3 (66.7 to 87.3) 89.3 (85.1 to 92.7) 64.3 (53.1 to 74.4) 94.4 (90.9 to 96.8)
Bruijn (2016)62
CL < 15mma 450 51.3 (34.8 to 67.6) 81.8 (77.7 to 85.4) 21.3 (13.5 to 30.9) 94.6 (91.7 to 96.7)
fFN at 10 ng/ml 455 93.8 (82.8 to 98.7) 32.2 (27.7 to 37.0) 14.0 (10.4 to 18.3) 97.8 (93.6 to 99.5)
fFN at 50 ng/mlb 455 89.6 (77.3 to 96.5) 62.2 (57.3 to 66.9) 21.8 (16.3 to 28.3) 98.1 (95.5 to 99.4)
fFN at 200 ng/ml 455 70.8 (55.9 to 83.0) 78.6 (74.3 to 82.5) 28.1 (20.3 to 37.0) 95.8 (93.1 to 97.7)
fFN at 500 ng/ml 455 29.2 (17.0 to 44.1) 94.3 (91.6 to 96.4) 37.8 (22.5 to 55.2) 91.9 (88.8 to 94.3)
Cooper (2012)49
fFN at 50 ng/mlc 291 33.3 (4.3 to 77.7) 89.8 (85.7 to 93.1) 6.5 (0.8 to 21.4) 98.5 (96.1 to 99.6)
Actim Partus 349 33.3 (4.3 to 77.7) 74.1 (69.1 to 78.6) 2.2 (0.3 to 7.7) 98.4 (96.1 to 99.6)
Danti (2011)50
CL < 20mma
(sample 1)
60 75.0 (19.4 to 99.4) 71.4 (57.8 to 82.7) 15.8 (3.4 to 39.6) 97.6 (87.1 to 99.9)
CL < 20mma
(sample 2)
102 75.0 (19.4 to 99.4) 83.7 (74.8 to 90.4) 15.8 (3.4 to 39.6) 98.8 (93.5 to 100.0)
Actim Partus 60 50.0 (6.8 to 93.2) 69.6 (55.9 to 81.2) 10.5 (1.3 to 33.1) 95.1 (83.5 to 99.4)
Eroglu (2007)51
fFN at 50 ng/mld 51 83.3 (35.9 to 99.6) 80.0 (65.4 to 90.4) 35.7 (12.8 to 64.9) 97.3 (85.8 to 99.9)
Actim Partus 51 83.3 (35.9 to 99.6) 84.4 (70.5 to 93.5) 41.7 (15.2 to 72.3) 97.4 (86.5 to 99.9)
CL < 20mm 51 66.7 (22.3 to 95.7) 95.6 (84.9 to 99.5) 66.7 (22.3 to 95.7) 95.6 (84.9 to 99.5)
Goyal (2016)52
CL < 25mme 60 80.5 (65.1 to 91.2) 31.6 (12.6 to 56.6) 71.7 (56.5 to 84.0) 42.9 (17.7 to 71.1)
Actim Partus 60 59.1 (43.2 to 73.7) 50.0 (24.7 to 75.3) 76.5 (58.8 to 89.3) 30.8 (14.3 to 51.8)
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
216
Test accuracy data for fetal fibronectin at 50 ng/ml
Quantity and quality of the data available for fetal fibronectin at 50 ng/ml
As can be seen in Table 63, eight of the 20 included studies42,43,49,51,54,56,57,60–62 report DTA data for fFN
measured at a 50-ng/ml threshold (in addition to data for at least one index test).
Two studies (APOSTEL-142,43 and Bruijn62) used the qfFN test and report data at 50 ng/ml. The APOSTEL-1
study did additionally use a qualitative version of the fFN test (Rapid fFN for TLiIQ system test), but data
for this test are not provided in the included papers.42,43 Three studies51,57,60,61 used the QuikCheck version
of the qualitative fFN test. One further study54 used the ELISA laboratory technique. The remaining two
studies49,56 did not report which test was used. More specifically, Ting et al.56 only state that the test used
was a bedside test that was ‘qualitatively reported’. Cooper et al.49 report using a fFN test manufactured
by Adeza Biochemical Corporation, but as this company produces both an ELISA testing method and the
Rapid fFN for TLiIQ system test,189 it remains unclear which test was used.
TABLE 62 Test accuracy results (against preterm birth within 7 days) for index tests, cervical length measurement
and fFN at 50 ng/ml (continued )
Study (study
name/first author
and year) and test
Number of
participants
Test accuracy results (%) (95% CI)
Sensitivity Specificity PPV NPV
Hadzi-Lega (2017)44
CL < 25mm 57 100.0 (54.1 to 100.0) 70.6 (56.2 to 82.5) 28.6 (11.3 to 52.2) 100.0 (90.3 to 100.0)
Actim Partus 57 83.3 (35.9 to 99.6) 76.5 (62.5 to 87.2) 29.4 (10.3 to 56.0) 97.5 (86.8 to 99.9)
PartoSure 57 83.3 (35.9 to 99.6) 90.2 (78.6 to 96.7) 50.0 (18.7 to 81.3) 97.9 (88.7 to 99.9)
Nikolova (2014 and 2015)60,61
CL < 25mm 203 57.1 (39.4 to 73.7) 72.6 (65.2 to 79.2) 30.3 (19.6 to 42.9) 89.1 (82.6 to 93.7)
fFN at 50 ng/mld 66 50.0 (21.1 to 78.9) 72.2 (58.4 to 83.5) 28.6 (11.3 to 52.2) 86.7 (73.2 to 94.9)
PartoSure 203 80.0 (63.1 to 91.6) 94.6 (90.1 to 97.5) 75.7 (58.8 to 88.2) 95.8 (91.5 to 98.3)
Riboni (2011)54
fFN at 50 ng/mlf 210 50.0 (15.7 to 84.3) 80.2 (74.0 to 85.5) 9.1 (2.5 to 21.7) 97.6 (93.9 to 99.3)
Actim Partus 210 50.0 (15.7 to 84.3) 83.7 (77.8 to 88.5) 10.8 (3.0 to 25.4) 97.7 (94.2 to 99.4)
Ting (2007)56
fFN at 50 ng/mlc 94 56.3 (29.9 to 80.2) 75.6 (64.6 to 84.7) 32.1 (15.9 to 52.4) 89.4 (79.4 to 95.6)
Actim Partus 94 70.6 (44.0 to 89.7) 77.9 (67.0 to 86.6) 41.4 (23.5 to 61.1) 92.3 (83.0 to 97.5)
Tripathi (2016)57
fFN at 50 ng/mld 468 23.8 (17.3 to 31.4) 99.1 (97.3 to 99.8) 92.3 (79.1 to 98.4) 73.2 (68.7 to 77.3)
Actim Partus 467 94.7 (89.9 to 97.7) 92.4 (88.9 to 95.1) 85.7 (79.5 to 90.6) 97.3 (94.8 to 98.8)
CL, cervical length.
a Other cut-off points available.
b Quantitative Rapid fFN 10Q Cassette.
c fFN testing method unclear.
d QuikCheck fFN.
e Raw data back calculated from sensitivity, specificity, PPV and NPV.
f fFN measured by ELISA.
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TABLE 63 Test accuracy results (against preterm birth within 7 days) for index tests and fFN at 50 ng/ml
Study (study
name/first author
and year) and test
Number of
participants
Test accuracy results (%) (95% CI)
Sensitivity Specificity PPV NPV
APOSTEL-1 (2016)42,43
fFN at 10 ng/ml 350 95.7 (87.8 to 99.1) 42.3 (36.5 to 48.4) 28.9 (23.2 to 35.3) 97.5 (93.0 to 99.5)
fFN at 50 ng/mla 350 91.3 (82.0 to 96.7) 64.8 (58.9 to 70.3) 38.9 (31.3 to 46.9) 96.8 (93.2 to 98.8)
fFN at 200 ng/ml 350 71.0 (58.8 to 81.3) 83.6 (78.8 to 87.8) 51.6 (41.1 to 62.0) 92.2 (88.1 to 95.1)
fFN at 500 ng/ml 350 42.0 (30.2 to 54.5) 95.7 (92.7 to 97.8) 70.7 (54.5 to 83.9) 87.1 (82.8 to 90.6)
Actim Partus 350 78.3 (66.7 to 87.3) 89.3 (85.1 to 92.7) 64.3 (53.1 to 74.4) 94.4 (90.9 to 96.8)
Bruijn (2016)62
fFN at 10 ng/ml 455 93.8 (82.8 to 98.7) 32.2 (27.7 to 37.0) 14.0 (10.4 to 18.3) 97.8 (93.6 to 99.5)
fFN at 50 ng/mla 455 89.6 (77.3 to 96.5) 62.2 (57.3 to 66.9) 21.8 (16.3 to 28.3) 98.1 (95.5 to 99.4)
fFN at 200 ng/ml 455 70.8 (55.9 to 83.0) 78.6 (74.3 to 82.5) 28.1 (20.3 to 37.0) 95.8 (93.1 to 97.7)
fFN at 500 ng/ml 455 29.2 (17.0 to 44.1) 94.3 (91.6 to 96.4) 37.8 (22.5 to 55.2) 91.9 (88.8 to 94.3)
Cooper (2012)49
fFN at 50 ng/mlb 291 33.3 (4.3 to 77.7) 89.8 (85.7 to 93.1) 6.5 (0.8 to 21.4) 98.5 (96.1 to 99.6)
Actim Partus 349 33.3 (4.3 to 77.7) 74.1 (69.1 to 78.6) 2.2 (0.3 to 7.7) 98.4 (96.1 to 99.6)
Eroglu (2007)51
fFN at 50 ng/mlc 51 83.3 (35.9 to 99.6) 80.0 (65.4 to 90.4) 35.7 (12.8 to 64.9) 97.3 (85.8 to 99.9)
Actim Partus 51 83.3 (35.9 to 99.6) 84.4 (70.5 to 93.5) 41.7 (15.2 to 72.3) 97.4 (86.5 to 99.9)
Nikolova (2014 and 2015)60,61
fFN at 50 ng/mlc 66 50.0 (21.1 to 78.9) 72.2 (58.4 to 83.5) 28.6 (11.3 to 52.2) 86.7 (73.2 to 94.9)
PartoSure 203 80.0 (63.1 to 91.6) 94.6 (90.1 to 97.5) 75.7 (58.8 to 88.2) 95.8 (91.5 to 98.3)
Riboni (2011)54
fFN at 50 ng/mld 210 50.0 (15.7 to 84.3) 80.2 (74.0 to 85.5) 9.1 (2.5 to 21.7) 97.6 (93.9 to 99.3)
Actim Partus 210 50.0 (15.7 to 84.3) 83.7 (77.8 to 88.5) 10.8 (3.0 to 25.4) 97.7 (94.2 to 99.4)
Ting (2007)56
fFN at 50 ng/mlb 94 56.3 (29.9 to 80.2) 75.6 (64.6 to 84.7) 32.1 (15.9 to 52.4) 89.4 (79.4 to 95.6)
Actim Partus 94 70.6 (44.0 to 89.7) 77.9 (67.0 to 86.6) 41.4 (23.5 to 61.1) 92.3 (83.0 to 97.5)
Tripathi (2016)57
fFN at 50 ng/mlc 468 23.8 (17.3 to 31.4) 99.1 (97.3 to 99.8) 92.3 (79.1 to 98.4) 73.2 (68.7 to 77.3)
Actim Partus 467 94.7 (89.9 to 97.7) 92.4 (88.9 to 95.1) 85.7 (79.5 to 90.6) 97.3 (94.8 to 98.8)
a Quantitative Rapid fFN 10Q Cassette.
b fFN testing method unclear.
c QuikCheck fFN.
d fFN measured by ELISA.
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As previously mentioned, in the APOSTEL-1 study, samples for the qfFN test (at 50 ng/ml) were collected
and frozen for later analysis (this was not the case for the Rapid fFN for TLiIQ system test). This could
potentially introduce a risk of bias as investigators may have known the outcome of the reference standard
when interpreting the test.42,43 However, as previously noted, owing to the nature of the test, the potential
for interpretation bias is minimal. For all other studies reporting fFN data at 50 ng/ml, the tests were
conducted and results analysed at the point of admission, before the reference standard of delivery within
7 days had occurred. However, for three of the studies,51,54,57 it is unclear whether or not assessors were
aware of the Actim Partus test results when analysing fFN tests. Again, although ‘cross-contamination’
between tests cannot be completely ruled out, the potential for such bias in these types of test is minimal.
One study (Riboni et al.54) uses the ELISA technique to determine fFN status (and possibly Cooper et al.49
as well, although this is unclear). ELISA is a quantitative technique that was used in a qualitative capacity
using 50 ng/ml as the threshold; this is the standard threshold, suggesting that in this study the threshold
was established a priori.54 However, neither Riboni et al.54 nor Cooper et al.49 explicitly report prespecification
of the threshold for this test. Of course, the APOSTEL-1 study also uses a qfFN test, but multiple prespecified
thresholds were used.42,43
An additional consideration in these 50-ng/ml fFN data is that one study60,61 reports fFN at 50-ng/ml
accuracy data for only 66 out of the 203 patients recruited and included in the PartoSure analyses.
The reasons for this are unclear.
Test accuracy of 50-ng/ml threshold for fetal fibronectin
Diagnostic test accuracy data for fFN at a threshold of 50 ng/ml (against the 7-day delivery reference standard)
are provided in Table 63. Sensitivity of fFN at the 50-ng/ml threshold ranged from 23.8% (95% CI 17.3% to
31.4%) in the study by Tripathi et al.57 to 91.3% (95% CI 82.0% to 96.7%) in APOSTEL-142,43 (qfFN data at
50 ng/ml). Specificity ranged from 62.2% (95% CI 57.3% to 66.9%) in Bruijn62 to 99.1% (95% CI 97.3% to
99.8%) in Tripathi et al.57 Values for PPV and NPV were also calculated and are presented in Table 63.
Again, it should be noted that these data do not cover all available evidence regarding test accuracy of fFN
at a threshold of 50 ng/ml and are based only on data reported by studies included in our systematic
review of Actim Partus, PartoSure and qfFN at thresholds other than 50 ng/ml.
Comparison of fetal fibronectin at 50-ng/ml test and index tests
In six studies,42,43,49,51,54,56,57 both fFN at a threshold of 50 ng/ml and Actim Partus were assessed in the same
sample. One study60,61 assessed fFN at a threshold of 50 ng/ml and PartoSure in the same sample, and
two studies42,43,62 assessed fFN at a threshold of 50 ng/ml and fFN at other thresholds in the same sample.
Note that the APOSTEL-1 study assessed more than one index test, in addition to fFN at 50 ng/ml, in the
same sample.42,43
When compared with Actim Partus, sensitivity (against the reference standard of preterm birth within
7 days) was higher for fFN at 50 ng/ml in one study,42,43 lower for fFN at 50 ng/ml in two studies56,57 and
the same for both tests in three studies.49,51,54 Specificity (against the reference standard of preterm birth
within 7 days) was lower for fFN than for Actim Partus in four of the six studies,42,43,51,54,56 and higher for
the other two studies.49,57 These data are presented in Table 63.
In the study that included both PartoSure and fFN at a threshold of 50 ng/ml,60,61 both sensitivity and specificity
(against the reference standard of preterm birth within 7 days) were higher for PartoSure [sensitivity 80%
(95% CI 63.1% to 91.6%) and specificity 94.6% (95% CI 90.1% to 97.5%)] than for fFN at 50 ng/ml
[sensitivity 50.0% (95% CI 21.1% to 78.9%) and specificity 72.2% (95% CI 58.4% to 83.5%)].
As would be expected, in the two studies assessing qfFN at a variety of thresholds (APOSTEL-1 and Bruijn),
as the threshold of fFN increased (< 10, < 50, < 200 or < 500 ng/ml) sensitivity decreased and the
specificity increased.42,43,62
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Relevant systematic reviews
The test accuracy data for fFN at 50 ng/ml presented above are based only on the studies included in the
systematic review of PartoSure, Actim Partus and qfFN (see Chapter 2, Results of the systematic review).
Recent systematic reviews were sought in order to identify other available data on fFN at 50 ng/ml (either
the older qualitative test or the modern quantitative test) in the prediction of preterm birth.
Data from systematic reviews of fetal fibronectin at a threshold of 50 ng/ml
One notable systematic review by Sanchez-Ramos et al.128 (2009), included 32 studies that used either a
qualitative fFN test or the quantitative test at a threshold of 50 ng/ml. In this review, pooled sensitivity (against
a reference standard of delivery within 7 days) was 76.1% (95% CI 69.1% to 81.9%) and pooled specificity
was 81.9% (95% CI 78.9% to 84.5%).128 More recently, Boots et al.129 (2014) published a systematic review
that included both studies assessing fFN at a threshold of 50 ng/ml and studies assessing cervical length
measurement. For fFN at 50 ng/ml, sensitivity and specificity estimates from 38 studies (against a reference
standard of delivery within 7 days) were similar to those reported in the previous review by Sanchez-Ramos
et al.;128 in the Boots et al.129 review, pooled sensitivity was 75% (95% CI 69% to 80%) and pooled
specificity was 79% (95% CI 76% to 83%). These values are also similar to those reported in recent NICE
guidance,24 in which across 20 studies of ‘low’ to ‘very low’ quality, sensitivity (against a reference standard of
delivery within 7 days) ranged from 56% (95% CI not reported) to 100% (95% CI not reported) and
specificity ranged from 61.9% (95% CI 59.6% to 62.5%) to 92% (95% CI not reported).
These systematic review data are also similar to the data for fFN at a threshold of 50 ng/ml from the
current overview (see Chapter 2, Heterogeneity between studies), which also ranged widely: sensitivity
(against the 7-day reference standard) ranged from 23.8% (95% CI 17.3% to 31.4%) to 91.3% (95% CI
82.0% to 96.7%) and specificity ranged from 62.2% (95% CI 57.3% to 66.9%) to 99.1% (95% CI
97.3% to 99.8%).
Test accuracy data for transvaginal cervical length
Quantity and quality of the data available for cervical length
As can be seen in Table 62, nine of the 20 included studies42–44,47,50–52,59–62 report DTA data for cervical
length (in addition to data for at least one index test).
Of these nine studies, four42,43,51,59,62 used the cervical length threshold recommended in the current NICE
guidance (< 15 mm).24 Three of these studies42,43,59,62 also reported test accuracy data at other thresholds
(not presented in this report). One study50 reported test accuracy of cervical length using the threshold of
< 20 mm. The remaining four studies44,47,52,60,61 all used a cervical length threshold of < 25 mm.
One study50 reports cervical length test accuracy data for two populations; all recruited women had their
cervical length measured. For those women with a cervical length of > 30 mm, the Actim Partus test was not
conducted (n = 42), and for those with a cervical length of < 30 mm, Actim Partus was conducted (n = 60).
Cervical length test accuracy data were available both for the women with a cervical length of < 30 mm
(n = 60) (i.e. for those women who also had an Actim Partus test) and for the whole sample (n = 102).
It should be noted here that cervical length measurement is a more subjective test (i.e. more open to
human interpretation) than any of the other tests (PartoSure, Actim Partus, qfFN or qualitative fFN) and is,
therefore, more dependent on clinicians’ experience/expertise and more open to potential (intentional or
unintentional) bias. Typically, it was reported that cervical length was measured by a trained investigator,
and that three measurements were taken and averaged. However, it is generally unclear whether or not
the clinicians measuring cervical length were blinded to the results of any biomedical test used. Indeed,
with the exception of the study by Eroglu et al.,51 all studies that evaluated cervical length did not clearly
describe whether or not clinicians were blinded to other test results.42–44,47,50,52,59–62 In Eroglu et al.,51 it was
explicitly stated that the assessor was blinded to other test results.
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Test accuracy of transvaginal cervical length measurement
Table 62 provides DTA data for the three studies42,43,59,62 assessing cervical length at a threshold of < 15 mm
(against the 7-day delivery reference standard). At this threshold, sensitivity ranged widely, from 33.3%
(95% CI 9.9% to 65.1%) in Bolotskikh et al.59 to 72.5% (95% CI 60.4% to 82.5%) in APOSTEL-1.42,43
Specificity was more similar across the four studies, ranging from 81.8% (95% CI 77.7% to 85.4%) in
Bruijn62 to 98.9% (95% CI 93.8% to 100.0%) in Bolotskikh et al.59
Against the 7-day delivery reference standard, sensitivity of cervical length at a threshold of < 20 mm was
75.0% (95% CI 19.4% to 99.4%) in both of the Danti et al.50 samples (n = 60 and n = 102), whereas
specificity was 83.7% (95% CI 74.8% to 90.4%) for the sample of n = 102 and 71.4% (95% CI 57.8% to
82.7%) in the sample of n = 60 (i.e. women with a cervical length of < 30 mm). Eroglu et al.51 also evaluated
cervical length at a threshold of < 20 mm against the 7-day delivery reference standard; sensitivity was lower
at 66.7% (95% CI 22.3% to 95.7%), but specificity was higher at 95.6% (95% CI 84.9% to 99.5%) than
Danti et al.50 Across the four studies providing data at a threshold of < 25 mm, and again against a 7-day
delivery reference standard, sensitivity ranged from 57.1% (95% CI 39.4% to 73.7%) in Nikolova et al.60,61
to 100.0% (95% CI 54.1% to 100.0%) in Hadzi-Lega et al.44 In these four studies, specificity ranged from
31.6% (95% CI 12.6% to 56.6%) in Goyal et al.52 to 72.6% (95% CI 65.2% to 79.2%) in Nikolova et al.60,61
Again, it should be noted that these data do not cover all available evidence regarding test accuracy of
cervical length at thresholds of < 15, < 20 or < 25 mm and are based only on data reported by studies
included in our systematic review of Actim Partus, PartoSure and qfFN at thresholds other than 50 ng/ml.
In addition, the large variation across these studies in sensitivity and specificity may be, at least in part,
owing to the different clinical personnel conducting the cervical length measurements.
Comparison of cervical length and index tests
Six studies42–44,47,50–52 assessed both cervical length measurement and Actim Partus in the same population.
Three studies assessed both cervical length measurement and PartoSure44,59–61 and two42,43,62 assessed both
cervical length and qfFN. Note that the study by Hazdi-Lega et al.44 and the APOSTEL-1 study42,43 both
assess two index tests.
Against the 7-day reference standard, sensitivity was higher for cervical length measurement than Actim
Partus in three studies (see Table 62).44,50,52 The cervical length threshold for a positive test result was
< 25 mm in Hazdi-Lega et al.44 and Goyal et al.,52 and < 20 mm in Danti et al.50 In one study,47 sensitivity
(against the 7-day reference standard) did not differ between Actim Partus and cervical length measurement
with a threshold of < 25 mm. In the remaining two studies,42,43,51 sensitivity was higher for Actim Partus
than for cervical length measurement with a threshold of < 15 mm. Specificity (against the 7-day reference
standard) was higher for Actim Partus than for cervical length in all studies except for Danti et al.50 and
Eroglu et al.,51 in which the specificity was higher for cervical length measurement (see Table 62).
When comparing the test accuracy of cervical length measurement with that of PartoSure (against the
7-day reference standard), sensitivity was higher for PartoSure than for cervical length measurement at a
threshold of < 15 mm in Bolotskikh et al.59 [100% (95% CI 73.5% to 100.0%) vs. 33.3% (95% CI 9.9% to
65.1%)] and lower for PartoSure than for cervical length at a threshold of < 25 mm in Hadzi-Lega et al.44
[83.3% (95% CI 35.9% to 99.6%) vs. 100% (95% CI 54.1% to 100%)], although CIs overlap in Hadzi-Lega
et al.44 Conversely, specificity was lower for PartoSure than for cervical length measurement at a threshold of
< 15 mm in Bolotskikh et al.59 [95.4% (95% CI 88.6% to 98.7%) vs. 98.9% (95% CI 93.8% to 100.0%)]
and higher for PartoSure than for cervical length measurement at a threshold of < 25 mm in Hadzi-Lega
et al.44 [90.2% (95% CI 78.6% to 96.7%) vs. 70.6% (95% CI 56.2% to 82.5%)], albeit with overlapping
CIs. In the third study,60,61 both sensitivity and specificity were higher for PartoSure than for cervical length at
a threshold of < 25 mm [sensitivity 80.0% (95% CI 63.1% to 91.6%) vs. 57.1% (95% CI 39.4% to 73.7%)
and specificity 94.6% (95% CI 90.1% to 97.5%) vs. 72.6% (95% CI 65.2% to 79.2%)], although, again,
CIs (for sensitivity) overlap.
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In comparison with qfFN, in APOSTEL-1,42,43 cervical length at a threshold of < 15 mm was most closely
matched to qfFN with the threshold of 200 ng/ml [sensitivity against the 7-day reference standard: 72.5%
(95% CI 60.4% to 82.5%) vs. 71.0% (95% CI 58.8% to 81.3%) and specificity against the 7-day reference
standard: 83.3% (95% CI 78.4% to 87.4%) vs. 83.6% (95% CI 78.8% to 87.8%)]. However, in Bruijn,62
the sensitivity and specificity (against the 7-day reference standard) of cervical length measurement at a
threshold of < 15 mm fell between sensitivities and specificities produced for qfFN at the 200-ng/ml and
500-ng/ml thresholds (see Table 62). This was particularly because sensitivity of cervical length at a threshold
of < 15 mm was lower in Bruijn than in APOSTEL-1 [51.3% (95% CI 34.8% to 67.6%) vs. 72.5% (95% CI
60.4% to 82.5%)], although the 95% CIs do overlap.42,43,62
Data from systematic reviews of cervical length measurement
In the Boots et al.129 review, cervical length measurement at a cut-off point of 15 mm was assessed in
24 studies (against a reference standard of delivery within 7 days), with pooled sensitivity reported as 74%
(95% CI 58% to 85%) and pooled specificity as 89% (95% CI 85% to 92%). Recent NICE guidance24
shows how the variability across studies is great: for cervical length measurement at a cut-off point of
< 15 mm, across eight studies of ‘very low’ quality, sensitivity (against a reference standard of delivery
within 7 days) ranged from 26.3% (95% CI 11.2% to 39.7%) to 97.7% (95% CI 86.9% to 99.9%) and
specificity from 83.0% (95% CI 70.0% to 93.0%) to 96.5% (95% CI 95.4% to 97.7%). These systematic
review data are similar to the data for cervical length measurement from the current overview (see Test
accuracy of transvaginal cervical length measurement and Table 62) in which, at a threshold of < 15 mm,
sensitivity (against the 7-day reference standard) showed great variability across studies, ranging from
33.3% (95% CI 9.9% to 65.1%) to 72.5% (95% CI 60.4% to 82.5%), and specificity was more similar
across studies, ranging from 81.8% (95% CI 77.7% to 85.4%) to 98.9% (95% CI 93.8% to 100.0%).
In the recent NICE guidance,24 at a cut-off point of < 25 mm (across five studies of ‘low’ and ‘very low’
quality), sensitivity (against a reference standard of delivery within 7 days) ranged from 60.0% (95% CI
48.3% to 64.7%) to 83.3% (95% CI 43.7% to 97.0%) and specificity ranged from 71.7% (95% CI
66.4% to 73.8%) to 96.9% (95% CI 91.6% to 99.5%). Again, these sensitivity data are similar to those in
the current overview in which, at a threshold of < 25 mm, sensitivity ranged from 57.1% (95% CI 39.4%
to 73.7%) to 100.0% (95% CI 54.1% to 100.0%). However, at this threshold, a wider range of specificity
was found in the current overview [ranging from 31.6% (95% CI 12.6% to 56.6%) to 72.6% (95% CI
65.2% to 79.2%)] than in the recent NICE guidance.24 The recent NICE guidance24 also included test
accuracy data for cervical length at a threshold of < 30 mm (across three studies of ‘very low’ quality), with
sensitivity (against a reference standard of delivery within 7 days) ranging from 89.3% (95% CI 71.8% to
97.2%) to 94.0% (95% CI 79.0% to 99.0%) and specificity from 42.0% (95% CI 37.0% to 47.0%) to
55.6% (95% CI 53.0% to 56.8%). The current overview does not provide test accuracy data for cervical
length at the < 30-mm threshold.
Summary
Overall summary tables for the DTA review, including cervical length data, are presented in Tables 37
and 38.
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TABLE 64 Summary of evidence and relative accuracy against the 7-day reference standard
Test Actim Partus PartoSure
qfFN at
10 ng/ml 200 ng/ml 500 ng/ml
Index tests
Actim Partus
PartoSure No difference (Hadzi-Lega et al.44)
qfFN at
10 ng/ml Sensitivity of fFN superior,
specificity of Actim Partus superior
(APOSTEL-142,43)
Indirect evidence only
200 ng/ml No difference (APOSTEL-142,43) Indirect evidence only
500 ng/ml Sensitivity of Actim Partus
superior, specificity of fFN superior
(APOSTEL-142,43)
Indirect evidence only
fFN at 50 ng/ml
qfFN at 50 ng/ml Specificity of Actim Partus
superior, no difference in
sensitivity (APOSTEL-142,43)
Indirect evidence only Sensitivity of fFN at 10 ng/ml
superior; specificity of fFN
at 50 ng/ml superior
(APOSTEL-142,43 and Bruijn62)
Sensitivity of fFN at 50 ng/ml
superior; specificity of fFN
at 200 ng/ml superior
(APOSTEL-142,43 and Bruijn62)
Sensitivity of fFN at 50 ng/ml
superior; specificity of fFN
at 500 ng/ml superior
(APOSTEL-142,43 and Bruijn62)
QuikCheck Sensitivity of Actim Partus superior
and specificity of fFN superior
(Tripathi et al.57). However, Eroglu
et al.51 showed no difference
between tests
Specificity of PartoSure
superior, no difference in
sensitivity (Nikolova et al.;60,61
note missing participants)
Indirect evidence only Indirect evidence only Indirect evidence only
ELISA No difference (Riboni et al.54) No evidence Indirect evidence only Indirect evidence only Indirect evidence only
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TABLE 64 Summary of evidence and relative accuracy against the 7-day reference standard (continued )
Test Actim Partus PartoSure
qfFN at
10 ng/ml 200 ng/ml 500 ng/ml
CLa
< 15mm No difference (APOSTEL-142,43) No evidence Sensitivity of fFN superior;
specificity of CL superior
(APOSTEL-142,43 and Bruijn62)
No difference (APOSTEL-142,43
and Bruijn62)
Sensitivity of CL superior or
no difference; specificity of
fFN superior (APOSTEL-142,43
and Bruijn62)
< 20 mm No difference (Danti et al.50 and
Eroglu et al.51)b
No evidence Indirect evidence only Indirect evidence only Indirect evidence only
< 25mm No difference (Azlin et al.,47 Goyal
et al.52 and Hadzi-Lega et al.44)
Specificity of PartoSure
superior or no difference;
sensitivity no difference
(Nikolova et al.60,61 and
Hadzi-Lega et al.44)
Indirect evidence only Indirect evidence only Indirect evidence only
CL, cervical length.
a Studies reporting accuracy of cervical length across multiple thresholds and data regarding the cut-off point closest to the 15-mm threshold (NICE guidelines24) are reported here.
b Danti et al.:50 a subset of recruited participants received the Actim Partus test, no difference between CL and Actim Partus was observed when compared in the population that received
both tests.
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TABLE 65 Summary table
Test Source (first author) Sensitivity (%) (95% CI) Specificity (%) (95% CI)
Test accuracy for the prediction of preterm delivery within 7 days
Studies assessing more than one index test
fFN at 10 ng/ml Bruijn42,43 (APOSTEL-1) (n = 350) 95.7 (87.8 to 99.1) 42.3 (36.5 to 48.4)
fFN at 200 ng/ml Bruijn42,43 (APOSTEL-1) (n = 350) 71.0 (58.8 to 81.3) 83.6 (78.8 to 87.8)
fFN at 500 ng/ml Bruijn42,43 (APOSTEL-1) (n = 350) 42.0 (30.2 to 54.5) 95.7 (92.7 to 97.8)
Actim Partus Bruijn42,43 (APOSTEL-1) (n = 350) 78.3 (66.7 to 87.3) 89.3 (85.1 to 92.7)
PartoSure Hadzi-Lega44 (n = 57) 83.3 (35.9 to 99.6) 90.2 (78.6 to 96.7)
Actim Partus Hadzi-Lega44 (n = 57) 83.3 (35.9 to 99.6) 76.5 (62.5 to 87.2)
Studies assessing a single index test
Actim Partus Pooled (16 studies) 77 (68 to 83) 81 (76 to 85)
Range (16 studies) 33.3 (4.3 to 77.7) to
94.7 (89.9 to 97.7)
50.0 (24.7 to 75.3)
to 93.5 (82.1 to 98.6)
PartoSure Pooled (4 studies) 83 (61 to 94) 95 (89 to 98)
Range (4 studies) 0 (0.0 to 97.5) to
100.0 (73.5 to 100.0)
90.2 (78.6 to 96.7) to
97.5 (96.8 to 99.9)
fFN at 10 ng/ml Range (2 studies) 93.8 (82.8 to 98.7) to
95.7 (87.8 to 99.1)
32.2 (27.7 to 37.0) to
42.3 (36.5 to 48.4)
fFN at 200 ng/ml Range (2 studies) 70.8 (55.9 to 83.0) to
71.0 (58.8 to 81.3)
78.6 (74.3 to 82.5) to
83.6 (78.8 to 87.8)
fFN at 500 ng/ml Range (2 studies) 29.2 (17.0 to 44.1) to
42.0 (30.2 to 54.5)
94.3 (91.6 to 96.4) to
95.7 (92.7 to 97.8)
Supplementary data from included studies
fFN at 50 ng/ml Range (8 studies) 23.8 (17.3 to 31.4) to
91.3 (82.0 to 96.7)
62.2 (57.3 to 66.9) to
99.1 (97.3 to 99.8)
CL < 15mm Range (3 studies) 33.3 (9.9 to 65.1) to
72.5 (60.4 to 82.5)
81.8 (77.7 to 85.4) to
98.9 (93.8 to 100.0)
CL < 20mm Danti50 (n = 60) 75.0 (19.4 to 99.4) 71.4 (57.8 to 82.7)
CL < 25mm Range (4 studies) 57.1 (39.4 to 73.7) to
100.0 (54.1 to 100.0)
31.6 (12.6 to 56.6) to
72.6 (65.2 to 79.2)
Data extracted from systematic reviews
fFN at 50 ng/ml Sanchez-Ramos;128 pooled (32 studies) 76.1 (69.1 to 81.9) 81.9 (78.9 to 84.5)
fFN at 50 ng/ml Boots;129 pooled (38 studies) 75 (69 to 80) 79 (76 to 83)
fFN at 50 ng/ml NICE guidance;24 range (20 studies) 56a to 100a 61.9 (59.6 to 62.5) to 92a
CL < 15mm Boots;129 pooled (24 studies) 74 (58 to 85) 89 (85 to 92)
CL < 15mm NICE guidance;24 range (8 studies) 26.3 (11.2 to 39.7) to
97.7 (86.9 to 99.9)
83.0 (70.0 to 93.0) to
96.5 (95.4 to 97.7)
CL < 25mm NICE guidance;24 range (5 studies) 60.0 (48.3 to 64.7) to
83.3 (43.7 to 97.0)
71.7 (66.4 to 73.8) to
96.9 (91.6 to 99.5)
CL < 30mm NICE guidance;24 range (3 studies) 89.3 (71.8 to 97.2) to
94.0 (79.0 to 99.0)
42.0 (37.0 to 47.0) to
55.6 (53.0 to 56.8)
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TABLE 65 Summary table (continued )
Test Source (first author) Sensitivity (%) (95% CI) Specificity (%) (95% CI)
Test accuracy for the prediction of preterm delivery within 48 hours
Studies assessing a single index test
Actim Partus Pooled (6 studies) 87 (74 to 96) 73 (62 to 82)
Range (6 studies) 65.7 (47.8 to 80.9) to
100 (47.8 to 100.0)
56.0 (34.9 to 75.6) to
82.4 (56.6 to 96.2)
PartoSure Werlen41 (n = 41) 0.0 (0.0 to 97.5) 97.5 (86.8 to 99.9)
CL, cervical length.
a 95% CI not reported.
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